PRACTICE GUIDELINE FOR THE  
Treatment of Patients With 
Major Depressive Disorder
Third Edition
WORK GROUP ON MAJOR DEPRESSIVE DISORDER
Alan J. Gelenberg, M.D., Chair
Marlene P . Freeman, M.D.John C. Markowitz, M.D.Jerrold F . Rosenbaum, M.D.Michael E. Thase, M.D.Madhukar H. T rivedi, M.D.Richard S. Van Rhoads, M.D., Consultant
INDEPENDENT REVIEW PANEL
Victor I. Reus, M.D., ChairJ. Raymond DePaulo, Jr., M.D.Jan A. Fawcett, M.D.Christopher D. Schneck, M.D.David A. Silbersweig, M.D.
This practice guideline was approved in May 2010 and published in October 2010. A guideline watch, summarizing
significant developments in the scientific literature since publication of this guideline, may be available athttp://www.psychiatryonline.com/ pracGuide/pracGuideT opic_7.aspx.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST
The Work Group on Major Depressive Disorder reports
the following potentially competing interests for the pe-
riod from May 2005 to May 2010:
Dr. Gelenberg reports consulting for Eli Lilly and Com-
pany, Pfizer, Best Practice, AstraZeneca, Wyeth, Cyber-
onics, Novartis, Forest Pharmaceuticals, Inc., GlaxoSmith-
Kline, ZARS Pharma, Jazz Pharmaceuticals, Lundbeck,
T akeda Pharmaceuticals North America, Inc., eResearch
T echnology, Dey Pharma, PGxHealth, and Myriad Genet-
ics. He reports serving on speakers bureaus for Pfizer,
GlaxoSmithKline, and Wyeth. He reports receiving re-search grant funding from Eli Lilly and Company, Pfizer,
and GlaxoSmithKline. He reports stock ownership in
Healthcare T echnology Systems.
Dr. Freeman reports that she received research support
from the Meadows Foundation, the National Institute forMental Health, the U.S. Food and Drug Administration,the Institute for Mental Heal th Research, Forest, Glaxo-
SmithKline and Eli Lilly and Company (investigator-initiated trials), and Pronova Biocare (research materials).She received an honorarium for case-based peer-reviewed
material for AstraZeneca’s website. She reports consulting
for Ther-Rx, Reliant, and Pamlab. She reports receivingan honorarium for speaking at an APA continuing medical
education program that was sponsored by Forest and an
honorarium for speaking at a continuing medication edu-cation program sponsored by KV Pharmaceuticals. She
reports receiving an honorarium from Leerink Swann for
participating in a focus group.
Dr. Markowitz reports consulting for Ono Pharma-
ceutical Co., Ltd. (2005). He reports receiving researchsupport from Forest Pharmaceuticals, Inc. (2005). He re-ports receiving grant support from the National Institute
of Mental Health (2005–2013), the National Alliance for
Research in Schizophrenia and Depression (2005), andMINT: Mental Health Initiative (2005). He reports re-
ceiving royalties from American Psychiatric Publishing, Inc.
(2005–2010), Basic Books (2005–2010), Elsevier (2005–2010), and Oxford University Press (2007–2010).
Dr. Rosenbaum reports attending advisory boards for
Bristol-Myers Squibb, Cephalon, Cyberonics, Forest Phar-maceuticals, Inc., Eli Lilly and Company, MedAvante,
Neuronetics, Inc., Novartis, Orexigen Therapeutics, Inc.,
Organon BioSciences, Pfizer, Roche Diagnostics, Sanofi-
aventis, Shire, and Wyeth. He reports consulting for Aus-
pex Pharmaceuticals, Compe llis Pharmaceuticals, EPIX
Pharmaceuticals, Neuronetic s, Inc., Organon BioSci-
ences, Somaxon, and Supernus Pharmaceuticals, Inc. Hereports receiving honoraria from lectureships for Boeh-ringer Ingleheim, Bristol-Myers Squibb, Cyberonics,
Forest Pharmaceuticals, Inc., Eli Lilly and Company, andSchwartz Pharma. He was involved in the creation of
the Massachusetts General Hospital Psychiatry Academy
(MGH-PA) and has served as a panelist in four satellitebroadcast programs. MGH-PA programs that have indus-
try support are always multi-sponsored, and curriculum
development by the Academy is independent of sponsor-
ship; the curricula from January 2005 to March 2009 in-
cluded sponsorship support from AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly and Company, Forest
Pharmaceuticals, Inc., GlaxoSmithKline, Janssen Medical
Affairs LLC, Ortho-McNeil Pharmaceutical, sanofi-aventis, Shire, and Wyeth. He reports equity holdings in
Compellis Pharmaceuticals,  MedAvante, and Somaxon.
Dr. Thase reports that he provided scientific consulta-
tion to AstraZeneca, Bristol-Myers Squibb, Eli Lilly &Company, Forest Pharmaceuticals, Inc., Gerson Lehman
Group, GlaxoSmithKline, Guidepoint Global, H. Lund-beck A/S, MedAvante, Inc., Neuronetics, Inc., Novartis,
Otsuka, Ortho-McNeil Pharmaceuticals, PamLab, L.L.C.,
Pfizer (formerly Wyeth-Ayerst Laboratories), Schering-Plough (formerly Organon), Shire U.S., Inc., Supernus
Pharmaceuticals, T akeda (Lundbeck), and T ranscept Phar-
maceuticals. He was a member of the speakers bureaus forAstraZeneca, Bristol-Myers Squibb, Eli Lilly and Com-
pany, GlaxoSmithKline, Pfizer (formerly Wyeth-Ayerst
Laboratories), and Schering-Plough (formerly Organon).He received grant funding from Eli Lilly and Company,
GlaxoSmithKline, the National Institute of Mental Health,
the Agency for Healthcare Research and Quality, andSepracor, Inc. He had equity holdings in MedAvante, Inc.,
and received royalty income from American Psychiatric
Publishing, Inc., Guilford Publications, Herald House,Oxford University Press, and W.W. Norton and Company.
His wife was employed as the group scientific director for
Embryon (formerly Advogent), which does business withBristol-Myers Squibb and Pfizer/Wyeth.
Dr. T rivedi reports that he was a consultant to or on
speaker bureaus for Abbott Laboratories, Inc., Abdi Ibra-him, Akzo (Organon Pharmaceuticals, Inc.), AstraZeneca,
Bristol-Myers Squibb Company, Cephalon, Inc., Cyber-
onics, Inc., Eli Lilly and Company, Evotec, Fabre Kramer
Pharmaceuticals, Inc., Forest Pharmaceuticals, Glaxo-SmithKline, Janssen Pharmaceutica Products, L.P ., Johnson
& Johnson P .R.D., Meade-Johnson, Medtronic, Neuro-
netics, Otsuka Pharmaceuticals, Parke-Davis Pharmaceuti-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
cals, Inc., Pfizer, Inc., Sepracor, Shire Development, Solvay
Pharmaceuticals, VantagePoint, and Wyeth-Ayerst Labo-
ratories. He received research support from the Agency forHealthcare Research and Quality, Corcept Therapeutics,
Inc., Cyberonics, Inc., Merck, National Alliance for Re-
search in Schizophrenia and Depression, National Insti-
tute of Mental Health, National Institute on Drug Abuse,
Novartis, Pharmacia & Upjohn, Predix Pharmaceuticals
(Epix), Solvay Pharmaceuti cals, Inc., and T argacept.
Dr. Van Rhoads reports no competing interests.
The Independent Review Panel, including Drs. Reus,
DePaulo, Fawcett, Schneck, and Silbersweig, report nocompeting interests. The Independent Review Panel re-viewed this guideline to assess potential biases and found
no evidence of influence from the industry and other re-lationships of the Work Group disclosed above. The
Steering Committee on Practice Guidelines also reviewed
this guideline and found no evidence of influence fromthese relationships. The development process for this
guideline, including the roles of the Work Group, Inde-
pendent Review Panel, Steering Committee, APA Assem-bly, and APA Board of T rustees is described in “Overview
of Guideline Development Process” on p. 11.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
AMERICAN PSYCHIATRIC ASSOCIATION 
STEERING COMMITTEE ON PRACTICE GUIDELINES
John S. McIntyre, M.D., Chair (1999–2009), Consultant (2009–2010)
Joel Yager, M.D., Vice-Chair (2008–2009), Chair (2009–2010)Daniel J. Anzia, M.D.
Thomas J. Craig, M.D., M.P .H.
Molly T. Finnerty, M.D.Bradley R. Johnson, M.D.
Francis G. Lu, M.D.
James E. Nininger, M.D., Vice-Chair (2009–2010)
Barbara Schneidman, M.D.
Paul Summergrad, M.D.Sherwyn M. Woods, M.D., Ph.D.
Michael J. Vergare, M.D.
M. Justin Coffey, M.D. (fellow)Kristen Ochoa, M.D. (fellow)
Jeremy Wilkinson, M.D. (fellow)
Sheila Hafter Gray, M.D. (liaison)
STAFF
Robert Kunkle, M.A., Director, Practice Guidelines Project
Robert M. Plovnick, M.D., M.S., Director, Dept. of Quality Improvement and Psychiatric Services
Darrel A. Regier, M.D., M.P.H., Director, Division of Research
MEDICAL EDITOR
Laura J. Fochtmann, M.D.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
CONTENTS
STATEMENT OF INTENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
OVERVIEW OF GUIDELINE DEVELOPMENT PROCESS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
GUIDE TO USING THIS PRACTICE GUIDELINE  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
OFF-LABEL USE OF MEDICATIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . 13
INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . 13
PART A: TREATMENT RECOMMENDATIONS  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
I. EXECUTIVE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . 15
A. Coding System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
B. Summary of Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . 15
1. Psychiatric management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
a. Establish and maintain a therapeutic alliance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . 15
b. Complete the psychiatric assessment  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
c. Evaluate the safety of the patient  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
d. Establish the appropriate setting for treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . 16
e. Evaluate functional impairment and quality of life . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
f. Coordinate the patient’s care with other clinicians . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
g. Monitor the patient’s psychiatric status . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
h. Integrate measurements into psychiatric management  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
i. Enhance treatment adherence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . 16
j. Provide education to the patient and the family  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
2. Acute phase  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . 17
a. Choice of an initial treatment modality  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
1. Pharmacotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2. Other somatic therapies  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
3. Psychotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . 17
4. Psychotherapy plus antidepressant medication  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
b. Assessing the adequacy of treatment response . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
c. Strategies to address nonresponse . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . 18
3. Continuation phase  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194. Maintenance phase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . 19
5. Discontinuation of treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
6. Clinical factors influencing treatment  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
a. Psychiatric factors  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
b. Demographic and psychosocial factors  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . 20
c. Co-occurring general medical conditions  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
II. FORMULATION AND IMPLEMENTATION OF A TREATMENT PLAN  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
A. Psychiatric Management  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
1. Establish and maintain a therapeutic alliance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 232. Complete the psychiatric assessment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
3. Evaluate the safety of the patient  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
4. Establish the appropriate setting for treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
5. Evaluate functional impairment and quality of life  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
6. Coordinate the patient’s care with other clinicians  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
7. Monitor the patient’s psychiatric status. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . 27
8. Integrate measurements into psychiatric management  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
9. Enhance treatment adherence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
10. Provide education to the patient and the family . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . 29
B. Acute Phase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .30
1. Choice of initial treatment modality . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 302. Pharmacotherapy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
a. Efficacy of antidepressant medications  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
1. Selective serotonin reuptake inhibitors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 3
2. Serotonin norepinephrine reuptake inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3. Other antidepressant medication s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
4. Tricyclic antidepressants  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . 35
5. Monoamine oxidase inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5
b. Side effects of antidepressant medications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
1. Selective serotonin reuptake inhibitors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 6
a. Gastrointestinal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36b. Activation/insomnia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
c. Sexual side effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
d. Neurological effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
e. Falls  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 8
f. Effects on weight . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
g. Serotonin syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
h. Drug interactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
i. Discontinuation syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
2. Serotonin norepinephrine reuptake inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 403. Other antidepressant medication s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
a. Bupropion  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
b. Mirtazapine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
c. Trazodone  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
d. Nefazodone  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
4. Tricyclic antidepressants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . 41
a. Cardiovascular effects  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
b. Anticholinergic side effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
c. Sedation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1
d. Weight gain. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
e. Neurological effects. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
f. Falls . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  .4 2
g. Medication interactions  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
5. Monoamine oxidase inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 2
a. Hypertensive crises . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42b. Serotonin syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
c. Cardiovascular effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
d. Weight gain  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
e. Sexual side effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
f. Neurological effects  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
c. Implementation of pharmacotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
3. Other somatic therapies  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . 44
a. Electroconvulsive therapy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
1. Side effects of electroconvulsive therapy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
2. Implementation of electroconvulsive therapy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
b. Transcranial magnetic stimulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . 46
c. Vagus nerve stimulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
4. Psychotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
a. Specific psychotherapies  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
1. Cognitive and behavioral therapies  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
2. Interpersonal psychotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
3. Psychodynamic psychotherapy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
4. Problem-solving therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
5. Marital therapy and family therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 486. Group therapy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . 48
b. Implementation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
c. Combining psychotherapy and medication  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
5. Complementary and alternative treatments  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
a. St. John’s wort . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . 50
b.S-adenosyl methionine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
c. Omega-3 fatty acids  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
d. Folate  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . 51
e. Light therapy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
f. Acupuncture  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
6. Assessing response and adequacy of treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
7. Strategies to address incomplete response . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
a. Maximizing initial treatments  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
b. Changing to other treatments  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
c. Augmenting and combining treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
C. Continuation Phase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . 56
D. Maintenance Phase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
E. Discontinuation of Treatment  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
III. SPECIFIC CLINICAL FEATURES INFLUENCING THE TREATMENT PLAN  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
A. Psychiatric Factors  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
1. Depressive symptoms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
a. Suicidal ideation and behaviors  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
b Major depressive disorder–related cognitive dysfunction  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 0
2. DSM depressive subtypes  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . 61
a. Psychotic features  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . 61
b. Catatonic features  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . 61
c. Melancholic features  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . 61
d. Atypical features  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
e. Seasonal pattern . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
3. Co-occurring psychiatric disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
a. Dysthymic disorder  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
b. Anxiety disorders  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
c. Dementia  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . 63
d. Substance use disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . 63
e. Personality disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
f. Eating disorders  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . 65
B. Demographic and Psychosocial Variables . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . .65
1. Major psychosocial stressors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 652. Bereavement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3. Culture and ethnicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . 66
4. Older age. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
5. Gender  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
6. Pregnancy and postpartum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . 69
a. Depression during pregnancy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
1. Risks of antidepressants during pregnancy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 692. Implementation of pharmacotherapy during pregnancy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
b. Postpartum depression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
7. Family history. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . 72
C. Treatment Implications of Co-occurring General Medical Conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . .72
1. Hypertension  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
2. Cardiac disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 723. Stroke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
4. Parkinson’s disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
5. Epilepsy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . 74
6. Obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . . 74
7. Diabetes  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
8. Sleep apnea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
9. Human immunodeficiency virus and hepatitis  C infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
10. Pain syndromes  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7611. Obstructive uropathy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
12. Glaucoma  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
PART B: BACKGROUND INFORMATION AND REVIEW OF AVAILABLE EVIDENCE . . . . . . . . . . . . . . . 77
IV. DISEASE DEFINITION, EPIDEMIOLOGY, NATURAL HISTORY, AND COURSE  . . . . . . . . . . . . . . . . . . . . . . . . . . . . .77
A. Disease Definition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . .77
B. Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .78
C. Natural History and Course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .81
1. Recurrence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . . 81
2. Interepisode status  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . . 81
3. Complications and prognosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
V. REVIEW AND SYNTHESIS OF AVAILABLE EVIDENCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . .81
A. Acute Phase Somatic Treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .83
1. Antidepressant medications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . 83
a. Selective serotonin reuptake inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . 83
b. Serotonin norepinephrine reuptake inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
c. Other antidepressant medications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
1. Bupropion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . 85
2. Mirtazapine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
3. Nefazodone and trazodone. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
d. Tricyclic antidepressants. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
e. Monoamine oxidase inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
2. Electroconvulsive therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . 87
3. Transcranial magnetic stimulation  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 894. Vagus nerve stimulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . 90
5. Complementary and alternative treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
a. St. John’s wort  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . 91
b.S-adenosyl methionine  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
c. Omega-3 fatty acids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
d. Folate. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
e. Light therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
f. Acupuncture. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
B. Specific Psychotherapies  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
1. Cognitive and behavioral therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
a. Cognitive-behavioral therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
b. Behavior therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
2. Interpersonal therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 943. Psychodynamic psychotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94
4. Marital therapy and family therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . 95
5. Problem-solving therapy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 956. Group therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
C. Psychotherapy Combined With Pharmacotherapy  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 6
D. Lack of Response to Pharmacotherapy in the Acute Phase  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
1. Maximizing initial treatments. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
2. Changing to other treatments. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 973. Augmenting and combining treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
E. Continuation Treatment  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . 98
F. Maintenance Treatment  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
PART C: FUTURE RESEARCH NEEDS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
APPENDIX: EDUCATIONAL RESOURCES FOR PATIENTS AND FAMILIES . . . . . . . . . . . . . . . . . . . . . 101
INDIVIDUALS AND ORGANIZATIONS THAT SUBMITTED COMMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
ACKNOWLEDGMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  . . . . . . . . . . . 103
REFERENCES  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 11
STATEMENT OF INTENT
The APA Practice Guidelines are not intended to be con-
strued or to serve as a standard of medical care. Standards of
medical care are determined on the basis of all clinical dataavailable for an individual patient and are subject to change
as scientific knowledge and technology advance and practice
patterns evolve. These parameters of practice should be con-sidered guidelines only. Adherence to them will not ensure
a successful outcome for every individual, nor should they
be interpreted as including all proper methods of care orexcluding other acceptable methods of care aimed at the
same results. The ultimate recommendation regarding a
particular clinical procedure or treatment plan must be
made by the psychiatrist in light of the clinical data, the psy-
chiatric evaluation, and the diagnostic and treatment op-tions available. Such recommendations should incorporate
the patient’s personal and sociocultural preferences and val-
ues in order to enhance the therapeutic alliance, adherenceto treatment, and treatment outcomes.
This practice guideline was approved in May 2010 and
published in October 2010.
OVERVIEW OF GUIDELINE 
DEVELOPMENT PROCESS
This practice guideline was developed under the direction
of the Steering Committee on Practice Guidelines. The
development process is detailed in a document entitled
“APA Guideline Development Process,” which is avail-able from the APA Department of Quality Improvement
and Psychiatric Services. Key features of this process in-
clude the following:
• A comprehensive literature review to identify all rele-
vant randomized clinical trials as well as less rigorously
designed clinical trials and case series when evidencefrom randomized trials was unavailable
• Development of evidence tabl es that reviewed the key
features of each identified study, including fundingsource, study design, sample sizes, subject characteris-
tics, treatment characteristics, and treatment outcomes
• Initial drafting of the guideline by a work group (“Work
Group”) that included psychiatrists with clinical and re-search expertise in major depressive disorder
• Production of multiple revised drafts with widespread
review; 15 organizations and 71 individuals submittedcomments.
• Review of the final draft by an Independent Review
Panel of experts with no relationships with industry,who were charged to evaluate the guideline recommen-dations for bias from potential conflicts of interest.
• Approval by the APA Assembly and Board of T rustees.
• Planned revisions at regular intervals.
Development of this APA practice guideline was not fi-
nancially supported by any commercial organization. Inaddition, the integrity of the guideline has been ensured
by the following mechanisms:
1. Work Group members were selected on the basis of
their expertise and integrity, and they agreed to dis-close all potential conflicts of interest before and during
their work on this guideline to the Steering Commit-
tee on Practice Guidelines and to each other. Employ-
ees of industry were not included on the group, andthe group was balanced to include some persons with
minimal industry relationships. As disclosed on pages
2–3, from initiation of work in 2005 to approval of theguideline in 2010, some members of the Work Group
on Major Depressive Disord er had relationships with
industry for which they received research grants or in-
come from consulting or speaking related to treat-
ments discussed in the guideline.
2. Iterative guideline drafts were broadly circulated to and
reviewed by the Steering Committee, other experts, al-lied organizations, and the APA membership; review-
ers were asked to disclose their own potential conflictsof interest relevant to evaluating their comments. Over
1,000 comments were received and were addressed by
substantive revisions by the Work Group. Oversight ofthe draft review and revision process was provided by
the chair and vice-chair of the Steering Committee and
by the Medical Editor, none of whom had relationshipswith industry.
3. In response to a 2009 report by the Institute of Med-
icine (1), which advocated that professional organiza-tions that develop and disseminate practice guidelines
should adopt a new policy that members of guideline
work groups have no significant relationships with in-dustry, the following process was implemented: An
independent review panel of experts (“Independent
Review Panel”) having no current relationships withindustry also reviewed the guideline and was charged
with identifying any possible bias. The Independent
Review Panel found no evidence of bias.
The Work Group and the Steering Committee dif-
fered on how to rate the strength of recommendation forpsychodynamic psychotherapy. Based on their review ofthe available empirical evidence on the use of psycho-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
12 APA PRACTICE GUIDELINES
dynamic psychotherapy in individuals with major depres-
sive disorder, the Work Group gave this treatment a level
III rating, i.e., “may be recommended on the basis of in-dividual circumstances.” The Steering Committee gave a
level II rating, “recommended with moderate clinical confi-
dence,” based on the long history of clinical experiencewith psychodynamic psychotherapy as well as findings
from several studies of patients who had depressive symp-
toms but not major depressive disorder per se.
Relevant updates to the literature were identified through
a MEDLINE literature search for articles published sincethe second edition of the guideline, published in 2000. Forthis edition of the guideline, literature was identified
through a computerized sear ch of MEDLINE, using Pub-
Med, for the period from January 1999 to December 2006.
Using the MeSH headings depression or depressive disor-
der, as well as the key words major depression, major de-pressive disorder, neurotic depression, neurotic depressive,
dysthymia, dysthymic, dysthymic disorder, endogenous de-
pression, endogenous depressive, melancholia, melan-cholic, psychotic depression, atypical depression, seasonal
depression, postpartum depression, postpartum depressive
symptoms, unipolar depression, unipolar depressive, orpseudodementia yielded 39,157 citations. An additional
8,272 citations were identified by using the key words de-
pression or depressive in combination with the MeSHheadings affective disorders or psychotic or the key words
psychosis, psychotic, catatonic, catatonia, mood disorder,
mood disorders, affective disorder, or affective disorders.These citations were limited to English language articles
on human treatments using the MeSH headings central
nervous system stimulants, hypnotics and sedatives, anti-convulsants, tranquilizing agents, electric stimulation ther-
apy, electroconvulsive therapy, psychotherapy, antidepres-
sive agents, and monoamine oxid ase inhibitors or the key
words antidepressant, antidepre ssants, antidepressive, anti-
depressive agents, antidepressive agents, second genera-tion, antidepressive agents tricyclic, antidepressive agents,tricyclic, fluoxetine, citalopram, escitalopram, paroxetine,
sertraline, venlafaxine, duloxetine, mirtazapine, nefazo-
done, trazodone, imipramine, desipramine, nortriptyline,
protriptyline, doxepin, trimipramine, amitriptyline, phe-
nelzine, tranylcypromine, isocarboxazid, moclobemide,
antipsychotic agents, testosterone, thyroid, tri iodothyro-
nine, thyroxine, omega 3, s adenosyl methionine, s adenosyl-
methionine, St. John’s wort, hypericum, selegiline, anti-
convulsant, anticonvulsants, antipsychotic, antipsychotic
agent, antianxiety, anti an xiety, benzodiazepine, benzodiaz-
epines, zolpidem, sedative, sedatives, hypnotic, hypnotics,zaleplon, eszopiclone, valproate, valproic acid, divalproex,carbamazepine, oxcarbazepine, gabapentin, topiramate,
lamotrigine, lithium, modafinil, methylphenidate, Adder-all, amphetamine, amphetamines, dextroamphetamine,
atomoxetine, electroconvulsive, vagal nerve stimulation,
vagus nerve stimulation, VNS, rTMS, rapid transcranialmagnetic, repetitive transcranial magnetic stimulation,
magnetic stimulation, deep brain stimulation, psychother-
apy, psychotherapeutic, psychotherapies, behavior therapy,behaviour therapy, cognitive therapy, cognitive behavior
therapy, cognitive behavioral analysis system, cognitive be-
havioral therapy, cognitive behaviour therapy, cognitive
behavioural therapy, psychoanalytic, interpersonal therapy,
interpersonal psychotherapy, group therapy, family ther-apy, marital therapy, couples therapy, psychoanalysis, psy-chodynamic, aversive therapy, desensitization, exposure
therapy, relaxation techniques, or progressive muscle relax-
ation. This yielded 13,506 abstracts, which were screened
for relevance with a very modest threshold for inclusion,
then reviewed by the Work Group.
The Psychoanalytic Electronic Publishing database
(http://www.p-e-p.org) was also searched using the termsmajor depression or major depressive. This search yielded112 references. The Cochrane databases were also searched
for the key word depression, and 168 meta-analyses were
identified. Additional, less formal, literature searches wereconducted by APA staff and individual Work Group mem-
bers and included references through May 2009. Sources
of funding were considered when the Work Group re-viewed the literature.
The broad scope of this guideline and the substantial
evidence base resulted in some practical tradeoffs. Onesuch tradeoff worth highlighting is the decision to build
upon literature reviews of the first and second editions of
the guideline, rather than re-do them. This decision is ac-knowledged to have resulted in an emphasis of study in
this guideline on newer treatments, because the majority
of studies about older treatments, including tricyclic anti-depressants and monoamine oxidase inhibitors, were pub-
lished in decades prior to 1999. Readers are advised that
the reviews of this older literature are described in theprevious editions of the guideline. The Work Group for
this edition considered the previous editions during their
evidence review, but for practical reasons, that effort is lesswell documented than the group’s analysis of the newer
literature. The treatment recommendations of this guide-
line, however, were developed to reflect the complete ev-idence base.
This document represents a synthesis of current scien-
tific knowledge and rational clinical practice regardingthe treatment of patients with major depressive disorder.
It strives to be as free as possible of bias toward any theo-
retical approach to treatment.  In order for the reader to
appreciate the evidence base behind the guideline recom-
mendations and the weight that should be given to each
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 13
recommendation, the summary of treatment recommen-
dations is keyed according to the level of confidence with
which each recommendation is made. Each rating of clin-
ical confidence considers the strength of the available ev-
idence. When evidence from randomized controlled trials
and meta-analyses is limited, the level of confidence mayalso incorporate other clinical trials and case reports as well
as clinical consensus with regard to a particular clinical
decision. In the listing of ci ted references, each reference
is followed by a letter code in brackets that indicates the
nature of the supporting evidence.
GUIDE TO USING THIS 
PRACTICE GUIDELINE
The Practice Guideline for the Treatment of Patients With Ma-
jor Depressive Disorder, Third Edition,  consists of three parts
(Parts A, B, and C) and many sections, not all of which will
be equally useful for all readers. The following guide isdesigned to help readers find the sections that will be most
useful to them.
Part A, “T reatment Recommendations,” is published
as a supplement to the American Journal of Psychiatry  and
contains general and specific treatment recommenda-
tions. Section I summarizes the key recommendations ofthe guideline and codes each recommendation according
to the degree of clinical confidence with which the recom-
mendation is made. Section II is a guide to the formula-tion and implementation of a treatment plan for the
individual patient. Section III,  “Specific Clinical Features
Influencing the T reatment Plan,” discusses a range of clin-
ical considerations that could alter the general recommen-
dations discussed in Section I.
Part B, “Background Information and Review of Avail-
able Evidence,” and Part C, “Future Research Needs,” arenot included in the American Journal of Psychiatry  sup-
plement but are provided with Part A in the complete guide-
line, which is available in print format from AmericanPsychiatric Publishing, Inc., and online through the Ameri-
can Psychiatric Association (http://www.psychiatryon-line.com). Part B provides an overview of major depressive
disorder, including general information on natural history,
course, and epidemiology. It also provides a structuredreview and synthesis of the evidence that underlies the
recommendations made in Part A. Part C draws from the
previous sections and summarizes areas for which moreresearch data are needed to guide clinical decisions.T o share feedback on this or other published APA
practice guidelines, a form is available athttp://mx.psych.org/survey/reviewform.cfm.
OFF-LABEL USE OF 
MEDICATIONS
Medications discussed in this practice guideline may not
have an indication from the U.S. Food and Drug Admin-
istration for the disorder or condition for which they are
recommended. Off-label use of medications by individualphysicians is permitted and common. Decisions about off-
label use can be guided by the evidence provided in the
APA practice guideline, other scientific literature, and clin-
ical experience.
INTRODUCTION
This guideline summarizes the specific approaches totreatment of individuals with major depressive disorder. It
presupposes that the psychiatrist has diagnosed major de-pressive disorder, according to the criteria defined in
DSM-IV-TR, in an adult pa tient and has evaluated the
patient to identify general medical conditions that may
contribute to the disease process (e.g., hypothyroidism,
pancreatic carcinoma) or complicate its treatment (e.g.,
cardiac disorders). The trea tment recommendations that
follow may also have some relevance for patients who
have depressive symptoms on the basis of other syn-
dromes, such as dysthymic disorder. Because many pa-tients have co-occurring psychiatric disorders, including
substance use disorders, the psychiatrist should also con-
sider applicable treatment guidelines for these diagnoses.When patients experience depressive symptoms in the
context of another disorder and do not meet the diagnos-
tic criteria for major depressive disorder, the APA practiceguideline pertaining to the primary diagnosis should be
consulted. For patients found to have depressive symp-
toms within the context of bipolar disorder, the psychiatristshould refer to APA ’s Practice Guideline for the Treatment of
Patients With Bipolar Disorder  (2). Recommendations on
the treatment of depressive disorders in children and ad-olescents can be found in the American Academy of Child
and Adolescent Psychiatry’s Practice Parameter for the As-
sessment and Treatment of Children and Adolescents With
Depressive Disorders  (3).
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
15Part A
TREATMENT RECOMMENDATIONS
I. EXECUTIVE SUMMARY
A. CODING SYSTEM
Each recommendation is identified as falling into one of
three categories of endorsement, indicated by a bracketedRoman numeral following the statement. The three cate-
gories represent varying levels of clinical confidence:
[I] Recommended with substantial clinical confidence
[II] Recommended with moderate clinical confidence
[III] May be recommended on the basis of individual cir-
cumstances
B. SUMMARY OF RECOMMENDATIONS
1. Psychiatric management
Psychiatric management consists of a broad array of inter-
ventions and activities that psychiatrists should initiate
and continue to provide to patients with major depressive
disorder through all phases of treatment [I].
a. Establish and maintain a therapeutic alliance
In establishing and maintaining a therapeutic alliance, it is
important to collaborate with the patient in decision mak-ing and attend to the patient’s preferences and concerns
about treatment [I]. Management of the therapeutic alli-
ance should include awareness of transference and counter-transference issues, even if these are not directly addressed
in treatment [II]. Severe or persistent problems of poor al-
liance or nonadherence to treatment may be caused by thedepressive symptoms themselves or may represent psy-
chological conflicts or psychopathology for which psycho-
therapy should be considered [II].
b. Complete the psychiatric assessment
Patients should receive a thorough diagnostic assessment in
order to establish the diagnosis of major depressive disor-der, identify other psychiatric or general medical conditions
that may require attention, and develop a comprehensive
plan for treatment [I]. This evaluation generally includes a
history of the present illness and current symptoms; a psy-chiatric history, including identification of past symptomsof mania, hypomania, or mixed episodes and responses to
previous treatments; a general medical history; a personalhistory including information about psychological develop-
ment and responses to life transitions and major life events;
a social, occupational, and family history (including mooddisorders and suicide); review of the patient’s prescribed
and over-the-counter medications; a review of systems; a
mental status examination; a physical examination; and ap-propriate diagnostic tests as indicated to rule out possible
general medical causes of depressive symptoms [I]. Assess-
ment of substance use should evaluate past and current useof illicit drugs and other substances that may trigger or ex-
acerbate depressive symptoms [I].
c. Evaluate the safety of the patient
A careful and ongoing evaluation of suicide risk is neces-
sary for all patients with major depressive disorder [I].
Such an assessment includes specific inquiry about sui-
cidal thoughts, intent, plans, means, and behaviors; iden-tification of specific psychiatric symptoms (e.g., psychosis,
severe anxiety, substance use) or general medical condi-
tions that may increase the likelihood of acting on suicidalideas; assessment of past and, particularly, recent suicidal
behavior; delineation of current stressors and potential
protective factors (e.g., positive reasons for living, strongsocial support); and identification of any family history of
suicide or mental illness [I]. In addition to assessing sui-
cide risk per se, it is important to assess the patient’s levelof self-care, hydration, and nutrition, each of which can be
compromised by severe depressive symptoms [I]. As part
of the assessment process, impulsivity and potential forrisk to others should also be  evaluated, including any his-
tory of violence or violent or homicidal ideas, plans, or in-tentions [I]. An evaluation of the impact of the depressionon the patient’s ability to care for dependents is an impor-
tant component of the safety evaluation [I]. The patient’s
risk of harm to him- or herself and to others should also be
monitored as treatment proceeds [I].
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
16 APA PRACTICE GUIDELINES
d. Establish the appropriate setting for treatment
The psychiatrist should determine the least restrictive
setting for treatment that will be most likely not only toaddress the patient’s safety, but also to promote improve-
ment in the patient’s condition [I]. The determination of
an appropriate setting for treatment should include con-sideration of the patient’s symptom severity, co-occurring
psychiatric or general medical conditions, available support
system, and level of functioning [I]. The determination of atreatment setting should also include consideration of the
patient’s ability to adequately care for him- or herself, to
provide reliable feedback to the psychiatrist, and to coop-erate with treatment of the major depressive disorder [I].
Measures such as hospitalization should be considered for
patients who pose a serious threat of harm to themselves
or others [I]. Patients who refuse inpatient treatment can
be hospitalized involuntarily if their condition meets thecriteria of the local jurisdiction for involuntary admission
[I]. Admission to a hospital or, if available, an intensive day
program, may also be indicated for severely ill patients wholack adequate social support outside of a hospital setting,
who have complicating psychiatric or general medicalconditions, or who have not responded adequately to out-patient treatment [I]. The optimal treatment setting and
the patient’s likelihood of benefit from a different level of
care should be reevaluated on an ongoing basis through-out the course of treatment [I].
e. Evaluate functional impairment and quality of life
Major depressive disorder can alter functioning in numer-ous spheres of life including work, school, family, social
relationships, leisure activities, or maintenance of health
and hygiene. The psychiatrist should evaluate the patient’sactivity in each of these domains and determine the pres-
ence, type, severity, and chroni city of any dysfunction [I].
In developing a treatment plan, interventions should be
aimed at maximizing the pati ent’s level of functioning as
well as helping the patient to set specific goals appropriateto his or her functional impairments and symptom sever-ity [I].
f. Coordinate the patient’s care with other clinicians
Many patients with major depressive disorder will be eval-uated by or receive treatment from other health care pro-
fessionals in addition to the psychiatrist. If more than one
clinician is involved in providing the care, all treating cli-nicians should have sufficie nt ongoing contact with the
patient and with each other to  ensure that care is coordi-
nated, relevant information is available to guide treatmentdecisions, and treatments are synchronized [I].
In ruling out general medical causes of depressive symp-
toms, it is important to ensure that a general medical eval-uation has been done [I], either by the psychiatrist or by
another health care professional. Extensive or specialized
testing for general medical causes of depressive symptomsmay be conducted based on individual characteristics of
the patient [III].
g. Monitor the patient’s  psychiatric status
The patient’s response to treatment should be carefully
monitored [I]. Continued monitoring of co-occurring
psychiatric and/or medical cond itions is also essential to
developing and refining a treatment plan for an individual
patient [I].
h. Integrate measurements into psychiatric management
T ailoring the treatment plan to match the needs of the
particular patient requires a careful and systematic assess-ment of the type, frequency, and magnitude of psychiatric
symptoms as well as ongoing determination of the thera-
peutic benefits and side effects of treatment [I]. Such assess-ments can be facilitated by integrating clinician- and/or
patient-administered rating scale measurements into ini-
tial and ongoing evaluation [II].
i. Enhance treatment adherence
The psychiatrist should assess and acknowledge potential
barriers to treatment adherence (e.g., lack of motivationor excessive pessimism due to depression; side effects of
treatment; problems in the therapeutic relationship; lo-
gistical, economic, or cultural barriers to treatment) andcollaborate with the patient (and if possible, the family) to
minimize the impact of these potential barriers [I]. In addi-
tion, the psychiatrist should encourage patients to articu-late any fears or concerns about treatment or its side effects
[I]. Patients should be given a realistic notion of what can
be expected during the different phases of treatment, in-cluding the likely time course of symptom response and
the importance of adherence for successful treatment and
prophylaxis [I].
j. Provide education to the patient and the family
Education about the symptoms and treatment of major
depressive disorder should be provided in language that isreadily understandable to the patient [I]. With the pa-
tient’s permission, family members and others involved in
the patient’s day-to-day life may also benefit from educa-tion about the illness, its effects on functioning (including
family and other interpersonal relationships), and its treat-
ment [I]. Common misperceptions about antidepressants(e.g., they are addictive) should be clarified [I]. In addition,
education about major depressive disorder should address
the need for a full acute course of treatment, the risk of re-lapse, the early recognition of recurrent symptoms, and the
need to seek treatment as early as possible to reduce the risk
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 17
of complications or a full-blown episode of major depres-
sio n [I]. P atients s ho uld also be  told ab out  t he  need  to
taper antidepressants, rather than discontinuing themprecipitously, to minimize the risk of withdrawal symp-
toms or symptom recurrence [I]. Patient education also
includes general promotion of healthy behaviors such asexercise, good sleep hygiene, good nutrition, and decreased
use of tobacco, alcohol, and other potentially deleterious
substances [I]. Educational tools such as books, pamphlets,and trusted web sites can augm ent the face-to-face educa-
tion provided by the clinician [I].
2. Acute phase
a. Choice of an initial treatment modalityT reatment in the acute phase should be aimed at inducingremission of the major depressive episode and achieving a
full return to the patient’s baseline level of functioning [I].
Acute phase treatment may include pharmacotherapy, de-pression-focused psychotherapy, the combination of med-
ications and psychotherapy, or other somatic therapies
such as electroconvulsive therapy (ECT), transcranial mag-netic stimulation (TMS), or light therapy, as described in the
sections that follow. Selection of an initial treatment mo-
dality should be influenced by clinical features (e.g., se-
verity of symptoms, presence of co-occurring disorders
or psychosocial stressors) as well as other factors (e.g., pa-tient preference, prior treatment experiences) [I]. Anytreatment should be integrated with psychiatric manage-
ment and any other treatments being provided for other
diagnoses [I].
1. Pharmacotherapy
An antidepressant medication is recommended as an ini-
tial treatment choice for patients with mild to moderate
major depressive disorder [I] and definitely should be pro-vided for those with severe major depressive disorder un-
less ECT is planned [I]. Because the effectiveness of anti-
depressant medications is generally comparable betweenclasses and within classes of medications, the initial selec-
tion of an antidepressant medication will largely be basedon the anticipated side effects, the safety or tolerability ofthese side effects for the individual patient, pharmacolog-
ical properties of the medication (e.g., half-life, actions on
cytochrome P450 enzymes, other drug interactions), and ad-ditional factors such as medication response in prior epi-
sodes, cost, and patient preference [I]. For most patients, a
selective serotonin reuptake inhibitor (SSRI), serotoninnorepinephrine reuptake inhibitor (SNRI), mirtazapine,
or bupropion is optimal [I]. In general, the use of nonselec-
tive monoamine oxidase inhibitors (MAOIs) (e.g., phenel-zine, tranylcypromine, isocarboxazid) should be restrictedto patients who do not respond to other treatments [I],
given the necessity for dietary restrictions with these med-
ications and the potential for deleterious drug-drug inter-actions. In patients who prefer complementary and alter-
native therapies, S-adenosyl methionine (SAMe) [III] or
St. John’s wort [III] might be considered, although evidence
for their efficacy is modest at best, and careful attention to
drug-drug interactions is needed with St. John’s wort [I].
Once an antidepressant medication has been initiated,
the rate at which it is titrated to a full therapeutic doseshould depend upon the patient’s age, the treatment set-
ting, and the presence of co-occurring illnesses, concom-itant pharmacotherapy, or medication side effects [I].
During the acute phase of treatment, patients should be
carefully and systematically monitored on a regular basis
to assess their response to pharmacotherapy, identify the
emergence of side effects (e.g., gastrointestinal symptoms,sedation, insomnia, activation, changes in weight, and car-
diovascular, neurological, anticholinergic, or sexual side ef-
fects), and assess patient safety [I]. The frequency of patientmonitoring should be determined based upon the patient’s
symptom severity (including suicidal ideas), co-occurring
disorders (including general medical conditions), coopera-tion with treatment, availability of social supports, and the
frequency and severity of side effects with the chosen treat-
ment [II]. If antidepressant side effects do occur, an initialstrategy is to lower the dose of the antidepressant or to
change to an antidepressant that is not associated with
that side effect [I].
2. Other somatic therapies
ECT is recommended as a treatment of choice for pa-
tients with severe major depressive disorder that is not re-
sponsive to psychotherapeutic and/or pharmacologicalinterventions, particularly in those who have significant
functional impairment or have not responded to numer-
ous medication trials [I]. ECT is also recommended forindividuals with major depressive disorder who have asso-
ciated psychotic or catatonic features [I], for those with an
urgent need for response (e.g., patients who are suicidalor nutritionally compromised due to refusal of food or flu-
ids) [I], and for those who prefer ECT or have had a pre-
vious positive response to ECT [II].
Bright light therapy might be used to treat seasonal af-
fective disorder as well as nonseasonal depression [III].
3. Psychotherapy
Use of a depression-focused psychotherapy alone is rec-ommended as an initial treatment choice for patients with
mild to moderate major depressive disorder [I], with clin-
ical evidence supporting the use of cognitive-behavioraltherapy (CBT) [I], interpersonal psychotherapy [I], psy-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
18 APA PRACTICE GUIDELINES
chodynamic therapy [II], an d problem-solving therapy
[III] in individual [I] and in group [III] formats. Factors
that may suggest the use of psychotherapeutic interven-tions include the presence of significant psychosocial
stressors, intrapsychic conflict, interpersonal difficulties,a co-occurring axis II disorder, treatment availability, or—most important—patient preference [II]. In women who
are pregnant, wish to become pregnant, or are breast-
feeding, a depression-focused psychotherapy alone is rec-ommended [II] and depending on the severity of symptoms,
should be considered as an initial option [I]. Consider-
ations in the choice of a specific type of psychotherapy in-clude the goals of treatment (in addition to resolving major
depressive symptoms), prior positive response to a specific
type of psychotherapy, patient preference, and the avail-
ability of clinicians skilled in the specific psychotherapeu-
tic approach [II]. As with pa tients who are receiving phar-
macotherapy, patients rece iving psychotherapy should be
carefully and systematically monitored on a regular basis toassess their response to treatment and assess patient safety[I]. When determining the frequency of psychotherapy
sessions for an individual patient, the psychiatrist should
consider multiple factors, including the specific type andgoals of psychotherapy, symptom severity (including sui-
cidal ideas), co-occurring disorders, cooperation with treat-
ment, availability of social supports, and the frequency ofvisits necessary to create and maintain a therapeutic rela-
tionship, ensure treatment adherence, and monitor and ad-
dress depressive symptoms and suicide risk [II]. Marital andfamily problems are common in the course of major de-
pressive disorder, and such problems should be identified
and addressed, using marital or family therapy when indi-cated [II].
4. Psychotherapy plus antidepressant medication
The combination of psycho therapy and antidepressant
medication may be used as an initial treatment for patients
with moderate to severe major depressive disorder [I]. In
addition, combining psycho therapy and medication may
be a useful initial treatment even in milder cases for pa-
tients with psychosocial or interpersonal problems, intra-
psychic conflict, or co-occurring Axis II disorder [II]. In
general, when choosing an antidepressant or psychother-apeutic approach for combinat ion treatment, the same is-
sues should be considered as when selecting a medicationor psychotherapy for use alone [I].
b. Assessing the adequacy of treatment response
In assessing the adequacy of a therapeutic intervention, it
is important to establish that treatment has been adminis-tered for a sufficient duration and at a sufficient frequency or,in the case of medication, dose [I]. Onset of benefit frompsychotherapy tends to be a bit more gradual than that
from medication, but no treatment should continue un-
modified if there has been no symptomatic improvementafter 1 month [I]. Generally, 4–8 weeks of treatment are
needed before concluding that a patient is partially respon-
sive or unresponsive to a specific intervention [II].
c. Strategies to address nonresponse
For individuals who have not responded fully to treat-
ment, the acute phase of treatment should not be con-cluded prematurely [I], as an incomplete response to
treatment is often associated with poor functional out-
comes. If at least a moderate improvement in symptoms
is not observed within 4–8 weeks of treatment initiation,
the diagnosis should be reappraised, side effects assessed,complicating co-occurring co nditions and psychosocial
factors reviewed, and the treatment plan adjusted [I]. It isalso important to assess the quality of the therapeutic al-liance and treatment adherence [I]. For patients in psy-
chotherapy, additional factors to be assessed include the
frequency of sessions and whether the specific approachto psychotherapy is adequately addressing the patient’s
needs [I]. If medications are prescribed, the psychiatrist
should determine whether pharmacokinetic [I] or phar-macodynamic [III] factors suggest a need to adjust med-
ication doses. With some TCAs, a drug blood level can
help determine if additional dose adjustments are re-quired [I].
After an additional 4–8 weeks of treatment, if the pa-
tient continues to show minimal or no improvement insymptoms, the psychiatrist should conduct another thor-
ough review of possible contributory factors and make ad-
ditional changes in the trea tment plan [I]. Consultation
should also be considered [II].
A number of strategies are available when a change in
the treatment plan seems nece ssary. For patients treated
with an antidepressant, optimizing the medication dose is
a reasonable first step if the side effect burden is tolerable
and the upper limit of a medication dose has not beenreached [II]. Particularly for those who have shown mini-
mal improvement or experienced significant medication
side effects, other options include augmenting the antide-pressant with a depression-focused psychotherapy [I] or
with other agents [II] or changing to another non-MAOI
antidepressant [I]. Patients may be changed to an antide-pressant from the same pharmacological class (e.g., from
one SSRI to another SSRI) or to one from a different class
(e.g., from an SSRI to a tricyclic antidepressant [TCA]) [II].For patients who have not responded to trials of SSRIs, a
trial of an SNRI may be helpful [II]. Augmentation of an-
tidepressant medications can utilize another non-MAOIantidepressant [II], generally from a different pharmaco-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 19
logical class, or a non-antidepressant medication such as
lithium [II], thyroid hormone [II], or a second-generation
antipsychotic [II]. Additional strategies with less evidencefor efficacy include augmentation using an anticonvulsant
[III], omega-3 fatty acids [III], folate [III], or a psychostim-
ulant medication [III], including modafinil [III]. If anxietyor insomnia are prominent features, consideration can be
given to anxiolytic and sedative-hypnotic medications
[III], including buspirone, benzodiazepines, and selectiveγ-aminobutyric acid (GABA) agonist hypnotics (e.g., zol-
pidem, eszopiclone). For patients whose symptoms havenot responded adequately to medication, ECT remains themost effective form of therapy and should be considered
[I]. In patients capable of adhering to dietary and medica-
tion restrictions, an additional option is changing to a non-
selective MAOI [II] after allowing sufficient time between
medications to avoid deleterious interactions [I]. T ransder-mal selegiline, a relatively selective MAO B inhibitor with
fewer dietary and medication restrictions, or transcranial
magnetic stimulation could also be considered [II]. Vagusnerve stimulation (VNS) may be an additional option for
individuals who have not responded to at least four ade-
quate trials of antidepressant treatment, including ECT[III].
For patients treated with psychotherapy, consideration
should be given to increasing the intensity of treatmentor changing the type of therapy [II]. If psychotherapy is
used alone, the possible need for medications in addition
to or in lieu of psychotherapy should be assessed [I]. Pa-tients who have a history of poor treatment adherence or
incomplete response to adequate trials of single treat-
ment modalities may benefit from combined treatmentwith medication and a depression-focused psychotherapy
[II].
3. Continuation phase
During the continuation phase of treatment, the patient
should be carefully monitored for signs of possible relapse
[I]. Systematic assessment of symptoms, side effects, ad-
herence, and functional status is essential [I] and may befacilitated through the use of clinician- and/or patient-
administered rating scales [II]. T o reduce the risk of re-
lapse, patients who have been treated successfully withantidepressant medications in the acute phase should con-
tinue treatment with these agents for 4–9 months [I]. In
general, the dose used in the acute phase should be usedin the continuation phase [II]. T o prevent a relapse of
depression in the continuation phase, depression-focused
psychotherapy is recommended [I], with the best evidenceavailable for CBT.Patients who respond to an acute course of ECT should
receive continuation pharmacotherapy [I], with the bestevidence available for the combination of lithium andnortriptyline. Alternatively, patients who have responded
to an acute course of ECT may be given continuation ECT ,
particularly if medication or psychotherapy has been inef-fective in maintaining remission [II].
4. Maintenance phase
In order to reduce the risk of a recurrent depressive epi-sode, patients who have had three or more prior major de-pressive episodes or who have chronic major depressive
disorder should proceed to the maintenance phase of treat-
ment after completing the continuation phase [I]. Mainte-
nance therapy should also be considered for patients with
additional risk factors for recurrence, such as the presenceof residual symptoms, ongoing psychosocial stressors, early
age at onset, and family history of mood disorders [II]. Ad-
ditional considerations that ma y play a role in the decision
to use maintenance therapy include patient preference, the
type of treatment received, the presence of side effects dur-
ing continuation therapy, the probability of recurrence, thefrequency and severity of prior depressive episodes (includ-
ing factors such as psychosis or suicide risk), the persistence
of depressive symptoms after recovery, and the presence ofco-occurring disorders [II]. Such factors also contribute to
decisions about the duration of the maintenance phase [II].
For many patients, particularly for those with chronic andrecurrent major depressive disorder or co-occurring medi-
cal and/or psychiatric disorders, some form of maintenance
treatment will be required indefinitely [I].
During the maintenance phase, an antidepressant med-
ication that produced symptom remission during the acutephase and maintained remission during the continuationphase should be continued at a full therapeutic dose [II]. If
a depression-focused psychotherapy has been used during
the acute and continuation phases of treatment, mainte-nance treatment should be considered, with a reduced
frequency of sessions [II]. Fo r patients whose depressive
episodes have not previously responded to acute or con-tinuation treatment with medications or a depression-
focused psychotherapy but who have shown a response to
ECT, maintenance ECT may be considered [III]. Main-tenance treatment with VNS is also appropriate for indi-
viduals whose symptoms have responded to this treatment
modality [III].
Due to the risk of recurrence, patients should be mon-
itored systematically and at regular intervals during themaintenance phase [I]. Use of standardized measurementaids in the early detection of recurrent symptoms [II].
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
20 APA PRACTICE GUIDELINES
5. Discontinuation of treatment
When pharmacotherapy is being discontinued, it is best
to taper the medication over the course of at least several
weeks [I]. T o minimize the likelihood of discontinuation
symptoms, patients should be advised not to stop medi-cations abruptly and to take  medications with them when
they travel or are away from home [I]. A slow taper ortemporary change to a longer half-life antidepressant may
reduce the risk of discontinuation syndrome [II] when dis-
continuing antidepressants or reducing antidepressant
doses. Before the discontinuation of active treatment, pa-tients should be informed of the potential for a depressive
relapse and a plan should be established for seeking treat-
ment in the event of recurrent symptoms [I]. After discon-
tinuation of medications, patients should continue to be
monitored over the next several months and should receiveanother course of adequate acute phase treatment if symp-
toms recur [I].
For patients receiving psychotherapy, it is important to
raise the issue of treatment discontinuation well in ad-vance of the final session [I], although the exact process by
which this occurs will vary with the type of therapy.
6. Clinical factors influencing treatment
a. Psychiatric factorsFor suicidal patients, psychiatrists should consider an in-
creased intensity of treatment, including hospitalization
when warranted [I] and/or combined treatment withpharmacotherapy and psychoth erapy [II]. Factors to con-
sider in determining the nature and intensity of treatmentinclude (but are not limited to) the nature of the doctor-patient alliance, the availability and adequacy of social sup-
ports, access to and lethality of suicide means, the presence
of a co-occurring substance use disorder, and past and fam-ily history of suicidal behavior [I].
For patients who exhibit psychotic symptoms during
an episode of major depressive disorder, treatment shouldinclude a combination of anti psychotic and antidepressant
medications or ECT [I]. When patients exhibit cognitivedysfunction during a major depressive episode, they mayhave an increased likelihood of future dementia, making it
important to assess cognition in a systematic fashion over
the course of treatment [I].
Catatonic features that occur as part of a major depres-
sive episode should be treated with a benzodiazepine [I] orbarbiturate [II], typically in conjunction with an antidepres-sant [II]. If catatonic symptoms persist, ECT is recom-
mended [I]. T o reduce the likelihood of general medical
complications, patients with catatonia may also requiresupportive medical interventions, such as hydration, nu-
tritional support, prophylaxis against deep vein thrombo-sis, turning to reduce risks of decubitus ulcers, and passiverange of motion to reduce risk of contractures [I]. If anti-
psychotic medication is needed, it is important to monitorfor signs of neuroleptic malignant syndrome, to which pa-
tients with catatonia may have a heightened sensitivity
[II].
When patients with a major depressive disorder also
have a co-occurring psychiatric illness, the clinician shouldaddress each disorder as part of the treatment plan [I]. Ben-zodiazepines may be used adjunctively in individuals with
major depressive disorder and co-occurring anxiety [II], al-
though these agents do not treat depressive symptoms, andcareful selection and monitoring is needed in individuals
with co-occurring substance use disorders [I].
In patients who smoke, bupropion [I] or nortriptyline
[II] may be options to simultaneously treat depression and
assist with smoking cessation. When possible, a period ofsubstance abstinence can help determine whether the de-
pressive episode is related to substance intoxication or
withdrawal [II]. Factors that suggest a need for antide-pressant treatment soon after cessation of substance use
include a family history of major depressive disorder and
a history of major depressive disorder preceding the on-set of the substance use disorder or during periods of so-
briety [II].
For patients who have a personality disorder as well as
major depressive disorder, psychiatrists should institutetreatment for the major depressive disorder [I] and con-
sider psychotherapeutic and adjunctive pharmacothera-peutic treatment for personality disorder symptoms [II].
b. Demographic and psychosocial factors
Several aspects of assessment and treatment differ be-
tween women and men. Because the symptoms of somewomen may fluctuate with gonadal hormone levels, the
evaluation should include a detailed assessment of mood
changes across the reproductiv e life history (e.g., men-
struation, pregnancy, birth control including oral contra-
ception use, abortions, menopause) [I]. When prescribing
medications to women who are taking oral contraceptives,the potential effects of drug-drug interactions must be
considered [I]. For women in the perimenopausal period,
SSRI and SNRI antidepressants are useful in amelioratingdepression as well as in reducing somatic symptoms such
as hot flashes [II]. Both men and women who are taking an-
tidepressants should be asked whether sexual side effectsare occurring with these medications [I]. Men for whom
trazodone is prescribed should be warned of the risk of
priapism [I].
The treatment of major depressive disorder in women
who are pregnant or planning to become pregnant re-quires a careful consideration of the benefits and risks of
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 21
available treatment options for the patient and the fetus [I].
For women who are currently receiving treatment for de-
pression, a pregnancy should be planned, whenever pos-sible, in consultation with the treating psychiatrist, who
may wish to consult with a specialist in perinatal psychia-
try [I]. In women who are pregnant, planning to becomepregnant, or breast-feeding, depression-focused psycho-
therapy alone is recommended [II] and should always be
considered as an initial option, particularly for mild to
moderate depression, for patients who prefer psycho-
therapy, or for those with a prior positive response to
psychotherapy [I]. Antidepressant medication should beconsidered for pregnant women who have moderate to
severe major depressive disorder as well as for those who
are in remission from major depressive disorder, are re-
ceiving maintenance medication, and are deemed to be at
high risk for a recurrence if the medication is discontin-ued [II]. When antidepressants are prescribed to a pregnant
woman, changes in pharmacokinetics during pregnancy
may require adjustments in medication doses [I]. Electro-convulsive therapy may be considered for the treatment of
depression during pregnancy in patients who have psy-
chotic or catatonic features, whose symptoms are severeor have not responded to medications, or who prefer treat-
ment with ECT [II]. When a woman decides to nurse, the
potential benefits of antidepressant medications for themother should be balanced against the potential risks to
the newborn from receiving antidepressant in the mother’s
milk [I]. For women who are depressed during the post-partum period, it is important to evaluate for the presence
of suicidal ideas, homicidal ideas, and psychotic symp-
toms [I]. The evaluation should also assess parenting skillsfor the newborn and for other children in the patient’s
care [I].
In individuals with late-life depression, identification
of co-occurring general medical conditions is essential, asthese disorders may mimic depression or affect choice or
dosing of medications [I]. Older individuals may also beparticularly sensitive to medication side effects (e.g.,
hypotension, anticholinergic effects) and require adjust-
ment of medication doses for hepatic or renal dysfunction[I]. In other respects, treatment for depression should par-
allel that used in younger age groups [I].
The assessment and treatment of major depressive dis-
order should consider the impact of language barriers, aswell as cultural variables that may influence symptom pre-
sentation, treatment preferences, and the degree to whichpsychiatric illness is stigmatized [I]. When antidepres-
sants are prescribed, the psychiatrist should recognize
that ethnic groups may differ in their metabolism and re-sponse to medications [II].Issues relating to the family situation and family his-
tory, including mood disorders and suicide, can also affecttreatment planning and are an  important element of the
initial evaluation [I]. A family history of bipolar disorder
or acute psychosis suggests a need for increased attention
to possible signs of bipolar illness in the patient (e.g., withantidepressant treatment) [I]. A family history of recur-
rent major depressive disorder increases the likelihood of
recurrent episodes in the patient and supports a need formaintenance treatment [II]. Family history of a response
to a particular antidepressant may sometimes help in
choosing a specific antidepressant for the patient [III]. Be-cause problems within the family may become an ongoing
stressor that hampers the patient’s response to treatment,
and because depression in a family is a major stress in it-
self, such factors should be identified and strong consid-
eration given to educating the family about the nature ofthe illness, enlisting the fam ily’s support, and providing
family therapy, when indicated [II].
For patients who have experienced a recent bereave-
ment, psychotherapy or antidepressant treatment should
be used when the reaction to a loss is particularly pro-
longed or accompanied by s ignificant psychopathology
and functional impairment [I]. Support groups may be
helpful for some bereaved individuals [III].
c. Co-occurring general medical conditions
In patients with major depressive disorder, it is important
to recognize and address the potential interplay betweenmajor depressive disorder and any co-occurring general
medical conditions [I]. Communication with other clini-
cians who are providing treatment for general medicalconditions is recommended [I ]. The clinical assessment
should include identifying any potential interactions be-tween medications used to treat depression and those usedto treat general medical conditions [I]. Assessment of pain
is also important as it can co ntribute to and co-occur with
depression [I]. In addition, the psychiatrist should con-
sider the effects of prescribed psychotropic medications
on the patient’s general medical conditions, as well as the
effects of interventions for such disorders on the patient’spsychiatric condition [I].
In patients with preexisting hypertension or cardiac
conditions, treatment with specific antidepressant agentsmay suggest a need for monitoring of vital signs or car-
diac rhythm (e.g., electrocardiogram [ECG] with TCA
treatment; heart rate and blood pressure assessment with
SNRIs and TCAs) [I]. When using antidepressant medi-
cations with anticholinergic side effects, it is important toconsider the potential for increases in heart rate in indi-viduals with cardiac disease, worsening cognition in individ-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
22 APA PRACTICE GUIDELINES
uals with dementia, development of bladder outlet
obstruction in men with prostatic hypertrophy, and precip-
itation or worsening of narrow angle glaucoma [I]. Someantidepressant drugs (e.g., bupropion, clomipramine,
maprotiline) reduce the seizure threshold and should be
used with caution in individuals with preexisting seizure dis-orders [II]. In individuals with Parkinson’s disease, the
choice of an antidepressant should consider that seroton-
ergic agents may worsen symptoms of the disease [II],that bupropion has potential dopamine agonist effects
(benefitting symptoms of Parkinson’s disease but poten-
tially worsening psychosis) [II], and that selegiline has an-tiparkinsonian and antidepressant effects but may interact
with L-dopa and with other antidepressant agents [I]. In
treating the depressive syndrome that commonly occurs
following a stroke, consideration should be given to the
potential for interactions between antidepressants andanticoagulating (including antiplatelet) medications [I].
Given the health risks associated with obesity and the ten-
dency of some antidepressant medications to contribute toweight gain, longitudinal monitoring of weight (either by
direct measurement or patient report) is recommended
[I], as well as calculation of body mass index (BMI) [II]. Ifsignificant increases are noted in the patient’s weight or
BMI, the clinician and patient should discuss potential ap-
proaches to weight control such as diet, exercise, change inmedication, nutrition consultation, or collaboration with
the patient’s primary care physician [I]. In patients who
have undergone bariatric surgery to treat obesity, adjust-ment of medication formulations or doses may be re-
quired because of altered medication absorption [I]. For
diabetic patients, it is useful to collaborate with the pa-tient’s primary care physician in monitoring diabetic con-
trol when initiating antidepressant therapy or making
significant dosing adjustments [II]. Clinicians should bealert to the possibility of sleep apnea in patients with depres-sion, particularly those who present with daytime sleepi-
ness, fatigue, or treatment-resistant symptoms [II]. In
patients with known sleep apnea, treatment choice shouldconsider the sedative side effects of medication, with mini-
mally sedating options chosen whenever possible [I]. Given
the significant numbers of individuals with unrecognizedhuman immunodeficiency virus (HIV) infection and the
availability of effective treatment, consideration should be
given to HIV risk assessment and screening [I]. For pa-tients with HIV infection who are receiving antiretroviral
therapy, the potential for drug-drug interactions needs to be
assessed before initiating any psychotropic medications [I].Patients who are being treated with antiretroviral medi-
cations should be cautioned about drug-drug interactions
with St. John’s wort that can reduce the effectiveness of
HIV treatments [I]. In patients with hepatitis C infection,
interferon can exacerbate depressive symptoms, makingit important to monitor patients carefully for worsening
depressive symptoms during the course of interferon
treatment [I]. Because tamoxifen requires active 2D6 en-zyme function to be clinically efficacious, patients who
receive tamoxifen for breast cancer or other indications
should generally be treated with an antidepressant (e.g.,citalopram, escitalopram, venlafaxine, desvenlafaxine)
that has minimal effect on metabolism through the cyto-
chrome P450 2D6 isoenzyme [I]. When depression oc-curs in the context of chronic pain, SNRIs and TCAs may
be preferable to other antidepressive agents [II]. When
ECT is used to treat major depressive disorder in an in-dividual with a co-occurring general medical condition,
the evaluation should identify conditions that could re-
quire modifications in ECT technique (e.g., cardiac con-ditions, hypertension, central nervous system lesions) [I];
these should be addressed insofar as possible and dis-
cussed with the patient as part of the informed consentprocess [I].
II. FORMULATION AND IMPLEMENTATION 
OF A TREATMENT PLAN
A. PSYCHIATRIC MANAGEMENT
For all patients with major depressive disorder, psychiat-ric management includes a broad array of possible inter-ventions and activities. Essential components include
educating the patient and when appropriate the family
about depression, discussing treatment options and inter-ventions, and enhancing adherence to treatment. Devel-oping a successful plan of treatment for individuals withmajor depressive disorder is also promoted by an initial,
thorough assessment of the patient. In addition, the psy-
chiatrist must determine the treatment setting that will bemost likely to enhance the patient’s safety as well as pro-
mote improvement in the patient’s condition. These ele-
ments of psychiatric management are described in moredetail below.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 23
1. Establish and maintain a therapeutic alliance
A psychiatric assessment begins with establishing thera-
peutic rapport and developing an alliance with the patient,
regardless of the treatment modalities ultimately selected.
The alliance itself may be the primary active therapeuticagent even for patients who receive monotherapy with
medication (4). T o establish and maintain a therapeutic al-
liance, it is important for the psychiatrist to be sensitive tothe patient’s concerns. By virtue of their depressed state,
patients often view themselves in a negative light. They
may feel unworthy of help, embarrassed or ashamed ofhaving an illness, guilty about placing burdens on family
members or the clinician, and distant or alienated from
others. Individuals may also have a negative view of prior
treatment experiences or have misconceptions about psy-
chiatric treatment, which can color the therapeutic rela-tionship. Such issues require open discussion to educate
the patient about the goals and framework of treatment
and to provide an empathic and trusting environment inwhich the patient feels comfortable expressing his or her
self-doubts, fears, and other concerns. Cultural and reli-
gious factors may influence the patient’s view of the depres-sive illness, his or her receptiveness to psychiatric treatment,
and his or her preference of treatment modalities (5–7).
Establishing a therapeutic alliance with a clinician of a dif-ferent background may present additional challenges for
some patients. Management of the therapeutic alliance
should also include awareness of transference and counter-
transference issues, even if these are not directly addressed
in treatment.
Because patients frequently have strong preferences
about treatment options, the psychiatrist should identifythe patient’s wishes for treatment and collaborate with the
patient in choosing among effective treatments. In addi-tion, treatment adherence can be enhanced by the delivery
of patient-centered care and by a strong treatment alli-
ance with the psychiatrist. Severe or persistent problemsof poor alliance or nonadherence to treatment may be
caused by the depressive symptoms themselves. They may
also represent psychological conflicts or a psychopatho-logical condition for which psychotherapy should be con-
sidered.
If possible and appropriate, the family should be in-
cluded in discussions about the patient’s illn ess and plans
for treatment. When family members are involved, they
can also be encouraged to play a helpful role in improvingthe patient’s adherence to treatment and supporting the
therapeutic alliance.
2. Complete the psychiatric assessment
Patients with symptoms of depression should receive a
thorough biopsychosocial assessment, both to determinewhether a diagnosis of major depressive disorder is war-
ranted and to identify the presence of other psychiatric or
general medical conditions. The general principles andcomponents of a complete psychiatric evaluation have been
outlined in APA’s Practice Guideline for Psychiatric Evalua-
tion of Adults, Second Edition  (8). The evaluation includes a
history of the present illness and current symptoms, in-
cluding vegetative symptoms and symptoms of mania or
psychosis, as well as a psychiatric history that particularlynotes current treatments, responses to previous treat-
ments, past hospitalizations or suicide attempts, and the
presence of co-occurring psychiatric disorders. Assessingthe severity of the specific symptoms of depression may
be aided by the use of standardized clinician- or patient-
administered rating scales such as those described in Sec-
tion II.A.8.
Many individuals with depression attempt to alleviate
symptoms through the use of alternative or complemen-tary treatments, over-the-counter or prescription medica-
tions or dietary regimens, or through use of caffeine,tobacco, alcohol, or other substances, which may precip-
itate or exacerbate depressive symptoms. Consequently,
each of these factors should be carefully assessed. The per-sonal history will include an assessment of psychological
development; a sexual history,  including history of sexual
abuse or assault; identification of early life trauma, includ-
ing physical, sexual, or emotional abuse or neglect; deter-
mination of responses to life transitions, major life events,
or significant traumas; a social history; and an occupationalhistory, including history of military service. Co-occur-
ring general medical conditio ns are common and can in-
fluence the diagnosis of major depressive disorder as well
as choices of treatment. Thus, a general medical history is
essential, along with a review of the patient’s current med-
ications; a review of systems, including assessment forpain; and any indicated diagnostic tests or physical exam-
inations. The latter may be done by the psychiatrist or by
another physician or medically trained clinician. A mentalstatus examination is crucial in identifying signs of depres-
sion, associated psychosis, co gnitive deficits, and factors
influencing suicide risk (e.g., suicidal ideas, anxiety), as
well as in identifying co-occurring psychiatric disorders.
Because major depressive disorder is associated with func-
tional impairment, the presence, type, and severity of thedysfunction should be evaluated. Impairments can include
deficits in interpersonal relationships and family func-
tioning, work performance, maintenance of health andhygiene, and deficits in quality of life. Whenever feasible,
assessment should also include input from family members
in order to determine the impact of the patient’s conditionon his or her family. Family members and significant oth-
ers can also report key elements of the patient’s history or
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
24 APA PRACTICE GUIDELINES
recent status that the patient may minimize or be unable
to recall or report accurately. In addition, family function-
ing may affect the outcome of the patient’s depressive ill-ness (9, 10).
A family history is also important to obtain and in-
volves the collection of the family pedigree including par-ents, grandparents, and number and sex of siblings and
children. For patients with children at home, information
on their symptom state may be useful because of the highpossibility of psychiatric problems in the offspring of a de-
pressed parent (11, 12). Such problems may require inter-
vention or may be an added stressor for the patient. Thefamily history includes history of depression or other mood
disorders, substance use disorders, psychosis, suicide, and
unusual behaviors in the patient’s relatives along with any
associated impairments. Because family history is a potent
and consistent risk factor for mental disorders, formulat-ing diagnosis and treatment decisions for the patient can
be aided by knowing the age of onset and severity of psy-
chiatric symptoms in the patient’s family, as well as relatives’psychiatric treatment history, especially the tolerability
and effectiveness of those treatments.
In establishing a diagnosis of major depressive disorder
as part of the initial assessment, other differential diag-nostic possibilities are important to consider. An initial
consideration in the differential diagnosis is mood disorderdue to a general medical condition. Specific medical condi-
tions that are important to consider and that may be associ-
ated with a major depressive episode include neurologicalconditions (e.g., stroke, Parkinson’s disease, dementia,
multiple sclerosis), thyroid disorders, metabolic conditions
(e.g., hypercalcemia), malignancy, and infectious diseases(13–15). Depressive symptoms that would otherwise be
diagnosable as major depressive disorder are diagnosed
instead as a mood disorder due to a general medical con-dition if the mood disturbance is judged to be the direct
physiological consequence of a specific general medical con-
dition. Similarly, medications used to treat general medicalconditions may induce depressive syndromes. Such medi-
cations include transplant anti-rejection agents, chemo-
therapy agents, interferon, ster oids, some antibiotics, and
others. Depression caused by medications is classified in
the DSM-IV-TR as other (or unknown) substance-
induced mood disorder (DSM-IV-TR code 292.84) (16).
Psychosocial stressors and other antecedent events,
and their possible contribution to the generation of de-pressive symptoms, should be explored in the course of apsychiatric assessment. Depressive symptoms are a com-
mon response to psychosocial stressors, particularly be-
reavement. Symptoms characteristic of a major depressiveepisode may arise after a significant loss; however, the di-
agnosis of major depressive disorder is generally not givenunless depressive symptoms are still present 2 monthsafter the loss, are particularly severe, or are uncharacter-
istic of or unrelated to bereavement, such as persistentsuicidal ideation or morbid preoccupation with worthless-
ness or guilt (16). Following a stressor, depressive symp-
toms that do not reach sufficient number or severity to beclassified as a major depressive episode may be better de-
scribed as an adjustment disorder. Despite the possible
presence of antecedent stressors, psychiatrists should notdismiss potentially disabling depressive symptoms as “nor-
mal,” thereby depriving patients of needed therapeutic at-
tention.
A thorough assessment of depression also includes the
evaluation of psychotic symptoms. Major depressive dis-order may be associated with mood-congruent and mood-
incongruent hallucinations and delusions. Depressed pa-
tients may not initially present with psychotic symptoms,and patients may wish to hide shaming or distressing
thoughts. Therefore, psychiatrists should carefully query
patients about such symptoms in order to provide appro-priate treatments for them (see Section III.A.2.a). Identify-
ing the presence of atypical, melancholic, or catatonic
features of depression is also important, as such featuresmay influence the choice of treatments (see Sections
III.A.2.b, III.A.2.c, and III.A.2.d). Considering that major
depressive episodes are common in the course of bipolar Idisorder and that recurrent major depressive episodes are
characteristic of bipolar II disorder (17), it is important to
consider bipolar disorders as part of the differential diagno-sis of major depressive disorder. This distinction is especially
important because the treatments for bipolar disorders of-
ten differ from those for major depressive disorder.
All patients who present for treatment for a major de-
pressive episode should be screened for a past history ofmanic or hypomanic episodes and for past adverse reac-tions to antidepressants that might be consistent with a
“switch” into hypomania or mania. Screening instruments
for manic and hypomanic episodes include the Mood Dis-orders Questionnaire (18) and the Screening Assessment
of Depression–Polarity, which includes three easily ad-
ministered dichotomous questions (19). However, sincepatients are often unaware of prior hypomanic or manic
episodes, even when questioned carefully, collateral
sources of information, such as family members livingwith the patient, may be crucial in uncovering such epi-
sodes. Clinical assessment sh ould also include whether or
not the patient is experiencing a mixed episode, which is
characterized by symptoms of both a major depressive ep-
isode and a manic episode that occur nearly every day for
at least 1 week.
It is also important to consider the frequency and chro-
nicity of prior episodes of major depressive disorder.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 25
Chronic forms of depression—such as dysthymic disorder,
“double depression” (dysthymic disorder and major de-
pressive disorder), and major depressive disord er with the
“chronic” specifier—are all depressions with a duration of
at least 2 years. In clinical studies, chronic depression has a
lower response rate than nonchronic depression, but be-cause the placebo-response rate is also lower, the relative
clinical benefit is comparable. The onset of benefit in
chronic depression appears more gradual than in nonchro-nic depression. However, despite a smaller response rate
and slower response, it is important to recognize that
chronic depression is not treatment refractory (20). Un-fortunately, however, in many patients, chronic depression
remains undiagnosed or, if diagnosed, undertreated (21).
The presence of a family history of a mood disorder
should also be determined. Family histories of major de-
pressive disorder and bipolar disorder are common inthose with major depressive disorder, but a family history
of bipolar disorder may indicate increased risk of bipolar
disorder in the patient. A family history of suicide is rele-vant in determining a patient’s suicide risk (22) and may
also signal the presence of an unrecognized mood disor-
der in a relative.
3. Evaluate the safety of the patient
Addressing safety concerns may take precedence over es-tablishing a full differential diagnosis or completing the
psychiatric assessment. Because of the increased rates of
suicide in depressed patients (22–24), a thorough and on-going evaluation of the patient’s suicide risk is essential.
Some components of an evaluation for suicidal risk are
summarized in T able 1. The psychiatrist should evaluatethe presence of suicidal ideation and behaviors, the extent
to which the patient has made plans for or begun to prepare
for suicide, the availability and lethality of the means forsuicide, and the degree to which the patient intends to act
on suicidal plans. A complete  assessment also includes clin-
ical factors that may increase the likelihood of a patient’s
acting on suicidal ideation, including a history of prior sui-
cide attempts and the presence of psychotic symptoms, se-
vere anxiety, panic attacks, impulsivity, and substance use.Patients should also be asked about a family history of sui-
cide and recent exposure to suicide or suicide attempts by
others. A suicide risk assessment should be individualizedto the particular circumstances of the patient by including
an evaluation of the patient’s strengths, motivation to seek
help, social support systems, and physical health.
Despite the best efforts of the psychiatrist, some pa-
tients may engage in self-harm (22). Even with careful as-sessments of suicide risk, the ability to predict suicidalbehavior is poor, with many false positives (i.e., patients
who appear more likely to make attempts or die by suicideTABLE 1. Factors to Consider in Assessing Suicide Risk
Lifetime history, nature, seriousness, and number of 
previous attempts and aborted attempts
Presence, history, and lethality of suicidal ideation, 
intent, or plans
Access to means for suicide and the lethality of those 
means, such as access to a firearm
Presence of hopelessness, psychic pain, decreased 
self-esteem, narcissistic vulnerability
Presence of severe anxiety, panic attacks, agitation, 
impulsivity
Presence and history of aggression and violence
Nature of cognition, such as loss of executive function, 
thought constriction (tunnel vision), polarized 
thinking, closed-mindedness, poor coping and problem-solving skills
Presence of psychotic symptoms, such as command 
hallucinations or poor reality testing
Presence of alcohol or other substance use
Presence of major psychiatric disorders, such as major 
depressive disorder, bipolar disorder, schizophrenia, 
anorexia nervosa, alcohol use disorder, other substance 
use disorders, cluster B personality disorders
Recent psychiatri c hospitalization
Presence of disabling medical illness, especially with 
poor prognosis, such as ch ronic pain, brain and spinal 
cord injury, malignant neoplasm, HIV or acquired immunodeficiency syndrome (AIDS), Huntington’s 
disease, chronic hemodialysis-treated renal failure, chronic obstructive pulmonary disease
Demographic features, such as age, race, marital status, 
sexual orientation
Presence of acute or chronic psychosocial stressors, which 
may include actual or perceived interpersonal losses, financial difficulties or changes in socioeconomic status, 
family discord, domestic partner violence, and past or 
current sexual or physical abuse or neglect
Absence of psychosocial support, such as poor 
relationships with family, unemployment, living alone, 
unstable or poor therapeuti c relationship, recent loss 
of a relationship
History of childhood traumas,  particularly sexual and 
physical abuse
Family history of or recent exposure to suicide
Absence of protective factors, such as children in the 
home, sense of responsibility to family, pregnancy, 
life satisfaction, cultural beliefs, or religiosity
Source:  Adapted from APA’s Practice Guideline for the Assessment
and Treatment of Patients With Suicidal Behaviors (22).
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
26 APA PRACTICE GUIDELINES
but who do not) as well as false negatives (i.e., patients
who appear less likely to make attempts or die by suicide
but who do). The assessment of suicide risk is complicatedby the fact that suicidal in dividuals often conceal their
thoughts and plans or act impulsively on short-lived sui-cidal thoughts, making their response to direct questionsan unreliable predictor of dangerousness to self. For this
reason, in addition to using direct questioning, the psychi-
atrist should also obtain information through observationand collateral history whenever possible (22, 25).
The risk of suicide should also be monitored as treat-
ment proceeds, since variations in depressive symptomsmay be associated with fluctuations in suicide risk. In
youth and young adults, increases in suicidal thoughts and
attempts have been reported early in the course of treat-
ment with antidepressants, al though no increases in mor-
tality rates were seen in clinical trials (26). Family members
can provide information that increases the likelihood of
early detection of harmful behaviors. It is also useful to
convey the expectation that family members will call thepsychiatrist if concerns for safety emerge (27). For informa-
tion about how suicidal ideation or behaviors affect the treat-
ment plan, see Section III.A.1.a.
Although the greatest risk surrounding depression in-
volves the patient’s health, a rare but also potentially di-sastrous outcome of depression is violence toward others,including homicide (28, 29). Psychosis, substance abuse,
impulsivity, and a history of aggression increase this risk
(30–32). Psychiatrists accordingly should assess not onlysuicidal risk but also history of violence, homicidal ide-
ation, and plans of violence toward others. Additional as-
sessment may be necessary under specific circumstances.For example, it is important to assess the impact of pa-
rental depression (including peripartum depression) onchildren in the home, with specific attention given to theparent’s vulnerability to neglect or harm the children (33).
Whenever suicidal or violent ideas are expressed or sus-
pected, careful documentation of the decision-making pro-cess is essential. In addition, patients who exhibit suicidal
or violent ideas or intent require close monitoring.
4. Establish the appropriate setting for treatment
T reatment settings for patients with major depressive dis-order include a continuum of possible levels of care, from
involuntary hospitalizations to partial hospital programs,skilled nursing homes, and in-home care. In general, pa-
tients should be treated in the least restrictive setting that
is most likely to prove safe and effective. The psychiatristshould choose an appropriate site of treatment after eval-
uating the patient’s clinical condition, including symptom
severity, co-occurring conditions, level of functioning, andavailable support system. The estimated degree of risk toself and to others is another significant determinant of
treatment setting. Decisions about treatment setting
should also include consideration of the patient’s ability toadequately care for him- or herself, provide reliable feed-
back to the psychiatrist, and cooperate with treatment of
the major depressive disorder.
Patients with suicidal or homicidal ideation, intention,
or plans require close monitoring. For those at significantrisk, measures such as hospit alization should be consid-
ered; hospitalization is usually indicated for patients who
are considered to pose a serious threat of harm to them-
selves or others. Patients who refuse can be hospitalizedinvoluntarily if their condition meets the criteria of the lo-
cal jurisdiction for involuntary admission. Severely ill pa-
tients who lack or reject adequate social support outside of
a hospital setting should be considered for admission to a
hospital or intensive day program, if available. In addition,patients who also have complicating psychiatric or general
medical conditions or who have not responded adequately
to outpatient treatment may need to be hospitalized.
The optimal treatment setting and the patient’s like-
lihood of benefit from a different level of care should bereevaluated on an ongoing basis throughout the course oftreatment. Unfortunately, the spectrum of treatment set-
tings available to patients is often limited by lack of avail-
ability of options in the geographic setting, lack of abilityto pay for care, and/or limitations imposed by third party
payers.
5. Evaluate functional impairment and quality of life
The assessment of a patient with major depressive disorderincludes a determination of the severity and chronicity of
symptoms. Even mild depression can impair function andthreaten life and the quality of life. In the extreme, de-
pressed people may be totally unable to function socially
or occupationally or even to feed and clothe themselvesand maintain minimal personal hygiene. Severely depressed
patients may be immobilized to the point of being bedrid-
den, with associated medical complications.
The psychiatrist should address impairments in func-
tioning and help the patient to set specific goals appropriateto his or her functional impairments and symptom severity.This will likely involve helping the patient to establish in-
termediate, pragmatic steps in the course of recovery. For
example, the psychiatrist may help patients who are havingdifficulty meeting commitments to develop a reasonable
plan to fulfill their obligations (e.g., work, family obliga-
tions), potentially by making alternative arrangements.The psychiatrist may advise other patients not to make ma-
jor life changes while in the midst of a major depressive
episode. Impairments in the patient’s overall quality of life
should also be assessed, which can be done by asking pa-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 27
tients what bothers them the most about their depression
and determining how their current activities and enjoy-
ment of life have been altered by their depressive symp-toms. The overall goals of treatment of major depressive
disorder should focus on alleviating functional impair-
ments and improving quality of life in addition to achievingsymptom resolution and episode remission.
6. Coordinate the patient’s care with other clinicians
The psychiatrist should assure that a comprehensive assess-
ment of general medical conditions is performed in order
to identify factors that may precipitate or exacerbate de-pressive symptoms. He or she may initiate the medical
evaluations or coordinate care with other appropriate clini-
cians. In some situations, review of medical records provided
by the patient will suffice. In other situations, particularly
when medical treatment is indicated, the psychiatrist should,with the patient’s permission, arrange for collaborative care
with other clinicians. Such collaboration may incorporate
discussion of prescribed medication, including dose changesand possible drug interactions as well as necessary diagnos-
tic procedures and medical monitoring, which may include
laboratory measures and ECG (34).
In treating the patient’s depressive illness, a multifaceted
approach is typically required that may include provisionof depression-focused psychotherapy, pharmacotherapy,ECT , or other therapeutic approaches. Under some cir-
cumstances, all aspects of treatment will be administered
by one psychiatrist, and this model of care may improveintegration of treatment components (35) or reduce over-
all treatment cost (36). In other situations, treatment may
require the coordinated effort of several clinicians. Thisdecision is frequently influenced by the clinicians’ ex-
pertise in providing the indicated therapeutic modality,
economic factors, availability of treatment, and by the pa-tient’s preferences. When this treatment model is used,
one team member must assume the primary overall re-
sponsibility for the patient’s care. This individual serves asthe coordinator of the treatm ent plan, advocates for the
appropriate level of care, oversees the family involvement,makes decisions regarding which potential treatment mo-dalities are useful and which should be discontinued, helps
assess the effects of medications, and monitors the pa-
tient’s safety. Because of the diversity and depth of medicalknowledge and expertise required for this oversight func-
tion, a psychiatrist is generally optimal for this role, al-
though this staffing pattern may not be possible in somehealth care settings. If the treatment is split, the psychia-
trist who is providing the psychiatric management and the
medication treatment should meet with the patient fre-quently enough to monitor his or her care. Ongoing co-ordination of the overall treatment plan is essential and is
enhanced by clear role definitions, plans for the manage-
ment of crises or relapses, and regular communicationamong the clinicians who are involved in the treatment.
Psychiatrists may at times serve as consultants to ongo-
ing treatment of depression by other prescribers. Healthcare professionals other than psychiatrists may prescribe
antidepressant medication for their patients for a variety of
reasons, including convenience, financial reasons, stigma,
and access to care issues (37). Primary care doctors, obste-
tricians, and physicians of other disciplines may screen for
depression and initiate treatment for patients. In fact, atleast one-fourth of patients presenting to primary care set-
tings may have major depressive disorder, and 70%–80%
of antidepressants are prescrib ed by a primary care physician
or medical subspecialist (38, 39). Regardless of whether thepsychiatrist is acting as a consultant or transferring ongo-ing care to another clinician (e.g., with transition from an
inpatient to outpatient setting), communication and coor-
dination of treatment are essential. Optimal communi-cation with other health care professionals can improve
overall treatment by assuring that medical conditions and
psychosocial issues are appropriately addressed. Good com-munication also decreases the risk that patients will receive
inconsistent information about treatment options and risks
and benefits. Furthermore, communication among clini-cians improves vigilance against relapse, side effects, and risk
to self or others.
7. Monitor the patient’s psychiatric status
As treatment progresses, different features and symptoms
of the patient’s illness may emerge or subside. The psychi-atrist should carefully and systematically monitor changes
in the patient’s psychiatric status, including major depres-
sive disorder symptoms, as well as symptoms of other po-tential co-occurring conditions  (T able 2). Monitoring the
patient’s status for the emergence of or changes in destruc-tive impulses toward self or others is especially crucial; ad-ditional measures such as hospitalization or more intensive
treatment should be considered for patients found to be at
higher risk. In addition, the patient should be monitoredfor treatment-emergent side effects, some of which may be
difficult to distinguish from symptoms of the underlying
depressive disorder or co-occurring medical conditions.Significant changes in a patient’s psychiatric status or the
emergence of new symptoms may warrant a diagnostic re-
evaluation of the patient. For example, patients who noteworsening irritability, increased difficulty sleeping, racing
thoughts, growing impulsivity, euphoria, or rapid shifts in
mood should be monitored more closely and may warrantre-evaluation and consideration of a possible bipolar dis-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
28 APA PRACTICE GUIDELINES
order diagnosis. Often family members or caregivers notice
changes in the status of the patient first and are therefore
able to provide valuable input to the psychiatrist.
8. Integrate measurements into psychiatric management
The integration of measurement tools into psychiatric man-agement, which has been referred to as measurement-based
care, may enhance the quality of care and improve clinical
outcomes (40). Clinician-rated and/or self-rated scales canhelp determine the trajectory of disease course and effects
of treatment. Many such scales are available in several ver-
sions that vary by number of items. Self-rated scales are con-venient to use but require review, interpretation, and discus-
sion with the patient. In research studies, commonly used
tools include the Inventory of Depressive Symptoms (IDS),
which is available in clinician-rated and self-rated versions
(http://www.ids-qids.org/), the clinician-rated HamiltonRating Scale for Depression (HAM-D) (http://healthnet.
umassmed.edu/mhealth/HAMD.pdf) (41, 42), the clinician-
rated Montgomery Asberg Depression Rating Scale(MADRS) (http://www.cnsforum.com/streamfile.aspx?file
name=MADRS.pdfandpath=pdf) (43), and the self-rated 9-
item Patient Health Questionnaire (PHQ-9) (http://www.depression-primarycare.org/clinicians/toolkits/materials/
forms/phq9/) (44, 45). The Beck Depression Inventory
(BDI, BDI-II) is another commonly used, copyrighted, 21-question multiple-choice self-rated instrument (46).
Systematic measurement of side effects can also assist in
the provision of treatment. Several self-report rating scaleshave been developed for assessing side effects of antidepres-
sant treatment and are available in English and Spanish ver-
sions (http://www.edc.pitt.edu/stard/public/ assessment_forms.html). The Frequency, Intensity, and Burden of Side
Effects Rating Scale (FIBSER), which has also been re-
ferred to as the Frequency and Intensity of Side EffectsRating/Global Rating of Side Effect Burden, uses three
global Likert scale ratings to assess side effects experienced
over the preceding week (47, 48). The Patient Rated Inven-tory of Side Effects (PRISE) is a 9-item scale that asks pa-
tients about the presence of side effects in eight organ system
domains, as well as about other side effects (47, 48). A cli-nician-administered scale, the T oronto Side Effects Scale,
that focuses on antidepressant medication side effects is
also available (http://ww1.cpa-apc.org:8080/publications/archives/cjp/2002/march/orAntidepressantsAppendix.asp)
(49). The Udvalg for Kliniske Undersøgelser (UKU) side
effect rating scale (50) (available at http:/ /www.cnsforum.com/streamfile.aspx?filename=UKU. pdfandpath=pdf) is
often used in research studies and may offer clinicians ad-
ditional questions that could be asked about side effects,but it is likely to be too detailed for routine clinical use.Although the use of rating scales is not yet common
practice in clinical settings, in part due to pragmatic con-
cerns (51), the use of such scales can be valuable in mon-
itoring symptoms and treatment progress. In addition,electronic monitoring is becoming more feasible, as elec-
tronic health records are more commonly utilized and
patients and psychiatrists have increased access to techno-logical tools that can help monitor and record symptoms.
Baseline data and information about treatment-emergent
changes can be collected systematically from the patientand electronically transmitted via telephone or the Inter-
net. In addition to providing secure electronic capture of
patient data, computerized decision support systems canbe useful in implementing evidence-based treatment for
major depressive disorder (52).
9. Enhance treatment adherence
For treatment to be successful, it is essential to support the
patient’s adherence to all details of the regimen by provid-ing education about the illness and its treatment, maintain-
ing a strong therapeutic alliance, mobilizing family and
other supports (including eliciting questions and clarifyingcommon misconceptions), evaluating factors affecting ad-
herence, and addressing barriers to adherence as they arise.
Major depressive disorder is often a chronic or recurrentcondition that requires patients to participate actively in
and adhere to treatment plans for long periods, despite the
fact that side effects or requirements of treatments may beburdensome. Patients may have strong preferences for mo-
dality of treatment or medication choice, particularly if
they or a family member have had past experience with thetreatment or medication. When feasible, factoring in these
preferences may improve adherence to treatment. During
the acute phase, patients with major depressive disordermay be poorly motivated, unduly pessimistic about their
chances of recovery with treatment, suffering from deficits
in memory, or poorly caring for themselves. During theTABLE 2. Items to Monitor Throughout Treatment
Symptomatic status, including  functional status, and 
quality of life
Degree of danger to self and others
Signs of “switch” to maniaOther mental disorders, including alcohol and other 
substance use disorders
General medical conditionsResponse to treatmentSide effects of treatmentAdherence to treatment plan
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 29
maintenance phase, euthymic patients may undervalue the
benefits of and focus on the burdens of treatment. The psy-
chiatrist should recognize these possibilities, emphasize theimportance of adherence for successful treatment and pro-
phylaxis, and encourage the pa tient to articulate any con-
cerns regarding adherence (e.g., side effects, costs of treat-
ment, scheduling conflicts, lack of transportation or child
care). Patient and family attitudes about depression and its
treatment can also influence adherence. Family memberscan play an important role in promoting optimism about
treatment, assisting patients with adherence and providing
the psychiatrist with input on side effects or other treat-ment-related concerns that may influence adherence.
Some aspects of adherence will vary with the type of
treatment being used. For example, patients in psychother-
apy may experience increased anxiety as they confront fear-
ful or difficult topics. This anxiety, in turn, may decreaseadherence to psychotherapy, and patients may begin to ar-
rive late to or miss therapy sessions. In patients who are
beginning treatment with a medication, common side ef-fects of medication options should be discussed. Patients
should be involved in treatment decisions and encouraged
to convey input on side effects that they consider reason-able or unbearable. Side effects such as weight gain, cog-
nitive dulling, sexual side effects, sedation or fatigue, and
agitation may represent different burdens to different in-dividuals. Emphasizing the following specific topics im-
proves adherence: 1) explaining when and how often to
take the medicine; 2) suggesting reminder systems, suchas pill boxes, alarms, etc.; 3) discussing the need to take
medication for at least 2–4 weeks before beneficial effects
may be noticed; 4) emphasizing the need to take medica-tion even after feeling better; 5) reviewing the need to
consult with the psychiatrist before discontinuing medi-
cation; 6) giving the patient an opportunity to express hisor her understanding of the medication, hearing his or her
concerns, and correcting any misconceptions, and 7) ex-
plaining what to do if problems or questions arise (53).Behavioral tailoring, which involves developing an indi-
vidualized approach to incorporating medication into the
daily routine and can also in clude simplifying the medica-
tion regimen, has demonstrated efficacy for individuals
with schizophrenia and may also be applicable to individuals
with other psychiatric illnesses (54). Adherence may alsobe improved by minimizing the cost and complexity of
medication regimens. Most antidepressant medications
are available in generic forms, which are generally less
costly. For individuals who cannot afford needed medi-
cations, some pharmaceutical companies offer patient as-
sistance programs. Information on such programs isavailable from pharmaceutical company Web sites, from
the Web site of the Partnership for Prescription Assistance(http://www.helpingpatients.org), and from Rx Assist(http://www.rxassist.org).
10. Provide education to the patient and the family
Education concerning major depressive disorder and itstreatments should be provided to all patients. Education is
an essential element of obtaining informed consent totreatment. Whenever possible, education should also be
provided to involved family members and significant oth-
ers, although generally the patient’s consent is requiredbefore such information can be  shared. Specific topics to
discuss may include that major depressive disorder is amedical illness and that effective treatments are both nec-
essary and available. This information may be especially
important for patients who attribute their illness to amoral defect, or for family members who are convinced
that there is nothing wrong with the patient. Education
regarding available treatment options will help patientsmake informed decisions, anti cipate side effects, and ad-
here to treatments. Patients with depression can becomeeasily discouraged in treatment, especially if there is lessthan a full initial response. The psychiatrist should en-
courage and educate patients to distinguish between the
hopelessness that is a symptom of depression and the rel-atively hopeful actual prognosis. In addition, for patients
treated with antidepressant medication or ECT , psychia-
trists may choose to discuss a predictable progression oftreatment effects: first, side effects may emerge, then neu-
rovegetative symptoms remit, and finally mood improves.
Often significant others notice symptomatic improve-ment before the patient does.
Given the chronic, episodic nature of major depressive
disorder, exacerbations are common. Patients, as well astheir families, if appropriate, should be instructed about
the significant risk of relapse. They should be educated
to identify early signs and symptoms of new episodes andthe stressors that may precede them. Patients should also
be instructed to seek adequate treatment as early in the
course of the new episode as possible to decrease the like-lihood of a full-blown exacerbation or complications.
Patient and family education also includes general pro-
motion of healthy behaviors such as good sleep hygieneand decreased use of caffeine, tobacco, alcohol, and other
potentially deleterious substances. For most individuals,
exercise carries benefits for overall health. Data generallysupport at least a modest improvement in mood symp-
toms for patients with major depressive disorder who en-
gage in aerobic exercise (55–61) or resistance training(62, 63). Regular exercise may also reduce the prevalence
of depressive symptoms in the general population, with
specific benefit found in older adults (64, 65) and individ-uals with co-occurring medical problems (57, 66).
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
30 APA PRACTICE GUIDELINES
B. ACUTE PHASE
1. Choice of initial treatment modality
The acute phase of treatment lasts a minimum of 6–12
weeks. During this phase, the aims of treatment are to in-
duce remission of symptoms and achieve a full return tothe patient’s baseline level of functioning. In addition to
general psychiatric management (described in Section
II.A), treatment may consist of pharmacotherapy or othersomatic therapies (e.g., ECT, light therapy), depression-
focused psychotherapy, or the combination of somatic and
psychosocial therapies. Selection of an initial treatment mo-dality is influenced by several factors, including the symp-
tom profile, the presence of co-occurring disorders or
psychosocial stressors, the patient’s prior treatment expe-rience, and the patient’s preference.
Psychiatrists should present patients with information
concerning the evidence for a broad range of treatmentoptions, including somatic th erapies and psychosocial in-
terventions. Antidepressant medications can be used as aninitial treatment modality by patients with mild, moder-ate, or severe major depressive disorder. Clinical features
that may suggest that medications are the preferred treat-
ment modality include a history of prior positive responseto antidepressant medications, the presence of moderate
to severe symptoms, significant sleep or appetite distur-
bances, agitation, patient preference, and anticipation ofthe need for maintenance therapy. Patients with major de-
pressive disorder with psychotic features require either
the combined use of antide pressant and antipsychotic
medications or ECT .
Psychotherapy may also be considered as monotherapy
for patients with mild to moderate major depressive dis-order. The availability of clinicians with appropriate train-
ing and expertise in specific psychotherapeutic approaches
can be a factor in choosing a psychotherapy (67). Other
factors that can influence this choice may be the psycho-
social context, patient preference, prior positive response
to psychotherapy, the presence of significant psychosocialstressors or interpersonal difficulties, co-occurring Axis II
disorders, or the stage, chronicity, and severity of the major
depressive episode. Specifically, many severely depressedpatients will require both a depression-focused psycho-
therapy and a somatic treatment such as pharmacotherapy.
Pregnancy, lactation, or the wish to become pregnant maytilt a decision toward psychotherapy as an initial treatment
(see Section III.B.6). Given the lower occurrence of side ef-
fects and suggestion of enduring benefits associated withdepression-focused psychotherapies (68), such treatments
might be preferable alternatives to pharmacotherapy for
some patients with mild to moderate depression.Combining a depression-focused psychotherapy and
pharmacotherapy may be a useful initial treatment choicefor patients with moderate to severe major depressive dis-order. Other indications for combined treatment include
chronic forms of depression, psychosocial issues, intra-
psychic conflict, interpersonal problems, or a co-occur-ring Axis II disorder. In addition, patients who have had a
history of only partial response to adequate trials of single
treatment modalities may benefit from combined treat-ment. Poor adherence with pharmacotherapy may also
warrant combined treatment with medications and psy-
chotherapy focused on treatment adherence.
Electroconvulsive therapy should be considered as a po-
tential treatment option for all patients with major depres-sive disorder who have psychotic features or catatonia and
for those with an urgent need for response, such as patients
who are suicidal or who are nutritionally compromised as aresult of refusing food. Electroconvulsive therapy may also
be the treatment modality of choice for patients with major
depressive disorder who have a high degree of symptom
severity. Other considerations include the presence of co-
occurring general medical conditions that preclude the useof antidepressant medications, a prior history of positive re-sponse to ECT, and patient preference. Evidence for TMS
is currently insufficient to support its use in the initial treat-
ment of major depressive disorder.
If a patient with mild depression wishes to try exercise
alone for several weeks as a first intervention, there is little toargue against it (Section II.A.10), provided the patient is suf-ficiently monitored for an abrupt worsening of mood or ad-
verse physical effects (e.g., ischemia or musculoskeletal
symptoms). The dose of exercise and adherence to an exer-cise regimen may be particularly important to monitor in the
assessment of whether an exercise intervention is useful for
major depressive disorder (69, 70). If mood fails to improveafter a few weeks with exercise alone, the psychiatrist should
recommend medication or psychotherapy. For patients withdepression of any severity and no medical contraindicationto exercise, physical activity is a reasonable addition to a
treatment plan for major de pressive disorder. The optimal
regimen is one the patient prefers and will adhere to.
Figure 1 summarizes treatment modalities that may be
appropriate during the acute phase of treatment depend-
ing on the severity of the patient’s symptoms and other as-sociated features of the depressive episode. It is important
to note that other factors may be relevant to treatment de-
cisions for individual patients and that determinations ofepisode severity are imprecise, although rating scales may
be helpful in assessing the magnitude of depressive symp-
toms and their effects on functional status and quality oflife (see Sections II.A.7 and II.A.8).
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 31
2. Pharmacotherapy
Antidepressant medications have been grouped as follows:
1) TCAs, which for the purposes of this guideline also
include the tetracyclic antidepressant medication ma-
protiline; 2) SSRIs, which include fluoxetine, sertraline,
paroxetine, fluvoxamine, citalopram, and escitalopram;3) SNRIs, which include venlafaxine, desvenlafaxine, and
duloxetine; 4) other antidepressant medications, includ-ing bupropion, nefazodone, trazodone, and mirtazapine;
and 5) MAOIs, which includ e phenelzine, tranylcypro-
mine, isocarboxazid, and the transdermal formulation of
selegiline. Although some studies have suggested superi-
ority of one mechanism of act ion over another, there are
no replicable or robust findings to establish a clinically
meaningful difference. For most patients, the effective-
ness of antidepressant medications is generally comparable
between classes and within classes of medications. Responserates in clinical trials typically range from 50% to 75% of
patients, with some evidence suggesting greater efficacy
relative to placebo in individuals with severe depressivesymptoms as compared with those with mild to moderate
symptoms (71–73). Although remission rates are less robust
and selective publication of positive studies could affect theapparent effectiveness of treatment (74, 75), these factors
do not appear specific to particular medications or medi-
cation classes.
Nevertheless, antidepressant medications do differ in
their potential to cause particular side effects such as adversesexual effects, sedation, or weight gain. Therefore, the
initial selection of an antidepressant medication will
largely be based on the tolerability, safety, and cost of themedication, as well as patient preference and history of
prior medication treatment (T able 3). Other factors in-
clude the medication half-life and potential for drug inter-actions related to properties such as plasma protein
binding or metabolism through the cytochrome P450
system (T ables 4 and 5). On the basis of these consider-ations, the following medications are optimal for most
patients: SSRIs, SNRIs, mirtazapine, and bupropion.
T able 6 provides the starting and usual doses of medica-tions that have been shown to be effective for treating
major depressive disorder.Modality
Severity of Illness PharmacotherapyDepression-Focused 
PsychotherapyPharmacotherapy in 
Combination With 
Depression-Focused 
PsychotherapyElectroconvulsive 
Therapy
Mild to Moderate Ye s Yes May be useful for 
patients with psycho-social or interpersonal 
problems, intrapsy-chic conflict, or 
co-occurring Axis II 
disorderYes, for certain 
patients
Severe Without 
Psychotic FeaturesYe s N o Ye s Ye s
Severe With 
Psychotic FeaturesYes, provide both 
antidepressant and antipsychotic 
medicationNo Y es, provide both 
antidepressant and 
antipsychotic 
medicationYe s
FIGURE 1. Recommended Modalities for Acute Phase Treatment of Major Depressive Disorder
TABLE 3. Factors to Consider in Choosing an Antidepressant 
Medication
Patient preference
Nature of prior response to medicationRelative efficacy and effectivenessSafety, tolerability, and anticipated side effectsCo-occurring psychiatric or general medical 
conditions
Potential drug interactionsHalf-lifeCost
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
32 APA PRACTICE GUIDELINES
In choosing an antidepressant medication, many psy-
chiatrists also consider the family history of response to
particular medications; however, the impact of this factor
on the likelihood of the patient’s response to these medi-
cations is unclear. Nevertheless, the medication experiencesof others close to the patient do influence the patient’s be-
lief about particular medications and pharmacotherapy in
general.
The presence of co-occurring psychiatric or general
medical conditions can be a si gnificant factor influencing
the choice of an antidepressant medication. For example,
TCAs are generally not optimal in patients with cardiovas-
cular conditions, cardiac conduction defects, closed angle
glaucoma, urinary retention, significant prostatic hyper-trophy, or eating disorders with significant malnutritionor purging. In older adults and others with malnutrition,autonomic disorders (e.g., diabetic neuropathy, Parkin-son’s disease), or low blood pressure, TCAs may exacer-
bate hypotension and orthostasis, resulting in syncope or
falls. Selective serotonin reuptake inhibitors and SNRIsmay be inappropriate for patients who are experiencing
sexual dysfunction. Patients who are receiving tamoxifen
for breast cancer or other indications should generally betreated with an antidepressant (e.g., citalopram, escitalo-
pram, venlafaxine, desvenlafaxine) that has minimal effect
on metabolism through the cytochrome P450 2D6 isoen-zyme, because reduced metabolism of tamoxifen through
CYP 2D6 is likely to be associated with lower levels of
tamoxifen’s active metabolite (76–79) with the possibility ofpoorer patient outcomes (80, 81).TABLE 4. Cytochrome P450 Enzyme Metabolism of Antidepressive Agentsa
1A2 2B6 2C9 2C19 2D6 3A4
Amitriptyline + + ++ ++ ++ +
Bupropion
Hydroxybupropionb++ ++ +
++
Citalopram ++ + ++
Desipramine + ++
Desvenlafaxine +
Duloxetine ++ ++
Escitalopram ++ + +
Fluoxetine
Norfluoxetineb+ ++ +++ +
++++
Imipramine ++ + ++ ++ ++
Maprotiline + ++
Mirtazapine
8-Hydroxymirtazapineb
Mirtazapine- N-oxideb++ + ++
+++
++
++
Nortriptyline + + ++ +
Paroxetine ++
Protriptyline ++
Selegiline + ++ + +
Sertraline ++++ ++ +
Venlafaxine
O-Norvenlafaxineb+ + ++
+++
Sources:  (82, 83). The extent to which each medication is a substrate for a specific enzyme is indicat ed as follows: +++ = exclusive su b-
strate, ++ = major substrate, + = minor substrate.
aInformation about drug metabolism and drug-drug interactions is constantly evolving. The information in this table can serve as a
guide; however, the reader is encouraged to access regularly updated online sources of drug-drug interactions.
bActive metabolite of parent compound.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 33
Because of the need for dietary restrictions and the po-
tential for serious side effects and drug interactions, use of
MAOIs is generally limited to patients who do not re-spond to other treatments. MAOIs may be particularly
effective for patients with major depressive disorder with
atypical features, although many psychiatrists prefer toprescribe SSRIs for such patients because of SSRIs’ greater
safety and tolerability and more favorable adverse effect
profile.
a. Efficacy of antidepressant medications
1. Selective serotonin reuptake inhibitors
Selective serotonin reuptake inhibitors currently availableinclude fluoxetine, sertraline, paroxetine, fluvoxamine,
citalopram, and escitalopram. A large body of literature
supports the superiority of SSRIs compared with placeboin the treatment of major depressive disorder. In more
than 10 systematic reviews and meta-analyses, the effec-
tiveness of SSRIs has been compared with that of other an-tidepressant medications, mainly TCAs. The SSRIs have
demonstrated comparable efficacy to the TCAs (84–88),even when anxiety symptoms are considered (85, 87–90).
Although a few analyses suggest small advantages of
SNRIs over SSRIs in rates of remission (91), a preponder-
ance of the data finds no sign ificant evidence of the supe-
riority of any other class or agents over SSRIs (84, 89, 90,92–95). One meta-analysis suggests a slight superiority ofescitalopram compared with  other SSRIs and venlafaxine
(93), and another found signif icantly greater efficacy for
escitalopram, sertraline, venlafaxine, and mirtazapine ascompared with duloxetine, fluoxetine, fluvoxamine, and
paroxetine (96), but other studies show no differences in
efficacy among individual SSRIs (84, 93–95, 97, 98).
2. Serotonin norepinephrine reuptake inhibitors
The serotonin norepinephrine reuptake inhibitors currently
available are venlafaxine, desvenlafaxine (the principalmetabolite of venlafaxine), and duloxetine. An immediate-
release form of venlafaxine is available, but most clinicians
prefer the extended-release formulation because it is ap-proved for once-daily dosing and may be less often asso-
ciated with reported withdrawal symptoms.TABLE 5. Cytochrome P450 Enzyme Inhibition by Antidepressive Agentsa
1A2 2A6 2B6 2C8 2C9 2C19 2D6 2E1 3A4
Amitriptyline + + +
Bupropion +++
Citalopram + + + +
Desipramineb++ ++ ++ + ++
Desvenlafaxine +
Duloxetine ++
Escitalopram ++
Fluoxetine
Norfluoxetinec++
+++++++ +
+++ +++
++++
Imipramine + + + +
Mirtazapine + +
Nortriptylined++ + + ++
Paroxetine + +++ + + +++ +
Selegiline + + + + + + +
Sertraline
Desmethylsertralinec++ +
+++
+++ ++
+++
+
Venlafaxine + + +
Sources:  (82, 83). The extent to which each medication is a substrate for a specific enzyme is indicated as follows: +++ = strong inhib -
itor, ++ = moderate inhibitor, + = weak inhibitor.
aInformation about drug metabolism and drug-drug interactions is constantly evolving. The information in this table can serve as  a
guide; however, the reader is encouraged to access regularly updated online sources of drug-drug interactions.
bAlso a metabolite of imipramine. cActive metabolite of parent compound. dAlso a metabolite of amitriptyline.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
34 APA PRACTICE GUIDELINES
TABLE 6. Dosing of Medications Shown To Be Effective in Treating Major Depressive Disordera
Generic NameStarting Dose 
(mg/day)bUsual Dose 
(mg/day)c
Selective serotonin reuptake inhibitorsd
Citalopram 20 20–60e
Escitalopram 10 10–20
Fluoxetine 20 20–60e
Paroxetine 20 20–60e
Paroxetine, extended release 12.5 25–75
Sertraline 50 50–200e
Dopamine norepinephrine reuptake inhibitord
Bupropion, immediate release 150 300–450
Bupropion, sustained release 150 300–400
Bupropion, extended release 150 300–450
Serotonin norepinephrine reuptake inhibitorsd
Venlafaxine, immediate release 37.5 75–375
Venlafaxine, extended release 37.5 75–375
Desvenlafaxine 50 50f
Duloxetine 60 60–120
Serotonin modulators
Nefazodone 50 150–300
T razodoneg150 150–600
Norepinephrine-serotonin modulator
Mirtazapined15 15–45
T ricyclics and tetracyclics
Amitriptyline 25–50 100–300
Doxepin 25–50 100–300
Imipramine 25–50 100–300
Desipramine 25–50 100–300
Nortriptyline 25 50–200
T rimipramine 25–50 75–300
Protriptyline 10–20 20–60
Maprotiline 75 100–225
Monoamine oxidase inhibitors (MAOIs)
Irreversible, nonselective inhibitors
Phenelzine 15 45–90
T ranylcypromine 10 30–60
Isocarboxazid 10–20 30–60
Irreversible, MAO B selective inhibitor
Selegiline transdermalh6 6–12
Reversible MAO A selective inhibitor
Moclobemide 150 300–600
aFor convenience, medications other than TCAs have been classified by their presumptive mechanism of action. However, the exact
mechanism of action of several medications has yet to be determined or varies by dose. bLower starting doses are recommended for
elderly patients and for patients with panic disorder, significant anxiety or hepatic disease, and co-occurring general medical  conditions.
cFor some of these medications (e.g., TCAs) the upper dosing limit reflects risk of toxicity or need for plasma level assessment , whereas
for other medications (e.g., SSRIs), higher doses can be used safely but without evidence for overall superior efficacy. dThese medica-
tions are likely to be optimal medications in terms of safety, th e patient’s acceptance of side effects, and the quantity and quality of clinical
trial data. eDose varies with diagnosis; see text for specific guidelines. fHas been used at doses up to 400 mg/day, although doses above
50 mg/day may not provide additional benefit. gThis medication is not typically used for this indication. hSelegiline selectively inhibits
MAO B at low doses but inhibits both MAO A and MAO B at the high er doses that are typically required for antidepressant activit y.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 35
Each of these medications is efficacious (i.e., superior
to placebo in controlled studies and meta-analyses) (95,
99), and venlafaxine (75–150 mg/day) and duloxetine(60 mg/day) showed comparable efficacy in a pair of trials
(100). For venlafaxine and pe rhaps desvenlafaxine, clini-
cally significant norepinephrine reuptake inhibition may
not be achieved for the average patient at lower therapeu-
tic doses, although desvenlafaxine has a much greater
bioavailability, resulting in a lower effective dose. In indi-vidual studies, venlafaxine and duloxetine are generally as
effective as SSRIs (see the meta-analyses of Nemeroff et
al. [101] and Thase et al. [102] for tabulated summaries ofindividual study results from the more than 40 relevant
randomized controlled trials). Results of comparative
studies of desvenlafaxine are not known at this time. Rel-
ative to SSRIs, some analyses of pooled data sets have sug-
gested a small advantage for SNRIs (91), which mightafford clinically modest benefits for patients with more se-
vere depression (102) or for patients who have not re-
sponded to prior trials of SSRIs (103). However, othermeta-analyses have shown equivalent efficacy for SSRIs
and SNRIs (95), whereas some have shown superiority of
individual medications but no clearcut medication classeffects (96). Relative to TCAs, venlafaxine’s efficacy is
comparable (91, 104, 105), whereas the more recently in-
troduced duloxetine and desvenlafaxine have not beensystematically compared with TCAs.
3. Other antidepressant medications
A number of other antidepressant medications differ struc-
turally or in their pharmacological action from medications
in the categories just described and are included here.
Although bupropion is classified as a norepinephrine
and dopamine reuptake inhibitor, the latter effect is rela-tively weak, and its mechanism of action remains unclear(106). There are three formulations of bupropion: im-
mediate release, sustained release, and extended release.
Bupropion is distinct from most antidepressants in nothaving an indication for th e treatment of any primary
anxiety disorder, and it may be less well tolerated thanother antidepressants among patients with significantanxiety. In addition, a meta-analysis showed that SSRIs
were modestly superior to bupropion for a subset of pa-
tients with major depressive disorder and anxiety (107).For individuals with low to moderate levels of anxiety, the
same meta-analysis showed that the efficacy of bupropion
in treating major depressive disorder was roughly com-parable to that of the SSRIs (107). Results of another
meta-analysis suggested that bupropion may be more likely
to improve symptoms of fatigue and sleepiness than atleast some of the SSRIs (108). Bupropion may be a good
choice for patients who have a goal of quitting smoking as
it has U.S. Food and Drug Administration (FDA) approvalfor this indication, reduces desire for nicotine, and dou-
bles rates of smoking cessation (109, 110). Patients typi-
cally experience minimal weight gain or even weight losson bupropion (111), and for this reason it may be an ap-
propriate antidepressant for patients who are overweight
or obese.
Mirtazapine is thought to work through noradrenergic
and serotonergic mechanisms , although this tetracyclic
compound is not a reuptake  inhibitor (112). Mirtazapine
has comparable efficacy to SSRIs (113).
T razodone is the oldest medication from this group
that is still in wide use. Although trazodone is an effectiveantidepressant, relative to placebo (105, 114, 115), in con-
temporary practice it is much more likely to be used in
lower doses as a sedative-hypno tic than as an antidepres-
sant. Despite widespread use of trazodone as a hypnotic,few data support its use for this indication.
Nefazodone has an analogous structure to trazodone but
somewhat different pharmaco logical properties. In com-
parative trials versus SSRIs, nefazodone showed compa-rable efficacy and overall tolerability (116).
4. Tricyclic antidepressants
T ricyclic antidepressants (amitriptyline, nortriptyline,
protriptyline, imipramine, desipramine, doxepin, and tri-
mipramine) are effective treatments for major depressivedisorder and have comparable efficacy to other classes of
antidepressants, including SSRIs, SNRIs, and MAOIs
(85, 105). The efficacy of subclasses of tricyclics (e.g., sec-ondary amines or tertiary amines) appears to be compara-
ble. TCAs may be particularly effective in certain
populations, such as in hospitalized patients (117, 118).Conventional wisdom is that this advantage is explained
by the superiority of TCAs (versus SSRIs) among the subsetof patients with melancholia or more severe depression,because such a specific advantage has not been consis-
tently documented in studies of less severely ill outpa-
tients (85, 105, 118).
5. Monoamine oxidase inhibitors
MAOIs currently used as antidepressants include phenel-
zine, tranylcypromine, isocarboxazid, moclobemide, andthe transdermally delivered formulation of selegiline.
MAOIs have comparable efficacy to other antidepres-
sants for outpatients with major depressive disorder andmay be appropriate for patients with major depressive dis-
order who have not responded to safer and more easily
used treatments (119, 120). In fact, the role of MAOIs inmajor depressive disorder is  now almost exclusively re-
served for patients who have not responded to at least sev-eral other pharmacotherapies. Studies have demonstratedthe effectiveness of MAOIs in patients who have not re-
sponded to other antidepressant medications, particularly
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
36 APA PRACTICE GUIDELINES
TCAs (119). However, the effectiveness of MAOIs rela-
tive to other strategies for treatment-resistant patients in
contemporary practice remains unclear, particularly forpatients who have not responded to multiple sequential
trials with SSRIs and SNRIs (121).
MAOIs have been shown to be particularly effective in
treating depressed patients with atypical features, so psy-chiatrists should consider using these medications for pa-
tients with symptoms such as reactive moods, reverse neu-rovegetative symptoms, and sensitivity to rejection (119,
120, 122). There do not appear to be any significant differ-
ences in efficacy among the older MAOIs (119), althoughthere are important individual differences in responsive-
ness, and these medications are not interchangeable.
There are no comparative studies of the newer transder-
mal (skin patch) formulation of selegiline; its efficacy has
only been established relative to placebo (123–125), andclinical experience is limited.
b. Side effects of antidepressant medications
The severity of side effects from antidepressant medica-
tions in clinical trials has been assessed both through the
frequency of reported side effects and through the fre-quency of treatment dropout. The likelihood of different
side effects varies among classes of antidepressant medi-
cations, among subclasses, an d among individual agents.
In addition, most newer antidepressants are better toler-
ated than TCAs (84–88, 97, 117, 126) and safer in over-
dose (127, 128).
When side effects occur duri ng treatment with an an-
tidepressant, an initial strategy is to lower the dose of theantidepressant or to change to an antidepressant that is
not associated with that side effect. As an example, bupro-
pion can be used if patients encounter sexual side effectswith an SSRI medication. When lowering the dose or dis-continuing the medication is not effective, additional strat-
egies may be considered. These additional strategies are
described in T able 7, which also lists prominent and clin-ically relevant side effects associated with particular med-
ication classes.
Serotonin syndrome, as the name implies, is presumed
to result from high levels of serotonin in the brain. Althoughit can occur with administration of one or more seroto-
nergic medications, it is most severe when an MAOI iscoadministered with another serotonergic medication.
Consequently, great care must be taken when changing
patients from another anti depressant medication to an
MAOI and from an MAOI to other antidepressant medi-
cations because of the persistent effects of discontinued
medications. A washout period is essential before and afterusing an MAOI. If the psychiatrist chooses to discontinue
a monoamine-uptake-blocking antidepressant medication(e.g., SSRI, SNRI, TCA) and substitute an MAOI, toxicinteractions can best be avoided by allowing at least a 2-week
washout period between medication trials (T able 8). Thelong half-life of the SSRI fluoxetine and its metabolites
necessitates a 5- to 6-week washout period or longer be-
fore the use of an MAOI. Additional information aboutserotonin syndrome with specific medication classes can
be found in Sections II.B.2.b.1.g. and II.B.2.b.5.b.
Because knowledge of potential drug-drug interactions
is frequently changing, it is useful to consult a frequentlyupdated drug information database before selecting an
antidepressant in a patient taking other medications.
1. Selective serotonin reuptake inhibitors
SSRIs have comparable tolerability overall, but the spe-
cific medications differ somewhat in their side effect pro-files, which may guide selection of an agent for an
individual patient. Pharmacokinetic issues, including half-
life and effect on the CYP-450 enzyme system, are addi-tional considerations in the choice of an SSRI.
a. Gastrointestinal
SSRIs commonly cause nausea, vomiting, and diarrhea
(98). These adverse events are generally dose dependentand tend to dissipate over the first few weeks of treatment.
In some patients, however, diarrhea persists.
b. Activation/insomnia
SSRIs sometimes precipitate or exacerbate restlessness, ag-itation, and sleep disturbances—side effects that often
attenuate with time. Anxiety may be minimized by intro-
ducing the agent at a low dose. Akathisia has also been re-ported in patients taking SSRIs (129) and may contribute
to reported restlessness or activation. If akathisia does oc-
cur, a beta-blocker or benzodiazepine can be tried to re-duce symptoms. Insomnia can be treated by using sleep
hygiene techniques or CBT as a first approach or by add-
ing a sedative-hypnotic medication or trazodone. Somehave found melatonin to be helpful in treating SSRI-
induced insomnia.
c. Sexual side effects
Although loss of erectile or ejaculatory function in menand loss of libido and anorgasmia in both sexes may be
complications of virtually an y antidepressant medication,
these side effects appear to be more common with SSRIs.
The psychiatrist should ascertain whether the reported sex-
ual dysfunction is a result of the antidepressant medication,
the underlying major depressive disorder, a co-occurringmedical disorder, a disturbance in a relationship, or a need
for education about sexual func tioning. If sexual dysfunc-
tion is determined to be a side effect of the antidepressant
medication, a number of strategies are available, including
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 37
TABLE 7. Potential Treatments for Side Effects of Antidepressant Medications
Side EffectAntidepressant Associated 
With Effect Treatmenta
Cardiovascular
Arrhythmias TCAs Avoid in patients with cardiac instability or ischemia. 
Attend to interactions with anti-arrhythmics.
Hypertension SNRIs, bupropion Monitor blood pressure. Keep dose as low as possible. 
Add antihypertensive.
Hypertensive crisis MAOIs Seek emergency treatment. If hypertension is severe, 
intravenous antihypertensive agents (e.g., labetalol, 
sodium nitroprusside) may be required.
Increase in cholesterol Mirtazapine Add a statin.
Orthostatic hypotension TCAs, trazodone, nefazodone, 
MAOIsAdd fludrocortisone. Add salt to diet.
AnticholinergicConstipation TCAs Encourage adequa te hydration. Add bulk laxative.
Delirium TCAs Evaluate for other possible contributors to delirium.Dry mouth TCAs, SNRIs, bupropion Suggest use of sugarless gum or candy.Urinary hesitancy TCAs Add bethanechol.Visual changes TCAs Add pilocarpine eye drops.
Neurologic
Headaches SSRIs, SNRIs, bupropion Assess for other etiologies (e.g., caffeinism, bruxism, 
migraine, tension headache).
Myoclonus TCAs, MAOIs Add clonazepam.Seizures Bupropion, TCAs, amoxapine Assess fo r other etiologies, and add anticonvulsant 
medication, if clinically indicated.
SexualArousal, erectile 
dysfunctionTCAs, SSRIs, SNRIs Add sildenafil, tadalafil, buspirone, or bupropion.
Orgasm dysfunction TCAs, SSRIs, venlafaxine, 
desvenlafaxine, MAOIsAdd sildenafil, tadalafil, buspirone, or bupropion.
Priapism T razodone Obtain emergency urological evaluation.
Other
Activation SSRIs, SNRIs, bupropion Administer in the morning.Akathisia SSRIs, SNRIs Add a beta-blocker or benzodiazepine.Bruxism SSRIs Obtain dental consultation, if clinically indicatedDiaphoresis TCAs, some SSRIs, SNRIs Add an α
1-adrenergic antagonist (e.g., terazosin), central 
α2-adrenergic agonist (e.g., clonidine), or 
anticholinergic agent (e.g., benztropine).
Fall risk TCAs, SSRIs Monitor blood pressure for evidence of hypotension or 
orthostasis; assess for sedation, blurred vision, or 
confusion; modify environment to reduce risk.
Gastrointestinal (GI) 
bleedingSSRIs Identify whether concomit ant medications may affect 
clotting.
(continued)
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
38 APA PRACTICE GUIDELINES
continuing treatment to assess whether the dysfunction
will disappear with time, lowering the dose, discontinuingthe antidepressant, or substituting another antidepressant
such as bupropion (130). Specific pharmacological treat-
ments that can be added for arousal difficulties, erectiledysfunction, or orgasm dysfunction include buspirone (131),
bupropion (132), sildenafil (133), and tadalafil (134). Other
phosphodiesterase inhibitors may be also useful in treatingsexual side effects, and a variety of other medications have
been used with anecdotal success (135, 136).
d. Neurological effects
Selective serotonin reuptake inhibitors can initially exac-erbate both migraine headaches and tension headaches.
These effects tend to be tran sient and improve within the
first few weeks of treatment. With continued treatment,
SSRIs may actually help prevent and treat migraine head-
aches (137, 138). Selective serotonin reuptake inhibitors
have also been associated with extrapyramidal side effects,including akathisia, dystonia , parkinsonism, and tardive
dyskinesia (139, 140). The incidence of such side effects isvery low with SSRIs but may be higher in older patients,especially those with Parkinson’s disease.e. Falls
Selective serotonin reuptake inhibitors, like other antide-
pressive agents, have been associated with an increasedrisk of falls. In studies of nursing home residents, SSRI
use has been associated with an approximately twofold in-
crease in the risk of a fall (141, 142). An even greater riskof falls in patients who were taking SSRIs was noted in a
community-based cohort study (143). Meta-analyses have
also documented an increased risk of falls in patientstreated with antidepressive agents, in general (144, 145).
The implications of this increase in fall risk are compli-
cated by the decrease in bone density that has been notedin depressed patients (146) and in patients treated with
SSRIs (147, 148). An increase in the risk of hip fractures
has also been noted (149). Rarely, SSRI use has been as-sociated with bradycardia, which could also contribute to
syncope and falls (150). In all patients, including those
treated with SSRIs, fall risk may be increased in individu-als receiving benzodiazepines or other hypnotic agents
(144, 145, 151) and in those receiving multiple medica-
tions (144, 145). Systematically reviewing patients’ medi-cation regimens may help to eliminate medications thatOther (continued)
Hepatotoxicity Nefazodone Provide education about and monitor for clinical 
evidence of hepatic dysfunction. Obtain hepatic function tests, if clinically indicated.
Insomnia SSRIs, SNRIs, bupropion Use morning dosing. Add a sedative-hypnotic at 
bedtime. Add melatonin. Provide CBT or education in 
sleep hygiene.
Nausea, vomiting SSRIs, SNRIs, bupropion Administer after food or in divided doses.
Osteopenia SSRIs If clinically indicated, obtain bone density monitoring 
and add specific treatment to reduce bone loss (e.g., 
calcium and vitamin D supplements, bisphosphonates, 
selective estrogen receptor agents).
Sedation TCAs, trazodone, nefazodone, 
mirtazapineUse bedtime dosing. Add modafinil or methylphenidate.
Severe serotonin syndrome MAOIs Obtain emergency evaluation. Consider admission to a 
critical care unit.
Weight gain SSRIs, mirtazapine, TCAs, 
MAOIsEncourage exercise. Obtain input from dietician. If 
changing antidepressants, consider a secondary amine 
(if a TCA is required) or other antidepressant with 
fewer weight issues (e.g., bupropion).
aInitial approaches to treatment-emergent side effects include decreasing or discontinuing the medication and changing to anothe r
antidepressant with a different side effect profile. T reatments included here are additional measures.TABLE 7. Potential Treatments for Side Effects of Antidepressant Medications (continued)
Side EffectAntidepressant Associated 
With Effect Treatmenta
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 39
may no longer be needed, although such interventions
have not been found to alter fall risk, per se (152). Inquir-
ing about a history of falls in the past year and assessing for
abnormalities in gait and balance can also help in identi-
fying patients at particular risk for falling (153).
f. Effects on weight
Weight gain, at times substantial, occurs in some patients
taking SSRIs (154). Patients who take paroxetine have a
higher incidence of weight gain than those who take otherSSRIs (98, 155). Fluoxetine causes an initial reduction in
weight, which tends to normalize with continued treatment
(156).
g. Serotonin syndrome
Use of SSRIs has been associated with the rare develop-
ment of a syndrome caused by an excess of central nervoussystem serotonergic activity. Features of serotonin syn-
drome include abdominal pain, diarrhea, flushing, sweat-
ing, hyperthermia, lethargy, mental status changes, tremorand myoclonus, rhabdomyolysis, renal failure, cardiovas-
cular shock, and possibly death (157). Although serotonin
syndrome can occur rarely with the use of SSRIs alone, it isusually associated with the simultaneous use of multiple
serotonergic agents and is most severe when SSRIs are given
together with MAOIs. Consequently, when an SSRI is be-ing changed to an MAOI or vice versa, particular attention
must be give to the duration of time between treatments
(Section II.B.2.b) to avoid precipitating a potentially lethalserotonin syndrome. Serotonin syndrome has also been re-
ported when SSRIs are used in combination with tramadol,
high-dose triptans, or the antibiotic linezolid, which alsohas some ability to inhibit MAO (158, 159).
h. Drug interactions
The potential for drug-drug interactions differs signifi-
cantly across the SSRIs. Selective serotonin reuptake in-
hibitors have variable effects on hepatic microsomal
enzymes and therefore cause both increases and decreasesin the blood levels of other medications. For example,
when SSRIs that strongly inhibit the CYP 2D6 isoenzyme(e.g., paroxetine, fluoxetine) are administered concomi-
tantly with tamoxifen, the metabolism of tamoxifen to its
active metabolite is reduced (76–79), resulting in a poten-
tial decrease in its efficacy in preventing breast cancer re-
lapse (80, 81). Interaction with other drugs was higher for
fluoxetine, fluvoxamine, and paroxetine than for sertra-line, citalopram, and escitalopram (98, 160, 161).
As described above, there can be a potentially lethal in-
teraction between SSRIs and MAOIs: the serotonin syn-drome. At least five half-lives should elapse between the
time an SSRI is stopped and an MAOI is started; for flu-
oxetine discontinuation, this means waiting approximately5–6 weeks before starting an MAOI; for discontinuation of
other SSRIs, approximately 2 weeks should pass before
starting an MAOI (162). A 2-week waiting period has beensuggested after discontinuing an MAOI before starting an
SSRI or another MAOI (T able 8).
i. Discontinuation syndrome
Selective serotonin reuptake inhibitors generally should
not be abruptly discontinued after extended therapy and,
whenever possible, should be tapered over several weeks
to minimize discontinuation-emergent symptoms. Clini-cal experience and a few controlled studies suggest that
among the SSRIs, discontinuation-emergent symptoms
are more likely with paroxetine than sertraline, citalo-pram, or escitalopram  and least likely to occur with fluox-
etine (due to the long elimination half-life of its primarymetabolite, norfluoxetine) (163, 164). Discontinuation-emergent symptoms include both flu-like experiences
such as nausea, headache, light-headedness, chills, and body
aches, and neurological symptoms such as paresthesias,
insomnia, and “electric shock-like” phenomena. These
symptoms typically resolve without specific treatmentover 1–2 weeks. However, some patients do experiencemore protracted discontinuation syndromes, particularly
those treated with paroxetine, and may require a slower
downward titration regimen. Another strategy is to changeto a brief course of fluoxetine, e.g., 10 mg for 1–2 weeks,
and then taper and discontinue the fluoxetine (165).TABLE 8. Required Washout Times Between Antidepressant Trials
To FromMinimum Washout Period 
(weeks)
MAOI Drug with long-half-life metabolites (e.g., fluoxetine) 5–6
Drug without long-half-life metabolites (e.g., TCAs, paroxetine, 
fluvoxamine, venlafaxine)2
 MAOI 2
Non-MAOI MAOI 2
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
40 APA PRACTICE GUIDELINES
2. Serotonin norepinephrine reuptake inhibitors
The most common side effects of the SNRIs (venlafaxine,
desvenlafaxine, and duloxetine) are similar to those seen
with SSRIs, including nausea and vomiting, sexual dys-function, and activation; like the side effects seen with
SSRIs, those with SNRIs can attenuate with continued
use. The SNRIs also are more likely to be associated with
side effects that reflect noradrenergic activity, including
increased pulse rate, dilated pupils, dry mouth, excessive
sweating, and constipation. Although all three SNRIs carrythe warning of increased blood pressure, this risk is greater
during therapy with venlafaxine at doses above 150 mg/day
(166) than with duloxetine at doses of 60–120 mg/day
(167) or desvenlafaxine at doses of 50–100 mg/day (168).
Because this blood pressure increase is dose-related, SNRI-induced hypertension may respond to dose reduction. In
the absence of a reduction in hypertension, a different an-
tidepressant medication may be considered. Alternatively,in a patient with well-controlled depressive symptoms, it
may be preferable to add an antihypertensive agent rather
than risk a depressive relaps e or recurrence with medica-
tion tapering. As with the SSRIs, abrupt discontinuation
of SNRIs should be avoided whenever possible. Discon-
tinuation symptoms, which are sometimes protracted, aremore likely to occur with venlafaxine (and, by implication,
desvenlafaxine) than duloxetine (100) and may necessitate a
slower downward titration regimen or change to fluoxet-ine. As described above (Section II.B.2.b), there can be a
potentially lethal interaction between SNRIs and MAOIs:
the serotonin syndrome.
3. Other antidepressant medications
a. Bupropion
Bupropion differs from other modern antidepressants by
its lack of direct effects on serotonergic neurotransmission
and, as a consequence, a virtual lack of sexual side effects(169). Neurologic side effects with bupropion include head-
aches, tremors, and seizures (106). The risk of seizures is
minimized by avoiding high doses (e.g., using no morethan 450 mg/day), avoiding rapid titration, using divided
dosing schedules for the immediate-release and sustained-
release formulations, and avoiding use of bupropion in pa-tients with risk factors for seizures. Bupropion should also
not be used in patients who have had anorexia nervosa or
bulimia nervosa because of elevated risk of seizures (170).The risk of seizures may also be increased by the con-
comitant use of inhibitors of CYP 2B6 (e.g., desipramine,
sertraline, paroxetine, fluoxetine) due to the resulting in-crease in bupropion blood levels. Bupropion has been as-
sociated with a low risk of psychotic symptoms, including
delusions and hallucinations. It should therefore be usedcautiously in patients with psychotic disorders. Other
side effects with bupropion include agitation, jitteriness,
mild cognitive dysfunction, insomnia, and gastrointesti-nal upset.
b. Mirtazapine
The most common side effects of mirtazapine include dry
mouth, sedation, and weight gain. For this reason, mir-
tazapine is often given at night and may be chosen for de-
pressed patients with initial insomnia and weight loss.Although these side effects tend to occur early in the
treatment course and may attenuate with continued use,
the weight gain associated with mirtazapine is greater than
that with other non-TCA, non-MAOI antidepressants (95)
and may make it a less attractive choice for some pa-tients. Mirtazapine increases serum cholesterol levels in
some patients (171). Although several patients treated
with mirtazapine were observed to have agranulocytosisin early studies, subsequent clinical experience has not con-
firmed an elevated risk (172).
c. Trazodone
The most common side effect with trazodone is sedation.
Because the sedation associated  with trazodone is greater
than that with other non-TCA, non-MAOI antidepres-
sants (95), this can be an advantage in patients with initial
insomnia (173). T razodone can also cause cardiovascular
side effects, including orthostasis, particularly among el-derly patients or those with preexisting heart disease. Use
of trazodone has also been associated with life-threat-
ening ventricular arrhythmias in several case reports
(173). T razodone also can cause sexual side effects, in-cluding erectile dysfunction in men; in rare instances, pri-
apism occurs, which might re quire surgical correction
(174, 175).
d. Nefazodone
Side effects with nefazodone include dry mouth, nausea,
constipation, orthostasis, and visual alterations (176). Se-
dation is also common and may necessitate a gradual
titration of nefazodone. However, in patients with insom-nia, the sedating properties of nefazodone can be helpful
in improving sleep (177). There appears to be a low inci-
dence of treatment-emergent sexual dysfunction (178,179) with nefazodone and, unlike trazodone, it has not
been associated with priapism. Nefazodone has also been
associated with rare but potentially fatal liver failure (180,181), which has limited its use in recent years. Drug-drug
interactions can also be problematic as nefazodone in-
hibits hepatic microsomal enzymes and can raise levels ofconcurrently administered me dications such as certain
antihistamines, benzodi azepines, and digoxin.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 41
4. Tricyclic antidepressants
a. Cardiovascular effects
Cardiovascular effects, including arrhythmias, can be
problematic with TCA treatment. Consequently, a pre-treatment ECG is indicated for patients with significant
cardiac risk factors and patien ts older than age 50 years.
Follow-up ECGs may also be indicated to identify the de-
velopment of conduction chan ges, typically during the
early phase of TCA use (182). T ricyclic antidepressantsact similarly to class Ia antiarrhythmic agents such as qui-nidine, disopyramide, and procainamide, which increase
the threshold for excitation by depressing fast sodium
channels, prolong cardiac cell action potentials through
actions on potassium channels, and prolong cardiac re-
fractoriness through actions on both types of channels(183). As a result, combinatio ns of TCAs with other class
I antiarrhythmic agents can exert additive toxic effects oncardiac conduction; patients wi th ventricular arrhythmias
taking another class I anti arrhythmic agent who require
TCA therapy should be under careful medical supervi-sion. Individuals with prolonged QT intervals, whetherpreexistent or medication induced, are predisposed to de-
velop ventricular tachycardia (184). Even patients with
normal pretreatment ECG results may develop atrio-
ventricular block with TCAs that reverts to normal after
discontinuation of antidepressant medication treatment
(185). Because of these effects on cardiac conduction,TCAs (like other class Ia antiarrhythmic agents) may
carry an increased risk of serious cardiac adverse effects,
including mortality (186–189). In addition, fatal arrhyth-mias can occur in the context of TCA overdose (190, 191).
In addition to causing arrhythmias, TCAs can cause a
number of other cardiovascular side effects, including
tachycardia (through muscarinic cholinergic blockade and
α-adrenergic blockade) or orthostatic hypotension (through
α-adrenergic blockade). Side effects such as orthostatic
hypotension may in turn lead to events such as dizziness,
falls, or fractures, which are of particular concern in elderlypatients (192). Of the TCAs, nortriptyline may be less likelyto contribute to orthostatic blood pressure changes (185).
Preexisting orthostasis, antihypertensive treatment, de-
hydration, and salt depletion, whether voluntary or a re-sult of diuretic treatment, may contribute to symptomatic
orthostatic hypotension with TCAs. If there is no medical
contraindication, patients with symptomatic orthostatic
hypotension should maintain adequate fluid intake and be
cautioned against extreme dietary salt restriction.
b. Anticholinergic side effects
All TCAs have antimuscarinic effects; tertiary amine tricy-
clic antidepressants produce the most anticholinergic sideeffects, whereas the secondary amines desipramine and
nortriptyline have less antimuscarinic activity (193). The
most common consequences of muscarinic blockade aredry mouth, impaired ability to focus vision at close range,
constipation, urinary hesitation, tachycardia, and sexual
dysfunction. Although patients can develop some degreeof tolerance to anticholinergic side effects, these symp-
toms may require treatment if they cause substantial dys-
function or interfere with adherence. Impaired visualaccommodation may be counteracted through the use of
pilocarpine eye drops. Dry mouth may be counteracted by
advising the patient to use su garless gum or candy and en-
suring adequate hydration. Constipation can be managed
by adequate hydration and the use of bulk laxatives. Anti-
depressant medications with anticholinergic side effects
should be avoided in patients with cognitive impairment,
narrow-angle glaucoma, or prostatic hypertrophy. T ricy-clic antidepressants can impair memory and concentration
and even precipitate anticholinergic delirium, particularly
in patients who are elderly, medically compromised, ortaking other anticholinergic medicines. Such toxic confu-
sional states may signal the presence of high TCA blood
levels and can improve with lowering of the dose (194).
c. Sedation
T ricyclic antidepressants also have affinity for histaminer-
gic receptors and produce varying degrees of sedation. In
general, tertiary amines cause greater sedation, while sec-ondary amines cause less (193). Sedation often attenuates
in the first weeks of treatment, and patients experiencing
only minor difficulty from this side effect should be en-couraged to allow some time to pass before changing anti-
depressant medications. Patients with major depressive
disorder with insomnia may benefit from sedation whentheir medication is given as a single dose before bedtime.
d. Weight gain
T ricyclic antidepressants can cause weight gain, possibly
through their histaminergic properties and/or blockade of
5-HT
2 receptors (195). The degree of weight gain appears
to vary by agent (e.g., greater weight gain with amitrip-
tyline and less with desipramine), is often dose dependent,
and is potentially reversible with cessation of TCA therapy.Regular monitoring of weight permits early detection of
weight gain and can allow the treating clinician and patient
to determine whether a management plan to minimize orforestall further weight gain is clinically indicated.
e. Neurological effects
T ricyclic antidepressants can cause myoclonus (196). Since
this may be a sign of toxicity, the clinician may wish to
check the blood level (if available) to ensure that it is notexcessive. If the level is nontoxic and myoclonus is not
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
42 APA PRACTICE GUIDELINES
bothersome to the patient, the agent may be continued
without a change in dose. If the myoclonus is problem-
atic and the blood level is within the recommended range,the patient may be treated with clonazepam at a dose of
0.25 mg t.i.d. Alternatively, the antidepressant medication
may be changed. In overdoses, TCAs can cause seizures.Some vulnerable patients may experience seizures even
on therapeutic doses of a TCA—especially clomipramine
and maprotiline (197). Amoxapine, a dibenzoxazepine-derivative tricyclic antidepressant, also produces seizures
in overdose and has active metabolites that block dopam-
ine receptors, conferring a risk  of extrapyramidal side ef-
fects and tardive dyskinesia (198).
f. Falls
Use of TCAs has been associated with an increased risk of
falls in a number of studies and meta-analyses, and the rel-ative risk of falling appears comparable to that with SSRI
treatment (141, 144, 145). Although systematic reviews
show a relatively minor effect of orthostatic hypotension onfall risk, TCAs may contribute to orthostasis and falls in in-
dividual patients (153). If orthostatic hypotension is prom-
inent or associated with gait or balance problems, it mayrequire further evaluation and treatment to minimize the
likelihood of falls (199). Other aspects of fall risk with
TCAs are similar to those that have already been describedfor patients treated with SSRIs (Section II.B.2.b.1.e). Other
causes of falls include bradycardia, cardiac arrhythmia, a
seizure, or ataxia.
g. Medication interactions
A number of medications that inhibit, induce, or are me-tabolized by hepatic micros omal enzymes can interact
with TCAs (200). For example, medications that induceCYP 3A4 such as carbamazepine or barbiturates will causea decrease in serum levels of TCAs. Drugs such as the an-
tipsychotic medication perphenazine or SSRIs such as flu-
oxetine or paroxetine can inhibit metabolism via CYP2D6, resulting in a reduced clearance and increased levels
of TCAs. T ricyclic antidepressa nts can also alter the phar-
macokinetics or pharmacodyna mics of other medications;
for example, TCAs can cause a lowering of valproate lev-els and reduce the activity of clonidine. Therefore, adjust-
ments in medication doses may be necessary when TCAsare administered concomitantly with other drugs for which
there is an interaction. The ability to obtain meaningful an-
tidepressant blood levels to guide dosing is an advantagewith several of the TCAs (e.g., nortriptyline, amitripty-
line, desipramine, imipramine) (201). Potentially danger-
ous interactions, including hype rtensive crises and seroto-
nin syndrome, can develop when TCAs are administered
with MAOIs (see Sections II.B.2.b and II.B.2.b.5.b), nore-
pinephrine, or epinephrine.5. Monoamine oxidase inhibitors
a. Hypertensive crises
A hypertensive crisis can occur when a patient taking an
MAOI ingests large amounts of tyramine or other vasoac-
tive amines in foods or medications (202). This reaction ischaracterized by the acute onset of severe headache, nau-
sea, neck stiffness, palpitations, profuse perspiration, and
confusion and can possibly lead to stroke and death (119).Dietary restrictions include avoiding foods such as aged
cheeses or meats, fermented products, yeast extracts, fava
or broad beans, red wine, draft beers, and overripe orspoiled foods (202, 203). A number of medications includ-
ing norepinephrine reuptake blocking drugs (e.g., SNRIs,
TCAs), sympathomimetic vasoconstrictive agents, and over-
the-counter decongestants can also produce a hyperten-
sive crisis when used in combination with MAOIs (202,204). Individuals with asthma who receive MAOIs should
be cautioned regarding interactions with sympathomimetic
bronchodilators, although other antiasthma agents ap-pear to be safe. Stimulants may be added to MAOIs, but
only with caution and in selected individuals with treatment-
resistant symptoms (205, 206).
At low doses (6 mg/24 hours), selegiline differs from
the older MAOIs in selectively blocking MAO B. In addi-tion, the transdermal delivery of selegiline bypasses en-zyme inhibition in the gut and first-pass metabolism in the
liver. As a result, a low-tyramine diet is not needed when
selegiline is prescribed at the minimum therapeutic dose.However, few safety data are available at higher doses at
which selegiline becomes nonselective and inhibits both
MAO A and MAO B. Consequently, a low-tyramine diet isneeded when doses of 9 mg/24 hours and higher are pre-
scribed as with other MAOIs (207, 208). Moclobemide,
which is available in Canada but not the United States, dif-fers from the above MAOIs in binding reversibly to MAO
and makes dietary restrictions unnecessary with moclobe-
mide. The potential for drug-drug interactions with sele-giline and moclobemide has not been fully studied, but
caution suggests that the same drug interactions should be
considered as when prescribing the older, nonselective, ir-reversible MAOIs.
Although some clinicians continue to recommend that
patients carry nifedipine as a self-administered antidote(e.g., 10 mg by mouth at the first sign of a hypertensive
crisis [209]), this practice has not been approved by the
FDA, and there are concerns about both the safety andefficacy of this strategy, which can produce dangerous
hypotension (210). Definitive treatment of hypertensive
crises usually involves intravenous administration of anantihypertensive agent (e.g., labetalol, sodium nitroprus-
side) in an emergency department setting.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 43
b. Serotonin syndrome
As discussed previously in Section II.B.2.b.1.g, serotonin
syndrome is caused by excess CNS serotonergic activityand is characterized by abdominal pain, diarrhea, flushing,
sweating, hyperthermia, lethargy, mental status changes,
tremor and myoclonus, rhabdomyolysis, renal failure, car-diovascular shock, and possibly death. Serotonin syndrome
most commonly occurs when MAOIs (including reversible
inhibitors of monoamine oxidase and selegiline) are takenin close proximity to other serotonergic agents, such as bus-
pirone or antidepressants (157, 204, 211). Consequently,
when patients are being changed from an SSRI other thanfluoxetine or an SNRI to an MAOI, a waiting period of at
least 2 weeks is needed between the discontinuation of one
medication and the initiation of the other. When changing
from fluoxetine to an MAOI, a waiting period of at least
5 weeks is needed before the MAOI is started (T able 8).Other medications that have been reported to produce se-
rotonin syndrome when used in conjunction with MAOIs
include synthetic opioids (e.g., dextromethorphan, meperi-dine, tramadol, propoxyphene, methadone), nonanti-
depressant tricyclic compounds (e.g., carbamazepine,
cyclobenzaprine), sibutramine, and over-the-counter coldproducts such as chlorpheniramine (204).
c. Cardiovascular effects
Orthostatic hypotension is commonly seen during MAOItreatment. Possible treatments for this side effect in-
clude adding dietary salt to increase intravascular volume,
or use of the mineralocorticoid fludrocortisone. Use ofMAOIs can also be associated with the development of
peripheral edema, which may be helped by the use of sup-
port stockings.
d. Weight gain
Weight gain is also commonly seen in patients treated
with nonselective MAOIs. Although clinical experience islimited, results of one 52-week study suggested that treat-
ment with transdermal selegiline may not be associated
with an increased risk of weight gain (212).
e. Sexual side effects
Sexual side effects seen with MAOI therapy include anor-
gasmia, decreased libido, and erectile or ejaculatory dys-function. Sexual side effects may diminish over time or
with reductions in MAOI doses. The transdermal formu-
lation of selegiline appears to have a relatively low risk ofsexual side effects (213).
f. Neurological effects
T reatment with MAOIs can also be accompanied by head-aches and insomnia; these side effects may diminish over
time with continued use. Other neurological effects seen
with MAOIs include sedation, myoclonic jerks, paresthe-sias, intense daytime drowsiness, and, rarely, peripheral
neuropathy.
c. Implementation of pharmacotherapy
Improvement with pharmacoth erapy can be observed as
early as the first 1–2 weeks of treatment, and improve-
ment continues up to 12 weeks. Many patients may show
partial improvement as early as the end of the first week(214–216). Others achieve improvement within the first
2–4 weeks (217–220). In short-term efficacy trials, all anti-
depressant medications appear to require at least 4–6 weeks
to achieve maximum therapeutic effects (221, 222). Thereis also evidence for continued accrual of benefit for an ad-
ditional 4–6 weeks (223). Furthermore, longer time to
therapeutic effect has been seen with studies conducted in
“real world” settings (224), as well as in studies of patientswith more chronic illness (225, 226) or patients with ma-
jor depressive disorder complicated with co-occurring med-
ical and/or Axis I disorders (224, 227).
Once an antidepressant medication has been selected,
it can be started at doses suggested in T able 6. Initial dosesshould be incrementally raised as tolerated until a thera-peutic dose is reached or the patient achieves remission,
provided there has been at least some improvement in
symptoms in the initial weeks of treatment (217–220). Forpatients who exhibit a partial response to treatment, doses
of antidepressant medications should be maximized, side
effects permitting, before changing to a different antide-pressant medication. In some instances, due to factors
such as rapid metabolism of medication (228, 229), patients
may require doses above those noted in FDA labeling. Pa-tients who have achieved some improvement during the
initial weeks of treatment should be encouraged to con-
tinue taking antidepressant medication for a total of atleast 4–8 weeks. If at least moderate improvement is not
observed with maximally tolerated doses after 4–8 weeks
of treatment, reappraisal and adjustment of the pharmaco-therapy should be considered. Patients with no improve-
ment in the initial weeks of treatment generally need an
earlier adjustment of treatment. For these patients, thepsychiatrist should consider  changing to another antide-
pressant rather than increasing the dose of the medication.For some antidepressant medications, the exact relation-ships between doses and major depressive disorder symp-
tom response have not been rigorously investigated with
fixed-dose studies, and minimum effective doses have notbeen clearly established; moreover, for other antidepres-
sant medications, some studies have failed to show dose-
response relationships (230, 231). Therefore, the initialdoses and usual adult doses in T able 6 are intended to
serve as general guidelines, and actual doses may vary
from individual to individual.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
44 APA PRACTICE GUIDELINES
Titration of the dose to full therapeutic doses generally
can be accomplished over the initial week(s) of treatment
but may vary depending on the development of side effects,the patient’s age, and the presence of co-occurring medical
and psychiatric conditions. In general, patients who are
older, are medically compromised, or have decreased abil-ity to metabolize and clear antidepressant medications will
require lower doses. In such patients, reduction of initial
and therapeutic doses to 50% of usual adult doses is oftenrecommended, and dose escalations should be made at a
slower rate than for younger and healthier adults. Doses
will also be affected by the side effect profile of medicationsand the patient’s ability to tolerate these side effects. Med-
ication doses should also be tailored to individual patients
depending on the potential for pharmacokinetic alterations
and drug-drug interactions.
Patients who have started taking an antidepressant
medication should be carefully and systematically moni-tored to assess their response to treatment, the emergence
of side effects, their clinical  condition, sa fety, and adher-
ence to treatment. Use of clinician- and patient-rated
scales can facilitate such assessments (see Section II.A.8).
Factors to consider when determining the frequency oftreatment visits include the severity of illness, the patient’s
cooperation with treatment, the availability of social sup-
ports, the presence of co-occurring general medical ill-nesses, and the progression of symptom change. Visits
should also be frequent enough to monitor and address
suicide risk and to actively promote treatment adherence,since attrition from treatment continues to be a major
hurdle in maximizing outcomes. Patients in clinical trials
appear to benefit from monitoring once a week or more.This frequency of monitoring enhances adherence rates
and likely helps patients avoid the demoralization that
may occur before the onset of beneficial effects (216). Inthe recently completed STAR*D (“Sequenced T reatment
Alternatives to Relieve Depression”) trial, up to six visits
were recommended during the first 12 weeks (acute phase)of measurement-based treatment at each of the four treat-
ment steps (40). In clinical practice, the frequency of
monitoring during the acute phase of pharmacotherapymay vary and can be as often as multiple times per week in
more complex circumstances. The method of monitoring
(e.g., face-to-face visits, telephone contact, or contact withanother clinician knowledgeable about the patient) may
vary depending on the clini cal context and the treatment
modality.
Although for most patients, monitoring of antidepres-
sant blood levels is not necessary, it may be useful for those
taking TCAs. For some medications, particularly nortrip-tyline, amitriptyline, desipramine, and imipramine, blood
drug levels correlate with both efficacy and side effects(201, 232, 233). When such medications are given, obtain-ing blood drug levels can be particularly informative when
patients have not responded to treatment with an adequatedose of antidepressant medication for an adequate dura-
tion; when patients are particularly vulnerable to the toxic
effects of a medication and require the lowest possibleeffective dose; when there are concerns about patient ad-
herence; and when there is concern that drug-drug inter-
actions are adversely affecting antidepressant medicationlevels. In time, genetic testin g may help guide selection or
dosing of antidepressants, but data are currently insufficientto justify the cost of such tests (229).
Some antidepressant medications, especially TCAs,
can cause significant morbidity and mortality in overdose(190, 191). Ingestion of a 10-day supply of a tricyclic agent
administered at a dose of 200 mg/day is often lethal. Early
on in treatment, it is prudent to dispense only small quan-tities of such antidepressant medications and keep in mind
the possibility that patients can hoard medications over
time. Alternatively, in patients who are suicidal, it may bepreferable to employ agents that are safer in overdose
such as the SSRIs, bupropion, or mirtazapine.
3. Other somatic therapies
a. Electroconvulsive therapy
Electroconvulsive therapy has the highest rates of response
and remission of any form of antidepressant treatment, with
70%–90% of those treated showing improvement (234–236). Although the remission rate with ECT appears to be
lower when it is used in community settings than when it is
used in clinical trials (237), the proportion of patients withmajor depressive disorder who respond to ECT is still
greater than the proportion who respond to antidepressant
medication. In addition, ECT has been associated with sig-nificant improvements in health-related quality of life (238).
Consequently, ECT should be considered for patients with
severe major depressive disorder that is not responsive topsychotherapeutic and/or pharmacological interventions,
particularly those with significant functional impairment
who have not responded to numerous medication trials(239). Electroconvulsive therapy may be particularly bene-
ficial and can be considered as a first-line treatment option
for severe major depressive disorder when it is coupled with
psychotic features (240, 241), catatonia (239, 242), suicide
risk (243), or food refusal leading to nutritional compro-
mise, as well as in other situations when a particularly rapidantidepressant response is required (240), such as with se-
verely ill inpatients (239). Electroconvulsive therapy is also
indicated as a first-line treatment for patients who have pre-viously shown a positive response to this treatment modality
or who prefer it (239).
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 45
1. Side effects of electroconvulsive therapy
Electroconvulsive therapy is a very safe treatment, and
there are no absolute contraindications to its use (239).
Risks of morbidity and mortality, in general, do not exceed
those associated with anesthesia alone (239, 244, 245).However, the presence of some medical conditions may
necessitate modifications in anesthesia or ECT adminis-
tration.
Electroconvulsive therapy may have cardiovascular side
effects, mediated by changes in the autonomic nervoussystem with the initial stimulus and subsequent seizureactivity (239). More specifically, ECT typically causes a
transient rise in heart rate and blood pressure, with asso-
ciated increases in cardiac wo rkload and intracranial pres-
sure. These effects can be managed by optimizing bloodpressure control prior to ECT and administering anti-hypertensive agents (e.g., short-acting beta-blockers or
calcium channel blockers) at the time of ECT (239). Ar-
rhythmias, which are usually transient, can also occur inconjunction with ECT and can be managed with usual
antiarrhythmic therapies if they do not resolve spontane-
ously (239).
Electroconvulsive therapy can also be associated with
cognitive effects, the most common of which is a period ofconfusion following the ECT and associated anesthesiathat generally lasts between 30 and 60 minutes (246).
Electroconvulsive therapy also is associated with antero-
grade amnesia, which typically resolves soon after the lastECT treatment (247). Some degree of retrograde amne-
sia, particularly for recent memories, may continue for a
longer period of time after the end of the ECT course(247) but is less pronounced for autobiographical memo-
ries than for impersonal memories (248). These cognitive
effects of ECT are related to electrode placement, stimulusdosage, age, and premorbid cognitive status (249–253).
Retrograde amnesia also improves over time, typically re-
solving within 6 months (248, 252), although some patientsreport incomplete recovery of memories, particularly for
events around the time of the treatment (247, 254). Rarely,
patients report more pervasive and persistent cognitivedisruption, the basis of which is uncertain (252, 255). For
many individuals, however, subjective memory (256) and
quality of life (238) is improved following ECT with theresolution of the major depressive episode and its associ-
ated deficits in memory or executive functioning (257,
258).
2. Implementation of electroconvulsive therapy
The evaluation preceding ECT consists of a psychiatric
history and examination to verify that ECT is indicated, a
general medical evaluation (including medical history andphysical examination with cognitive assessment, vital signs,and any specifically indicated laboratory, radiologic, or
imaging studies) to define factors that may influence the
risk of ECT, and an anesthesia  evaluation to identify and
address the nature and extent of anesthetic risk and the
need for modification of medications or anesthetic tech-nique (239). This evaluation should include a summary oftreatment indications, treatment risks, and a suggestion of
any indicated additional evaluative procedures, alterations
in treatment, or modifications in ECT technique (239). Inassessing indications for cauti on (e.g., recent myocardial
infarction, cardiac arrhythmias, intracranial space-occu-pying lesions), the relative risks and benefits should becarefully weighed in collaboration with an anesthesiolo-
gist, a general medical physician, and other specialists, as
necessary. Once completed, the pre-ECT evaluation will
serve as the basis for a specific, individualized discussion
of the risks and benefits of ECT relative to other thera-peutic options as part of the informed consent process.
With the patient’s permission, it is helpful to educate the
patient’s family about ECT and involve them in discus-sions relating to consent.
An additional aspect of de cision-making prior to ECT
relates to the use of psychotropic medications during theECT course. There is growing use of ECT combined with
antidepressant medication. Although data supporting this
practice are still few, it does not appear to increase side ef-fects and may augment response (259, 260). An additional
goal of combination treatment is to minimize the risk of
relapse between the end of the ECT course and the attain-ment of full antidepressant effectiveness. Antipsychotic
medications are typically continued during the ECT
course (239, 261), although most data on this practice comefrom studies of patients with schizophrenia who are re-
ceiving ECT. The safety of combining lithium and ECT
has been questioned, although there are conflicting data(239, 262). Medications that have anticonvulsant proper-
ties are often discontinued or given at decreased doses
during the ECT course to minimize effects on seizure in-duction (239, 261). With benzodiazepines, there is some
evidence that concurrent use may diminish ECT effective-
ness, particularly when right unilateral electrode place-ment is used (263).
Electroconvulsive therapy may be administered either
unilaterally or bilaterally (using a bitemporal or bifrontalelectrode placement). Compared with patients who re-
ceive bilateral treatment, most patients who receive right
unilateral electrode placement with low stimulus intensi-ties experience fewer cognitive effects but less therapeutic
benefit (253). Stimuli of higher intensity (i.e., 500% above
seizure threshold) are associat ed with antidepressant ef-
fects more comparable to those seen with bilateral elec-
trode placements, although such stimulus intensities are
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
46 APA PRACTICE GUIDELINES
not always achievable with existing ECT devices (264). Re-
gardless of what electrode placement is chosen, stimulus
dosing should be individualized and stimulus parametersadjusted to induce an adequate generalized seizure, which
is typically at least 20 seconds or greater in motor duration
and 30 seconds in EEG duration (239). Failure to inducean adequate seizure should be followed immediately by
restimulation at higher energies until an adequate seizure
is elicited.
Electroconvulsive therapy is typically administered
2–3 times/week; less frequent administration has been as-sociated with less cognitive impairment but also a longerlag in the onset of action (265). In clinical practice, the
need for ECT to be administered at this frequency could
produce logistical barriers for some patients who would
either require hospitalization or transportation after ECT
sessions. The acute course of ECT treatment typicallyconsists of six to 12 treatments and generally does not ex-
ceed 20 treatments (239, 266). It is important that treat-
ment continue until symptoms have remitted or clearlyreached a plateau, since relapse rates appear to be greater
and overall prognosis worse if ECT is discontinued pre-
maturely (237). Use of a formal rating scale may be help-ful in assessing symptom response as well as the cognitive
side effects of treatment, permitting adjustments in the
treatment parameters or frequency (239, 267).
For more detail on the administration of ECT, see APA ’s
The Practice of Electroconvulsive Therapy: Recommendationsfor Treatment, Training, and Privileging  (A T ask Force Report
of the American Psychiatric Association)  (239).
b. Transcranial magnetic stimulation
T ranscranial magnetic stimulation (TMS) uses a specifically
designed magnetic coil that is placed in contact with the
head to generate rapidly alternating magnetic-resonance-imaging-strength magnetic fields and produce electrical
stimulation of superficial cortical neurons. Based on the
results of a multisite randomized sham-controlled clinicaltrial of high-frequency TMS over the left dorsolateral
prefrontal cortex (268), TMS was cleared by the FDA in
2008 for use in individuals with major depressive disorderwho have not had a satisfactory response to at least one
antidepressant trial in the current episode of illness. How-
ever, another large randomized sham-controlled trial ofTMS added to antidepressant pharmacotherapy showed
no significant benefit of left dorsolateral prefrontal cortex
TMS (269). In comparisons of actual TMS versus sham
TMS, most (270–272) but not all (273) recent meta-anal-
yses have found relatively small to moderate benefits of
TMS in terms of clinical re sponse. Although the primary
studies used in these meta-analyses are highly overlapping
and the variability in TMS stimulus parameters and treat-ment paradigms complicates the interpretation of re-search findings, these meta-analyses also support the use
of high-frequency TMS over the left dorsolateral pre-frontal cortex. Lesser degrees of treatment resistance may
be associated with a better acute response to TMS (274).
In comparison with ECT , TMS has been found in ran-
domized studies to be either less effective than ECT (275)or comparable in efficacy to ECT (276–278), but in the
latter studies TMS was more effective and ECT was lesseffective than is typically seen in clinical trials. A fewer
number of studies have compared cognitive effects of
TMS and ECT. One randomized trial found no signifi-cant difference between TMS and non-dominant uni-
lateral ECT on performance on neuropsychological tests
at 2 and at 4 weeks of treatment (276), although a small
open-label trial reported a greater degree of memory dif-
ficulties with ECT than with TMS shortly after the treat-ment course (279).
Across all studies, TMS was well tolerated and was asso-
ciated with low rates of treatment dropout (270, 280).T ransient scalp discomfort and headaches were the most
commonly reported side effects (280).
In clinical practice, the need for daily TMS could pro-
duce logistical barriers for some patients.
c. Vagus nerve stimulation
Vagus nerve stimulation is approved for use in patientswith treatment-resistant depression on the basis of its po-
tential benefit with long-term treatment. There is no in-
dication for the use of VNS in acute phase treatment ofdepression, as data showed no evidence for acute efficacy
(281, 282). Further information on the use of VNS as an
adjunct to other antidepressive treatments is provided inSection II.B.7.c.
4. Psychotherapy
There has been considerable research on time-limited
psychotherapies for major depressive disorder, although
the number of studies is smaller than for pharmacothera-pies. Most research has focused on individual, in-person,
outpatient treatment, in part based on the needs and con-
straints of research methods. However, research has alsobegun to explore psychotherapies in differing formats,
including groups, over the telephone, and with computer
assistance.
When psychotherapy is part of the treatment plan, it
must be integrated with psychiatric management (SectionII.A) and any other treatments (e.g., pharmacotherapy) thatare being provided. Clinical considerations and other
patient factors should be considered in determining thenature and intensity of psychotherapy. T ypically psycho-
therapy is given in an ambulatory setting, although some
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 47
psychotherapies might benefit depressed inpatients, given
adequate lengths of stay and courses of treatment (283–
285). Like pharmacotherapy, the effectiveness of psycho-therapy will vary with the skill and training of the therapist.
Patient factors, such as the nature and duration of depres-
sive symptoms, beliefs and attitudes toward psychotherapy,and early life experiences (e.g., history of trauma) also affect
treatment response to psychotherapy. Psychotherapy is
particularly useful in addressing the psychosocial stressorsand psychological factors that have an impact on the devel-
opment or maintenance of depressive symptoms.
Cognitive-behavioral therapy, interpersonal psycho-
therapy (IPT), and behavioral psychotherapies (e.g., be-
havioral activation) have demonstrated acute efficacy in
treating major depressive disorder. There is less evidencefor other psychotherapies. However, one meta-analysis
found no large differences in long-term efficacy betweenany of the major psychotherapies, including dynamic psy-
chotherapy, for mild and moderate depression (286). In
terms of longer term outcomes, psychotherapy is generallyfound to have more prolonged effects than pharmacother-
apy after cessation of active treatment. In particular, IPT
and CBT have shown lasting benefits in maintaining remis-sion (287–289). These time-limited treatments are essen-
tially equipotent with antidepressant medications for
outpatients with mild to moderate acute depression butprobably should be used in conjunction with medication
for severe or melancholic major depressive disorder. Some
research has suggested patient and illness characteristicsthat might predict differential benefits of CBT over IPT ,
and vice versa, for patients with major depressive disorder
(e.g., see reference 290), but such preliminary findings re-quire replication.
Cognitive-behavioral therapy and IPT appear less ef-
fective than pharmacotherap y for chronic depression, at
least as acute monotherapy (291–296). Nonetheless, in
patients who respond to medication, psychotherapy may
foster the development of social skills and confidence af-ter years of depression-related impairments (297).
Psychotherapy carries its own “side effects.” A psycho-
therapy that requires considerable time or patience maybe poorly tolerated. The work of psychotherapy itself may
generate anxiety or other strong feelings, which may be
difficult for patients to manage. An indirect measure ofthe relative side effects and tolerability of psychotherapy
can be obtained from the dropout rates in clinical trials;
however, many other factors can also affect these rates(e.g., other burdens of the research trial, specific features
of the clinical management provided, logistical barriers in
attending appointments). Depending on what can reason-ably be expected with the given type of psychotherapy, the
psychiatrist should consider a change in the intensity ortype of psychotherapy and/or addition or change to med-
ication if psychotherapy for major depressive disorder has
not resulted in significant improvement in 4–8 weeks.
a. Specific psychotherapies
1. Cognitive and behavioral therapies
In the treatment of depressed patients, psychotherapiesthat focus primarily on aspects of cognitive patterns and
those that emphasize behavioral techniques can be used
alone, but are generally used in combination. Cognitive-behavioral therapy combines  cognitive psychotherapy
with behavioral therapy and maintains that irrational
beliefs and distorted attitudes toward the self, the environ-
ment, and the future perpetuate depressive affects andcompromise functioning. The goal of CBT is to reducedepressive symptoms by challenging and reversing these
beliefs and attitudes and encouraging patients to change
their maladaptive preconceptions and behaviors in reallife (298).
Cognitive-behavioral therapy is an effective treatment
for major depressive disorder. In meta-analyses, CBT hasgenerally surpassed control conditions in efficacy and has
had equal efficacy compared with other empirically sup-
ported psychotherapies (i.e., IPT and behavior therapy)(299). Studies comparing the effectiveness of CBT with
pharmacotherapy, however, are methodologically challeng-
ing to conduct, and results are inconsistent (296, 300).Also unclear is whether CBT is less effective for patients
with more severe depressive symptoms.
Behavior therapy for major depressive disorder is based
on theoretical models drawn from behavior theory (301)and social learning theory (302 ). Behavioral activation is a
newly articulated behavioral intervention with some pos-
itive preliminary results that merit further study (288,
303). Specific behavior therapy techniques include ac-
tivity scheduling (304, 305), self-control therapy (306),social skills training (307), and problem solving (308). Be-
havior therapy involves graded homework, scheduling of
enjoyable activities, and minimizing unpleasant activities(309). Behavior therapy has demonstrated efficacy, at times
superior to cognitive therapy, in treating major depressive
disorder (310).
2. Interpersonal psychotherapy
The focus of IPT is on current life changes, including
losses, role disputes and role transitions, social isolation,
deficits in social skills, and other interpersonal factors thatmay interact with the development of the depressiveepisode (311, 312). In IPT the goal is to intervene by iden-
tifying the current trigger of the depressive episode, facil-
itating mourning in the case of bereavement, promotingrecognition of related affects, resolving role disputes and
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
48 APA PRACTICE GUIDELINES
role transitions, and building social skills to improve rela-
tionships and to acquire needed social supports. In IPT ,
major depressive disorder is defined as a medical illness,and the illness, rather than the patient, is blamed for the
symptoms. Interpersonal psychotherapy’s medical model
makes it highly compatible with pharmacotherapy incombined treatment.
Interpersonal psychotherapy is an efficacious treat-
ment for major depressive disorder (296, 313). Studieshave shown efficacy of this treatment in depressed pri-
mary care patients and patients with more severe depres-
sion (311). The efficacy of IPT has been demonstrated foradolescents, pregnant and postpartum women, and geri-
atric patients (311). Interpersonal psychotherapy can also
be used as a monthly maintenance therapy to prevent
relapse (289, 314, 315). Some studies have also suggested
possible subgroups in whom IPT may show differentialefficacy, specifically among HIV-positive patients (316)
and patients who have co-occurring obsessive personality
traits and who are single and not living with others (317).Furthermore, for patients with severe life events, IPT may
have advantages over therapies that do not focus on such
events directly.
3. Psychodynamic psychotherapy
The term “psychodynamic psychotherapy” encompasses a
range of brief to long-term psychotherapeutic interven-tions (318–320). These interventions derive from psycho-
dynamic theories about the etiology of psychological
vulnerability, personality development, and symptom for-mation as shaped by development and conflict occurring
during the life cycle from earliest childhood forward (321–
325). Some of these theories focus on conflicts related toguilt, shame, interpersonal relationships, the management
of anxiety, and repressed or unacceptable impulses. Others
address developmental psychological deficits produced byinadequacies or problems in the relationship between the
child and emotional caretakers, resulting in problems of
self-esteem, sense of psychological cohesiveness, and emo-tional self-regulation (323, 326–330).
Psychodynamic psychotherapy may be brief but usu-
ally has a longer duration than  other psychotherapies, and
its aims extend beyond immediate symptom relief. These
goals are to modify underlying  psychological conflicts and
deficits, which increase the patient’s vulnerability to depres-
sive affect and the development of major depressive disor-
der. Psychodynamic psychotherapy is therefore broader
than most other psychotherapies, encompassing both cur-rent and past problems in interpersonal relationships,
self-esteem, and developmental conflicts associated with
anxiety, guilt, or shame. Time-limited, structured psycho-dynamic psychotherapy may focus more on understand-ing the psychological basis of the presenting symptoms or
on a selected underlying conflict. Sometimes a goal of psy-
chodynamic psychotherapy, brief or extended, may be tohelp the patient accept or adhere to necessary pharmaco-
therapy (331).
Although psychodynamic psychotherapy is often used
in clinical practice, its efficacy in the acute phase of majordepressive disorder remains less well studied in controlled
trials than the efficacy in this phase of some other forms ofpsychotherapy. This research is reviewed in Part B, Sec-
tion V .B.3.
4. Problem-solving therapy
Problem-solving therapy is a manual-guided, brief treat-
ment lasting six to 12 sessions. This therapy, often admin-
istered by nurses or social workers, has been used to
prevent depression in elderly and/or medically ill patients,and it has also been used to treat patients with relatively
mild depressive symptoms. The approach combines ele-
ments of cognitive therapy (addressing negative assess-ments of situations) and IPT (focal problem solving). Some
studies have reported modest improvement in patients
with mild depressive symptoms. Although problem solv-ing therapy has had limited testing for patients with major
depressive disorder, it may have a role in targeted patient
populations with mild depression (332–335).
5. Marital therapy and family therapy
Marital and family problems are common in the course ofmood disorders, and comprehensive treatment often de-
mands assessing and addressing these problems. Marital
and family problems may be the consequence of major de-pressive disorder but may also increase vulnerability to
developing major depressive disorder or retard recovery
from it (336–339). A number of marital and family ther-
apies have been shown to be effective in the treatment
of depression. T echniques include behavioral approaches(338), problem-focused approaches (340), and strategicmarital therapy (341, 342). Family therapy has also been
found to be helpful in the treatment of more severe forms
of depression in conjunction with medications and hospi-talization (343).
6. Group therapy
Group psychotherapy is widely practiced, but research on
its application to major depressive disorder is limited.Specific types having some data to support their efficacy
include CBT (344–347) and IPT (348–351). Meta-analyses
of the relative effectiveness of psychotherapeutic approachesconducted in group format versus individual format have
not involved patients with rigorously defined major depres-
sive disorder (352–355).
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 49
On the basis of a very limited controlled study, support-
ive group therapy has been suggested to have utility in the
treatment of major depressive disorder. In a study of de-pressed outpatients, a mutual support group and group
CBT were found to be equally effective in reducing de-
pressive symptoms (346). In a study of HIV-positive pa-tients with mild to moderate major depressive disorder,
structured supportive group therapy plus placebo yielded
similar decreases in depressive symptoms to structuredgroup therapy plus fluoxetine (356). Individuals experienc-
ing stressors such as bereavement or chronic illness may
benefit from contact with others facing similar challenges.
Medication maintenance support groups may also of-
fer benefits, although data from controlled trials for pa-tients with major depressive disorder are lacking. Such
groups inform the patient and family members about
prognosis and medication issues, providing a psychoedu-cational forum that contextualizes a chronic mental illness
in a medical model.
The efficacy of self-help groups led by lay members
(357) in the treatment of major depressive disorder hasnot been well studied. However, one investigation of
group therapies found that a higher proportion of de-pressed outpatients had remission following treatment in
groups led by professionals than had remission following
participation in groups led by nonprofessionals (346).Further study is needed on the possibility that self-help
groups may serve a useful role in enhancing the support
network and self-esteem of participating patients withmajor depressive disorder and their families.
Overall, group therapy has some evidence to support
its use as well as the potential advantage of lowered cost,inasmuch as one or two therapists can treat a larger num-
ber of patients simultaneously. This advantage needs to be
weighed against the difficulties in assembling the group,the lesser intensity of focus patients receive relative to in-
dividual psychotherapy, and potentially adverse effects
from interactions with other group members.
b. Implementation
It can be useful to establish an expected duration of psy-
chotherapy at the start of treatment. Communicating this
expectation may help mobilize the patient and focus treat-ment goals, yet there are few data available on the optimal
duration of specific depression-focused psychotherapies.
In many trials, CBT and IPT have been delivered in ap-proximately 12–16 weekly sessions. In a subanalysis of one
clinical trial, CBT delivered in 16 weeks was more effec-
tive than CBT delivered in 8 weeks for those with severemajor depressive disorder (358). Moreover, evidence sug-
gests benefit from monthly continuation phase treatment
with IPT in reducing the probability of relapse (314). Inaddition, patients with chronic, treatment-resistant de-
pression may require long-term treatment.
The optimal frequency of psychotherapy has not been
rigorously studied in controlled trials. The psychiatristshould consider multiple factors when determining the
frequency for individual patients, including the specifictype and goals of the psychotherapy, the frequency neces-
sary to create and maintain a therapeutic relationship, the
frequency of visits required to ensure treatment adher-
ence, and the frequency necessary to monitor and address
suicide risk and other safety concerns. Time-limited brief
psychotherapies may mobilize many depressed patients tomore rapid improvement. The severity of illness, the pa-
tient’s cooperation with treatment, availability of social
supports, cost, geographic accessibility, and presence of
co-occurring general medical problems may also influ-
ence visit frequency. The frequency of outpatient visitsduring the acute phase is generally weekly but may vary
based on these factors. Some experienced clinicians find
that sessions are needed at least twice weekly, at least ini-tially, for patients with moderate to severe depression.
Regardless of the type of depression-focused psycho-
therapy that is selected, the clinician should carefully andsystematically monitor the patient’s response to treatment,
which can be facilitated by the use of clinician- and patient-
rated scales at regular intervals (see Section II.A.8). If 4–8weeks of treatment do not yield at least moderate im-
provement ( ≥20% diminution in symptoms), the clinician
should thoroughly review and reappraise the treatment
plan.
c. Combining psychotherapy and medication
Several meta-analyses of studies of the combination of
psychotherapy and pharmacotherapy for patients withmajor depressive disorder have documented a modest ad-
vantage for the combination as  compared with one or the
other modality alone (359–361). Particularly large addi-
tive effects have been observed in individual studies of pa-
tients with chronic depression (362), patients with severe
recurrent depression (359), and hospitalized patients(285). Combined treatment might therefore be consid-
ered a treatment of first choice for patients with major de-
pressive disorder with more severe, chronic, or complexpresentations. Combining family therapy with pharmaco-
therapy has also been found to improve posthospital care
for depressed patients (343).
Dual treatment combines the unique advantages of each
therapeutic modality: while pharmacotherapy may provideearlier symptomatic relief, psychotherapy yields broaderand longer lasting improvement (363). Psychotherapy can
also be used to address issues that arise during pharmaco-
therapy, such as decreased adherence. However, the advan-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
50 APA PRACTICE GUIDELINES
tage of routinely combining interventions may be modest
for patients with less severe depressive symptoms (359).
There are no empirical data from clinical trials to help
guide the selection of particular antidepressant medicationsand particular models of psychotherapeutic approaches
for individuals who will receive the combination of bothmodalities. In general, the same issues that influence these
decisions when choosing a monotherapy will apply, and
the same doses of antidepressant medication and the samefrequency and course of psychotherapy should be used for
patients receiving combination modality treatments as are
used for patients receiving them as a monotherapy.
Results from a series of recent studies provide indirect
evidence that for patients who have had only a partial re-sponse to pharmacotherapy, adding a course of CBT may
be an effective strategy for preventing relapse (363–368).During 12 weeks of treatment in the STAR*D study, cog-nitive therapy was as effective as either augmenting with
bupropion or buspirone or changing antidepressants to
bupropion, sertraline, or venlafaxine. However, patientswho did not respond to an initial course of citalopram were
less likely to accept cognitive therapy as a change or aug-
mentation option than they were to accept a different med-ication option (369), perhaps due to the nature of the study
design.
5. Complementary and al ternative treatments
As defined by the National Center for Complementary
and Alternative Medicine, complementary and alternativemedicine is “a group of diverse medical and health care
systems, practices, and products that are not presently con-
sidered to be part of conventional medicine.” As the defi-nitions are usually applied, “complementary” therapies are
used conjunctively with conv entional medicine, “alterna-
tive” therapies are used in place of conventional medicine,
and “integrative” medicine makes use of all therapies ap-
propriate to an individual patient’s needs.
The use of integrative therapies is increasingly com-
mon, although training and comfort with complementary
and alternative modalities vary greatly by practitioner.
Many patients do not spontaneously disclose use of comple-
mentary or alternative treatments to health care profession-
als, so it is particularly important that direct inquiry aboutsuch treatments be part of routine health care questions.At this time, there are several modalities that have mod-
est evidence for antidepressant efficacy and deserve
further study. Some of these modalities can be recom-mended with enthusiasm for their general health benefits;
however, patients should be informed that evidence for
their antidepressant efficacy as monotherapy is limited orabsent.a. St. John’s wort
St. John’s wort is a plant widely used to treat depressive
symptoms. Overall, studies of St. John’s wort show greaterconsensus and support for benefits in mild to moderate ma-
jor depressive disorder, as compared with less consistent
findings in patients with more severe symptoms. One re-view of 14 short-term, double-blind trials conducted in
outpatients with mild to moderate symptoms of major de-
pressive disorder concluded that St. John’s wort in doses of300 mg/day and 1,800 mg/day had efficacy that was supe-
rior to placebo (105). St. John’s wort had generally compa-
rable efficacy and fewer side effects than low-dose TCAtreatment (e.g., 30–150 mg/day of amitriptyline) (105), but
doses at the low end of this range would not be expected to
produce therapeutic benefits. However, in the two largest
controlled studies conducted in the United States (370,
371), effects of St. John’s wort did not differ from placebo,which somewhat limits confidence in the magnitude of the
antidepressant actions of St. John’s wort. In addition, prep-
arations of St. John’s wort are not regulated by the FDA asa drug and lack standardization of their ingredients, com-
position, and potency. Based on the evidence cited, St.
John’s wort would not meet the FDA ’s minimum require-ments to be declared an effective antidepressant and is not
recommended for general use in treating depression.
Another important consideration with St. John’s wort
is the potential for drug-drug interactions (372–374). St.John’s wort appears to induce the metabolism of drugs via
CYP 3A4, reducing the efficacy of medications, includingantiretroviral medications, immunosuppressants (includ-
ing cyclosporine), antineopl astic agents, anticoagulants
(including warfarin), oral contraceptives, and hormone
replacement therapy (373, 374). Unwanted pregnancies
have been reported with concomitant St. John’s wort and
oral contraceptive use (373, 375, 376), and rejection of trans-planted organs has been observed when St. John’s wort is
taken concurrently with cyclosporin (374). The significant
decreases in antiretroviral medication levels with con-comitant St. John’s wort use suggest that these medica-
tions will be less effective in treating HIV infection (374).
Effects of St. John’s wort on P-glycoprotein have also beenobserved, altering the phar macokinetics and pharmaco-
dynamics of medications such  as digoxin that are trans-
ported by this route (374). Apart from affecting bloodlevels of nonpsychiatric medications, the safety and effi-
cacy of the combined use of St . John’s wort with other an-
tidepressant medications is not known. The combined use
of St. John’s wort with MAOIs is contraindicated.
b. S-adenosyl methionine
S-adenosyl methionine is a naturally occurring molecule.
In humans, it is concentrated in the liver and the brain and
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 51
serves as a methyl donor in the synthesis of biologically
active compounds such as phospholipids, catecholamines,
and the neurotransmitters dopamine and serotonin (377).Cerebrospinal fluid levels of SAMe are lower in individu-
als with severe major depre ssive disorder, compared with
control subjects (378), and treatment with SAMe increases
CSF SAMe and 5-hydroxyindoleacetic acid levels (379).
S-adenosyl methionine is available for both parenteral and
oral administration (380).
Some data support the efficacy and tolerability of SAMe
in patients with major depr essive disorder. Oral, intrave-
nous, and intramuscular formulations have been assessed
and appear efficacious in at least pilot studies (381–383).
Like St. John’s wort, SAMe is not regulated by the FDA
and lacks standardization of its composition and potency.
S-adenosyl methionine has been compared with TCAs
and has been reported to have greater efficacy while be-
ing more tolerable (381). It is unclear at present how
SAMe compares to SSRIs in efficacy and cost-efficiency.
While some data support the use of SAMe as monother-apy and as augmentation therapy, the data at this time, as
with St. John’s wort, are insufficient to make a recom-
mendation for its use in the treatment of major depres-sive disorder.
c. Omega-3 fatty acids
Most studies of omega-3 fatty acids for major depressivedisorder have been adjunctive studies, in which patients
were already receiving antidepressant medications but still
met the criteria for major depressive disorder. Studies varyin the omega-3 fatty acids used (eicosapentaenoic acid
[EPA], docosahexaenoic acid [DHA], or the combination),
and doses and durations of study trials have also varied. It isdifficult to interpret the literature on this treatment given
the heterogeneity in study design and outcomes.
Omega-3 fatty acids are generally recommended as an
adjunctive therapy for mood disorders, as health benefits,including those for cardiovascular health, are well es-
tablished, and individuals with psychiatric disorders maybe at greater risk for obesity, metabolic problems, and
other health problems than the general population (384,
385). More evidence is required to establish a definitiverole in the acute treatment of major depressive disorder.
Doses of 1–9 grams have been studied in mood disorders,
with a majority of evidence supporting use of lowerdoses. Adjunctive EPA or the combination of EPA and
DHA (the combination found in most commercially
available brands) appears most useful, with less evidencefor DHA alone for the trea tment of major depressive
disorder. Further data are needed to ascertain the role ofomega-3 fatty acids as monotherapy for major depressivedisorder.d. Folate
Folate has been primarily assessed as a predictor of anti-
depressant medication response and as an adjunctive
treatment. Low folate blood levels have been associatedwith lack of response and slower response to fluoxetine for
major depressive disorder (386, 387), and higher folate
levels at treatment baseline appear associated with betterresponse to antidepressants (388). Folate has been studied
as an adjunctive treatment compared with placebo in ad-
dition to fluoxetine, with significantly greater improve-ment in those receiving folate, especially among female
patients (389).
Folate is a low-risk intervention with general health
benefits. Folate protects against neural tube defects in
early pregnancy. In general, 0.4–1 mg of folate is recom-mended for women of reproductive age. Considering the
modest evidence that supports folate as an augmentation
strategy and its attractive risk-benefit profile, folate canbe recommended as a reasonable adjunctive strategy for
major depressive disorder that carries little risk and may
decrease birth defects in the case of pregnancy. Data areinadequate to suggest efficacy as a monotherapy.
e. Light therapy
Bright light therapy appears effective for seasonal affec-tive disorder and nonseasonal major depressive disor-
der, as demonstrated in generally short-term, placebo-
controlled trials (390–394), although some studies havemethodological limitations (395). The mechanism of ac-
tion for light therapy is not clear but appears to involve
the serotonergic neurotransmitter system (396, 397).There is some evidence that light therapy may hasten the
response to treatment with antidepressant medication
(398). Open-label data also support light therapy for patientswith major depressive disorder that has not responded to
antidepressant medication (399). Greater intensity of light
is associated with efficacy (400). Light therapy also mayaugment the antidepressant benefits of partial sleep dep-
rivation (401, 402). Monitoring for mania and hypomania
may be appropriate with initiation of light therapy, as hy-pomania has been reported (392). However, in general
bright light therapy is a low-risk and low-cost option for
treatment.
f. Acupuncture
Acupuncture is a treatment modality that is part of tradi-tional Chinese medicine. Its efficacy is somewhat difficult
to assess, as much of the research is published in Asian lan-
guages and overlooked in ty pical literature searches. In
addition, there is significan t variation in the acupuncture
techniques used as well as limited descriptions of method-ology and diagnosis (403). One randomized trial showed
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
52 APA PRACTICE GUIDELINES
comparable benefits of electroacupuncture and amitripty-
line (404), and another small randomized trial in depressed
women showed benefits of acupuncture relative to a sham
control (405). However, a subsequent larger study did not
replicate these results (406), and a recent meta-analysis
concluded that acupuncture was not associated with anybenefits in treating major depression in terms of response
or remission rates (407). Assuming needles are properly
sterilized, there do not appear to be substantial risks ofacupuncture treatment. However, based on current evi-
dence, acupuncture is not recommended in the treatment
of major depressive disorder.
6. Assessing response and adequacy of treatment
The goal of acute phase treatment for major depressive dis-
order, insofar as possible, is to achieve remission and a re-
turn to full functioning and quality of life. Remission isdefined as at least 3 weeks of the absence of both sad mood
and reduced interest and no more than three remaining
symptoms of the major depressive episode (
408). However,
it is not uncommon for patients to have substantial but in-
complete symptom reduction or improvement in function-
ing during acute phase treatment. A number of studies haveprovided compelling evidence that even mild residual
symptoms at the end of a depressive episode are associated
with significant psychosocial disability, compared with as-ymptomatic remission (
40 9); a more than three times faster
relapse to a subsequent major depressive episode (410); andin first-episode patients, a more chronic future course (410–412). The presence of mild residual symptoms has been
shown to be an even stronger predictor of a subsequent re-
turn to a major depressive episode than a prior history ofmultiple episodes of major depressive disorder (410). For
this reason, it is important not to conclude the acute phase
of treatment prematurely for partially responsive patients.Throughout treatment, both the patient’s response and the
adequacy of treatment must be vigilantly and systematically
monitored. Use of structured measures of depressionsymptom severity, side effects, treatment adherence, and
functional status can facilitate  identification of patients who
have not had a complete response to treatment (40, 44).
If a patient is found to have an incomplete treatment
response, the treatment itself should be evaluated. Medi-
cations must be thoughtfully selected and given at an ad-equate dose and for an adequate duration. Similarly,
psychotherapy must be well chosen for the patient, skill-
fully executed, and conducted over an appropriate periodof time with an adequate frequency of visits. In addition to
being caused by inadequate treatment, poor response may
result from multiple other factors (413) that are enumer-ated in T able 9.For pharmacotherapy, determination of the adequacy of
treatment requires ensuring that antidepressant medica-tions have been used for an adequate dose and duration.
This can be assessed using standardized measurement in-
struments (414). Generally, adequate treatment with anantidepressant medication for at least 4–6 weeks is neces-
sary before concluding that a patient is not responsive or
only partially responsive to a particular medication (218,221). For patients with no improvement in symptoms
during the initial weeks of treatment, treatment should be
reevaluated and possibly changed. Furthermore, there islittle evidence to support extending antidepressant medi-
cation trials beyond 6 weeks in patients who have shown
no response. Patients with chronic forms of depression orwith co-occurring Axis I disorders or general medical
conditions may require a longer duration of acute phase
treatment before concluding that a different treatmentstrategy is indicated (224).
For psychotherapy, treatment should be reassessed if
there has not been meaningful improvement after a fewmonths, depending on what can reasonably be expected for
the given type of psychotherapy. Patients should be reas-
sessed every 3–4 months to ensure adequate improvement.Regardless of treatment modality, lack of improvement
over time warrants reconsideration of interventions, given
the large number of available treatment options.
7. Strategies to address incomplete response
The psychiatrist should consider a change in treatmentfor patients who have not fully responded to an adequateacute phase treatment over a sufficient time, generally
4–8 weeks. The treatment plan can be revised by imple-
menting one of several therapeutic options, including op-TABLE 9. Potential Reasons for Treatment Nonresponse
Inaccurate diagnosis
Unaddressed co-occurring medical or psychiatric 
disorders, including substance use disorders
Inappropriate selection of therapeutic modalitiesInadequate dose of medication or frequency of 
psychotherapy
Pharmacokinetic/pharmacodynamic factors affecting 
medication action
Inadequate duration of treatmentNonadherence to treatmentPersistent or poorly tolerated side effectsComplicating psychosocial and psychological factorsInadequately trained therapist or poor “fit” between 
patient and therapist
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 53
timizing the initial treatment, changing to a different
treatment, and combining treatments. These options areoutlined in Figure 2 and described in more detail below.
Following any change in treatment, the patient should
continue to be closely monitored. If there is not at least amoderate improvement in major depressive disorder
symptoms after an additional 4–8 weeks of treatment, the
psychiatrist should conduct another thorough review. Thisreappraisal should include the following: verifying the pa-
tient’s diagnosis and adherence; uncovering and address-
ing clinical factors that may be preventing improvement,such as the presence of co-occurring general medical con-
ditions or psychiatric conditions (e.g., alcohol or substance
abuse); evaluating for potential drug-drug interactions;obtaining collateral information from those involved with
the patient; and uncovering and addressing psychosocial,
psychological, and personality factors that may be imped-ing recovery (T able 9). If no new information is uncovered
to explain the patient’s lack of adequate response, othertreatment options should be considered, including ECT
and a consultation from an expert in mood disorders. De-spite optimal treatment, some patients may continue to
have chronic depressive sympto ms. For these patients, the
psychiatrist should add a disease management component
to the overall treatment pl an. This component involves
setting realistic expectations, improving functioning, anddeveloping self-management skills (415, 416).
a. Maximizing initial treatments
For patients who have not fully responded to treatment
for depression, an initial strategy is to optimize the inten-sity of psychotherapy or maximize the dose of medication,
especially if the upper limit of the antidepressant dose has
not been reached. Decisions about pharmacotherapy willinvolve a balancing of efficacy, side effects, and medica-
tion adherence. Dose escalation and management of side
effects at critical decision points are essential in order toavoid premature discontinuation of the chosen antide-Response
None or Partial Full
Initial weeks Assess adherence. If clinical severity 
warrants and treatment is well tolerated, 
consider increasing medication dosage or 
intensity of psychotherapy, especially if there is no response. If symptoms are 
severe or life-threatening, consider ECT.If treatment is well-tolerated, maintain 
current treatment approach.
At 4–8 weeks In patients treated with an antidepressant, 
consider increasing the dose (if well tolerated), changing to a different 
antidepressant, and changing to or 
augmenting with psychotherapy. 
Augmentation therapy or ECT may 
also be considered.
For insufficient response to psychotherapy, 
consider changing the intensity or type of psychotherapy and/or adding or changing to medication.
For ECT, see guideline text.Go to continuation phase.
Throughout treatment In patients who have significant side effects with antidepressant treatment, consider 
changing to a different antidepressant, reducing the dose, or treating the side effect. 
Also consider changing to psychotherapy or ECT.
If trials of two medications from the same antidepressant class have been ineffective, 
consider changing antidepressants to a different class.
For patients with difficulty tolerating psychotherapy, consider changing the intensity or 
type of therapy and/or adding  or changing to medication.
FIGURE 2. Assessment of Treatment Tolerability and Adequacy of Response
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
54 APA PRACTICE GUIDELINES
pressant medication and to maximize the dose and dura-
tion of the antidepressant therapy (40, 218).
Because of pharmacokinetic and pharmacodynamic
differences among individuals, some patients may requiredoses higher than those approved by the FDA to achieve
adequate blood levels of a medication and receive thera-peutic benefits. Patients who have had their dose in-
creased should be monitored for increased severity of side
effects; dose increases should be considered only for pa-tients who do not have significant or intolerable side ef-
fects while taking the medication. Frequent follow-up
contact (either in person or via the phone) may be neces-sary to address symptoms, side effects, and patient adher-
ence in order to personalize treatment to the specific
clinical needs of the patient. When available and clinically
meaningful, therapeutic ranges for blood levels of antide-
pressant medications are useful in optimizing medicationdosing (201, 232, 233).
Individual differences are common in the time to re-
sponse and the tolerability of treatments. For patients whohave shown a partial response to treatment, particularly
those with features of personality disorders and prominent
psychosocial stressors, extending the antidepressant med-ication trial (e.g., by 4–8 weeks) may allow up to one-third
of patients to respond more fully (417–419).
In patients who are receiving psychotherapy, similar
principles apply in terms of monitoring and adjustingtreatment in the context of nonresponse or difficulty tol-
erating psychotherapy (331). Factors to be considered in-clude the frequency of sessions, the type of psychotherapy
being used, the quality of the therapeutic alliance, and the
possible need for medications in lieu of or in addition topsychotherapy. Whereas increasing the frequency of ther-
apy sessions is a reasonable approach to nonresponse, this
approach is based on clinical wisdom and has not beensystematically studied.
b. Changing to other treatments
Changing to a different non-MAOI antidepressant medi-
cation is a common strategy for patients with treatment-
resistant major depressive disorder, especially those whohave not shown at least partial response to the initial med-
ication regimen. Although there are no specific patient
characteristics that predict which medication to choose(420), results from STAR*D suggest that changing to a
second-step treatment results in additional remission rates
of about 25%, and further changes are associated with con-tinued remission, albeit at lower rates (about 13%–14%).
T reatment can be changed to a non-MAOI antidepressant
medication from the same pharmacological class (e.g.,from one SSRI to another SSRI) or to one from a different
class (e.g., from an SSRI to a TCA) (369, 421–422). Addingor changing to a depression-focused psychotherapy shouldalso be considered for patients with major depressive dis-
order who do not respond fully to medication treatment.Other strategies for patients who do not respond ade-
quately to pharmacotherapy include changing to an
MAOI after allowing sufficient time between medicationsto avoid hazardous interactions (see T able 8). T ranscranial
magnetic stimulation could also be an option, as it appears
to be safe and well tolerated (270, 280). In addition, it hasshown small to moderate benefits in most (268, 270–272)
but not all (269, 273) clinical trials and recent meta-anal-
yses. Recent randomized trials suggest that quetiapinemonotherapy also produces a greater reduction in depres-
sive symptoms than placebo (423, 424), with comparable
efficacy to duloxetine (424), although the potential side ef-
fects of second-generation antipsychotic treatment need
to be taken into consideration. ECT remains the most ef-fective therapy for patients with treatment-resistant symp-
toms (239, 425), although results of clinical trials differ
on whether patients with medication-resistant symptomshave responses to ECT that are comparable to those of
patients without documented medication resistance (426–
428).
c. Augmenting and combining treatments
Pharmacotherapy can be combined with a depression-
focused psychotherapy, both as an initial treatment plan,and as a strategy to address nonresponse to treatment in
one modality or the other. See Section II.B.4.c above for
further information about combining pharmacotherapy
and psychotherapy.
Antidepressant medications can be augmented with an-
other non-MAOI antidepressant or with other, nonanti-
depressant agents. The addition of a second non-MAOI
antidepressant may be helpful, particularly for patientswho have had a partial response to antidepressant mono-therapy (429). One option is to add a second non-MAOI
antidepressant medication from a different pharmacolog-
ical class, taking care to av oid drug-drug interactions. An-
other option is to add an adjunctive, nonantidepressant
medication—such as lithium, thyroid hormone, an anti-
convulsant, a psychostimulant, or a second-generation(atypical) antipsychotic. More information about these
strategies is given later in this section.
Some limited evidence and clinical experience support
the addition of bupropion to an SSRI. This combinationis generally well tolerated, although bupropion, a moder-
ately potent inhibitor of CYP 2D6, increases blood levelsof some SSRIs (430). In one study, combined treatment
with bupropion and an SSRI resulted in better outcomes
than either therapy alone (431). Another commonly usedstrategy is the combination of mirtazapine and an SSRI or
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 55
venlafaxine. Generally, mirtazapine 15–30 mg at bedtime
is added to the incompletely effective antidepressant and
titrated up to 45 mg/day on the basis of response and tol-erability (432).
For patients with pronounced anxiety or persistent
insomnia not adequately relieved by an SSRI or SNRI, ad-
junctive use of anxiolytic and sedative-hypnotic medica-
tions is common (433, 434). These include benzodiazepinessuch as clonazepam (435) and selective GABA agonists suchas zolpidem (436) and eszopiclone (437). Buspirone has also
been used adjunctively in anxious individuals (429). Al-
though adjunctive therapy of anxiety or insomnia can has-ten symptomatic relief, there is no evidence of sustained
benefit, and some patients have difficulty stopping the anx-
iolytic or hypnotic medication (438, 439).
Lithium, thyroid hormone, and stimulants are some-
times combined with antidepressants to augment re-sponse. Lithium is the most extensively studied of these
adjuncts (440–443) and may also reduce the long-term
risk of suicide (444). The interval before full response toadjunctive lithium is said to be in the range of several days
to 6 weeks. The blood level required to enhance the ef-
fects of antidepressants still has not been confirmed. If ef-fective and well tolerated, lithium should be continued at
least for the duration of acute treatment and perhaps be-
yond the acute phase for purposes of relapse prevention.
Thyroid hormone supplementation, even in euthyroid
patients, may increase the effectiveness of antidepressantmedication treatment, whether used as an augmentationagent (445, 446) or in combination with an antidepressant
from the outset of therapy (447). The dose typically used
for this purpose is 25 mcg/day of triiodothyronine, in-creased to 50 mcg/day if the response is inadequate after
about a week. The duration of treatment required has not
been well studied.
Second-generation antipsychotic medications may in-
crease the rates of response or remission of depressivesymptoms in patients who typically have not responded tomore than two medication trials (448), even when psy-
chotic symptoms are not present. Generally, in clinical
practice, lower doses are used for antidepressant augmen-tation than for treatment of psychosis. For example, the
combination of olanzapine and fluoxetine has been exten-
sively studied (449–452) and is typically initiated with 6 mgof olanzapine and 25 mg of fluoxetine daily and titrated up-
ward as tolerated to a maximum of 18 mg of olanzapine and
75 mg of fluoxetine daily. Aripiprazole has received FDAapproval for augmentation of antidepressive agents and is
typically initiated at 2.5–5 mg/day and titrated upward as
tolerated to a maximum of 15  mg/day (453). With quetia-
pin
e, doses of
 25 to 400 mg/day have been used, with ben-
efits for depressive symptoms found in some (454, 455) butnot all (456) clinical trials. Risperidone augmentation, in
doses of up to 3 mg daily (457, 458) also appears to improve
the response to antidepressant agents. In most of these trials,the onset of the effect of second-generation antipsychotic
augmentation has been rapid, although the magnitude of
the advantage relative to placebo has been relatively mod-est. In the only two trials to utilize active comparison
groups, the combination of olanzapine and fluoxetine was
not significantly more effective at study endpoint than con-tinued therapy with nortriptyline (450) or venlafaxine (451).
Naturalistic follow-up data also suggest that long-term
weight gain can be problematic for many patients receivingsecond-generation antipsychotic augmentation therapy,
particularly with the olanzapine-fluoxetine combination
(459). In addition, a recent meta-analysis suggests that the
rate at which SGA augmentation is discontinued is nearly
four-fold greater than study discontinuation among sub-jects randomly assigned to placebo (448). When compared
with other strategies for antidepressant nonresponders, aug-
mentation with a second-generation antipsychotic carriesdisadvantages: the high cost of many agents, the significant
risk of weight gain and other metabolic complications (e.g.,
dyslipidemia, hypertriglyceridemia, glucose dysregulation,diabetes mellitus), and potential risk of hyperprolactine-
mia, tardive dyskinesia, neuroleptic malignant syndrome,
and QT c prolongation. Thus, the advantages and disadvan-tages of antipsychotic medications should be considered
when choosing this augmentation strategy. In addition,
when augmentation with a se cond-generation antipsychotic
is effective, it is uncertain how long augmentation therapy
should be maintained.
Many clinicians find that augmentation of antidepres-
sants with low doses of stimulants such as methylphenidateor dextroamphetamine may help ameliorate otherwise
suboptimally responsive depr ession (460–462), although
not all clinical trials have shown benefits from this strat-
egy (463). More recently, the novel compound modafinil
has shown modest benefit when combined with SSRIs, re-lated to specific effects on residual symptoms such as fa-
tigue and hypersomnolence (464–467). Although there
are no clear guidelines regarding the length of time stim-ulants or modafinil should be coadministered, in one ex-
tension study the effects of modafinil were maintained across
12 weeks of additional therapy (468). Physicians prescrib-ing modafinil for this off-label use should become familiar
with rare but dangerous cutaneous reactions to it, includ-
ing reported instances of Stevens-Johnson syndrome,toxic epidermal necrolysis, drug rash with eosinophilia
and systemic symptoms (469), and cytochrome P450 in-
teractions. Modafinil can also induce CYP 3A4 and rendercontraceptive medications an d other medications metab-
olized through this route ineffective.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
56 APA PRACTICE GUIDELINES
Although their use in this context has not been exten-
sively evaluated, anticonvulsants such as carbamazepine,
valproic acid, and lamotrigine may offer some benefit inthe treatment of medication-resistant major depressive
disorder (121, 429, 470–473).
A rarely used strategy is the combined use of a TCA or
trazodone and an MAOI (474, 475). The combination of a
TCA and an MAOI has been used for more than three
decades for treatment of some of the most treatment-resistant depressive disorders; however, the risk of drug-
drug interactions necessitates careful monitoring (119).Of particular concern with these combinations is the sero-tonin syndrome, characterized by delirium, hyperthermia,
hyperreflexia, myoclonus, and, rarely, death (see Section
II.B.2.b.5.b). Use of an MAOI in combination with a
TCA and related antidepressants should probably not be
considered until other pharmacological strategies for pa-tients with treatment-resistant illness have been exhausted;
psychiatrists and patients choosing to use the combina-
tion of an MAOI and a TCA should be well acquaintedwith the potential hazards and carefully weigh the relative
risks and benefits of such a strategy.
Vagus nerve stimulation was approved for use in pa-
tients whose symptoms have not responded to at leastfour adequate trials of antidepressant medications and/or
ECT . Acute benefits were not observed in the sham-controlled portion of the VNS trial (282). When com-
pared with a parallel treatment-as-usual arm, the long-
term (1–2 year) open-label extension showed small (476,477) but persistent (478) improvements in symptoms with
VNS that could be clinically significant for some patients.
Other open-label studies have also shown some benefitwhen VNS is used simultaneo usly with pharmacotherapy
(479–481).
As with any surgical device  implantation, there is a
small risk of postsurgical infection (482). A majority of in-
dividuals experience hoarseness or voice alteration during
stimulation, and coughing, dyspnea, and neck discomfortare common (281, 481) but generally are tolerable to pa-
tients (282, 479). Patients also need to be informed of the
implications of having an implanted VNS device for fu-ture medical care (482). For example, with a VNS device
in place, brain MRI requires the use of a special send-
receive coil. The VNS device may affect the operation ofother implanted devices such as cardiac pacemakers or
defibrillators and other procedures such as diathermy, and
whole body or radiofrequency receive-only MRI are con-traindicated. VNS is also contraindicated in the presence
of bilateral or left cervical vagotomy.
Relative to other antidepressive treatments, the role of
VNS remains a subject of debate. However, it could beconsidered as an option for patients with substantial symp-toms that have not responded to repeated trials of antide-pressant treatment.
C. CONTINUATION PHASE
Continuation phase pharmaco therapy is strongly recom-
mended following successful acute phase antidepressanttherapy, with a recommended duration of continuation
therapy of approximately 4–9 months (assuming good andconsistent control of depression symptoms). The goal of
continuation treatment is to prevent relapse (i.e., the re-
emergence of significant depressive symptoms or dys-function) in the vulnerable period immediately following
remission (i.e., a complete alleviation of symptoms) (408,
410, 411). The possibility of relapse should be carefullymonitored during the continuation phase as this is when
risk of relapse is highest (483). Within the first 6 months
following recovery from a major depressive episode, re-lapse of depressive symptoms is common, with the propor-
tion of patients with relapse ranging from 20% of patients
in mixed samples (484–487) to as many as 85% of severelydepressed inpatients receiving treatment with ECT (234,
488, 489). These studies also show that relapse rates are
greater if antidepressant treatment (including ECT) isdiscontinued or reduced in dose or intensity following re-
covery (234, 489, 490). There is evidence that patients
who do not completely recover during acute treatmenthave a significantly higher risk of relapse (and a greater
need for continuation treatment) than those who have no
residual symptoms (227, 491, 492). Similarly, patientswho have not fully achieved remission with psychother-
apy are at greater risk of relapse in the near term (364,
365, 367, 493, 494). T o reduce the risk of relapse duringthe continuation phase, treatment should generally con-
tinue at the same dose, intensity, and frequency that were
effective during the acute phase. Although the number ofrandomized controlled trials of antidepressant medica-
tions in the continuation phase is limited, the available
data indicate that patients treated for a first episode of un-complicated major depressive disorder who exhibit a sat-
isfactory response to an antidepressant medication should
continue to receive a full therapeutic dose of that agent forat least 4–9 months after achieving full remission (105,
225, 495).
Published studies for the continuation phase with older
TCAs as well as newer medications have consistentlyshown efficacy of these medications in preventing relapse,
compared with placebo. Lithium has also been shown tohave efficacy in preventing relapse (496).
Cognitive-behavioral therapy may prevent relapse of
depression when used as augmentation to medicationtreatment. It may also bestow an enduring, protective ben-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 57
efit that reduces the risk of relapse after the treatment has
ended (363). Cognitive group therapy helps to prevent re-
lapse and recurrence for patients in remission after a ma-jor depressive episode (497). Mindfulness-based cognitive
therapy is a variant of cognitive therapy that encourages
patients to pay attention to their thoughts and feelings inthe moment and to accept them rather than judging or
trying to change or disprove them. Among patients with
remitted depression, mindfulness-based cognitive ther-apy groups may reduce risk of relapse for patients who
have already experienced three or more episodes (498).
Such benefits for CBT (and potentially, for other psycho-therapies) would offer an ad vantage over pharmacother-
apy, which works only as long  as the patient continues the
antidepressant medication.
Continuation therapy is also essential in reducing re-
lapse risk after an acute co urse of ECT (239). Although
relapse occurs for many patients regardless of continua-
tion strategy (234, 488, 489), remission of symptoms fol-
lowing successful treatment with ECT may be maintainedwith either pharmacotherapy or continuation ECT (234).
Research shows that continuation ECT is comparable in
efficacy to the combination of  nortriptyline and lithium
(234) and that the latter combination is superior to
nortriptyline alone in preventing relapse (489). Although
there is limited information regarding prognostic factors,relapse may be less likely among patients with melan-
cholic depression who receiv e continuation ECT after re-
mission with acute ECT than  among those who receive
continuation pharmacotherapy after remission with acuteECT (499).
Given the significant risk of relapse during the contin-
uation phase of treatment, it is essential to assess depres-sive symptoms, functional status, and quality of life in a
systematic fashion, which can be facilitated by the use ofperiodic, standardized measurements. It is often helpful
for patients and families to identify particular signs (e.g.,
lack of engagement in specific activities that are usually en-joyed, specific “signal” symptoms or patterns of thought)
that are typical of their earlier depressive episodes and may
suggest the beginnings of a depressive relapse. Further-more, any sign of symptom pe rsistence, exacerbation, or
reemergence or of increased psychosocial dysfunctionduring the continuation period should be viewed as a har-binger of possible relapse.
If a relapse does occur during the continuation phase, a
return to the acute phase of treatment is required. An initialstep is often to increase the dose of medication (500) or,
with continuation ECT, to increase the frequency of
treatment (501). For patients receiving psychotherapy, an
increased frequency of sessions or a shift in the psycho-
therapeutic focus may be needed. It is also essential to de-termine whether any specific precipitants are contributingto the relapse of depression. For example, the onset or
worsening of psychosocial stressors, substance use disor-ders, or general medical conditions can contribute to in-
creased depressive symptoms. In addition, decreased
treatment adherence or reductions in medication bloodlevels (e.g., due to drug-drug interactions or increased cig-
arette use) can also prompt a depressive relapse.
D. MAINTENANCE PHASE
Patients with chronic and/or recurrent major depressive
disorder who complete the continuation phase without
relapse proceed to the maintenance phase of treatment, in
which the goal is to protect susceptible patients against re-currence of subsequent depression.
Patients who have had three or more prior major de-
pressive episodes should receive maintenance treatment.Within the first 6 months following recovery from a ma-
jor depressive episode, 20% of patients will experience a
recurrence (484). Between 50% and 85% of patients willhave at least one lifetime recurrence, usually within 2 or 3
years (502), although there is little consistency in the time
to recurrence for any individual patient (484). Patientswho have had a prior major depressive episode also have a
high risk of experiencing subsequent affective episodes
other than another major depressive episode, such as amanic, hypomanic, or dysthymic episode (503). The num-
ber of lifetime major depressive episodes is significantly
associated with the probability of recurrence, such that the
risk of recurrence increases by 16% with each successive
episode (484).
Maintenance therapy should be considered more
strongly for patients with additional risk factors for recur-rence, such as the presence of residual symptoms, ongoing
psychosocial stressors, family history of mood disorders,and the severity of prior episodes (504) (see T able 10). Ad-
ditional considerations that may play a role in the decision
to use maintenance therapy include patient preference,the presence of side effects during continuation therapy,
and the severity of prior depressive episodes, including
factors such as psychosis or suicide risk. Due to the risk ofrecurrence and the importance of early detection of recur-
rent symptoms, patients should be monitored periodically
and in a systematic fashion during the maintenance phase;such assessments can be facilitated by the use of standard-
ized rating scales, as described in Section II.A.8.
In general, the treatment that was effective in the acute
and continuation phases should be used in the maintenancephase.
Among the therapeutic options available for mainte-
nance treatment, antidepressant medications have received
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
58 APA PRACTICE GUIDELINES
the most study. There have been more than 30 trials of phar-
macotherapy in the maintenance phase, and results have
generally demonstrated the effectiveness of antidepres-
sant medication for relapse prevention (105, 226, 314, 505–507). Many of these trials used TCAs (314, 506), although
results of trials involving newer antidepressant medica-
tions have been assessed in a recent meta-analysis (507).Lithium has also been used as maintenance treatment for
major depressive disorder (441). Despite this, there is lim-
ited information on many of the clinical decisions involvingmedication use in the maintenance phase. Even though
lower doses of medication are less likely to produce side
effects, results from one study suggest that full doses aresuperior to lower doses in the maintenance phase (508).
Particularly if medications are well-tolerated, it is gener-
ally advisable to prescribe the same antidepressant medi-cation doses for maintenance therapy that were effective
in prior phases of treatment. Even with adequate mainte-
nance treatment, pharmacotherapy is not invariably suc-cessful in preventing relapse and return of symptoms, which
still occur in as many as 25% of individuals (509, 510). It is
unclear whether some relapses during maintenance ther-apy are loss of therapeutic efficacy, a phenomenon that
has been referred to as tachyphylaxis, but many such re-
lapses appear related to inadequate prophylactic effectsof medication (511). When relapses occur, clinicians
typically address them using the same approaches described
to treat incomplete responses to treatment, such as in-creasing the dose of medication, changing to a different
medication, or adding another medication or a depression-
focused psychotherapy to augment therapeutic response(510, 512).
There have been fewer investigations of the effective-
ness of psychotherapy in the maintenance phase. Nonethe-less, several studies have shown that acute psychotherapies
for major depressive disorder also have maintenance ben-
efits. For example, even once-monthly maintenance IPThas been shown to forestall relapse in patients at high risk
for relapse (289, 314, 315, 513). Most of these studies have
used once-monthly maintenance IPT , but research hasnot demonstrated that frequency of sessions affects out-
come (289). In one study, maintenance cognitive therapy
delivered over 2 years was as effective as maintenancemedication for recurrent major depressive disorder (514).
Combining psychotherapy—such  as CBT, cognitive ther-
apy, or IPT—with pharmacotherapy in the maintenance
phase has also been considered by investigators. Some
results suggest that the combination of antidepressant
medications plus psychotherapy may be more effective in
preventing relapse than treatment with single modalities
(314, 365, 506, 515, 516).
For patients receiving treatment with pharmacother-
apy and/or psychotherapy, the frequency of visits duringthe maintenance phase should be set according to theclinical condition and the specific treatments being used.
The frequency can range from as low as once every several
months for stable patients who require only psychiatricmanagement and medication monitoring to as high as
once or twice per week for those receiving psychodynamic
psychotherapy. For CBT and IPT , maintenance-phasetreatments usually involve a decreased frequency of visits
(e.g., once a month). The duration of the maintenance
phase will vary depending on the frequency and severityof prior major depressive episodes, the tolerability of
treatments, and patient preferences. For many patients,
some form of maintenance treatment may be required in-definitely.
Electroconvulsive therapy has also been used in the
maintenance phase, although evidence for its benefitscomes largely from case reports (239). Patients who exhibit
repeated episodes of moderate or severe major depressive
disorder despite optimal pharmacological treatment or pa-tients who are medically ineligible for such treatment may
be maintained with periodic ECT. Although the optimal
frequency and duration of maintenance phase ECT treat-ments has not been well studied, maintenance ECT is
often administered monthly; individuals for whom this
is insufficient may find treatment at more frequent inter-vals to be beneficial (501).
E. DISCONTINUATION OF TREATMENT
If maintenance-phase treatment is not indicated, stablepatients may be considered for discontinuation of treat-
ment after the continuation phase. The precise timing
and method of discontinuing psychotherapy and pharma-TABLE 10. Risk Factors for Recurrence of Major Depressive 
Disorder
Persistence of subthreshold depressive symptoms
Prior history of multiple episodes of major depressive 
disorder
Severity of initial and any subsequent episodesEarlier age at onsetPresence of an additional nonaffective psychiatric 
diagnosis
Presence of a chronic general medical disorderFamily history of psychiatric illness, particularly mood 
disorder
Ongoing psychosocial stressors or impairmentNegative cognitive stylePersistent sleep disturbances
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 59
cotherapy for major depressive disorder have not been
systematically studied.
The decision to discontinue treatment should be based
on the same factors considered in the decision to initiatemaintenance treatment (T able 10), including the probabil-
ity of recurrence, the frequency and severity of past epi-sodes, the persistence of depressive symptoms after
recovery, the presence of co-occurring disorders, and pa-
tient preferences. The type of treatment being received
may also play a role in the decision making. In general,
psychotherapy has a longer lasting treatment effect and
carries a lower risk of relapse following discontinuationthan pharmacotherapy. In terms of timing, patients should
be advised not to discontinue medications before holidays,
significant events (e.g., weddings), or stressful events.
Patients should be carefully monitored during and im-
mediately after treatment discontinuation to ensure thatremission is stable. The highest risk for a relapse is seen in
the first 2 months after discontinuation of treatment.
Hence, it is important to schedule a follow-up visit duringthis period to ensure stability.
When pharmacotherapy is being discontinued, it is
best to taper the medication over the course of at leastseveral weeks. Such tapering allows for the detection of
recurring symptoms at a time when patients are still par-
tially treated and therefore more easily returned to fulltherapeutic treatment if needed. In addition, such taper-
ing can help minimize the incidence of antidepressant
medication discontinuation syndromes, particularly withparoxetine and venlafaxine (98, 163, 164). Discontinuation
syndromes are problematic because their symptoms in-
clude disturbances of mood, energy, sleep, and appetiteand can therefore be mistaken for or mask signs of relapse
(517). Consequently, patients should be advised not to
stop medications abruptly and to take medications withthem when they travel or are away from home. Discontin-
uation syndromes have been found to be more frequent af-
ter discontinuation of medications with shorter half-lives,and patients maintained on short-acting agents shouldhave their medications tapered gradually over a longer pe-
riod (518, 519). Another strategy is to change to a brief
course of fluoxetine, e.g., 10 mg for 1–2 weeks, and thendiscontinue the fluoxetine (165). The psychiatrist should
closely monitor patients withdrawing from antidepres-
sants and provide reassurance that symptoms are time-limited and can be addressed by more gradual tapering
(see Section II.B.2.b.1.i).
How to end psychotherapy is typically dependent on
the type of therapy. For time-limited approaches, termi-nation is usually broached from the initiation of treatment
and periodically revisited, as  the therapist-patient dyad
notes which session they are in, how many remain, and
how they have progressed toward defined goals. In dy-
namically oriented psychotherapy, the therapist typically
raises termination as an issue well in advance of the final
session, using the opportunity to explore remaining andunresolved issues in transference.
Before the discontinuation of active treatment, pa-
tients should be informed of the potential for a depressiverelapse. Early signs of major depressive disorder should be
reviewed, often with a family member, and a plan estab-
lished for seeking treatment in the event of recurrentsymptoms. Patients should continue to be monitored
over the next several months to identify early evidence of
recurrent symptoms. Again, systematic assessment ofsymptoms, side effects, adherence, and functional status
during this period of high vulnerability is strongly rec-
ommended. If a patient does suffer a recurrence after dis-continuing medication, treatment should be promptly
reinitiated. Usually, the previous treatment regimen to
which the patient responded in the acute and continuationphases should be reinitiated (520). Patients who have a re-
currence following discontinuation of antidepressant
therapy should be considered to have experienced anothermajor depressive disorder episode and should receive
adequate acute-phase treatment followed by continua-
tion-phase treatment and possibly maintenance-phasetreatment.
III. SPECIFIC CLINICAL FEATURES INFLUENCING THE 
TREATMENT PLAN
A. PSYCHIATRIC FACTORS
1. Depressive symptoms
a. Suicidal ideation and behaviorsBecause suicide is the worst outcome of major depressivedisorder, a patient’s risk for suicide must be assessed re-peatedly over the course of treatment. For patients who
report suicidal ideation, intention, or planning, close sur-
veillance is necessary (see Sections II.A.3 and II.A.4). Psy-chiatrists should consider greater intensity of treatment
for suicidal patients, including hospitalization when war-
ranted and/or combined treatment with pharmacother-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
60 APA PRACTICE GUIDELINES
apy and psychotherapy. In patients at high risk for suicide
and in whom a particularly rapid antidepressant response
is required, consideration should be given to the use ofECT (239, 243, 521). Patients with major depressive dis-
order who present to an emergency department with sui-
cidal ideation, or who have made a suicide attempt, shouldbe triaged to determine their level of safety and establish
the appropriate level and setting of care. Upon entrance
to the emergency department, they should be searched topermit removal of potentially dangerous items, such as
weapons and personal belongings that could cause harm
(e.g., sharp objects, belts, shoes, medications). Factors toconsider in determining the nature and intensity of treat-
ment include (but are not limited to) access to and lethal-
ity of suicide means, past and family history of suicidal
behavior, co-occurring substance abuse, the availability
and adequacy of social supports, and the nature of thedoctor-patient alliance.
T o lower the risk of suicide, the psychiatrist should also
treat modifiable risk factors, such as anxiety (especiallypanic attacks), insomnia, agit ation, psychotic symptoms,
and substance abuse (22), in addition to treating the majordepressive episode. Among inpatients who died by suicide,Busch et al. (522) observed that a great majority were
admitted for indications other than suicidal ideation, and
anxiety and agitation were common, suggesting that suchsymptoms should be addressed if they are present. Family
members can also play an important role in detecting and
preventing suicidal behaviors. When permitted by the pa-tient, the psychiatrist should educate those close to the
patient concerning appropriate interventions and encour-
age communication.
There has been a growing controversy about the risk of
suicidal ideas and behaviors (sometimes referred to as“suicidality”) after initiation of antidepressant treatment.Although information on such risk continues to evolve, a
predictive relationship to suicide has never been demon-
strated. Clinical experience has long suggested that pa-tients may develop the energy and capacity to act on self-
destructive plans made earlier in the course of their illnessif neurovegetative and psychomotor symptoms respondto antidepressant treatment before mood improves. More
recently, meta-analyses of data from clinical trials have
shown statistically significant increases in suicidal thoughtsor behaviors in individuals age 25 years or younger who
are treated with antidepressant medication, compared
with placebo, with an approximately 1.5- to 2.5-fold in-crease in the relative risk (26, 523–530). In percentage
terms, it is estimated that one to three of 100 individuals
age 25 years or younger could potentially have an increasein suicidal thoughts or behaviors with antidepressant
treatment (26), although there has been no evidence of in-creased mortality in the study subjects as a result of suicide(531). T o alert clinicians to the need for vigilance and
communication during the initial phase of antidepressanttreatment, the FDA has issued a black-box warning per-
taining to children, adolescent s, and young adults that ad-
vises of this increase in the risk of suicidal thinking and
behavior; information on the warning is available on the
FDA Web site at http://www.fda.gov/cder/drug/antide-
pressants/default.htm. In making decisions about treat-ment, this awareness of a potential increase in suicidal
thinking and behavior in chil dren, adolescents, and young
adults must be balanced against the negative effects, in-
cluding suicide, of untreated depression (532) as well as
the demonstrated benefits of antidepressant treatment
(523, 533–535). For adults age 65 years or older, a review
of the evidence from clinical trials showed a decrease in
the risk of suicidal thinking or behaviors with antidepres-sant treatment, with no change in risk detected for other
adults (age 25 to 64 years) (536).
For additional details about the treatment of suicidal
individuals, clinicians are encouraged to consult APA’sPractice Guideline for the Assessment and Treatment of Pa-
tients With Suicidal Behaviors  (22).
b. Major depressive disorder–related cognitive dysfunction
Cognitive inefficiency and impairment are common fea-
tures of major depressive disorder. Many depressed patientsreport slowed thoughts, poor concentration, distractibility,
and reduced capacity to process information. They also dis-
play diminished attention to self-care and to their environ-ment. T ransient cognitive impairment, especially involving
attention, concentration, and memory storage and retrieval,
are demonstrable through neuropsychological testing (537).In extreme cases, especially in elderly patients, these deficits
are so prominent that patients appear to have dementia. Forindividuals who exhibit symptoms of a dementia syndrome,it is crucial that any underlying depressive disorder be iden-
tified and treated.
Among depressed patients, the differential diagnosis of
cognitive dysfunction includes degenerative dementias(such as Alzheimer’s disease and Pick’s disease) and revers-
ible causes (such as vitamin B
12 deficiency, folate deficiency,
testosterone deficiency, substance use). Several clinical fea-
tures help distinguish major depressive disorder–related
cognitive dysfunction from other dementia syndromes.When performing cognitive tasks, depressed patients gen-
erally exert less effort and report greater incapacity than do
patients with dementia. The latter, especially in more ad-vanced stages, typically do not recognize their cognitive
failures, since insight is impaired. In contrast, depressed
patients may report being unable to think or remember.
Patients with major depressive disorder–related cognitive
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 61
dysfunction lack the signs of cortical dysfunction (i.e., apha-
sia, apraxia, agnosia) enco untered in dementias such as
Alzheimer’s disease (538, 539). Nevertheless, distinguishing
dementia from depression-related cognitive dysfunction
can be difficult, particularly as  the two may coexist. For fur-
ther discussion of the co-occurrence of dementia and de-
pression, the reader may also wish to consult APA’s Practice
Guideline for the Treatment of Patients With Alzheimer’s Dis-ease and Other Dementias, Second Edition  (539).
The detection of major depressive disorder–related
cognitive dysfunction alerts the psychiatrist to the needfor treatment of the underlying major depressive disorder,which should in turn reduce the signs and symptoms of
the cognitive dysfunction. Although initially reversible,
major depressive disorder–related cognitive dysfunction
increasingly appears to be a harbinger of subsequent de-
mentia (540, 541). In addition, research suggests that cer-tain types of executive cognitive dysfunction predict greater
disability and limited treatment response in geriatric pa-
tients with depression (542, 543).
2. DSM depressive subtypes
a. Psychotic features
Major depressive disorder is sometimes accompanied by
hallucinations or delusions, which may be congruent orincongruent with the depressed mood. Recognition of
psychosis is essential among patients with major depres-
sive disorder as it is often undetected, resulting in ineffec-tive treatment (544–546). Psychotic features constitute a
risk factor for recurrent major depressive disorder and re-
current psychosis and hence indicate the need for mainte-nance treatment.
Electroconvulsive therapy is highly effective in treating
psychotic depression (241) and can be considered as afirst-line treatment option whenever major depressive
disorder is associated with psychotic features (239, 243,
547). Pharmacotherapy can also be used as a first-linetreatment option for major depressive disorder with psy-
chotic features. Psychotic depression typically responds
better to the combination of an antipsychotic and an an-
tidepressant medication rather than treatment with either
component alone (547–549), although some research has
shown comparable responses for antidepressive treatmentor antipsychotic treatment alone (550, 551). Lithium aug-
mentation is helpful for some patients who have not re-
sponded to combined treatment with antidepressant andantipsychotic medication (262, 552).
b. Catatonic features
A catatonic syndrome sometimes occurs in the context of
major depressive disorder (553–556) and is characterizedby at least two of the following manifestations: immobil-ity, as evidenced by catalepsy or stupor; extreme agitation;
extreme negativism; peculiarities of voluntary movement,as evidenced by posturing, stereotyped movements, man-
nerisms, or grimacing; and echolalia or echopraxia (556,
557). The presence of catatonia should prompt a thor-ough differential diagnosis as it can also occur in asso-
ciation with general medical conditions and with several
other psychiatric disorders, including bipolar disorderand schizophrenia (556, 558, 559). Catatonic signs often
dominate the clinical presentation and may be so severe as
to be life-threatening, compelling the consideration of ur-gent somatic treatment. Patients with catatonic features
may also need supportive medical interventions including
hydration, nutrition, prophyla xis against deep vein throm-
bosis, turning to prevent bed sores, and passive range ofmotion to prevent contractures. Intravenous administra-tion of a benzodiazepine (e.g., lorazepam, diazepam) or a
barbiturate (e.g., amobarbital) may induce rapid relief
(242, 553) and can be followed by continued oral admin-istration for patients who show an initial response. When
such intervention is ineffective, the clinician should con-
sider the urgent use of ECT (239, 242). The efficacy ofECT in catatonia is well documented in the case series
literature (239) and is usually apparent after a few treat-
ments. After catatonic manifestations recede, antidepres-sant medication treatments may be needed during acute
and maintenance phases of treatment. In addition to anti-
depressant medications, ongoing treatment may includeECT, lithium, antipsychotics, or a combination of these
approaches, depending upon the patient’s condition. Pa-tients with catatonia may have an increased susceptibilityto neuroleptic malignant syndrome when exposed to an-
tipsychotic medications (560), and this should be consid-
ered in planning treatment.
c. Melancholic features
Melancholic features describe characteristic somatic
symptoms, such as the loss of interest or pleasure in all, or
almost all, activities or a lack of reactivity to usually plea-surable stimuli. Other symptoms include worsened de-
pression in the morning, early morning awakening, and
significant anorexia or weight loss, among others (16).Major depressive disorder with melancholic features is re-
sponsive to both pharmacoth erapy and ECT. Serotonin
norepinephrine reuptake inhibitors and TCAs may have
an advantage over SSRIs for this patient population (561,
562). Psychotherapy may be less appropriate for patients
with melancholia (563), particularly if the symptoms pre-vent engagement with the therapist (e.g., lack of interest
in activities). Major depressive disorder with melancholic
features may also be associated with an added risk of sui-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
62 APA PRACTICE GUIDELINES
cide (564) and an increased risk of subsequent recurrence
despite the use of maintenance pharmacotherapy (509).
d. Atypical features
Major depressive disorder with atypical features is charac-
terized by a pattern of marked mood reactivity and at least
two additional symptoms, including leaden paralysis, along-standing pattern of interpersonal rejection sensitivity,
significant weight gain or increase in appetite, and hyper-
somnia (the latter two of which are considered reversedvegetative symptoms) (16). The phrase “atypical features”
distinguishes this depressive subtype from the more classi-
cal “endogenous” presentation of depression, but it does
not connote an uncommon or unusual form of depression.
Atypical features are more common in women, are associ-ated with an earlier age at on set of depression and a greater
degree of associated anxiety disorders, and frequently havea more chronic, less episodic course, with only partial in-terepisode recovery (565, 566). These atypical features are
also common in the depressed phase of bipolar I disorder
and bipolar II disorder (567, 568), indicating a need forcareful screening for manic or hypomanic episodes in pa-
tients who present with atypical depressive symptoms.
In the treatment of major depressive disorder with
atypical features, MAOIs have greater efficacy than TCAs(122, 569–572). Some data also support the use of SSRIs,
bupropion, and CBT in this  patient population (573–
577). Electroconvulsive therapy is also effective in treat-
ing patients with atypical features (578). The presence and
severity of specific symptoms as well as safety consider-ations should help guide the choice of treatment for major
depressive disorder with atypical features. For example, if
a patient does not wish to, cannot, or appears unlikely toadhere to the dietary and medication precautions associ-
ated with MAOI treatment, the clinician should consider
alternative antidepressant medication or psychotherapy.
e. Seasonal pattern
A seasonal pattern of major depressive disorder is charac-
terized by a regular temporal relationship between partic-ular periods of the year and the onset and remission of
symptoms, which is not the result of seasonally related
psychosocial stressors (e.g.,  seasonal unemployment, sig-
nificant anniversaries). The most common presentation
in the northern hemisphere is the regular appearance of
symptoms between early October and late November andregular remission from mid-February to mid-April. Epi-
sodes of major depressive disorder with seasonal pattern
frequently have atypical features such as hypersomnia andovereating. Some of these patients experience manic or
hypomanic episodes as well; hence, it is important to di-
agnose bipolar disorder when appropriate.The entire range of treatments for major depressive
disorder may be used to treat major depressive disorderwith seasonal pattern, either in combination with or as analternative to light therapy. As a primary treatment, light
therapy may be recommended as a 1- to 2-week time-limited
trial (395), primarily for outpatients with clear seasonalpatterns. For patients with more severe forms of major
depressive disorder with seasonal pattern, the use of light
therapy is considered adjunc tive to pharmacological in-
tervention. In terms of specific antidepressive agents, the
extended release formulation of bupropion is FDA approved
for use with patients who have major depressive disorderwith seasonal pattern.
3. Co-occurring psychiatric disorders
Co-occurring psychiatric disorders generally complicate
treatment. Patients with major depressive disorder who
also have other psychiatric disorders have greater symp-tom severity and are more challenging to treat than pa-
tients with major depressive disorder alone. Yet the
presence of co-occurring Axis I or Axis II disorders shouldnot lead clinicians to conclude that patients are untreat-
able. Furthermore, other Axis I or Axis II disorders may
masquerade as major depressive disorder or may seem toco-occur with the depression. In these cases, the other ap-
parent disorders evanesce with successful treatment of theunderlying major depressive disorder.
a. Dysthymic disorder
Dysthymic disorder is a chronic mood disorder with
symptoms that fall below the threshold for major depres-
sive disorder. Because of this, it may escape notice and
may be inadequately treated. Nonetheless, it can causesignificant suffering and disability. In some patients, both
dysthymic disorder and major depressive disorder (so-
called “double depression”) may be diagnosed.
In the treatment of dysthymic disorder and chronic
major depressive disorder, there is demonstrated efficacyfor antidepressant medications, including TCAs, SSRIs,other newer agents, and MAOIs. Unfortunately, clinical
trials provide little evidence of the relative efficacies of
particular agents (105, 579). In general, pharmacotherapyof dysthymic disorder resembles that for episodes of
major depressive disorder; responses to antidepressant
medications by patients with dysthymic and chronicmajor depressive disorders have been comparable to the
responses by patients with major depressive disorder
episodes (580). In “double depression,” antidepressantmedication can reverse not only the acute major depres-
sive episode but also the co-occurring dysthymic disorder
(581).
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 63
Patients with dysthymic disorder, as well as patients
with chronic and severe major depressive disorder, typi-
cally have a better response to the combination of phar-macotherapy and psychotherap y than to either alone
(294, 295), although results of combined treatment stud-ies have been mixed and complicated by methodologicalproblems (582).
b. Anxiety disorders
As a group, anxiety disorders are the most commonly oc-curring psychiatric disorders in patients with major de-
pressive disorder (583). A 2005 epidemiological study
found that among individuals with major depressive dis-
order, 62% also met the criteria for generalized anxiety
disorder, 52% for social phobia, 50% for posttraumaticstress disorder (PTSD), 48% for panic disorder, 43% for
specific phobia, and 42% for obsessive-compulsive disor-
der (584). In addition, agitation and anxiety, includingpanic attacks, are frequent co-occurring symptoms of
major depressive disorder. Th e appearance of anxiety and
agitation in patients in a major depressive episode, particu-
larly when accompanied by racing or ruminative thoughts,
should alert the clinician to the possibility of a mixed
mood state of a bipolar spectrum disorder (585).
In studies of major depressive disorder with a co-
occurring anxiety disorder, both depressive symptoms andanxiety symptoms respond to antidepressant medicationtreatment (586). However, TCAs and SSRIs may initially
worsen rather than alleviate anxiety symptoms, including
panic attacks; patients should be so advised, and thesemedications should be introduced at low doses and slowly
increased when treating such patients. Adjunctive anti-
panic agents, such as benzodiazepines, may be necessaryas well. Selective serotonin reuptake inhibitors are bene-
ficial for patients with co-o ccurring depression and social
anxiety disorder (587) and co-occurring depression and
PTSD (588). Bupropion is comparable to SSRIs in thetreatment of patients with major depressive disorder and
low to moderate levels of anxiety (82), but studies vary asto whether bupropion is (589) or is not (590) effective in
the treatment of panic disorder. Because benzodiazepines
are not antidepressants and carry their own adverse effectsand toxicity, including abus e and dependence, benzodiaz-
epines should not be the pr imary pharmacological agents
for patients with major depressive disorder who have co-occurring anxiety symptoms. These agents may be used
adjunctively with other antidepressive treatments, how-
ever (591). Psychotherapies such as CBT, behavioral ther-apy, and IPT may also be used to treat anxiety symptoms
in the context of major depressive disorder (591, 592).
Obsessive-compulsive symptoms are also common in
patients with major depressive episodes. In addition, ob-sessive-compulsive disorder may appear as a co-occurringcondition in some patients with major depressive disor-
der. Clomipramine and SSRIs have demonstrated efficacyin managing obsessive-compulsive symptoms in addition
to treating depression (593–595).
c. Dementia
Patients with dementia are predisposed to depression, and
the psychiatrist should therefore screen for depression in
this population, although this is sometimes challenging
(539). One screening tool is the Cornell Scale for Depres-sion in Dementia, which incorporates self-report with
caregiver and clinician ratings of depressive symptoms
(596). T reatment of major depressive disorder in the cog-
nitively impaired patient requires careful supervision and
monitoring of the patient’s pharmacotherapy; this mayentail education of home health aides, nursing home staff,
and others. Antidepressants are likely to be efficacious in
treatment of depressive symptoms, but they do not im-prove cognition, and data on antidepressant use in pa-
tients with dementia are limited (597–599). Individuals
with dementia are particularly susceptible to the adverseeffects of muscarinic blockade on memory and attention.
Therefore, individuals with dementia generally do best
when given antidepressant medications with the lowestpossible degree of anticholinergic effect, e.g., bupropion,
fluoxetine, sertraline, trazodone, and, of the tricyclic
agents, desipramine or nortriptyline (600). Alternatively,some patients do well when given stimulants in small
doses. Electroconvulsive therapy is also effective in major
depressive disorder superimposed on dementia. It shouldbe used if medications are associated with an excessive risk
of adverse effects, are not tolerated, or if immediate reso-
lution of the major depressive disorder episode is medi-cally indicated (such as when it interferes with the
patient’s acceptance of food).  In individuals with demen-
tia, ECT treatment may be associated with a transient
worsening of the patient’s cognitive status (239, 601, 602).
APA ’s Practice Guideline for the Treatment of Patients With
Alzheimer’s Disease and Other Dementias, Second Edition
(539) contains more information about the treatment of
depression and dementia.
d. Substance use disorders
Major depressive disorder frequently occurs with alcohol
or other substance abuse or dependence. Therefore, the
psychiatrist should obtain a detailed history of the pa-
tient’s substance use. With the patient’s permission, familymembers, friends, or co-workers can be collateral sources
of information. If the evaluation reveals a substance use
disorder, this should be addressed in treatment. A patientwith major depressive disorder who has a co-occurring
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
64 APA PRACTICE GUIDELINES
substance use disorder is more likely to require hospital-
ization, more likely to attempt suicide, and less likely to
adhere to treatment than a patient with major depressivedisorder of similar severity uncomplicated by substance
use (603–608).
Detoxifying patients before initiating antidepressant
medication therapy is advisable when possible (110). An-tidepressants may be used to treat depressive symptoms
following initiation of abstinence if symptoms do not im-prove over time. It is difficult to identify patients who should
begin a regimen of antidepressant medication therapy
soon after initiation of abstinence, because depressivesymptoms may have been induced by intoxication and/or
withdrawal of the substance. A family history of major de-
pressive disorder, a history of major depressive disorder
preceding alcohol or other substance abuse, or a history of
major depressive disorder during periods of sobriety raisesthe likelihood that the patient might benefit from antide-
pressant medication, which may then be started early in
treatment. Comparing the temporal pattern of symptomswith the periods of use and abstinence of the substance
may help to clarify the patient’s diagnosis. Repeated, lon-
gitudinal psychiatric assessments may be necessary to dis-tinguish substance-induced depressive disorder from co-
occurring major depressive disorder, particularly because
some individuals with substance use disorders reducetheir substance consumption once they achieve remission
of a co-occurring major depressive disorder.
Co-occurring substance use, especially with stimulant
drugs, raises the risk of deleterious interactions with MAOIs,although few such events have been reported (609). Ben-
zodiazepines and other sedative-hypnotics carry the po-tential for abuse or dependence and should rarely be
prescribed to patients with co-occurring substance use
disorders, except as part of a brief detoxification regimen.Hepatic dysfunction and hepatic enzyme induction fre-
quently complicate pharmacotherapy of patients with al-
coholism and other substance abuse. These conditionsmay require careful monitoring of blood levels (as appro-
priate for the medication), therapeutic effects, and side ef-
fects to avoid the opposing risks of either psychotropicmedication intoxication or underdosing.
For individuals with nicotine dependence who wish to
stop smoking, bupropion and nortriptyline treatment in-crease smoking cessation rates by about twofold (109) and
would be useful to consider when selecting a specific an-
tidepressive agent (110).
e. Personality disorders
For patients who exhibit symptoms of both major depres-
sive disorder and a personality disorder, psychiatrists
should consider appropriate treatment for each. Majordepressive disorder should generally be the initial target;if evidence of a personality disorder persists when the de-
pressive symptoms have resolved, psychotherapeutic andadjunctive pharmacotherapeuti c approaches may be help-
ful (610–615). Patients with virtually any personality dis-order exhibit a less satisfactory antidepressant medicationtreatment response, in terms of both social functioning
and residual major depressive disorder symptoms, than do
individuals without personality disorders (616). Personal-ity disorders tend to interfere with treatment adherence
and development of a psychoth erapeutic relationship. Fur-
thermore, many personality disorders increase the risk of
episodes and increase time to remission of major depres-
sive disorder (617, 618). Patients with various personality
disorders also showed high rates of new-onset major de-
pressive episodes in a large prospective study (619) and were
at higher risk of attempting suicide than patients withouta co-occurring personality disorder (620).
Axis II diagnoses should be made with caution during a
major depressive episode, as depressive symptoms may ex-aggerate or mimic personality traits. T reatment of the de-
pressive disorder for these patients can cause the apparent
personality disorder symptoms to remit or greatly dimin-ish. Depressed patients may believe that their current
symptoms have been present from early life, when in fact
they only began with the current episode. Such misper-ceptions often hinder accurate diagnosis. Some Cluster C
personality disorders (e.g., avoidant, dependent, obses-
sive-compulsive) may reflect the residual impact of recurrent
depressive symptoms and may remit with maintenance
therapy (621).
Patients with borderline personality disorder have a
particularly high rate of major depressive disorder: 20%in a community sample (622) and 50% in clinical samples
(623). About 10%–15% of patients with major depressivedisorder have co-occurring borderline personality disor-
der (624), and the percentage increases significantly in
hospital and partial hospital samples. Patients with bor-derline personality disorder often exhibit mood lability,
rejection sensitivity, inappropriate intense anger, and de-
pressive “mood crashes.” These symptoms are also com-mon in patients with depression, particularly with atypical
features, complicating the di agnosis of these disorders.
Antidepressants are in general less effective in treating de-
pressive episodes in patients with major depressive disor-
der and borderline personality disorder (625–629), with
an overall response rate to all therapies of 20% (630).
For patients with major depr essive disorder and border-
line personality disorder, the personality disorder mustalso be addressed in treatment. Symptoms of both dis-orders can initially be treated with an SSRI or SNRI. Be-
havioral impulsivity and dyscontrol can also be treated
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 65
with low-dose antipsychotics, lithium, and some antiepi-
leptic medications. Monoamine oxidase inhibitors, al-
though efficacious, are not recommended due to the risk ofserious side effects and the difficulties with adherence to
dietary restrictions. Psychotherapeutic approaches such as
dialectical behavioral therapy and psychodynamic psy-chotherapy have been useful in treatment of borderline
personality disorder as well. In patients with borderline
personality disorder particular attention must be paid tothe maintenance of therapeutic rapport, which is frequently
disrupted, and to the risk of self-harm and suicide, which
occurs in 8%–10% of such individuals. More informationabout the treatment of borderline personality disorder can
be found in APA’s Practice Guideline for Treatment of Patients
With Borderline Personality Disorder  (610).
f. Eating disorders
Eating disorders are also common in patients with majordepressive disorder (631). Selective serotonin reuptake
inhibitors are the best studied medications for treatment
of eating disorders, with fluoxetine having the most evi-dence for the effective treatment of bulimia nervosa (170).
Antidepressants may be less effective in patients who are
severely underweight or malnourished, and normalizingweight should take priority in these patients. Although
SSRIs and psychotherapy are widely used for patients
with anorexia nervosa, the evidence base on which thesepractices rest is modest. Patients with chronic anorexia
nervosa have in general been less responsive to formal
psychotherapy. On the other hand, evidence strongly sup-ports the use of CBT in the treatment of bulimia nervosa.
Other therapies (e.g., IPT, group therapies, family ther-
apy) and medications such as SSRIs have also been studiedand have demonstrated effectiveness for this disorder.
Bupropion should be avoided in individuals with eating
disorders due to the increased risk of seizures in these pa-tients. Electroconvulsive therapy has not generally been
useful in treating eating disorder symptoms. Although
there are few data to guide treatment of co-occurring ma-jor depressive disorder and eating disorders, it is reason-
able to optimize treatment of both disorders based on
these and other consideratio ns. More information about
the treatment of eating disorders can be found in APA ’s
Practice Guideline for the Treatment of Patients With Eating
Disorders, Third Edition  (170).
B. DEMOGRAPHIC AND PSYCHOSOCIAL 
VARIABLES
1. Major psychosocial stressors
Major depressive disorder may follow a substantial ad-verse life event, especially one that involves the loss of animportant relationship or life role. This is particularly
true in initial episodes of depression, with psychosocial
stressors being less associated with the onset of recurrentepisodes (632). Lower socioeconomic status, nonmarried
status, unemployment, urbanization, and violent trauma
seem to increase the risk of developing major depressivedisorder, whereas religious belief may decrease it (633–
635). Among those exposed to trauma, the prevalence of
major depressive disorder seems to be higher among per-sons who develop PTSD than among those who do not
(636). A recent meta-analysis underlined that among ref-
ugees, PTSD was diagnosed in one of 10 and one in 20 hadmajor depressive disorder (637).
Marital discord has been identified as a potent risk factor
in women for the development of depression (638, 639).
Problems in the family setting may become an ongoing
stressor that hampers the patient’s response to treatment.Ambivalent, abusive, rejecting, or highly dependent family
relationships may predispose an individual to major depres-
sive disorder. The psychiatrist should screen for such fac-tors and consider family therapy, as indicated, for these
patients. Family therapy may be conducted in conjunction
with individual and pharmacologi cal therapies. Even for in-
stances in which there is no apparent family dysfunction, it
is important to provide the family with education about the
nature of the illness and to enlist the family’s support andcooperation with the treatment.
The psychiatrist may choose to treat a major depressive
episode with an antidepressant, even if a major stressorpreceded the episode. Nonetheless, attention to the rela-
tionship of both prior and concurrent life events to the
onset, exacerbation, or maintenance of major depressivedisorder symptoms is an important aspect of the overall
treatment approach and may enhance the therapeutic al-
liance, help to prevent relapse, and guide the currenttreatment. A close relationship between a life stressor and
major depressive disorder suggests the potential utility of
a psychotherapeutic intervention coupled, as indicated,with somatic treatment.
2. Bereavement
Bereavement is a particularly severe stressor that can trig-ger a major depressive episode. However, grief, the natural
response to bereavement, resembles depression, and this
sometimes causes confusion. Psychiatrists treating be-reaved individuals should differentiate symptoms of normal
acute grief, complicated grief, and major depressive disor-
der, as each of these disorders requires a unique manage-ment plan. Normal grief should be treated with support
and psychoeducation about symptoms and the course of
mourning; complicated grief requires a targeted psycho-therapy, with or without concomitant medication (535,
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
66 APA PRACTICE GUIDELINES
640); and major depressive disorder should be treated with
medication and/or depression-focused psychotherapy.
Acute grief is the universal reaction to loss of a loved
one, and it is a highly dysphoric and disruptive state (641).Acute grief is characterized by prominent yearning and
longing for the person who died, recurrent pangs of sad-ness and other painful emotions, preoccupation with
thoughts and memories of the person who died, and rela-
tive lack of interest in other activities and people. Despitethe similarity with depression, only about 20% of be-
reaved people meet the criteria for major depressive dis-
order. Successful mourning leads to resolution of acutegrief over a period of about 6 months. Integrated grief re-
mains as a permanent state in which there is ongoing sad-
ness about the loss often accompanied by ongoing feelings
of yearning for the person who died. However, when the
death is accepted, and grief integrated, the person is againinterested in his or her own life and other people.
Complicated grief is a recently recognized syndrome in
which symptoms of acute grief are prolonged, associatedwith intense and persistent yearning and longing for the
deceased person, and complicated by guilty or angry ru-
minations related to the death and/or avoidance behavior.Studies of individuals bereaved by the attacks of Septem-
ber, 11, 2001, have demonstrated that complicated grief is
a distinct condition from either major depressive disorderor PTSD (642, 643). It is important to note that treatment
for depression is not effective in relieving symptoms of
complicated grief (640).
Although DSM-IV-TR excludes the diagnosis of major
depressive disorder during the first 2 months followingbereavement, major depressive disorder in the wake of be-reavement can impede the course of mourning. Bereave-
ment-related depression responds to antidepressant
medication and should be treated; otherwise it is likely tobecome chronic and impairing (644). There is no indica-
tion that depression in the context of bereavement differs
from other major depressive episodes, and data indicatethat chronicity of bereavement-related depression over
13 months is similar to chronicity of depression in other
contexts (644).
3. Culture and ethnicity
An appreciation of cultural and ethnic variables is impor-tant to the accurate diagnosis of major depressive disorder
and in the selection and conduct of psychotherapy andpharmacotherapy (645–647). Although major depressivedisorder is seen across cultural and ethnic groups, and the
age at onset, gender differences, and prevalence of co-oc-
curring conditions are simila r across cultures, the actual
incidence and prevalence of depression vary (648–656).
Furthermore, some evidence suggests that patients of dif-ferent cultures express depressive symptoms differently,particularly somatic and psychomotor symptoms (657).
Specific cultural variables may also influence the assess-ment of major depressive disorder symptoms. For exam-
ple, in some cultures, depressive symptoms may be more
likely to be attributed to physical diseases (658). In addi-tion, language barriers can impede accurate psychiatric
diagnosis and effective treatm ent (659), and, even when
speaking the same language, individuals of different cul-
tures may use different psychological terms to describe
their symptoms (6, 7). In addition, the importance of in-
dividual experience should not be underestimated in thetherapeutic relationship (660). The assessment and treat-
ment process can also be influenced by religious beliefs
(5). Individuals with high levels of religious involvement
may have diminished rates of major depressive disorder
(661, 662).
Differences in the utilization of psychiatric services by
some cultural and ethnic groups have been well docu-mented. Relative to Caucasians, African Americans andLatinos appear less likely to receive treatment for mood
disorders (663–665).
Several studies have underscored the lower frequency
of use of antidepressant drugs (and more specifically,SSRIs) (648, 666–669), ECT (670), and psychotherapy
(671, 672) in minority groups, compared with Caucasians. Iftreatment for depression is initiated, African Americans are
disproportionately more likely to receive pharmacother-
apy (672), to drop out of treatment (673), and to developchronic symptoms (674) than are Caucasian patients.
These differences in mental health service use by minority
populations appear to have a number of potential causes.Cultures and ethnicities may differ in the degree to which
psychiatric illness is stigmatized (675) and in the prefer-
ences of individuals for treatment (676–678). For exam-ple, studies have found that Hispanic individuals were
more likely to prefer counseling than whites, whereas Af-
rican Americans varied across studies in their relativepreference for counseling rather than pharmacotherapy
(6, 679). Service use by minority populations is more af-
fected by financial constraints (including those related toinsurance) and social barriers (e.g., stigma) than the use of
comparable services by Caucasians (664, 680, 681). In ad-dition, pharmacological factors may play a role in patient
preferences and adherence, as ethnic groups may differ in
their relative rates of metabolism (682–684) and side ef-
fects and response to antidepressant medications (685–688).
4. Older age
The combined prevalence of major depression, dysthymic
disorder, and “minor” depression in individuals over age
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 67
60 years has been reported to be as high as 25%, and ma-
jor depressive disorder has been reported to be present in
14%–42% of nursing home residents (689). Elderly pa-tients typically display more vegetative signs and cogni-
tive disturbance but report less subjective dysphoria than
younger patients. Major depressive disorder may conse-quently be misattributed to physical illness, dementia, or
the aging process itself. For older adults with chronic
illness or physical disability, including those expected toremain in a long-term care facility, depression may be er-
roneously regarded as expected or inevitable, and therefore
untreatable (690). As a result, it is common for major de-pressive disorder to be undiagnosed and untreated among
older adults.
As in all depressed individuals, a suicide risk assessment
is an essential element of the evaluation process in older
individuals. Although older adults constitute only 13% ofthe U.S. population, they account for 19% of all suicides,
with elderly white men having the highest rates of com-
pleted suicides (691). This increase in suicide risk with ag-ing in some demographic groups should be taken into
consideration when estimating suicide risk and develop-
ing a plan to reduce such risk.
Several general medical conditions common among
older adults are risk factors for depression. In addition,the presence of depression of ten exacerbates the course of
the co-occurring medical condition and is a risk factor for
poor outcomes. For example, elderly patients who are de-
pressed and recovering from hip fractures have poorerfunctional outcomes from rehabilitative care and are less
likely to return to full ambulation, compared with older
adults with hip fractures who are not depressed (692–694). There is also frequent co-occurrence of major de-
pressive disorder and cardiovascular disease; 25% or more
of those with cardiovascular disease also have major de-
pressive disorder, and co-occurring depression increases
the morbidity and mortality of cardiovascular illness
(695–697). The term vascular depression has been used todescribe depression occurring in late life in patients with
clinical evidence of cerebrovascular disease (698), al-
though at this time it has not been established as a uniquesubtype of depression. In addition, major depressive dis-
order is a complication of cere bral infarction (see Section
III.C.3). There is also a high prevalence of major depres-
sive disorder among patients with dementia, and mood
symptoms may precede cognitive symptoms and diagno-
sis of dementia (see Section III.A.3.C).
Just as patients with medical conditions should be
screened for depression, patients exhibiting symptoms ofdepression should be thoroughly evaluated for the pres-ence of co-occurring medical conditions, as major depres-
sive disorder and general medical illnesses frequentlycoexist, especially in elderly patients (696, 699). This eval-
uation should include a systematic review of the patient’s
medications. Some medications have been reported to in-duce depressive symptoms (e.g., beta-blockers), although
they may simply be producing lethargy and fatigue that
mimic depression (700, 701). Consequently, the psychia-trist must carefully assess whether a given medication is
contributing to depressive symptoms before prematurely
altering what may be a valuable treatment. Patients un-dergoing their first major depressive episode in old age
should be assessed for an undiagnosed neurological or
other general medical disorder that may be responsiblefor the depressive symptoms. Similarly, frequently co-
occurring symptoms of major depressive disorder, such as
lassitude or pain, may mimic symptoms of a general med-
ical condition. Pain in older adults, especially from ortho-
pedic sources, may contribute significantly to the presenceof depression in this population (702).
Once the patient has been thoroughly assessed, the
treatment considerations for depressed geriatric patientsare essentially the same as for younger patients. A meta-
analysis has shown that SSRIs; TCAs; and cognitive-
behavioral, behavioral, and psychodynamic therapies areall superior to placebo in the acute treatment for depres-
sion in subjects older than age 55 years (703–708). In ad-
dition, treatments for depression have been shown to beeffective in nursing home populations (709, 710), as well
as in inpatient and traditional outpatient settings of care.
However, compared with younger individuals, older pa-tients may be more likely to experience relapses and less
likely to achieve a full response to treatment with antide-
pressant medications (711–714). In contrast, ECT is notonly effective as a treatment for depression among older
individuals, but those over age 65 years actually have bet-
ter response rates than younger patients (715). Consid-eration should also be given to combined treatment with
pharmacotherapy and psychotherapy, as evidence for the
efficacy of stand-alone psychotherapy, such as CBT, isweak (716). Although the role of stimulants for antide-
pressant monotherapy is very limited, these compounds
have some role in apathetic major depressive disorder inelderly patients with complicating general medical condi-
tions. Late-life depression asso ciated with vascular disease
has also been found to respond well to treatment with an-
tidepressants (717) and, in one unreplicated study, to
TMS (718). Furthermore, in a recent randomized con-
trolled trial, administering escitalopram prophylacticallyto patients who had experienced a stroke resulted in
lower rates of depression at 12 months (334). Psychoso-
cial factors are also frequent contributors to depressionamong older adults and should be addressed as part of the
treatment plan (719, 720).
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
68 APA PRACTICE GUIDELINES
There are several considerations in prescribing medi-
cations for elderly patients. As with any patient, the psychi-
atrist should attempt to use as few medications as possible,and this is especially important given the complexity and
multiplicity of issues in elderly patients. It is often useful
to use medications that address several issues at once, suchas choosing mirtazapine for a depressed, elderly patient with
weight loss and insomnia. Elderly patients typically require
a lower oral dose than younger patients to yield a partic-ular blood level, and they tolerate a given blood level less
well. Nevertheless, the blood levels at which antidepres-
sant medications are maximally effective for elderly pa-tients appear to be the same as those for younger patients
(721, 722). Dose regimens should be adjusted for age-
related metabolic changes, with close attention paid to
hepatic and renal metabolic function. For patients who
are receiving other medications, careful attention shouldbe paid to potential drug interactions (160, 161, 723–725)
(T ables 4 and 5).
Elderly patients are particularly prone to orthostatic
hypotension and cholinergic blockade; for this reason,SSRIs, SNRIs, and other antidepressants should be con-
sidered over MAOIs or TCAs. Among the TCAs, de-sipramine and nortriptyline should be considered over
amitriptyline, imipramine, and doxepin, due to increas-
ing sensitivity to side effects and toxicity with advancingage. T reatment with SSRIs causes the syndrome of in-
appropriate antidiuretic hormone secretion (SIADH) at a
higher rate in elderly patients than in younger patients (726,727). Patients taking SSRIs have a three times greater risk
of developing SIADH than patients taking other antide-
pressants, with the greatest risk among elderly patients(728).
For maintenance treatment, one study has shown that
antidepressant medication (nortriptyline) and IPT are ef-fective for elderly patients with recurrent major depres-
sive disorder (315), yet a trend toward superior response
was observed for combined pharmacotherapy and IPT ,compared with pharmacoth erapy alone. Another study
demonstrated that paroxetine (but not monthly psycho-therapy) was effective as maintenance therapy for elderlypatients (729). For older patients with particularly se-
vere or treatment-resistant depressive illness, addition of
maintenance ECT to nortriptyline appears to improvetreatment outcome (730). Among elderly patients who
have had prior depression, the risk of developing another
episode of major depressive disorder is substantially in-creased in those who develop or report sleep disturbance
(731). Sleep disturbances may function as independent
predictors of depression and are not simply prodromal de-pressive symptoms.A body of systematic evidence suggests a particular
value for various forms of collaborative or team-basedcare for elderly patients. Such care combines, for example,specialty mental health consultation/intervention with
primary care management or community-based outreach
and monitoring of care (732, 733). Older adults with de-pression can benefit from integration of mental health
services in the setting where they typically receive their
general medical care. It has been shown that support foralgorithm-driven depression care processes within the
primary care outpatient practice can lead to increased
treatment adherence and improved clinical outcomes, in-cluding a reduction in mortality (734).
5. Gender
As part of the diagnostic a ssessment of a woman with ma-
jor depressive disorder, there should be a detailed inquiry
regarding reproductive life history and mood symptoms
associated with reproductive life events, such as menses,use of oral contraceptive agents, peripartum, infertility,
menopause, and pregnancy loss due to abortions, miscar-
riages, and perinatal losses. Although associations be-tween reproductive factors and major depressive disorder
are neither widespread nor consistent, some women may
be particularly vulnerable to fluctuations in gonadal hor-mone levels (735). The perimenopausal transition has
been identified as a high-risk period for new-onset major
depressive disorder, with high variability of sex hormonesas a risk factor (736, 737). Women in the perimenopausal
transition may benefit from the use of serotonergic anti-
depressants, for mood and also for somatic symptoms suchas hot flashes (738).
Since women are often caretakers in families, psycho-
social stresses such as caring for an ill husband, child, orparent must be carefully assessed. T reating depressed
mothers is associated with improved prognosis for their
children as well (739). Maternal remission from depression
was associated after 3 months with significantly decreased
diagnoses and symptoms in their children, compared with
children of mothers whose depression had not remitted.Thus, treating depressed mothers may crucially benefit
both the patients and their children.
The patient’s gender also factors into other treatment
considerations for major depressive disorder. For exam-ple, the risks of certain adverse effects from treatments
may also differ by gender. When prescribing trazodone tomen, it is important to provide education about the risk of
priapism (174). Older men typically have prostatic hyper-
trophy, making them particularly sensitive to anticho-linergic effects of some antidepressants on the bladder
outlet. While both men and women may experience de-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 69
creased libido or anorgasmia while taking SSRIs, men
may also experience ejaculato ry dysfunction (740). Some
women who are taking birth control pills require higher
doses of TCA medications because of the induction of the
hepatic enzymes responsible for medication metabolism.
Similarly, medications that induce hepatic enzymes, suchas anticonvulsants used as adjunctive treatment, reduce
the effectiveness of contraceptives.
6. Pregnancy and postpartum
Major depressive disorder during pregnancy and postpar-
tum presents unique treatment considerations. During
these periods, approximately 10% to 15% of perinatal
women will experience major depressive disorder, which
is at least as common as rates reported for women in non-
reproductive states (741, 742). Evaluation and communi-cation of risks and benefits of antidepressants during
pregnancy and breast-feeding is challenging and must in-
clude the risks of untreated maternal mood disorder, thelimited body of research that informs safety of antidepres-
sants, and the general lack of prospective long-term data
following antidepressant exposure in utero and throughlactation.
Depression-focused psychotherapy or other nonmedi-
cation therapies may be considered first for some women,and psychotherapy should be considered as part of the
treatment plan whenever possible. As childbearing is a life
stressor with psychosocial repercussions that may be ame-nable to psychotherapy, psyc hotherapy may serve to min-
imize medication exposure in some women. Althoughthere is little controlled research, psychotherapies appearefficacious in antenatal and postpartum depression, with
IPT being the best studied (743, 744). Therefore, depres-sion-focused psychotherapies such as IPT and CBTshould be considered in the treatment plan as a first-line
treatment or in combination with medication to minimize
medication exposure, especially if the individual has expe-rienced a good response to a particular psychotherapy in
the past or strongly prefers to avoid medication.
a. Depression during pregnancy
Psychiatrists should be familiar with the management of
major depressive disorder in the context of pregnancy
(745). More than 80% of women in the United States willhave children (746), and about half of pregnancies are
unplanned (747). Therefore, pregnancies—including un-
planned pregnancies—are likely to occur during the courseof treatment of major depressive disorder, as it is often a
chronic and/or recurrent cond ition that is a major cause
of disability during the reproductive years and dispropor-
tionately affects women, compared with men. In consid-eration of the high prevalence of both unplanned pregnancy
and major depressive disorder in women, the risks and
benefits of antidepressants and untreated maternal de-pression during pregnancy should be discussed with all fe-
male patients who have reproductive potential. Whenever
possible, a pregnancy should be planned in consultationwith a treating psychiatrist, who may wish to consult with
a specialist in perinatal psychiatry. For women who are
pregnant or planning to become pregnant, decisionsabout treatment for depression require weighing multiple
benefits and risks for the woman as well as for the fetus.
Making such decisions may require several discussions
and will generally involve discussions with the patient’s
partner as well as her obstetrician.
Antidepressant medications carry some reported risks
in pregnancy (see below), but so does untreated depres-
sion. Suicide risk, marital discord, the inability to engagein appropriate obstetrical care, and difficulty caring for
other children must also be considered. There are also se-
rious and well-characterized risks to the fetus of exposureto maternal major depressive disorder, including the pos-
sibility of low birth weight secondary to poor maternal
weight gain (or frank weight loss) and increased risk of ob-stetrical complications such as premature delivery (748).
Antidepressant efficacy has not been determined for
pregnant women, and questions remain as to whethermedications have equivalent efficacy during pregnancy,
compared with the nonpregnant state. Some safety data
are available, but the findings often conflict, making datainterpretation challenging and difficult to apply to the
care of individual patients. Nevertheless, antidepressant
medication should be considered and discussed as an op-tion with pregnant women who have moderate to severe
major depressive disorder.
For women who are in remission from major depres-
sive disorder and receiving maintenance medicationand/or for women deemed to be at high risk for a recur-
rence if the medication is discontinued, the risks of treat-ment with medications must also be weighed against the
risks of alternative treatment options and untreated de-
pression. Relapse rates for women with a history of majordepressive disorder are high during pregnancy, especially
if antidepressants are discontinued (749).
1. Risks of antidepressants during pregnancy
The impact of the duration and timing of antidepressant
exposure during pregnancy requires further study. Wisneret al. (750) reviewed the risks associated with the use of
antidepressants during pregnancy, and a growing body of
complicated literature has followed. Overall, risk of ter-atogenicity with antidepressants following first trimester
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
70 APA PRACTICE GUIDELINES
exposure appears to be low, although some rare birth de-
fects have been observed to occur at higher rates with use
of specific SSRIs (751, 752). First-trimester paroxetineexposure has been associated  with cardiac malformations,
a finding that resulted in changes in FDA labeling for par-oxetine from C to D (753); labeling changes have beenmade to all SSRI antidepressants with regard to this pos-
sibility when used during pregnancy. There have been
conflicting results regarding whether first-trimester par-oxetine exposure and cardiac teratogenicity are associated
(754, 755). For fluoxetine, one study (756) found a higher
incidence of three or more minor physical anomalies ininfants exposed to fluoxetine than in a control group, and
fetuses exposed to fluoxetine after 25 weeks’ gestation had
lower birth weights, which were associated with lower
maternal weight gain. Although one case-control study
reported a potential association between late antenatalSSRI use and the rare but serious condition of persistent
pulmonary hypertension in the newborn (PPHN) (757),
two subsequent retrospective chart review studies showedno such association (758, 759). An additional case-control
study (760) showed a marginally significant increase in the
relative risk of PPHN with SSRI use, but the estimatedrate of PPHN occurrence was 1.5 per 1,000 births, which
is less than the rate of 2.7 per 1,000 births reported by oth-
ers (758) in non-SSRI exposed infants. Therefore, whilemany physicians are concerned about the reported associ-
ation between SSRIs and PPHN, the preponderance of
evidence from published studies on this topic does notsupport an association. Use of  SSRIs may also be associ-
ated with prematurity (761, 762), although untreated de-pression and stress during pregnancy may also contributeto the risk of prematurity (748, 763). Some naturalistic
studies and health care utili zation studies suggest that
antidepressants are associated with shorter length of ges-
tation (761, 762), but there have been no randomized stud-ies of the treatment of antenatal major depressive disorder
that would adequately control for untreated maternal de-pression, antidepressant use, and confounding variables
related to treatment selection. With late pregnancy anti-
depressant use, some but not all studies show a risk ofmedical complications such as prematurity and a transient
neonatal withdrawal/adaptation syndrome (761, 764). The
syndrome in the neonate appears to be associated with an-tidepressant use in the third trimester, has been reported
in babies exposed in utero to TCAs and SSRIs, and in-
cludes transient symptoms such as jitteriness, tremor, dif-ficulty with feedings, and other symptoms (764). Several
studies, involving relatively small samples, have examined
effects of antidepressant exposure during pregnancy onsubsequent childhood behavior and development and
found minimal (765) or no (766–768) effects on language,cognition, or motor or behavioral development indepen-dent of maternal depressed mood during pregnancy and
the child’s early life (766, 767).
2. Implementation of pharmacotherapy 
during pregnancy
No controlled trials inform the use of antidepressants
during pregnancy. Dose requirements may change during
pregnancy because of changes in volume of distribution,hepatic metabolism, protein binding, and gastrointestinal
absorption. Pharmacokinetic changes in late pregnancy
may result in lower blood levels, with clinical implica-tions, although more study is needed to develop monitor-
ing and dosing guidelines. The limited data in this area
demonstrate that pregnant women metabolize TCAs and
SSRIs more rapidly in late pregnancy (769–774).
A number of factors influence antidepressant choice
during pregnancy. If a woman has had a history of a goodresponse to or is already ta king a particular antidepres-
sant, it is logical to consid er that antidepressant among
first-line treatments in an effort to minimize the numberof different medication exposures. Using a single agent is
also preferable to using several medications concomi-tantly. Because paroxetine use is classified as having a higher
level of risk than other SSRIs, it should not be considered
a first-line treatment when selecting a new antidepressantfor a pregnant patient. Fluoxetine has the longest half-life
and is mor e like ly to b e d emonstr ated  at high le vels in
newborns after in utero exposure. Sertraline has beendemonstrated to have lower cord blood levels than other
SSRIs, although the clinical s ignificance of this is un-
known (775). Although there are few data for bupropion
and safety in pregnancy, its benefits for smoking cessation
may make it especially useful in women who have major
depressive disorder and who smoke cigarettes, as tobaccois a known teratogen. Given these data, it is recommended
that consideration be given to using an antidepressant
with some available safety information that has beenstudied in pregnant women. For women who discontinue
medication during pregnancy and are deemed at risk for
postpartum depression, medication can be restarted fol-lowing delivery.
Electroconvulsive therapy is also recommended as a
treatment option for major depressive disorder duringpregnancy (239). The current literature supports the
safety for mother and fetus, as well as the efficacy of ECT
during pregnancy (239). The psychiatrist should considerECT for pregnant patients with moderate to severe de-
pression who are unresponsive to or unsuitable for phar-
macotherapy, for pregnant patients with major depressivedisorder with psychotic features, and for pregnant pa-
tients electing to use this modality as a matter of prefer-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 71
ence after having weighed the relative risks and benefits of
ECT and other treatment options. For details on the use
of ECT during pregnancy, refer to The Practice of Electro-
convulsive Therapy: Recommendations for Treatment, Train-
ing, and Privileging (A T ask Force Report of the American
Psychiatric Association)  (239).
b. Postpartum depression
Major depressive disorder with postpartum onset is de-
fined in DSM-IV-TR as a major depressive episode with
onset within 4 weeks of delivery. However, the occurrence
and course of major depressive disorder in childbearingwomen is heterogeneous, and definitions of postpartum
depression may evolve with continued research (16, 776).
In major depressive disorder with postpartum onset, anx-
iety symptoms are more prevalent than in major depres-
sive disorder occurring at other times (777). It is notuncommon for women with postpartum depression to
experience obsessions and/or compulsions, and obses-
sions may often involve thoughts of harming the baby,which must be differentiated from postpartum psychosis.
Psychiatrists should provide psychoeducation about ma-
jor depressive disorder to pregnant and postpartumwomen and their families to improve the detection of ma-
jor depressive disorder during pregnancy and the postpar-
tum period.
Several other psychiatric conditions may follow child-
birth (778). The transient 7- to 10-day depressive condi-tion referred to as “postpartum blues” is by definition toomild to meet the criteria for major depressive disorder and
does not require medication. In addition to providing re-
assurance, psychiatrists should encourage mothers whoexperience postpartum blues to increase psychosocial sup-
port and obtain help with the care of the infant. Puerperal
psychosis is a more severe disorder complicating one totwo of 1,000 births. Although postpartum psychosis is
rare, women with this disorder may have homicidal im-
pulses toward the newborn; for this reason, careful assess-ment of homicidal as well as suicidal ideation, intention,
and plans is important. Postpartum psychosis must always
be treated as a psychiatric emergency, with hospitalizationconsidered for the safety of the mother and baby (779).
Many patients who have had episodes of this type ulti-
mately prove to have bipolar disorder (780).
The woman’s parenting skills for both the newborn
baby and any other children in her care must be carefullyassessed. Untreated maternal major depressive disorder,and specifically postpartum depression, have negative
consequences for children, with adverse effects on attach-
ment and child development (781, 782). Major depressivedisorder can seriously interfere with the new mother’s abil-ity to provide physically and emotionally appropriate care
for her baby and other children. The psychiatrist should
work with the patient to develop a plan to manage this ef-fect, such as enlisting family  members to assist with child
care.
Antidepressants are often prescribed for postpartum de-
pression, according to the same principles delineated for
other types of major depressive disorder, despite a limited
number of controlled studies. T wo placebo-controlled tri-als of SSRIs (fluoxetine and paroxetine) have been pub-
lished for the treatment of postpartum depression, with
fluoxetine appearing more efficacious than placebo andparoxetine being comparable to placebo on primary out-
come measures of depressive symptoms (783, 784). Wisner
et al. (785) did not find a difference in response and remis-
sion rates in a randomized controlled trial of sertraline ver-
sus nortriptyline for postpartum major depressive disorder.Open studies of other antidepressants in postpartum
women suggest efficacy, although some studies included
only a small number of participants (786). Paroxetine aloneand paroxetine plus CBT both produced a significant change
from baseline in one study, but there was no placebo-only
group for comparison (787).
Patients and clinicians are often concerned about the
risks of possible exposure to antidepressants duringbreast-feeding. These risks, however, must be weighedagainst the well-known, and at times profound, risks to
the woman and her children of untreated postpartumdepression. Mothers should be counseled regarding therelative risks and benefits when making these treatment
decisions. Antidepressant medications are considered
compatible with breast-feeding, but long-term data arenot available regarding risks and benefits. Although there
have been some suspected case reports of adverse effects
in breast-feeding infants exposed to maternal antidepres-sants, most studies show low levels of exposure via breast
milk, with the exception of fluoxetine, which appears to
have a dose-related risk for detectable levels in infant sera(788, 789). At this time, there are no studies which have
determined a “safe” amount and duration of antidepres-
sant exposure in the fetus and newborn. However, ex-
posure to antidepressants via breast milk is considered
substantially lower than in-utero exposure. Women who
elect to breast-feed while taking antidepressants should besupported in doing so, given the widely known health
benefits (e.g., immune system effects) to infants who are
breast-fed. Similarly, women who elect to bottle-feedshould also be supported in this decision. Some women
will not accept treatment with antidepressant medication
while they are breast-feeding. Depression-focused psy-chotherapy can be recommended instead.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
72 APA PRACTICE GUIDELINES
7. Family history
Major depressive disorder is one and one-half to three
times as common among those with a first-degree biolog-
ical relative affected with the disorder as in the general
population. In addition, the rates of depression, anxiety,and other disorders are increased more than two- to six-
fold in the offspring of depressed parents. A family history
of depression is associated with an earlier age at onset ofdepression (790), and children of depressed parents are
more likely to have depression with a chronic and recur-
rent course (791). Furthermore, a family history of recur-rent major depressive disorder increases the chances that
the patient’s own illness will be recurrent and that the pa-
tient will not fully recover between episodes (792). A fam-
ily history of bipolar I disorder, bipolar II disorder, or
acute psychosis probably incr eases the chances that the
patient’s own major depressive disorder is a manifestation
of bipolar rather than unipolar depression, and that anti-
depressant medication therapy may incite a switch tomania (793). Patients with such a family history should be
questioned particularly closely regarding a prior history
of mania or hypomania and should be carefully observedfor signs of a switch to mania during treatment with anti-
depressant medication.
There are no real predictors of response to individual
antidepressants, yet in the absence of other informationclinicians sometimes rely on family history of therapeutic
benefit to select a specific medication for a family mem-ber. Although it does not have specific support in the lit-
erature, this practice appears reasonable.
C. TREATMENT IMPLICATIONS OF CO-
OCCURRING GENERAL MEDICAL CONDITIONS
In patients with co-occurring medical conditions, there is
a higher prevalence of major depressive disorder than inthe general population. Furthermore, co-occurring med-
ical conditions in patients with major depressive disorder
are associated with poorer outcome (794, 795). A numberof medical conditions are known to cause mood symp-
toms, such as stroke, hypoth yroidism, carcinoma of the
pancreas, and many others. Apart from directly causing
depressive symptoms, debilitating, painful, and chronic
medical conditions often constitute an ongoing stressor
that predisposes patients to depressive episodes. Never-theless, a depressive episode, in any context, is never a
“normal” response to illness and consequently warrants
treatment.
In addition to the increased risk of major depressive
disorder with general medical conditions, depressive epi-sodes increase the risk of certain general medical conditions,such as heart disease. (796). Due to the interrelationship
between depression and medical illness, it is very impor-
tant to recognize and treat depressive symptoms in med-ically ill patients, and vice versa. The psychiatrist should
also attend to the potential for interactions between anti-
depressants and the co-occurring medical conditions aswell as any nonpsychiatric me dications that the patient
may be taking.
1. Hypertension
The presence of treated or untreated hypertension may in-fluence the choice of an antidepressant, as a few antidepres-sant medications have been associated with increases in
blood pressure. With SNRIs such as venlafaxine and dulox-
etine, dose-dependent elevations in blood pressure are
usually mild, although more severe hypertension has also
been observed (166, 797). However, another study foundno increase in hypertension with duloxetine dosed up to
80 mg/day (798). Hypertension induced by SNRIs may re-
spond to a decrease in the medication dose, or an alternativeantidepressant medication may be considered. Alterna-
tively, for a patient with well-controlled depressive symp-
toms, it may be preferable to add an antihypertensive agentrather than risk a depressive relapse or recurrence with
medication tapering.
Antihypertensive agents and antidepressant medica-
tions may interact to either in tensify or counteract the ef-
fect of the antihypertensive  therapy (799). The action of
antihypertensive agents that  block alpha receptors (e.g.,
prazosin) may be intensified by antidepressant medica-tions that block these same receptors, notably the TCAs
and trazodone. T ricyclic antidepressants may antagonizethe therapeutic actions of guanethidine, clonidine, or al-
pha-methyldopa. Concomitant antihypertensive treat-
ment, especially with diuretics, increases the likelihoodthat TCAs, trazodone, or MAOIs will induce symptomatic
orthostatic hypotension.
Side effects of antihypertensi ve agents, such as fatigue
or sexual dysfunction, may also confound the evaluationand interpretation of depressive symptoms. It has also
been thought that beta-blockers, especially propranolol,may account for depressive symptoms in some patients,
but this association has been questioned (700, 701).
2. Cardiac disease
Depression increases the risk of cardiovascular disease
(800). In addition, patients who are depressed following amyocardial infarction have an increased rate of mortality,
compared with patients without depression (801–803).
Following an acute myocardial infarction, the decreasedsurvival rates of depressed patients may in part be due to
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 73
lower heart rate variability in these patients, compared
with nondepressed patients (804). Particularly in patients
with a history of major depressive disorder (805), there isevidence that the depressive  symptoms associated with
cardiac illness respond to antidepressants (717, 806, 807).However, studies in which the attempt has been made toinfluence cardiac-related mortality through treatment of
depression have shown mixed results (808–811).
A depressed patient with a history of a cardiac problem
should be monitored for the emergence of cardiac symp-toms, ECG changes, persistent tachycardia, or orthostatic
blood pressure decrements. Consultation with the pa-tient’s cardiologist before and during antidepressant med-
ication treatment may be advisable, especially for patients
who have recently had a myocardial infarction. Increases
in heart rate and blood pressure may be associated with
the use of agents with noradrenergic properties such asSNRIs and stimulants; thus, changes in heart rate and blood
pressure should be assessed after treatment with these
agents is instituted in patients with coronary artery dis-ease, hypertension, or congestive heart failure. Although
TCAs have been used effectively to treat major depressive
d is o r d e r  i n  p a t i e nt s  w i t h  s o m e  f o r ms  o f  i s c h e m i c  h e a r tdisease (812), psychiatrists should take particular care in
using TCAs for patients with a history of ventricular ar-
rhythmia, subclinical sinus node dysfunction, conductiondefects (including asymptomatic conduction defects), pro-
longed QT intervals, or a rece nt history of myocardial in-
farction (184, 185, 813–818). Selective serotonin reuptake
inhibitors, SNRIs, and bupropion appear to be safer for
patients with preexisting car diac disease; several SSRIs
have been used safely in patients with cardiac disease in
large clinical trials (807, 809, 810, 819). Electroconvulsive
therapy can also be used safely in individuals with cardiac
disease or arrhythmias, although specialist consultationand modifications in ECT technique or anesthesia may be
indicated (239, 245, 820–822). Monamine oxidase inhibi-
tors do not adversely affect cardiac conduction, rhythm,or contraction but may induce orthostatic hypotension
and have risks relating to drug-food and drug-drug inter-
actions.
3. Stroke
Depression is observed in approximately one-third toone-half of individuals in the weeks to months following a
stroke, with a substantial proportion developing major
depressive disorder (334, 823, 824). Although conclusionsof meta-analyses are mixed (825, 826), some research
suggests that antidepressant treatment immediately fol-
lowing a stroke may reduce rates of depression (334) andpossibly mortality (827). Among psychotherapeutic ap-proaches to preventing depression after stroke, problem-
solving therapy has been best studied, but findings are in-
consistent (334, 825).
When depression develops after a stroke, it has detri-
mental effects on quality of life (823). In addition, thepresence of depression 1 month following a stroke hasbeen associated with an incr ease in subsequent mortality
(828). Use of screening tools such as the PHQ-9 may helpto identify depressive episodes after stroke (829), and caremanagement may improve outcomes once poststroke de-
pression is recognized (830). Psychotherapies have not
been well studied as treatments for poststroke depression;however, a meta-analysis of randomized trials that have
been conducted did not show  efficacy (825). Findings on
the therapeutic effects of an tidepressants in post-stroke
depression have been mixed, perhaps due to the substan-
tial heterogeneity of study populations and designs (831,832). Although a meta-analysis did not show any differ-
ence in the rate of depressive remission with antidepres-
sant treatments compared with placebo (832), patientsreceiving an antidepressant did show more improvement
in depressive symptoms (831, 832) and a greater propor-
tion were classified as treatment responders (831). Individ-ual randomized controlled trials have shown therapeutic
benefits for several SSRIs, including fluoxetine, sertraline,
and citalopram (833–836), an d for the TCA nortriptyline
(837, 838); however, not all studies have shown benefit for
some of these agents (837, 839–841). Nevertheless, for in-
dividuals with poststroke depressive symptoms, a trial ofantidepressant therapy may be considered, with SSRIs
being better tolerated and having fewer contraindications
in this older and more medically ill population (842, 843).However, in individuals who are receiving concomitant
treatment with anticoagulant (e.g., warfarin) or antiplatelet
(e.g., dipyridamole, clopidogrel, aspirin) medications, it isimportant to consider the potential for an increased bleed-
ing risk due to drug-drug interactions with antidepres-
sants (844, 845).
4. Parkinson’s disease
Major depressive disorder occurs to some degree in 40%–50% of patients with Parkinson’s disease. Patients with
Parkinson’s disease experience alterations of serotonergic
and noradrenergic systems that may induce depression.There is no evidence favoring any particular antidepres-
sant medication from the standpoint of therapeutic effi-
cacy and safety for patients with Parkinson’s diseasecomplicated by major depressive disorder (846). A meta-
analysis of placebo-controlle d studies identified a clear
benefit for both active treatment and placebo, but it did
not find differences between them (847). Although SSRIs
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
74 APA PRACTICE GUIDELINES
can be used, there is some risk of worsening of Parkinson’s
disease symptoms (increases in “off” time and exacerba-
tion of tremor) with agents that are primarily serotonergic(848). Bupropion, in contrast, exerts a beneficial effect on
the symptoms of Parkinson’s disease in some patients but
may also induce psychotic symptoms, perhaps because ofits agonistic action in the dopaminergic system (849).
Noradrenergic agents and SNRIs may also be preferable
to SSRIs. Nonselective MAOIs (e.g., tranylcypromine,phenelzine, isocarboxazid) may adversely interact with 
L-
dopa products (850). Selegiline, also known as L-depre-
nyl, is a selective type B MAOI recommended in the treat-ment of Parkinson’s disease. Selegiline loses its specificity
for MAO B in doses greater than 10 mg/day. As a result, it
may induce serotonin syndrome when given in higher
doses in conjunction with serotonin-enhancing antide-
pressant medications. The theoretical benefits of the an-timuscarinic effects of some of the tricyclic agents in the
treatment of patients with major depressive disorder with
Parkinson’s disease are offset by the memory impairmentthat may result. Amoxapine, an antidepressant medication
with dopamine-receptor-blocking properties, should beavoided for patients who have Parkinson’s disease. Lith-ium may, in some instances, induce or exacerbate parkin-
sonian symptoms. Electroconvulsive therapy exerts a
transient beneficial effect on  the symptoms of idiopathic
Parkinson’s disease in many patients (851, 852); however,
it might occasionally worsen 
L-dopa-induced dyskinesias
and induce a transient interictal delirium (853), which ne-
cessitates reductions in doses of dopamine agonist medi-
cations (239).
5. Epilepsy
The prevalence of depression in individuals with epilepsy
appears to be increased in secondary and tertiary care cen-ter samples, although in population-based studies this in-
crease is not well established (854). On the other hand,
major depressive disorder significantly increases the riskof unprovoked seizures even after the adjustment of age,
sex, length of medical follow-up, and medical therapies
for depression (855). In addition, some antidepressantdrugs, such as TCAs and bupropion, lower the seizure
threshold and have a dose-dependent epileptogenic po-
tential. This seizure risk is intermediate for immediate-release formulations of bupropion, maprotiline, and
TCAs (in particular, clomipramine) and low for sustained-
release formulations of bupropion (17, 197, 856).
Major depressive disorder in patients with seizure dis-
orders can usually be safely and effectively managed ac-cording to the same principles outlined for patientswithout seizures. In particular, SSRIs and SNRIs are notlikely to increase the risk of developing seizures (856–
858). However, blood levels of TCAs may be increased by
several antiepileptic drugs, increasing the side-effect bur-den of the anticholinergic and other side effects of tricy-
clics (859).
Some anticonvulsants appear useful for treatment and
prophylaxis of mood disorders (e.g., carbamazepine, val-proate, lamotrigine). Thus, in patients with depression and
epilepsy, consideration can be given to concomitant pre-scription of an anticonvulsant  (or elevating the dose of an
existing anticonvulsant). Nevertheless, anticonvulsant com-pounds may also have a negative effect on mood for somepatients (859). For example, barbiturates and possibly vi-
gabatrin have been associated  with an increased risk for
depression (860). In addition, a recent FDA statement notedthat increased rates of depression and suicide risk may be
associated with anticonvulsants (861).
6. Obesity
Many individuals with major depressive disorder will beoverweight or obese, given the high prevalence of excess
weight in the general population (862). In addition, rates
of depression may be increased in obese individuals, par-ticularly among women and in those with a body mass in-
dex (BMI) greater than 40 (863). Individuals with obesity
resulting from binge eating disorder also have higher ratesof depression (170). In the subgroup of patients with atyp-
ical depression, increased eating and weight gain are
symptomatic of the depressive disorder (864). For otherpatients, the lack of motivati on and energy that occur with
depression can make it difficult to maintain an exerciseregimen or nutritional dietary habits. In addition, treat-ment with many antidepressant medications appears to
lead to weight gain (865) and also makes it more difficult
to lose weight in a structured weight management program(866).
In treating individuals with major depressive disorder
who are overweight or obese, the effects of treatment onweight should be considered in selecting a therapeutic ap-
proach. If pharmacotherapy is used, the selection of an an-
tidepressant medication should include consideration ofits relative tendency to contribute to weight gain, which
is generally greatest with mirtazapine, TCAs (tertiary
TCAs more so than secondary TCAs), and MAOIs andless prominent with SSRIs and SNRIs (865). Bupropion is
generally weight neutral and has been associated with
modest weight reduction when used to treat major de-pressive disorder in obese adults (867, 868). Longitudinal
monitoring of weight, either by direct measurement or
patient report, can permit monitoring of BMI, as well asearly intervention if weight gain becomes a problem with
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 75
antidepressant treatment. Patients’ concerns about weight
gain may also contribute to poor adherence, and monitor-
ing of weight can facilitate su ch discussions. The impact
of weight on medication dosing should also be consid-
ered. In one study, greater relative body weight was asso-
ciated with a lesser likelihood of response to a fixed dosetrial of an antidepressant (869), perhaps suggesting a need
for increases in medication dose with increasing body
weight.
Psychotherapeutic approaches to treatment avoid the
potential for medication-induced weight gain and mayalso have modest benefits in weight management. Cogni-tive-behavioral therapy has shown efficacy in the treat-
ment of binge eating disorder (170, 870) and could
potentially be used in addressing obesity (871) and medi-
cation-induced weight gain (872).
The increasing use of surgical treatments for obesity
also has implications for the treatment of patients withmajor depressive disorder. Depression is common among
bariatric surgical candidates and, in and of itself, is not acontraindication for surgery (873–877). Long-term fol-
low-up studies show improvements in co-occurring gen-
eral medical conditions (878), as well as decreases indepressive symptoms and improved quality of life with
weight loss (879–881). However, weight loss after surgery
may be less pronounced in individuals with a lifetime di-agnosis of major depressive disorder (882) or in those with
severe psychiatric illness that has required hospitalization
(883). Close follow up is important following bariatricsurgery in order to assess for changes in psychiatric symp-
toms, assist patients in the psychological and psychosocial
adaptation to weight loss, and adjust medication regi-mens. Particularly following jejunoileal bypass or bilio-
pancreatic diversion, but also following gastric bypass
procedures, altered dissolution (884) and absorption ofmedication may require adjusting the dose of medication
or changing from a slow-release to an immediate-release
formulation (875).
7. Diabetes
Diabetes mellitus is common in the general population,
particularly in overweight or obese individuals (885).
However, it is not clear whether an association exists be-tween diabetes and major depressive disorder, as meta-
analyses and epidemiologic studies yield mixed results
(886–888). Some patients may have reduced adherence todiet and medications when depressed (889), but there are
inconsistent findings on whether successful treatment of
depression (with medication, psychotherapy, and/or col-laborative care) improves glycemic control (889–896). How-
ever, when initiating antidepressant therapy or makingsignificant dosing adjustments, it is useful to collaboratewith the patient’s primary care physician in monitoring
diabetic control because fluctuations in fasting blood glu-cose may occur. Some evidence suggests that use of TCAs
may be associated with worsened glycemic control, and
other antidepressants (such as SSRIs) may be preferable toTCAs for patients with diabetes (896, 897).
8. Sleep apnea
The possible contribution of obstructive sleep apnea (OSA)to depressive symptoms is an important consideration, par-ticularly in patients who are obese, report excessive daytime
sleepiness, or have treatment-resistant depressive symp-
toms. Symptoms such as fatigue and poor sleep quality can
occur in sleep apnea as well as in major depressive disorder,
requiring a careful assessment to distinguish whether eitheror both disorders are present. Underrecognition of OSA is
common, and rates of OSA appear to be increasing with the
increasing prevalence of obesity (898). Although the proto-typical sleep apnea patient is likely to be obese with a his-
tory of snoring, sleep apnea may still be present even in the
absence of these findings (899). Individuals with OSA orexcessive daytime sleepiness appear to have greater rates of
depression than comparison groups (900–902), although the
rates of depressive symptoms and major depressive disor-der diagnosis fluctuate across studies (903). In addition, ep-
idemiological findings suggest an increasing likelihood of
depression with increasing sleep-related breathing disorderseverity (904). With initiation of continuous positive airway
pressure treatment, improvement in OSA symptoms has
been associated with decreased depressive symptoms (905,906), in addition to reductions in OSA-associated health
risks (898). Consequently, recognition and treatment of
OSA is important among individuals with major depressivedisorder. Identification of OSA is also important to treat-
ment planning, as use of sedating medications can exacer-
bate OSA and worsen daytime sleepiness, with associatedcomplications (907).
9. Human immunodeficiency virus and hepatitis C infections
According to the Centers for Disease Control and Pre-vention, more than one million individuals in the UnitedStates were living with HIV infection by the end of 2003
(908), with increased rates among individuals with psychi-
atric disorders, including substance use disorders (909).Estimates suggest that at least one-fifth of infected indi-
viduals have unrecognized infection (910), necessitating
increased efforts to identify HIV infection (911), giventhe availability of effective treatment (912). Consequently,
clinicians treating patients with major depressive disorder
should consider screening for HIV .
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
76 APA PRACTICE GUIDELINES
Rates of major depressive disorder are increased among
individuals with HIV infection, compared with HIV-nega-
tive individuals (913). When treating major depressive dis-order in patients who also have HIV , antidepressant
medications can be used safely and effectively (914, 915),
although high placebo response rates and high study attri-tion rates have sometimes confounded interpretation of re-
search findings (916, 917). When antidepressants are used,
SSRIs are better tolerated than TCAs (918, 919). In indi-viduals who are receiving treatment with antiretroviral
agents, it is important to check for potential drug-drug in-
teractions when choosing a medication regimen (920). Sig-nificant interactions can also oc cur if St. John’s wort is taken
by patients receiving antiretroviral medications. Althoughfew studies have been conducted in patients who meet di-
agnostic criteria for major depressive disorder, individual
and group psychotherapies using interpersonal, cognitive-behavioral, and psychoeducational approaches have also
been associated with reductions in depressive symptoms
among patients with HIV infection (316, 921–926).
Persons with mental illness also have elevated rates of
infection with hepatitis C (927), and infection with hepati-tis C is commonly present in individuals with HIV infec-tion (928). Among individuals with hepatitis C, depressive
symptoms are common, and many patients fully meet the
criteria for major depressive disorder (929). T reatment ofhepatitis C with interferon appears to be associated with a
further increase in the risk for depression, although find-
ings vary depending upon the study population, concomi-tant medications (e.g., ribavirin), and the type of interferon
used for therapy (930, 931). The increase in depressive
symptoms with interferon treatment may also be moreprominent in patients with greater levels of pretreatment
depression (932). This suggests a need for careful monitor-
ing if patients with current major depressive disorder areadministered interferon, particularly since many patients
treated with interferon have unrecognized or insufficiently
treated depression (933). Studies in which antidepressantmedications were administered concomitantly with inter-
feron have shown inconsistent prophylactic effects (934,
935). However, antidepressant therapy does seem to be ef-fective when used to treat depression that develops in the
course of interferon therapy for hepatitis C infection (936,
937). Consequently, major depressive disorder should notbe viewed as a contraindication to the treatment of hepatitis
C infection, particularly given the severe long-term hepatic
complications associated wi th chronic infection (938).
10. Pain syndromes
Pain syndromes and major depressive disorder frequentlyco-occur. Although the reported prevalence of pain
among depressed patients varies with cultural differencesand study design, one-half to two-thirds of depressed in-dividuals will typically note some type of pain (702, 939–
941). Conversely, in primary care settings, individualswith pain symptoms are about twice as likely to be de-
pressed as those without pain, and the rates of depression
are further increased if pain is chronic or involves multipletypes of pain (940, 942). It is important to note that indi-
viduals with co-occurring pain and depression tend to
have worse treatment outcomes and poorer overall func-tioning than those with either condition alone (940, 942–
944). Consequently, every patient with depression should
be assessed for the presence, nature, location, and severityof pain complaints.
Overall, antidepressant treatment has been associated
with reductions in pain symptoms among individuals with
psychogenic or somatoform pain disorders (945). How-
ever, among trials of second-generation antidepressants inindividuals with co-occurring pain and depression, dulox-
etine, venlafaxine, and paroxetine seem to be of compara-
ble but relatively minor benefit (939, 946, 947).
Neuropathic pain is commonly associated with diabetic
peripheral neuropathy but may also have other etiologiessuch as postherpetic neuralgia. For neuropathic pain ingeneral, evidence-based guidelines recommend the use of
TCAs or SNRIs (948, 949). Of the antidepressant medica-
tions, TCAs have been found to be most effective in de-creasing pain associated with both postherpetic neuralgia
(950, 951) and diabetic neuropathy (949, 952) but have no
apparent effect on HIV-associated neuropathic pain (949).Given the greater tolerability of SNRI antidepressants,
these agents may sometimes be chosen before a TCA for a
patient with co-occurring depression and neuropathic pain.In addition, if a TCA is used, therapeutic drug monitoring
may be helpful, given the wide variability of TCA blood
levels across individuals (953).
Similar effects have been found for the use of antide-
pressants to prevent migraine and tension-type headaches.In patients with and without co-occurring depression,TCAs show greater efficacy than SSRIs (954, 955), but
SNRIs also have some evidence for efficacy (956, 957). In
individuals with tension-type headaches, addition of stressmanagement therapy may augment the effects of TCA
treatment (958).
Antidepressant treatment is also recommended for in-
dividuals with fibromyalgia, as it is associated with reduc-tions in pain and often leads to improvements in function,
with the best evidence available for amitriptyline (959).Beneficial effects are observed in those with or without
co-occurring major depressive disorder (960–962). Al-
though evidence from controlled trials is more limited fornonpharmacological approaches  than for antidepressant
treatment, education, exercise, and CBT are generally rec-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 77
ommended for the treatment of fibromyalgia in combina-
tion with antidepressant medication (963, 964).
In the context of rheumatoid arthritis, antidepressant
medications also appear to be effective in reducing pain aswell as treating depressive symptoms (965–967). Evidence
for psychosocial treatment is less consistent, with mind-fulness meditation and emotion regulation therapy being
associated with reduced pain and enhanced coping in in-
dividuals with rheumatoid arthritis and depression (968),but CBT having mixed results (966, 968). In individuals
with co-occurring depression and osteoarthritis, collabo-
rative depression care has been associated with reducedpain severity, improved function, and enhanced quality of
life in those with low pain scores at baseline but had no ef-
fect when compared with usual treatment in those with
severe arthritis pain (969, 970).
For individuals with chroni c low back pain, there are
conflicting opinions about the utility of antidepressantmedications in reducing pain or improving function, even
in the presence of co-occurring depression (971, 972).Nevertheless, antidepressant medications may still be in-
dicated to treat depression on the basis of individual cir-
cumstances.
Since depressed patients with concurrent pain are of-
ten treated by primary care physicians and other medicalspecialists with a variety of potent analgesic medications,including narcotics, psychiatrists treating such patients
are advised to be in contact with these other physicians
initially and on a regular ongoing basis as indicated. Thepurposes of such contacts are to review the entire treat-
ment plan, to assure that all prescribing physicians are
aware of the full extent of pharmacological interventions,to coordinate specific prescribing areas and responsibili-ties so that patients do not receive prescriptions for the
same medications or have their doses for given medica-
tions adjusted by several different prescribing clinicians,and to set up a mechanism and plan whereby all prescrib-
ing clinicians consistently keep one another informed
about changes in their treatment plans and prescriptions.
11. Obstructive uropathy
Enlarged prostate size and other causes of bladder outletobstruction are relative contraindications to the use of an-
tidepressant medication com pounds with antimuscarinic
effects. For this reason, tertiary amine TCAs are best
avoided in these patients. Benzodiazepines, trazodone,
and MAOIs may also retard bladder emptying. The anti-
depressant medications with the least propensity to do
this are SSRIs, SNRIs, and bupropion. If a TCA is chosen,
the secondary amine desipramine is the least likely tocause urinary hesitancy or retention.
12. Glaucoma
Medications with anticholiner gic potency may precipitate
acute narrow-angle glaucoma in susceptible individuals(i.e., those with shallow ante rior chambers) (973). Patients
with glaucoma receiving local miotic therapy may be
treated with antidepressant medications, including those
possessing anticholinergic properties, provided that theirintraocular pressure is monitored during antidepressant
medication treatment. Prescription of agents lacking
anticholinergic activity avoids this risk. Other agentssometimes used in psychiatry, e.g., topiramate and related
sulfa-based medications, may cause acute angle closure
glaucoma by ciliary body edema, a different mechanism(974).
Part B
BACKGROUND INFORMATION AND REVIEW 
OF AVAILABLE EVIDENCE
IV. DISEASE DEFINITION, EPIDEMIOLOGY, NATURAL HISTORY, 
AND COURSE
A. DISEASE DEFINITION
The DSM-IV-TR criteria for major depressive episode and
major depressive disorder are listed in T able 11. The cardi-nal feature of a major depressive episode is either a de-pressed mood or loss of interest or pleasure in usual activi-
ties that persists over a period of at least 2 weeks and is
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
78 APA PRACTICE GUIDELINES
accompanied by a constellation of depressive symptoms
such as changes in eating or sleeping patterns, fatigue, dif-
ficulty concentrating, indecision, thoughts of death or sui-cide, or feelings of worthlessness, helplessness, or hopeless-
ness (16). It is important to note that these symptoms must
represent a change from the in dividual’s usual self and cause
clinically significant distress or impairment. In addition,
they cannot be attributable to bereavement or another dis-
order, including a substance-induced condition or a generalmedical condition. In some individuals, hallucinations or
delusions may occur in the context of a major depressive ep-
isode, in which case the episode would be specified as “Se-vere With Psychotic Features.” When psychotic features
are present, they may either be mood congruent (typically
involving themes such as guilt, punishment, personal inad-
equacy, or disease) or mood incongruent. Although not a
part of the DSM-IV-TR criteria, anxiety and somatic symp-toms (particularly muscular, respiratory, and genitourinary)
can also be seen in the context of major depressive disorder
(975). Episodes of major depression may also be distin-guishable by their longitudinal course (e.g., chronic if
symptoms are present for at least 2 years, postpartum onset
if symptoms occur within 4 weeks postpartum, seasonal pat-tern if the timing of episodes is regularly associated with a
specific time of year) (16) and characteristic subsets of epi-
sode features (T able 12).
B. EPIDEMIOLOGY
Information on the current prevalence of major depres-sive disorder comes from two large community surveys,the National Comorbidity Survey Replication (NCS-R)
study (976) and the National Epidemiologic Survey of Al-
coholism and Related Conditions (NESARC) (655). Inthe NCS-R, the lifetime prevalence of major depressive
disorder among the 9,090 adult participants was 16.2%,
with a 12-month prevalence of 6.6%. The NESARC, whichincluded more than 43,000 adults found slightly lower
prevalence rates than the NCS-R (13.25% lifetime and
5.28% 12-month), perhaps because the sample includedpreviously omitted groups of individuals with lower prev-
alence rates (655). A number of sociodemographic factors
appears to be associated with an increased prevalence ofmajor depressive disorder, including female sex, being
middle-aged, being never or previously married, having a
low income, being unemployed, or being disabled (655,976), In the NESARC, being Native American increased
risk relative to being Caucasian, whereas being Asian,
Hispanic, or black decreased risk (655).
The impact of major depressive disorders on individu-
als and their families is substantial. Virtually all individualsin the NCS-R who had a major depressive episode in thepreceding 12-month period experienced significant levels
of symptom severity as assessed by an independent rating
scale (976). For more than 50% of individuals, symptomswere rated at severe or very severe (976) and were associ-
ated with substantial role impairment (977).
Major depressive disorder rarely occurs in isolation;
anxiety disorders, substance use disorders, personality dis-orders, and impulse control disorders commonly co-occur
with major depressive disorder in community samples (655,976) as well as in individuals in psychiatric treatment (978).
In the NCS-R, major depressive disorder was found to co-
occur with at least one other DSM-IV disorder in two-thirds of those surveyed (976), but from a temporal stand-
point major depressive disorder was the primary diagnosis
in only about 12% of these individuals (976). In contrast, in
a study of patients in psychiatric treatment in the United
States, 84% of major depressive disorder patients had atleast one co-occurring condition: 61% had a co-occurring
Axis I condition, 30% a co-occurring Axis II condition, and
58% a co-occurring Axis III condition (978). Anxiety disor-ders were the most common co-occurring disorder in the
prior 12 months in both the NCS-R (57.5% of the sample)
(976) and the NESARC (36.1% of the sample) (655). Ofthe anxiety disorders, the greatest association was seen with
generalized anxiety disorder and the weakest association
with specific phobia (655). Substance use disorders in thepreceding 12-month period were less common in the
NCS-R (8.5%) (976) than in the NESARC, in which
14.1% of the individuals with major depressive disorderhad an alcohol use disorder, 26.0% had nicotine depen-
dence, and 4.6% had another substance use disorder (655).
Personality disorders were present in 37.9% of individualswith major depressive disorder in the NESARC (655). Ob-
sessive-compulsive, paranoid, schizoid, and avoidant per-
sonality disorders were most common among subjects withmajor depressive disorder; avoidant, dependent, paranoid,
and schizoid personality disorders had greater odds ratios
for association with major depressive disorder than otherpersonality disorders (655).
T reatment of major depressive disorder does not always
occur and may be delayed. The average time to treatmentin the NESARC was approximately 3 years, and only about
60% of the sample with major depressive disorder received
treatment (655). The NCS-R also evaluated history andadequacy of treatment for major depressive disorder (976).
Of respondents who reported having had a major depres-
sive episode in the last year, just more than one-half had re-ceived treatment but less than one-half of these individuals
(about one-fifth of the total) received adequate treatment(976). These findings highlight the need for changes in thedelivery of mental health services to enhance the timeliness
and quality of care for major depressive disorder.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 79
TABLE 11. DSM-IV-TR Criteria for Major Depressive Episode and Major Depressive Disorder
Diagnosis Criterion/Symptom Description 
Major depressive episode A. At least five of the following symptoms have been present during the same 
2-week period and represent a change from previous functioning; at least one 
of the symptoms is either 1) depressed mood or 2) loss of interest or pleasure 
(do not include symptoms that are clearl y due to general medical condition or 
mood-incongruent delusions or hallucinations).
1. Depressed mood most of the day, nearly every day, as indicated either by 
subjective report (e.g., feels sad or empty) or observation made by others 
(e.g., appears tearful)
2. Markedly diminished interest or pleasure in all, or almost all, activities 
most of the day, nearly every day (as indicated either by subjective account 
or observation made by others)
3. Significant weight loss when not dieting or weight gain (e.g., a change of 
more than 5% of body weight in a month), or decrease or increase in appetite nearly every day
4. Insomnia or hypersomnia nearly every day
5. Psychomotor agitation or retardation nearly every day (observable by 
others, not merely subjective feelings of restlessness or being slowed down)
6. Fatigue or loss of energy nearly every day7. Feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-reproach or guilt about being 
sick)
8. Diminished ability to think or concentrate, or indecisiveness, nearly every 
day (either by subjective account or as observed by others)
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal 
ideation without a specific plan, or a suicide attempt or specific plan for committing suicide
B. The symptoms do not meet criteria for a mixed episode.
C. The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning.
D. The symptoms are not due to the direct physiological effects of a substance 
(e.g., a drug of abuse, a medication) or a general medical condition (e.g., 
hypothyroidism).
E. The symptoms are not better accounted for by bereavement, i.e., after the loss 
of a loved one, the symptoms persist for longer than 2 months or are 
characterized by marked functional im pairment, morbid preoccupation with 
worthlessness, suicidal ideation, psychotic symptoms, or psychomotor 
retardation.
Major depressive disorder, A. Presence of a single major depressive episode.
single episode B. The major depressive episode is not better accounted for by schizoaffective 
disorder and is not superimposed on schizophrenia, schizophreniform disorder, 
delusional disorder, or psychotic disorder not otherwise specified.
C. There has never been a manic episode, a mixed episode, or a hypomanic 
episode.
(continued)
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
80 APA PRACTICE GUIDELINES
Major depressive disorder, 
recurrentA. Presence of two or more major depressive episodes (each separated by at least 
2 months in which criteria are not met for a major depressive episode).
B. The major depressive episodes are not better accounted for by schizoaffective 
disorder and are not superimposed on  schizophrenia, schizophreniform 
disorder, delusional disorder, or psychotic disorder not otherwise specified.
C. There has never been a manic episode, a mixed episode, or a hypomanic 
episode
Source. Reprinted from Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, T ext Revision.  Washington, DC, American
Psychiatric Association, 2000. Copyright © 2000, American Psychiatric Association.
TABLE 12. Selected DSM-IV-TR Major Depressive Episode Specifiers
Criteria for Melancholic Features Specifier
A. Either of the following, occurring during the most severe period of the current episode:
1. loss of pleasure in all, or almost all, activities2. lack of reactivity to usually pleasurable stimuli (does not feel much better, even temporarily, when something 
good happens)
B. Three (or more) of the following:
1. distinct quality of depressed mood (i.e., the depressed mood is experienced as distinctly different from the 
kind of feeling experienced after the death of a loved one)
2. depression regularly worse in the morning3. early morning awakening (at least 2 hours before usual time of awakening)4. marked psychomotor retardation or agitation5. significant anorexia or weight loss6. excessive or inappropriate guilt
Criteria for Atypical Features SpecifierA. Mood reactivity (i.e., mood brightens in response to actual or potential positive events)B. T wo (or more) of the following features:
1. significant weight gain or increase in appetite2. hypersomnia3. leaden paralysis (i.e., heavy, le aden feelings in arms or legs)
4. long-standing pattern of interpersonal rejection sensitivity (not limited to episodes of mood disturbance) that 
results in significant social or occupational impairment
C. Criteria are not met for With Melancholic Features or With Catatonic Features during the same episode.
Criteria for Catatonic Features Specifier
The clinical picture is dominated by at least two of the following:
1. motoric immobility as evidenced by catalepsy (including waxy flexibility) or stupor2. excessive motor activity (that is apparently purposeless and not influenced by external stimuli)3. extreme negativism (an apparently motiveless resistance to all instructions or maintenance of a rigid posture 
against attempts to be moved) or mutism
4. peculiarities of voluntary movement as evidenced by posturing (voluntary assumption of inappropriate or 
bizarre postures), stereotyped movements, prominent mannerisms, or prominent grimacing
5. echolalia or echopraxiaTABLE 11. DSM-IV-TR Criteria for Major Depressive Episode and Major Depressive Disorder (continued)
Diagnosis Criterion/Symptom Description 
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 81
C. NATURAL HISTORY AND COURSE
The age at onset of major depr essive disorder varies widely,
although the average age at onset is the late 20s. Although
the onset of the first episode is rarely before puberty, the dis-
order may begin at any age (655, 976). Symptoms of major
depressive disorder typically develop over days to weeks.Prodromal symptoms, including generalized anxiety, panic
attacks, phobias, or depressive symptoms that do not meet
the diagnostic threshold may occur over the preceding sev-eral months. In some individuals, however, major depressive
disorder may develop suddenly, as in the wake of severe psy-
chosocial stress. The duration of a major depressive episode
also varies. The mean duration of a major depressive episode
was 16 weeks in the NCS-R (976), with a median duration forthe longest depressive episode of 24.3 weeks in the NESARC
(655). In treated patients, the median time to recovery from amajor depressive episode is approximately 20 weeks (979).Untreated, episodes typically last 6 months or longer. Some
patients with major depressive disorder eventually have a
manic or hypomanic episode, and they will then receive anew diagnosis of bipolar I disorder or bipolar II disorder.
1. Recurrence
Major depressive disorder is unremitting in 15% of patients
and recurrent in 35%. About half of those with a first-on-
set episode recover and have no further episodes (502).After three episodes, the risk of recurrence approaches
100% in the absence of prophylactic treatment. Individu-
als with major depressive di sorder superimposed on dys-
thymic disorder carry a greater risk for having recurrent
episodes of major depressive disorder than those without
dysthymic disorder (410). When major depressive disor-der is recurrent, its course varies. Some people have epi-
sodes separated by many years of normal functioning,
others have clusters of episodes, and still others have in-creasingly frequent episodes as they age.
2. Interepisode status
Functioning usually returns to the premorbid level betweenepisodes. However, 20%–35% of patients have persistent
residual symptoms and social or occupational impairment.
Patients who continue to have depressive symptoms but fallbelow the diagnostic threshold for major depressive disor-
der are considered to be in partial remission. Residual de-
pressive symptoms increase the risk of relapse. Anxiety andsomatic symptoms are particularly prominent residual
symptoms of major depressive disorder (980).
3. Complications and prognosis
Major depressive disorder adversely affects the patient and
others. The most serious complication of a major depres-sive episode is suicide (including suicide/homicide). Major
depressive disorder is also associated with significant med-
ical comorbidity and complicates recovery from other
medical illnesses, such as myocardial infarction (see Section
III.C.1). Beyond its impact on the patient alone, major de-pressive disorder also affects th e patient’s marital, parental,
social, and vocational functioning (981). The disorder, es-pecially when recurrent or chronic, may distress other in-dividuals in the patient’s social network, e.g., children,
spouse, and significant others. If the patient is a parent, the
disorder may affect his or her ability to fulfill parental roleexpectations (982) and increase the likelihood of children
becoming depressed as well (see Section III.B.5). Major de-
pressive episodes are associated with occupational dysfunc-tion, including unemployment, absenteeism, and decreased
work productivity (977, 983). In fact, in terms of the level of
disability for the population as a whole, major depressivedisorder was second only to chronic back and neck pain in
disability days per year (977).
The prognosis for major depressive disorder depends on
many factors, such as treatment status, availability of sup-ports, chronicity of symptoms, and the presence of co-oc-
curring medical and psychiatric conditions. With treatment,however, the prognosis is generally good (984). Most pa-
tients will respond to acute treatment, and continuation and
maintenance treatment with acutely active treatments hasbeen shown to lower the risk and severity of relapse.
V. REVIEW AND SYNTHESIS OF AVAILABLE EVIDENCE
T ranslating the product of science into a decision about asingle human patient raises the concept of epistemology:how we know what we think we know and how certain we
can be about that knowledge. Like all guidelines, this one
is an attempt to distill clinical research into recommenda-tions that will be clinically applicable to the unique indi-vidual who presents for treatment. Science can neverprovide all of the answers that a doctor or patient wishesand, at times, the knowledge base may consist primarily of
accumulated wisdom from clinical experience. In addi-
tion, every scientific protocol reflects a series of compro-mises, and each compromise may restrict internal and/or
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
82 APA PRACTICE GUIDELINES
external validity, as described later in this section. No one
study, with its inevitable limit s, can reveal “truth.” The
wise scientist—and physician—demands replication. When
multiple trials, with different methods, come to similar
conclusions, the clinician can be reasonably confident in
the results.
Many aspects of the design of research studies can influ-
ence the interpretation of the data and their implication forclinical practice. When translating efficacy evidence toclinical practice, it is important to assess the adequacy of
the sample size (given modest effect sizes of antidepres-
sant treatments), the nature and validity of the controlcondition, the length of the treatment trial, the nature of
the participant population, the type  and reliability of the
outcome measure, and publication bias (in favor of posi-tive trials) (74, 985, 986).
Some issues also exist that are specific to pharmaco-
therapy trials. First, it is important to consider whetherand what type of comparison group was used (e.g., pla-
cebo or active agent). In trials of antidepressant medica-tion treatments, high placebo response rates could make
detection of true treatment effects difficult in well-
controlled trials, as well as explain observed treatment ef-fects in trials with less robust controls. It is also important
to consider whether trials were blinded and, if so, whether
medication side effects could reveal the identity of activeagents. Issues related to the outcomes measured in trials
are important as well. A variety of different outcome mea-
sures are employed, and a report of “efficacy” could referto symptom reduction (e.g., reduction in the frequency or
severity of major depressive disorder symptoms), re-
sponse (e.g., reduction in major depressive disorder symp-toms below a threshold), or prevention of relapse. Despite
the fact that a 2006 American College of Neuropsycho-
pharmacology task force report (408) emphasized the need
to aim for remission as a primary goal, studies may not bedesigned and powered statistically to assess remission as a
primary outcome. Until recently most research studieshave reported response rates, often defined as a reduction
by 50% in the measured severity of depression. In addi-
tion, data often come from short-term (6- to 12-week)efficacy trials that cannot show whether treatments are ef-
fective over the medium- and long-term. There has also
been recent concern that the apparent effect size of anti-depressants has been exaggerated, due to the lack of re-
porting or selective publication of negative clinical trial
data (74, 75). A national database of clinical trial data(http://clinicaltrials.gov/) is being expanded in an effort to
make these data available and transparent (987). However,
most meta-analyses were published prior to this initiative,and previously conducted studies will not be subject to the
provisions of recent regulations (988).Evaluating the efficacy of psychotherapeutic ap-
proaches for major depressive disorder can also be chal-
lenging. Although there have been a number of well-designed trials of CBT and IPT in large samples, for some
other types of psychotherapy, few or no clinical trials have
been conducted. In studies evaluating psychotherapyagainst a variety of control conditions such as waiting lists,
other forms of psychotherapy, medications, placebos, or a
no-control group, it is difficult to make comparisons of theobserved treatment effect sizes among trials. Some trials
have not examined the effects of psychotherapy exclusively
among patients with major depressive disorder and maynot have specifically assessed improvement in major de-
pressive disorder as an outcome. In other trials, the nature
of the psychotherapeutic inte rvention has been insuffi-
ciently described, making it difficult to apply the studyfindings to psychotherapeutic approaches used in practice.
In evaluating the impact of a particular intervention,
several statistical concepts are helpful to understand. If onestarts with the assumption that the treatment group and thecontrol group are equivalent (i.e., no effect of treatment),
the p value indicates the probability that the treatment
group will show an outcome that is equal to or more extremethan the observed treatment outcome (989). Although spe-
cific values of p (e.g., 0.05) are commonly considered to be
statistically significant, the p value does not address thepossibility, known as a type II error, that the treatment
group and control group will have similar outcomes even
though the treatment is actually effective. This possibilitycan be reduced, to some extent, by using sufficiently sized
research samples, which should be calculated as part of the
study design (i.e., power analysis). Because these conceptsare difficult to grasp and provide limited information about
the clinical importance of an observed impact of treatment,
several other measures are often used. One approach to in-dicating the benefit of a treatment relative to a control con-
dition is the number needed to treat (NNT), which is the
number of individuals who would have to be treated to pre-vent one negative outcome (or benefit one patient) (990).
When applied to adverse effects, such a measure is termed
the number needed to harm (NNH). The effect size is ameasure of the magnitude of the difference between the
treatment group and the control group, which also consid-
ers the variability of the measurements. When the statisticCohen’s d is used to measure the size of a treatment effect,
a general rule-of-thumb is that d=0.2 represents a small ef-
fect, d=0.5 represents a medium effect, and d=0.8 (orgreater) represents a large effect of the intervention (991).
In addition to being used in describing the results of indi-
vidual studies, effect sizes are also used in comparing andsynthesizing the results of multiple clinical trials through
meta-analyses.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 83
A. ACUTE PHASE SOMATIC TREATMENTS
1. Antidepressant medications
a. Selective serotonin reuptake inhibitors
Many studies and meta-analyses have compared SSRIs
among themselves as well as with other classes of anti-
depressants. Differences in efficacy and tolerability be-
tween SSRIs and TCAs, assessed through a meta-analysis
of 102 studies (85), found no overall difference in efficacybetween TCAs and SSRIs. However, TCAs appeared
more efficacious in inpatients (p=0.012), and amitripty-
line was more effective than SSRI comparators (p=0.012),
although publication bias could not be excluded. By con-
trast, SSRIs as a class (p <0.01) and, more specifically, par-
oxetine (p=0.001), fluoxetine (p <0.01), sertraline (p <0.05),
and citalopram (p <0.01) had a significantly lower rate of
dropouts for side effects. Other meta-analyses have com-pared the SSRIs among themselves and with other newer
antidepressant agents. Cipriani and colleagues (96) per-
formed a multiple-treatments meta-analysis, which encom-passed 117 randomized controlled trials and 25,928 subjects.
Incorporating efficacy and treatment discontinuation, they
found the greatest degree of overall acceptability withescitalopram and sertraline, with greatest efficacy for
mirtazapine, escitalopram, ve nlafaxine, and sertraline as
compared with duloxetine, fluoxetine, fluvoxamine, par-oxetine, and reboxetine. Gartlehner and colleagues (95)
also compared the benefits and side effects of second-
generation antidepressants including SSRIs using 6 good-or fair-quality systematic reviews or meta-analyses and
155 good- or fair-quality double-blind, placebo-con-
trolled, or head-to-head randomized controlled trials of atleast 6 weeks' duration to assess efficacy and 35 observational
studies with at least 100 participants and follow-up of at
least 12 weeks to assess harms. Although the side effectprofiles and onset of action differed among the antide-
pressants, no differences in efficacy or effectiveness were
found.
A systematic review of 28 randomized studies (89) showed
that, even in anxious depression, SSRIs (fluoxetine, parox-etine, citalopram, sertraline, and escitalopram) are com-parable in efficacy to other antidepressant medications
(bupropion, amitriptyline, mirtazapine, imipramine, nefaz-
odone, and venlafaxine), both in depression and anxiety
parameters. When compared with venlafaxine, fluoxetinewas less effective both in depression and anxiety scores,
while paroxetine was less effective in anxiety scores only.No differences were found between venlafaxine and the
other SSRIs.
A Cochrane meta-analysis (84) that included 132 ran-
domized studies (almost all double blind) did not find sig-nificant differences in fluoxetine efficacy versus TCAs.When fluoxetine was compared with newer antidepres-
sants, venlafaxine was superior, and within the class of
SSRIs, sertraline was significantly superior. However, flu-
oxetine was significantly better tolerated than TCAs as aclass and, more specifically, was better tolerated than ami-
triptyline, clomipramine, desipramine, and imipramine; no
differences were noted in comparison with all of the othermedications. Similar meta-analyses compared sertraline(126) and escitalopram (992) to other antidepressive agents.
Although differences were small, there was a trend for ser-
traline to be more acceptable and efficacious than compar-ator antidepressants, including TCAs, SSRIs, and several
newer antidepressants (126). Escitalopram was found to be
more efficacious than citalopr am and fluoxetine in terms of
response and remission of depressive symptoms and was as-sociated with lower rates of treatment discontinuation thansubjects receiving duloxetine (992).
Another meta-analysis of 21 studies (98) compared ef-
ficacy and tolerability of each SSRI (except escitalopram)against the SSRI class overall and showed no difference in
efficacy among the drugs. Ra tes of dropout due to side
effects were significantly lower in patients treated with
sertraline (p <0.05) and significantly higher in patients
treated with fluvoxamine (p< 0.01), although the dropout
rate in fluvoxamine-treated patients appeared to vary withmedication dose. In this meta-analysis, side effects and
discontinuation reactions were observed more often with
paroxetine than with other SSRIs. Interaction with otherdrugs was higher with fluoxetine, fluvoxamine, and parox-
etine than with sertraline and citalopram, although citalo-
pram was overrepresented in deaths due to overdose.
A systematic review based on 18 randomized, double-
blind trials (94), which compared escitalopram with either
citalopram, venlafaxine, paroxetine, sertraline, or bupro-pion, found no differences in efficacy between escitalopram
and the other medications (except for the comparison
with citalopram, which showed a significant difference intwo of four studies). Rates of study withdrawal due to side
effects were lower with esci talopram than with venlafax-
ine (p <0.05) or paroxetine (p <0.05).
Another meta-analysis of 32 randomized clinical trials
studied the efficacy and tolera bility of antidepressants in
people older than age 55 years (704). This study found
that there was no difference in efficacy between TCAs and
SSRIs, but SSRIs were better tolerated. Compared with
patients who were taking TCAs, patients who were takingSSRIs were less likely to withdraw from the study overall
or because of side effects, in particular. The qualitative
analysis of side effects showed a small increase in gas-trointestinal and neuropsychiatric side effects associated
with TCAs.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
84 APA PRACTICE GUIDELINES
Overall, the findings of multiple randomized trials and
meta-analyses indicate comparable efficacies for SSRIs
relative to TCAs, although some data suggest greater ef-ficacy for TCAs in inpatient samples. Selective serotonin
reuptake inhibitors also appear to have comparable effi-
cacy to other non-TCA antidepressants, although ven-lafaxine shows superior efficacy in some studies, and
comparisons of SSRIs and MAOIs have not been done. In
terms of tolerability, SSRIs show consistently fewer drop-outs in clinical trials than TCAs, and side effects are also
reported less often with SSRIs. There also do not seem to
be significant differences in efficacy among the SSRIs.Fluvoxamine appears to have more side effects and more
problems with drug interactions than the other SSRIs;
drug interactions are also more problematic with fluoxe-
tine and paroxetine than with citalopram, escitalopram, or
sertraline.
b. Serotonin norepinephrine reuptake inhibitors
The efficacy of venlafaxine, desvenlafaxine, and duloxetine,
which are classified as SNRIs, and mirtazapine, which
(although not an SNRI) also enhances both serotonin and
norepinephrine neurotransmission, has been demon-strated in placebo-controlled studies of depressed patients
(101, 102, 105, 113, 993, 994, 995). A number of studies
have contrasted these “dual-action” antidepressants withthe SSRIs. Although most individual studies have not
found statistically significant differences (see, for exam-
ple, references 226 and 421), meta-analyses of controlledstudies of venlafaxine (101, 104, 996, 997), duloxetine
(102), and mirtazapine (113) using SSRIs as comparators
have generally documented small (i.e., 4%–10%) albeit
reliable differences in the likelihood of response or re-
mission favoring the dual-actio n drugs. Papakostas et al.
(995) similarly found an average difference of 4% in re-
sponse/remission rates in a meta-analysis of a broader
grouping of antidepressant drugs that affect norepineph-
rine and serotonin. These average effects are generallybelow the magnitude of difference that is widely consid-
ered to be clinically significan t. It is possible that a small
average difference in an overall pool of patients may ob-
scure larger and more meaningful differences among
selected subgroups of depressed patients (e.g., more se-
verely depressed patients [102], inpatients [561], or post-menopausal women [998]), but this suggestion has yet to
be confirmed by analyses of larger data sets. At present,
the efficacy of desvenlafaxine has only been establishedversus placebo (993, 994); there are not yet any published
studies assessing its benefits relative to other antide-
pressants. Nevertheless, as the principal active metaboliteof venlafaxine, it is likely to have a comparable efficacy
profile.Perahia et al. (999) conducted a randomized controlled
trial of duloxetine versus paroxetine and placebo in an
outpatient setting in patients who met the criteria formajor depressive disorder. After 8 weeks, duloxetine at
80 mg/day (N=93) and at 120 mg/day (N=103) was found
to be superior to placebo (N=99). However, paroxetinewas not superior to placebo in this study. Perahia et al. also
conducted a relapse prevention study (1000), in which pa-
tients were randomly assigned to receive duloxetine orplacebo for 26 weeks after a 12-week open-label treat-
ment phase. The 136 patients who received duloxetine
had a relapse rate of 23%, compared with the 39% relapserate among the 142 patients who received placebo
(p≤0.005). A large cohort study by Raskin et al. (1001)
followed 1,279 patients in 52 treatment centers taking80–120 mg/day of duloxetine over 52 weeks. Patients
were assessed by multiple instruments at 6, 28, and 52weeks. At 6 weeks, 50.8% achieved a score of <8 on the
HAM-D. The rate of response increased to 75.6% at week28 and 81.7% at week 52, with no safety concerns identi-fied in the course of the study.
Venlafaxine extended release (XR) has also been ex-
tensively studied. Rudolph and Feiger (1002) conductedan 8-week outpatient trial of venlafaxine XR compared
with fluoxetine and placebo. In this trial, 100 patients re-
ceived venlafaxine XR (75–225 mg/day), 193 received flu-oxetine (20–60 mg/day), and 98 received placebo.
Remission rates, determined by an HRSD score of <8,
were 37% in the venlafaxine XR arm, 22% in the fluoxetine
arm, and 18% in the placebo arm. Sauer et al. (1003)
compared 76 patients who received venlafaxine XR (75–
150 mg/day) with 75 patients who received amitriptyline(75–150 mg/day). Venlafaxine XR yielded response rates
of 39.5%, compared with 41.7% for amitriptyline. Saiz-
Ruiz et al. (1004) followed 59 patients receiving venlafax-ine over 6 months. Seventy percent of these patients com-
pleted the study, and the response rate, determined by a
50% reduction in the HRSD score, was 81%. In anothercohort study, Mitchell et al. (1005) found response rates at
8 weeks to be 52.6%, measured by the MADRS, among
312 patients with treatment-resistant illness taking venla-faxine in an open-label trial. Response rates at 10 months
as measured by the MADRS increased to 73% in 149 pa-
tients who continued treatment in an extension phase ofthe study (1006).
Fewer studies have been conducted with desvenlafax-
ine; however, meta-analysis shows that it also is efficaciousin the acute treatment of major depressive disorder (99).
In the nine randomized, double-blind, placebo-con-
trolled 8-week long trials with desvenlafaxine, there were1,342 subjects in fixed dose study arms (50, 100, 200, or
400 mg/day), 463 subjects in flexible dose study arms
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 85
(100–400 mg/day), and 1,108 subjects in placebo study
arms. Desvenlafaxine showed greater efficacy than pla-
cebo in rates of response as well as remission, with nogreater benefit (and greater discontinuation rates) at doses
greater than 50 mg daily. Overall rates of treatment dis-
continuation due to adverse effects were 3% for placeboand 12% for desvenlafaxine (168). T reatment emergent
adverse effects included transient nausea and erectile dys-
function in men. Mean blood pressure was statistically in-creased in the desvenlafaxine group, but this change was
clinically significant in only 2% of desvenlafaxine sub-
jects, compared with 1% of the placebo group.
c. Other antidepressant medications
1. Bupropion
Meta-analyses of controlled trials have shown that bupro-
pion is superior to placebo and is generally comparable in
efficacy to both TCAs and SSRIs (105, 169, 1007). Allthree formulations of bupropion are superior to placebo
(106), and early studies with the immediate-release for-
mulation found it to be ge nerally comparable in efficacy
to the TCAs (105, 1008–1011). The newer sustained-
release and extended-release formulations have been pri-
marily compared with the SSRIs, and meta-analyses haveestablished comparable efficacy (169, 1012).
Several studies have compared bupropion sustained re-
lease (SR) to SSRIs and placebo. A randomized controlledtrial by Croft et al. (1013) compared bupropion SR to ser-
traline and placebo over 8 weeks of treatment and found
both drugs to have efficacy superior to placebo. Bupro-pion SR had a lower rate of sexual dysfunction than ser-
traline. These findings were confirmed in a 16-week studythat again compared bupropi on SR with sertraline and
placebo (1014). Another 8-week study found bupropion
SR, but not sertraline, to be superior to placebo and again
documented lower rates of sexual dysfunction with bupro-pion SR than sertraline (1015). Similar results were found
when bupropion SR was compared with other SSRIs. One
study comparing bupropion SR with paroxetine foundequivalent efficacy (1016). In another trial, with approxi-
mately 150 patients in each  arm, bupropion had similar
efficacy to fluoxetine with a significantly lower burden of
side effects (1017). Lower rates of sexual dysfunction have
also been found with bupropion compared with sertraline
(1013–1015) or paroxetine (1016). A survey of 6,297 pa-tients in primary care settings found the incidence of sexual
dysfunction with bupropion to be 22%–25%. This inci-
dence was comparable to the incidence with nefazodone(28%) but lower than that with SSRIs and venlafaxine
(36%–43%) (1018). Several small studies have examinedwhether bupropion might serve as a potential treatmentfor SSRI-induced sexual side effects, with varying results
(132, 1019, 1020).
Bupropion has also been studied as a treatment for anx-
iety associated with major depressive disorder. In onelarge trial, patients were randomly assigned to receive bu-
propion SR (N=234), sertraline (N=225), or placebo(N=233). Patients treated with bupropion SR or sertraline
experienced significantly greater relief from anxiety symp-
toms than those who receiv ed placebo. Compared with
sertraline, bupropion appeared to be associated with sim-
ilar relief of anxiety in patients with major depressive dis-
order (1021).
Bupropion has also been shown to reduce the risk of re-
lapse following successful antidepressant treatment withbupropion. In a 44-week double-blind trial of bupropion
responders (1022), patients were randomly assigned to con-
tinue taking bupropion or change to placebo. Continuedtreatment with bupropion after acute phase response re-
duced the risk of relapse, compared with placebo, with few
differences in side effects reported between the two groups.
2. Mirtazapine
The efficacy of mirtazapine has been established in pla-
cebo-controlled studies (1023, 1024), two individual stud-ies versus venlafaxine (1025, 1026), and in meta-analyses
of studies comparing it to TCAs (1027–1029) and SSRIs
(1030). Quitkin et al. (1030) analyzed three studies com-paring patients with major depressive disorder treated
with mirtazapine (N=289) to patients treated with fluoxe-
tine or paroxetine (N=285). Although mirtazapine andSSRIs had similar efficacy over 6–8 weeks, a greater pro-
portion of patients had onset of therapeutic benefit at
week 1 with mirtazapine as compared with an SSRI (13%versus 6%). In a meta-analysis by Watanabe et al. (1031),
mirtazapine was superior to SSRIs in response and remis-
sion rates at 2 weeks (12 trials), although it was compara-ble to SSRIs at the end of treatment (6–12 weeks). In a
subgroup analysis, mirtazapine produced greater response
than paroxetine (three trials) and venlafaxine (two trials).At 2 weeks as well as at the end of 6–12 weeks’ treatment
(8 trials used to obtain outcomes), mirtazapine had com-
parable efficacy to TCAs. A meta-analysis of six studies(1027) found mirtazapine to have comparable efficacy to
amitriptyline over 6–8 weeks, with both drugs showing
superiority to placebo.
Several randomized controlled trials have compared
mirtazapine to SSRIs. Benkert et al. (1032) randomly as-signed patients with major depressive disorder to treat-ment with mirtazapine (N=127) or paroxetine (N=123)
over 6 weeks, and Wade et al. (1033) randomly assigned
197 primary care patients with HAM-D scores of at
least 18 to mirtazapine (N=99) or paroxetine (N=98) over
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
86 APA PRACTICE GUIDELINES
24 weeks of treatment. In both studies, the treatments had
equal efficacy at study endpoint, but mirtazapine demon-
strated a different profile of side effects. Another trial ran-domly assigned elderly depressed patients (at least age
65 years) to mirtazapine (N=126) or paroxetine (N=120)
over 8 weeks (1034). Compared with paroxetine, mirtaza-pine showed a greater benefit at day 14, had less attrition
for side effects, and was significantly more effective in im-
proving sleep. It was also more effective in reducingHAM-D scores by the study endpoint, although response
and remission rates were not significantly different. T wo
randomized trials, one 8 weeks long (N=299) (1035) andthe other a 6-week study (N=132) in Chinese patients,
have compared treatment with mirtazapine to fluoxetine
and found no differences in overall efficacy, although the
onset of improvement and side effect profiles differed aswith paroxetine. A similar pattern of outcomes was alsoobserved when mirtazapine was compared with citalopram
(N=270) in an 8-week trial (1036) and when an oral disin-
tegrating form of mirtazapine was compared with sertra-line (N=345) in another 8-week trial (1037).
Mirtazapine has also been compared with venlafaxine
(both immediate release [IR] and extended release [XR]forms) in randomized controlled trials. In an 8-week trial,
Guelfi et al. (1025) followed patients with major depres-
sive disorder (HAM-D scores of at least 25) receiving mir-tazapine (N=78) and venlafaxine IR (N=79). Mirtazapine
and venlafaxine did not differ  significantly in depression
outcomes, although sleep was better with mirtazapine,
and significantly more patients taking venlafaxine IR (15%)
dropped out due to side effects, compared with patients
taking mirtazapine (5%). A similar 8-week trial (1026)found no significant differences in final outcome or toler-
ability between venlafaxine XR and mirtazapine, although
mirtazapine showed greater benefit during the first 15 daysof therapy.
Patients with major depressive disorder who were not
responsive or who were intolerant of two prior treatmentswith antidepressants were randomly assigned to treat-
ment with mirtazapine (N=114) or nortriptyline (N=121)
for up to 12 weeks as part of the STAR*D trial (471). Re-mission rates were 12% for mirtazapine and 20% for nor-
triptyline. There were no significant differences in any
outcome measure, and the medications were comparablytolerated. Neither mirtazapine nor nortriptyline was par-
ticularly effective as monotherapy for patients who had
not benefited from two consecutive treatment trials.
Mirtazapine has been shown to decrease rates of re-
lapse following acute phase treatment. Thase et al. (1038)compared 78 patients who received mirtazapine to 78 pa-tients who received placebo over 9 months following an
8- to 12-week treatment with an antidepressant. Patientstaking mirtazapine had about a 50% reduction in relapserates. However, patients taking mirtazapine gained 1.4 kg
more weight than those taking placebo across the 9 monthsof continuation phase therapy.
3. Nefazodone and trazodone
The efficacy of nefazodone has been established in pla-
cebo-controlled trials, with efficacy comparable to both
TCAs and SSRIs (105, 1039–1042); however, its recent
use has been limited after case reports suggested a risk ofrare but potentially fatal hepatotoxicity (180). While an
early review of trazodone (114) concluded that trazodone
is as effective as TCAs in the treatment of depression,
other investigators have found trazodone to be less effec-
tive than other antidepressant medications (115, 1043–1045), a conclusion supported by the results of at least one
meta-analysis (93). In a review of 18 studies from 1980
through 2003, Mendelson (173) found that trazodone, whencompared with various control groups, did improve sleep.
However, it was also associat ed with significant side ef-
fects, and tolerance may develop with prolonged use.
d. Tricyclic antidepressants
Since the first trial in which a tricyclic compound (imi-
pramine) was shown to improve major depressive disorder
symptoms (1046), hundreds of subsequent randomizedcontrolled trials have demonstrated the efficacy of this an-
tidepressant class as a treatment for major depressive dis-
order (105). Several reviews of this early literaturesuggested that approximately 50%–75% of patients with
major depressive disorder treated with tricyclic and re-
lated antidepressant medications respond, compared with25%–33% of patients who receive placebo (487, 1047–
1049). The efficacy of indivi dual agents and subclasses of
tricyclics (e.g., secondary amines or tertiary amines) ap-
pears to be comparable, although amitriptyline may pos-
sess a slightly stronger effect across all studies (1050), and
the tertiary amine tricyclics (amitriptyline, clomipramine,and imipramine) may have a stronger antidepressant ef-
fect than the secondary amine tricyclics and maprotiline
in studies of hospitalized depressed patients (117).
The meta-analysis of Barbui et al. (1050) reviewed 181
randomized controlled trials of amitriptyline, generally of6–8 weeks’ duration, in inpatient and outpatient settings.Amitriptyline was found to be superior to SSRIs in studies
of inpatients, but there was no difference in efficacy in
outpatients. Selective serotonin reuptake inhibitors were
better tolerated. Arroll et al. (1051) compared TCAs with
SSRIs in a meta-analysis of 15 randomized controlled tri-
als in primary care settings. Both TCAs and SSRIs wereeffective, but tolerability comparisons across studies fa-
vored SSRIs. Wohlfarth et al. (1052) reviewed 30 random-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 87
ized controlled trials conducted between 1979 and 1991,
with a combined sample size of 1,555 men and 2,331 women.
T ricyclic antidepressants were more effective than pla-cebo across age and gender groups.
Several trials have compared TCAs against interper-
sonal therapy and CBT and against the combination ofTCAs and IPT or CBT . Reynolds et al. (1053) followed
80 patients who were at least age 50 years and had a bereave-
ment-related depression in a 16-week factorial designtrial in which patients received IPT or case management
and nortriptyline or placebo. Nortriptyline (with or with-
out IPT) was more effective than placebo (with or withoutIPT). Patients receiving combined nortriptyline and IPT
had the highest study completion rate. Interpersonal psy-
chotherapy alone (i.e., IPT plus placebo) was not found
to be an effective treatment for bereavement-related ma-
jor depressive disorder. However, in a continuation trial(N=107) over 24 months (315), combination therapy was
found to be more effective than monotherapy in patients
age 70 years or older. All patients had been first stabilizedon combination nortriptyline and IPT before entering
the continuation phase. In a 16-week randomized con-
trolled trial among 102 elderly patients with major de-pressive disorder, Thompson et al. (1054) found that
combined treatment with CBT and nortriptyline was su-
perior to CBT alone, which was superior to nortriptylinealone. Combined treatment was particularly effective in
patients with severe depressi on, as measured by HAM-D
scores.
For patients with major depressive disorder who re-
ceived ECT following a prior nonresponse to treatment
with an antidepressant, van den Broek (1055) found that12 patients randomly assigned to receive imipramine
(200–300 ng/mL plasma level) had a greater improvement
in all measures in preventing relapse than the 15 patientsrandomly assigned to receive placebo.
Results of some investigations have suggested that TCAs
are particularly effective for patients with more severesymptoms of major depressive disorder (1056–1060), as well
as for patients with melancholia (562, 1061–1063). Superior
efficacy for TCAs, compared with SSRIs, has been docu-mented in meta-analyses of inpatient studies (117).
e. Monoamine oxidase inhibitors
Monoamine oxidase inhibitors have also been shown in
multiple trials to be effective treatments for major depres-sive disorder. Although some earlier comparisons employ-
ing lower doses of MAOIs found TCAs to be superior,
MAOIs are now considered to have comparable efficacyto TCAs for most patients with major depressive disorder
(119, 120, 1064–1067). Results of several investigations
suggest that MAOIs may be particularly effective in treat-ing subgroups of patients with major depressive disorder
with atypical features such as reactive moods, reversed
neurovegetative symptoms, and sensitivity to rejection(572, 1068, 1069). Monoamine oxidase inhibitors have
also been shown to be effective treatments for some pa-
tients who have not responded to other antidepressantmedications (1064, 1067, 1070, 1071).
In more recent controlled trials, 6 mg/24 hours of
transdermal selegiline was compared with placebo in 177adults with major depressive disorder in a 6-week trial
(1072). The transdermal patch was found to be more ef-
fective than placebo and was well tolerated without theneed for dietary restrictions. These findings were repli-
cated in two subsequent studies by Amsterdam (124)
(N=365; dose, 6 mg/24 hours; duration, 6 weeks) and
Feiger et al. (125) (N=265; dose, 6–12 mg/24 hours; du-
ration, 8 weeks).
T ranylcypromine in doses of 30–60 mg/day has been
compared with the combination of venlafaxine IR (up to300 mg/day) and mirtazapine (up to 60 mg/day) in 109 pa-tients with treatment-resistant depression in a 12-week
randomized trial (121). Neither the MAOI (7% remission
rate) nor the combination strategy (14% remission rate)were particularly effective in this group of difficult-to-
treat depressed patients, although efficacy was compro-
mised by the use of low tranylcypromine doses. Mono-amine oxidase inhibitor therapy was significantly less well
tolerated and had a significantly higher dropout rate.
Limited evidence suggests that the nonselective MAOIs
have comparable efficacy. Tranylcypromine and phenelzinewere found to have similar response rates (44% and 47%,
respectively) in a 5-week trial of 77 patients with severe ma-jor depressive disorder who had been nonresponsive to a
TCA or SSRI medication (1073). Clinical experience sug-
gests that some patients who fail to benefit from one ofthese MAOIs may benefit from a different one—after al-
lowing a several-week period of washout.
2. Electroconvulsive therapy
The efficacy of ECT has been demonstrated in multipleclinical trials, including trials of real versus sham ECT. In
a meta-analysis of the efficacy of ECT in the treatment ofdepressive disorders, the six trials (256 patients) that in-
cluded sham ECT controls yielded a standard effect size
of 0.91 favoring real ECT, consistent with a strong effectof active ECT (235). In th e one sham ECT study that
used unilateral ECT, no difference was found, but thetreatment was not delivered sufficiently above the seizurethreshold to be effective (236). In comparison with phar-
macotherapy, meta-analyses similarly show an advantage
for ECT with a standard effect size of 0.80 across 18 trials
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
88 APA PRACTICE GUIDELINES
(1,144 participants) (235). Comparisons of ECT against
specific antidepressant classes show ECT to be superior
to SSRIs, TCAs, and MAOIs (236, 425). In terms of tech-nical aspects of ECT administration, meta-analyses show
a more substantial effect of bilateral ECT than unilateral
ECT (236), with a standard effect size of 0.32 for 22 trialsand 1,408 participants (235). However, many of the in-
cluded studies did not adjust the stimulus doses of ECT to
account for differences in seizure threshold across pa-tients, which may have increased the apparent benefit of
bilateral ECT. When stimulus dosing was assessed, higher
stimulus doses relative to the patient’s seizure thresholdwere associated with greate r benefit than stimulus doses
closer to the seizure threshold (standard effect size = 0.73for seven trials and 342 participants) (235). The efficacy of
ECT given twice weekly did not differ from that of ECT
given 3 times/week (236).
Much information about ECT response and specific
factors that predict response has come from the Consor-tium for Research in ECT (CORE) study, a large trialfunded by the National Institute of Mental Health (NIMH)
in which continuation pharmacotherapy was compared
with continuation ECT . In the acute phase of that trial inwhich 253 patients were treated with bitemporal ECT
3 times/week, 79% of the sample had an acute sustained re-
sponse, with remission occurring in 75% of patients afterECT (mean number of treatments = 8 ± 3). Response to
ECT occurred rapidly, with over one-half of patients show-ing response by the end of the first week of treatment (240).Suicidal ideation also resolved rapidly during the course of
ECT, with substantial resolution in 38% by the end of the
first week, 61% by the end of the second week, and 80% bythe end of the treatment course (243). Individuals who were
older (715) or who exhibited psychosis (241) or atypical fea-
tures (578) had a greater likelihood of achieving remission,although the presence of melancholic features was not as-
sociated with a greater likelihood of response (499). Also,
unlike prior studies that had shown reduced rates of remis-sion with ECT in patients with treatment-resistant depres-
sion (1074, 1075), the CORE study found that neither
resistance to antidepressants as a whole nor resistance toany specific class of antidepr essants was associated with an
altered response to ECT (426).
In contrast to the high rates of ECT response found in
the CORE study and in meta-a nalyses of clinical efficacy
trials, ECT appears to have a lower rate of response whendelivered in community settings. Prudic et al. (237) exam-ined clinical outcomes following ECT and over 6 months
of follow-up in 347 patients who received ECT at one of
seven hospitals in the New York metropolitan area. Re-mission occurred in only about one-third to one-half of
the sample, and two-thirds of those with remission expe-rienced a relapse during the follow-up period. Having re-sidual symptoms, psychotic features, or a co-occurring
personality disorder conferred a heightened risk of re-lapse.
Other studies have delineated technical factors relating
to the efficacy of ECT, includi ng stimulus intensities and
electrode placements. Sackeim et al. (253) randomly as-
signed 96 depressed patients to treatment with a bitempo-
ral or right unilateral electrode placement at a low dose orhigh dose relative to the patient’s seizure threshold. Pa-
tients treated with bilateral ECT had comparable response
rates regardless of stimulus dose (65% for low dose versus63% for high dose), whereas patients receiving low-dose
right unilateral ECT had only a 17% response, and those
receiving high-dose right unilateral ECT had an interme-
diate response (43%). In a subsequent randomized double-
blind study of 80 depressed patients, an even higher doseof right unilateral ECT was used (500% above the seizure
threshold). At this stimulus dose, right unilateral ECT
showed comparable efficacy to bilateral ECT (65%) andsuperior efficacy to right unilateral ECT given at 50% or
150% above seizure threshold, for which the response
rates were 35% and 30%, respectively. That high-doseright unilateral ECT has comparable benefits to bilateral
ECT has also been shown in two randomized studies by
McCall et al., one of which included 77 patients and usedright unilateral ECT at eight times the seizure threshold
(1076) and one of which included 72 patients and used a
high fixed dose of 403 millicoulombs for right unilateralECT (1077).
Several smaller studies have examined bifrontal elec-
trode placement in comparison with bitemporal or rightunilateral electrode placements. Bailine et al. (1078), who
studied 48 patients with scores of 17 or higher on the 17-
item version of the Hamilton Rating Scale for Depression(HAM-D-17) who were randomly assigned equally to
receive bifrontal or bitemporal ECT (mean number of
treatments = 6 ±  2.5), reported no difference in remission
rates between the two groups. Ranjkesh et al. (1079)
found no difference in HAM-D scores among patients re-
ceiving at least eight sessions of bifrontal (moderate dose,N=15), bitemporal (low dose, N=15), or right unilateral
(high dose, N=15) electrode placement in an Iranian in-
patient sample of patients with an initial score of 16 orhigher on the 24-item Hamilton Rating Scale for De-
pression (HAM-D-24). Similarly, Eschweiler et al. (1080)
compared the effects of six right unilateral ECT treat-ments (250% stimulus intensity of titrated threshold) and
six bifrontal ECT treatments (150% of threshold) over
a 3-week period in a randomized double-blind trial of92 patients and found no difference in response rates be-
tween the two electrode placements.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 89
In addition to efficacy an d ECT technique, the cogni-
tive effects of ECT have been a focus of considerable
study, typically as a part of studies examining various elec-trode placements. In terms of the time to recover reorien-
tation after ECT , Sackeim et al. (253) found that patients
receiving bilateral ECT took substantially longer to re-gain their orientation than patients receiving right unilat-
eral ECT, and the time to regain orientation increased
with the stimulus dose. In addition, the time to regain ori-entation immediately after ECT ,  as well as the patient’s
baseline cognitive status, predicted the patient’s cognitivestatus after the ECT course and at 2-month follow-up as-sessment (251). Regardless of the stimulus dose of right
unilateral ECT that was used, bilateral ECT was associated
with more prominent effects on cognition at follow-up as-
sessments (253, 1081). Relative to bilateral ECT (at one
and one-half times the seizure threshold), high-dose rightunilateral ECT (at eight times the seizure threshold) pro-
duced comparable effects on memory, and neither electrode
placement produced prolonged anterograde amnesia(1076). Lisanby et al. (248) studied 55 patients with major
depression in a randomized double-blind trial of bitem-
poral and right unilateral ECT at low and high stimulusdoses and compared the patients’ function on a Personal and
Impersonal Memory T est with that of a parallel group of
normal control subjects. Bitemporal ECT was found tocause more prominent impairments that were most nota-
ble for impersonal events and that were independent of
stimulus dose or clinical outcome. Studies of other elec-trode placements have shown either no difference (1080)
or beneficial effects (1078, 1079) of bifrontal electrode
placement relative to bitemporal electrode placement. An-other factor that may relate to memory dysfunction is the
number of ECT treatments administered per week, with
two studies showing less prominent amnesia with twice-weekly ECT rather than ECT given 3 times/week (1082).
The cognitive effects observed in naturalistic commu-
nity settings also appear to differ from those observed inresearch trials (252). The seven hospitals in the community
study showed considerable variation from one another
immediately after ECT and at the 6-month follow-up as-sessment. These differences seemed primarily related to
differences in ECT technique across sites, with use of sine
wave stimulation and bilateral ECT being associated withgreater and more persistent cognitive effects on several
cognitive measures, compared with brief pulse and right
unilateral ECT. Given the lower efficacy rates for ECTthat were also seen in the community sample, residual or
recurrent depressive symptoms may also have contributed
to the poorer cognitive outcomes. These findings suggesta need to optimize efficacy as well as minimize cognitive
effects in clinical practice.3. Transcranial magnetic stimulation
A substantial number of studies of TMS have been con-
ducted, but most have had small sample sizes, and the stud-
ies overall have yielded heterogeneous results. Further
complicating the interpretation of the TMS literature isthe variability in stimulation intensities (relative to the mo-
tor threshold), stimulus parameters (e.g., pulses/second,
pulses/session), anatomical localization of stimulation, andnumber of TMS sessions in the treatment course. A recent
meta-analysis of 24 studies (with a total of 1,092 subjects)
found that individuals with treatment-resistant depressionwere more likely to respond to TMS than to sham treat-
ment (25% with TMS versus 17% with sham; NNT=6)
(270). However, for active treatment and for sham treat-
ment, remission occurred in fewer than 10% of subjects
(270). Another meta-analysis that included 33 studies alsofound active TMS to be more effective than sham treat-
ment in patients with major depression but also noted sub-
stantial variability across studies (271). Studies withstimulation intensities below 90% of motor threshold ap-
peared to show less benefit (271). Based on a meta-analysis
that included six independent trials of left dorsolateral pre-frontal cortex TMS in a total of 195 patients, older individ-
uals and those with treatment-resistant depressive episodes
may also be less likely to respond (1083). Another meta-analysis of these six clinical trials found TMS to be no dif-
ferent from sham treatment overall in the treatment of ma-
jor depression; however, the power within these studies todetect a difference was generally low (273). Schutter (272)
also examined studies of TMS over the left dorsolateral pre-
frontal cortex and found an overall weighted mean effect sizeof 0.39 for TMS based on findings from 30 studies and
1,164 patients. This meta-analysis did not find any differ-
ences in the response of individuals with medication-resis-tant major depression as compared with those without
documented medication resistance, nor did it find any evi-
dence of study heterogeneity or publication bias. Multipleearlier meta-analyses also demonstrated benefits of TMS
(1084–1087), but include an overlapping set of studies with
those assessed in more recent meta-analyses. If anything,however, earlier studies demonstrated less efficacy for
TMS than more recent studies (272, 1088). The duration
of TMS effects has not been well studied, but one meta-analysis of 14 studies showed a robust response to TMS
compared with sham TMS after 2 weeks of treatment (stan-
dardized mean difference = −0.35; 95% confidence interval
= −0.66 to −0.04), but no statistically significant benefit of
active TMS at 2-week follow-up (1089).
The largest published trial of TMS was a randomized,
double-blind, multisite study of patients who had not re-
sponded to one to four prior trials of antidepressant ther-
apy and were free of other medications at the time of the
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
90 APA PRACTICE GUIDELINES
study (268). Subjects received sham TMS (N=146) or ac-
tive TMS delivered to the left dorsolateral prefrontal cor-
tex, 5 times/week for 4–6 weeks with 10 pulses/second and3,000 pulses/session at 120% of motor threshold. At
weeks 4 and 6 of the study there was a trend for greater
improvement in MADRS scores in the active TMS group,but this result did not reach statistical significance. Rates
of remission also did not differ between the two groups,although secondary outcome measures, including theHAM-D and response rates, did indicate a beneficial ef-
fect of TMS. In an open-label extension study of this trial
(1090), 85 subjects who had received sham TMS showedsignificant reductions in MADRS scores after changing to
active TMS; 42.4% of these patients met response crite-
ria, and 20% had remission of their depressive symptoms
by 6 weeks. Of subjects who had received active TMS and
continued to receive an addi tional 6 weeks of treatment
(N=73), 26% showed a response to TMS, and 11% achieved
symptom remission. Subsequent analysis of the data from
these trials (274) showed that lesser degrees of treatmentresistance were associated with better response to TMS.
The lack of a co-occurring anxiety disorder also appeared
t o  b e  a s s o c i a t e d  w i t h  a  b e t t e r  r e s p o n s e  t o  T M S  i n  t h eopen-label extension phase of the trial.
In another large multisite trial conducted in Europe, 127
subjects with treatment-resistant depression who were beingtreated with antidepressant medication (venlafaxine or mir-
tazapine) were randomly assigned to receive active (N=62)
or sham (N=65) TMS delivered to the left dorsolateral
prefrontal cortex, 5 times/week with 10 pulses/second and
2,000 pulses/session at 110% of motor threshold for 3 weeks.The two groups did not differ in their degree of improve-ment on the MADRS, HAM-D, or BDI scales, and a sim-
ilar proportion of individuals in each group (31%) were
classified as having responded to treatment (269).
Other smaller studies have compared TMS with ECT ,
with variable results. One of these studies showed ECT tobe substantially more effective than TMS acutely in termsof HRSD scores and the proportion of responders at the
end of the study, and, on the majority of outcome mea-
sures, ECT retained this benefit over TMS after 6 monthsof follow-up (275). In the other studies that compared
TMS with ECT, rates of remission and response were
comparable for the two treatments, although the responseand remission rates for ECT in these studies were some-
what lower than typically reported in clinical ECT trials,
and rates of response to TMS were higher than those re-ported in sham controlled trials of TMS (276–278, 1091).
An additional randomized single-blind trial compared the
responses of individuals who received 2 weeks of thrice-weekly unilateral ECT with the responses of individuals
who received one unilateral ECT session and four TMSsessions each week (1092) and found no statistically sig-nificant differences in efficacy or side effects between the
two approaches. The cognitive effects of TMS and ECThave been assessed in one open study (279), in which sub-
jects treated with TMS reported memory to be unchanged
or improved approximately 9 days after the treatmentcourse as compared with unilateral ECT , which was asso-
ciated with a greater degree of subjective, retrograde, and
anterograde memory difficulties shortly after the end of
the treatment course. A subsequent randomized single-
blind trial (276) showed no significant difference between
individuals who received TMS and those who receivedunilateral ECT when neuropsychological performance was
tested at 2 and at 4 weeks of treatment. However, there
was a trend for worsened performance in those receiving
ECT versus a trend for improved performance in those
receiving TMS.
Analysis of aggregate safety data from more than 10,000
treatment sessions with 325 patients treated at 23 clinicalsites in the United States, Australia, and Canada showedthat TMS was well tolerated, with less than 5% of subjects
leaving the study due to adverse effects and no seizures or
deaths observed (280). The most common adverse effectswere transient headaches or scalp discomfort. Overall, side
effects of treatment were mild to moderate in intensity and
dissipated over the initial week of treatment.
4. Vagus nerve stimulation
The FDA approved VNS for treatment-resistant depres-sion based on efficacy data from two different samples, for
which acute and longer term data are available. The first
sample consisted of 60 outpatients with chronic or recur-rent major depressive disorder, bipolar I disorder, or bipo-
lar II disorder who had not responded to at least two
medication trials from different antidepressant classes. Thiscohort was first followed in an open-label fashion with 10
weeks of active stimulation after a 2-week period to permit
recovery from surgery (281). On the primary outcome mea-sure, the 28-item Hamilton Rating Scale for Depression
(HAM-D-28), 30.5% of the sample showed a response (de-
fined as at least a 50% reduction from the baseline HAM-D-28 score) and 15.3% of the sample had a full remission
of symptoms (defined as HAM-D-28 of less than 11). Re-
sponse was less likely to occur in patients who had receiveda greater number of unsuccessful antidepressant trials or
who had received ECT prior to VNS. This cohort was then
followed for up to 2 years naturalistically, with changes topsychotropic medications and VNS stimulus parameters
permitted (479). In a last-observation-carried-forward anal-
ysis, response rates were 44% and 42% after 1 and 2 years,
respectively, with remission rates of 27% and 22% at 1 and
2 years, respectively (479).
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 91
A subsequent VNS trial was a multisite randomized
trial with 235 participants that included an acute sham-
controlled phase (282) and a longer term naturalistic fol-low-up phase (477) and comparison with a relatively similar
treatment-as-usual sample. In the acute phase, nonpsy-
chotic outpatients with treatment-resistant major depres-sive disorder (N=210) or patients with depressed phase
bipolar disorder (N=25) received 10 weeks of active or
sham treatment after 2 weeks of recovery from implanta-tion surgery. In terms of response (i.e., at least 50% reduc-
tion in HAM-D-24 score), there was no significant
difference with VNS treatment (15.2% response vs. 10%for sham). These findings may be confounded by the fre-
quent occurrence of hoarseness or voice alteration with
stimulation (281), which may have affected the blinding of
the study subjects or investigators. During the longer
term naturalistic follow-up phase, in which changes inmedication were permitted, the active VNS group re-
ceived 9 additional months of VNS, and the sham group
received 12 months of VNS (282). A repeated-measureslinear regression analysis of the primary outcome measure
showed significant reductions in HAM-D-24 scores, with
response and remission rates of 27.2% and 15.8%, respec-tively, at the study endpoint (282). A similar but nonran-
domized treatment-as-usual group (N=124) showed a
response rate of 13%, suggesting a benefit of VNS (476).
T o determine whether the benefits of VNS were dura-
ble, data from the studies described earlier in this sectionwere combined, and the persistence of the antidepressiveresponse was determined (478). Of individuals who had
shown an early response (by 3 months of VNS), 66.7% and
64.6% of the overall group had maintained that response at1 and 2 years, respectively. Of those who had shown a late
response (by 12 months of VNS), 68.5% had maintained
that response at 2 years, suggesting persistent benefits ofVNS.
An additional uncontrolled multisite European trial
showed somewhat lower rates of sustained response (44%)at 1 year of VNS treatment, although overall response and
remission rates at 1 year were 53% and 33%, respectively
(481). Other smaller, open-label trials have been recentlyreviewed and also show reductions in depressive symptoms
when VNS is used in combination with other antidepres-
sive treatments for individuals with treatment-resistant de-
pression (480).
Across all studies, VNS was generally viewed as toler-
able (480). Rates of study dropout were low (about 1%)during the initial 3 months of treatment (282), with about
80% of subjects continuing with VNS at the end of 2 years
(479). Voice alteration or hoarseness occurred in abouttwo-thirds of subjects in conjunction with stimulation
(281). Coughing occurred in about one-quarter of individ-uals (281), and dyspnea and neck pain were also commonly
reported (481).
5. Complementary and alternative treatments
a. St. John’s wort
Despite a large number of trials examining St. John’s wort
(usually in the form of Hypericum perforatum  extract), there
is no consensus on its efficacy in major depressive disorder.
A 2005 Cochrane meta-analysis (1093) provided a sum-
mary of treatment studies utilizing St. John’s wort for the
treatment of major depressive disorder. The published stud-ies demonstrate heterogeneity in methods used and great
inconsistency in study outcomes. A number of double-
blind studies have demonstrated its superiority over pla-
cebo, although some have not (370, 371). In addition, St.
John’s wort may have better tolerability than TCAs and
SSRIs, and several randomized studies have shown nonin-
feriority relative to approved antidepressant medications,although the distinctive taste of St. John’s wort extract mayhave caused some unblinding during the studies.
Among the larger and most rigorous recently pub-
lished placebo-controlled trials, the studies by Shelton etal. (371) (N=200) and Davidson et al. (370) (N=340) did not
demonstrate a difference between St. John’s wort and pla-
cebo on primary outcome measures, but Lecrubier et al.(1094) found a significant difference between St. John’s wort
and placebo in mild to moderate depression (N=375). In
addition, a recent review of 14 short-term, double-blindtrials conducted in outpatients with mild to moderate
symptoms of major depressive disorder demonstrated that
St. John’s wort in doses of 300 mg/day and 1,800 mg/dayhad efficacy superior to placebo and was generally com-
parable to low-dose TCA treatment (e.g., 30–150 mg/day
of amitriptyline) (105). Side effects were observed in alower proportion of individuals taking St. John’s wort
than among those taking a TCA (25% vs. 40%) (105).
b. S-adenosyl methionine
A number of studies have found SAMe to be efficacious in
oral doses that range from 800 mg/day to 1,600 mg/day. In
a double-blind trial, 15 inpatients with major depressivedisorder received oral SAMe or placebo for 21 days (1095).
Six of nine patients receiving SAMe demonstrated response
as defined by a reduction of 50% or more in HAM-Dscores, and depression ratings compared with placebo were
significantly lower in the SAMe group than in the placebo
group at days 14 and 21. Side effects were mild and tran-sient. In a meta-analysis of studies comparing effects of
SAMe with those of TCAs, SAMe was found to have better
tolerability and greater efficacy in the treatment of depres-sion, although the doses of TCAs were subtherapeutic in
some studies (381). Data from two multicenter studies also
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
92 APA PRACTICE GUIDELINES
demonstrated that parenteral and oral formulations of
SAMe were comparable in efficacy to the TCA imipramine
(1096), although side effects were significantly more fre-quent in the imipramine-treated group. In one of the larger
controlled trials, which included 293 participants, Pancheri
et al. (382) found SAMe (administered intramuscularly at adose of 400 mg/day) and imipramine (administered by
mouth at a dose of 150 mg/day) to be similarly efficacious in
a 4-week trial. Other studies have focused on specific sub-groups of patients, such as HIV-positive patients and post-
menopausal women (1097, 1098).
c. Omega-3 fatty acids
T wo large meta-analyses found benefits of omega-3 fatty
acids overall in mood disorder trials (384, 385) but also
highlighted the heterogeneity of study designs and re-
sults. The one monotherapy study of DHA for major de-pressive disorder in adults did not demonstrate benefit of
DHA over placebo (1099), although small trials in major
depressive disorder in children and in pregnant womendid demonstrate a benefit of monotherapy with omega-3
fatty acids (EPA and DHA) (1100, 1101).
d. Folate
In a study by Coppen and Bailey (389) that included
127 subjects, 94% of women who received fluoxetine and500 mcg/day of folate responded to treatment, compared
with 61% of those who received fluoxetine and placebo
(p<0.005). Patients who received folate were also less
likely to report side effects (p <0.05).
e. Light therapyIn a meta-analysis, Golden et al. (395) found clinically sig-
nificant benefit of bright light therapy in seasonal major de-pressive disorder (eight studies), with a large effect size(0.84), and in nonseasonal major depressive disorder in
three studies with a medium effect size (0.53). However, the
authors, who were participants of an APA work group onthe topic of light therapy, determined that many of the
studies of light therapy for mood disorders had method-
ological flaws, including small sample sizes, with only 13% ofthe studies they assessed meeting the inclusion criteria for
their meta-analysis. Bright light therapy in nonseasonal
major depressive disorder was not found to be significantlymore efficacious than placebo in trials when used adjunc-
tively in addition to antidepressants. As determined by the
APA work group, an adequate placebo condition requires amaximum dose of 300 lux (versus at least 3,000 lux-hours
for an active treatment condition for bright light treat-
ment). Randomized, placebo-controlled studies haveranged from 7–42 days in treatment duration, with provi-
sion of between 2,500–10,000 lux illuminance of white
light, with delivery time between 0.5–6 hours/day. Somepublished studies were found to have bright light exposure
at levels too high to constitute  a scientifically valid control
condition, and the difficulty in creating a reasonable con-
trol condition for bright light therapy may have contributed
to the limited evidence base to date. Control groups have in-
cluded lower doses of white light, red light, active lightavoidance, negative air ionizer, and no treatment. Despite
heterogeneity of designs and results, evidence supports the
efficacy of bright light as a monotherapy for acute majordepressive disorder. Individualization of a regimen may be
required in terms of lux, length of exposure, and time of day
of delivery. In addition, patients should be monitored foremergence of mania during treatment (1102).
f. Acupuncture
Assessment of the evidence base for acupuncture is compli-
cated by the fact that many reports are in Asian languages
and therefore often overlooked by English language litera-ture searches. Results from studies in acupuncture are dif-
ficult to interpret, because the description of the methods is
often limited and there is variability in diagnosis and in in-terventions (403). Wang et al. (407) published a recent
meta-analysis of eight trials of acupuncture and depression
chosen from more than 200 studies on the basis of havinga randomized design, specific diagnostic criteria for de-
pression, and specific acupuncture interventions (manual,
electro-acupuncture, or laser). The depression criteria in-cluded DSM, International Classification of Diseases, and
Chinese Classification of Mental Disorders criteria. The
meta-analysis did not demonstrate a benefit of acupunctureover control conditions on either response rates or remis-
sion but was based on a small number of trials with variable
methodological quality. Consequently, additional system-atic study is required to assess the role of acupuncture for
major depressive disorder
.
There have been few randomized, double-blind, placebo-
controlled studies to inform the use of acupuncture for de-pression. In one published study, Allen et al. (405) compared
38 women, ages 18–45 years, who were assigned to three dif-ferent groups: an acupuncture regimen specifically chosen to
address their depression, sham acupuncture, or a waiting-list
control condition. The active acupuncture group experi-enced a significantly greater remission rate. However, Allen
et al. (406) failed to replicate these results in a larger random-
ized trial, in which 151 patients with major depressive disor-der received acupuncture specific for depression, sham
acupuncture, or a waiting-list condition. After 8 weeks, there
was no evidence of benefit for the acupuncture interventionspecific for depression, compared with sham acupuncture or
the waiting-list condition. Response rates were 22% for the
depression-specific acupuncture treatment and 39% for thesham acupuncture treatment.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 93
In another randomized study, Luo et al. (404) compared
effects of electro-acupuncture combined with placebo med-
ication to the effects of amitriptyline in 241 inpatients.Electro-acupuncture appeared equivalent to amitriptyline
at a dose of 150–175 mg/day in treating depression, with
greater improvement for symptoms of anxiety, cognitiveproblems, and somatization; it also resulted in a lower side
effect burden than amitriptyline. However, no group re-
ceived the placebo medication alone, and no sham treat-
ment was used to elucidate nonspecific benefits of acu-
puncture treatment.
B. SPECIFIC PSYCHOTHERAPIES
1. Cognitive and behavioral therapies
a. Cognitive-behavioral therapyIn the three decades since its first evaluation as a treat-
ment for major depressive disorder, CBT has been exten-sively studied in controlled trials. When meta-analyses
have quantified the efficacy of CBT compared with no
treatment or minimal treatment, effect sizes have beenfairly robust, generally near or above one standard devia-
tion in the outcome measures (514, 1103–1106). Relative
to other treatments, estimates of CBT efficacy frommeta-analyses have been less consistent, although effect
sizes for CBT have generally been comparable to those
for other short-term forms of psychotherapy (e.g., IPTand brief dynamic psychotherapy) (1107).
Factors relating to the administration of CBT may in-
fluence response. Some data suggest that the efficacy ofCBT may vary depending upon the severity of major de-
pressive disorder, with less  efficacy in individuals with
more severe symptoms (1108). Individuals with moderate
to severe depression may need more skilled CBT thera-
pists to achieve therapeutic benefits (67). Other trials have
failed to show a differential response to treatments on thebasis of initial symptom severity, possibly because of lack
of statistical power (1109, 1110).
Recent research has raised questions about the relative
strengths of the cognitive and the behavioral componentsof CBT. Dimidjian et al. (310) randomly assigned 241 pa-
tients with major depressive disorder to receive CBT ,behavioral activation, paroxetine, or placebo. Among pa-
tients with more severe depression, behavioral activation
had similar efficacy to medication, and both were superiorto CBT. This study shows that behavioral interventions
may be preferable to cognitive techniques for patients
with more severe depressive symptoms.
According to a data synthesis of studies conducted be-
tween 1980 and October 2004, conducted by Hollon et al.(363), CBT and IPT can be as effective as medications in
the acute treatment of depressed outpatients. Comparable
rates of medication and CBT response have also been foundin a number of randomized trials. For example, Jarrett et al.
(576) compared CBT to phenelzine and placebo in a 10-
week randomized trial that included 108 patients with ma-jor depressive disorder with atypical features. Cognitive-be-
havioral therapy had comparable efficacy at achieving
response (indicated by a HAM-D score of 9 or lower), andboth were superior to placebo in an intent-to-treat analysis.
In another study, DeRubeis et al. (67) reported that among
240 patients randomly assigned to receive paroxetine, CBT,
or placebo, CBT was comparable to paroxetine but was not
clearly superior to placebo at 8 weeks. In addition, at 16
weeks, CBT and paroxetine showed comparable rates of re-
sponse and remission in individuals with moderate to severe
major depressive disorder.
In subanalyses of the NIMH T reatment of Depression
Collaborative Research Program study, CBT was less ef-fective than imipramine plus clinical management amongindividuals with moderate depression (defined by scores
of 20 or higher on the HAM-D or scores of 50 or lower on
the Global Assessment of Functioning); there was also atrend for CBT to be less effective than IPT (1108). No
differences were observed between CBT, IPT, imip-
ramine plus clinical management, or placebo plus clinicalmanagement among less severely depressed subjects. At
study endpoint as well as at 18-month follow-up, there
were no significant differences among these treatmentgroups in degree of symptom reduction or ratings of cur-
rent clinical condition. However, at the 18-month follow-
up assessment, patients receiving IPT or CBT reported asignificantly greater capacity to establish and maintain in-
terpersonal relationships and to recognize and understand
sources of their depression than patients in the imip-ramine plus clinical management group or the placebo
group (1111).
Unlike medications, CBT decreases the risk of relapse
even after this treatment is terminated (363), and continu-ing CBT in the maintenance phase further decreases this
risk. In a maintenance treatment study by Paykel et al. (368),158 patients with partial remission from a major depres-
sive episode while taking medication were randomly as-
signed to clinical management or clinical management andCBT. Cognitive-behavioral therapy was given in 16 ses-
sions over 20 weeks, with two booster sessions at 72 weeks.
Relapse reduced from 47% to 29% with CBT, and CBT was
associated with higher remission  rates. Bockting et al. (497)
also compared treatment as usual (including medication)to treatment as usual and CBT in a German outpatientsample of 187 patients. Cognitive-behavioral therapy had
“significant protective effect” that increased with number
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
94 APA PRACTICE GUIDELINES
of prior episodes. For patients with five or more prior de-
pressive episodes, CBT lowered relapse from 72% to
46%. This study suggests that psychotherapy may have aprotective effect, especially for more severely ill patients.
b. Behavior therapy
Although numerous trials have examined the efficacy of
behavior therapy, relatively few have employed randomassignment and adequate control conditions. T wo meta-
analyses found behavior therapy superior to a waiting-
list control condition (observed in seven of eight trials)(487, 1107). Results of individual clinical trials have sug-
gested that behavior therapy may be superior in efficacy
to brief dynamic psychotherapy (1112, 1113) and gener-
ally comparable in efficacy to cognitive therapy (1114–
1117) or pharmacotherapy (283). One post hoc examina-tion of clinical trial data found that response to behavior
therapy may be more likely in patients with less initial se-
verity of major depressive disorder symptoms (1118),but other studies have not found this relationship (1119–
1121).
More recently, “dismantling  studies” comparing the full
CBT package to some of its elements suggest that behav-ioral activation, the behavioral component of CBT, may
be as efficacious or more efficacious than CBT as a whole,particularly for patients with greater depressive severity
(310, 1122). Behavioral activation not only outperformed
CBT and placebo with respect to more severely depressedpatients, but it was as efficacious as medications regardless
of severity (310) and more enduring following treatment
termination (288). In addition, activity scheduling, a be-havioral activation treatment in which patients learn how
to increase the number of pleasant activities and interac-
tions with their environment, was found in a meta-analy-sis to be an effective treatment for depression (706).
2. Interpersonal therapy
Like CBT , IPT was developed to treat patients with majordepressive disorder and has demonstrated efficacy in aseries of randomized clinical trials (1123, 1124). In the
NIMH T reatment of Depression Collaborative Research
Program study, IPT had greater efficacy than pill placeboplus clinical management and was comparable to imip-
ramine plus clinical management for patients with more
severe major depressive disorder, whereas cognitive ther-apy was not superior to placebo. Among patients with
mild depressive severity (defined as scores less than 20 on
the HAM-D or greater than 50 on the Global Assessmentof Functioning scale), IPT , CBT, and imipramine plus
clinical management did not differ from placebo plus clin-
ical management (1108). The degree to which patient andtherapist can resolve the interpersonal crisis on which IPTfocuses (e.g., a role transition) appears to correlate with
symptomatic improvement (1125).
Other studies have found IPT effective in treating
pregnant and postpartum women with major depressivedisorder (743, 1126) and depressed patients in a develop-
ing country (351). A controlled trial of IPT has also dem-onstrated its effectiveness for depressed primary care
patients (1127). After 8 mo nths, the propor tions of pa-
tients treated with IPT , nortriptyline, or usual care who
achieved remission were 46%, 48%, and 18%, respectively.
In a study of depressed HIV-positive patients, greater im-
provements were observed after IPT or IPT plus imip-
ramine than after supportive psychotherapy or CBT (316).
However, a large recent study found no benefit for IPTover clinical management in depressed cardiac patients
(807).
Many trials have been conducted comparing IPT , both
as monotherapy and augmentation, to various controlconditions and active comparators, both in acute phase
treatment and continuation and maintenance therapy.
Generally, IPT is superior to treatment as usual and is an
effective augmentation strategy for patients receiving
pharmacotherapy. A meta-analysis of 13 studies of IPT
conducted from 1974 to 2002 reported that, in nine of the
studies, IPT was superior to placebo (1123). In addition,
IPT was more efficacious than CBT . However, the com-bination of IPT and medications was not significantly
more effective than medication monotherapy for acute or
prophylactic treatment.
3. Psychodynamic psychotherapy
Psychodynamic psychotherapy has been used widely inclinical practice for the treatment of patients with depres-sive symptoms and syndromes and is sometimes preferred
by patients (361). However, its efficacy in major depres-
sive disorder has not been adequately studied in con-trolled trials. Using the available evidence to determine
the efficacy of psychodynamic psychotherapy in the treat-
ment of major depressive disorder is complicated by severalproblems. In some early studies, variants of psychody-
namic psychotherapy served as a nonspecific comparison
treatment to other psychotherapeutic interventions, butthe details of the psychodynamic psychotherapy employed
were poorly defined (1107). Subsequently, some clinical
trials of psychodynamic psychotherapy have reportedshort- and long-term therapeutic benefits (as described in
references 1128–1130), but few of these trials were ran-
domized or assessed treatment fidelity; some includedconcomitant pharmacotherapy,  and most studied patients
with a multiplicity of symptoms  and diagnoses, such as de-
pressed patients who did not meet the DSM-IV criteriafor major depressive disorder. These limitations make it
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 95
difficult to draw conclusions from meta-analyses that in-
corporate a variety of study populations and designs (286,
1130, 1131). A recent meta-analysis (1132) acknowledgedthat the quality of available studies on psychodynamic
psychotherapy for treatment of depression was not opti-
mal. In addition, use of low-quality studies in meta-anal-yses of psychotherapy may lead to overestimations of
effect sizes (1133). With these caveats, some findings from
meta-analyses of short-term (1132) and long-term (1130)psychodynamic psychotherapy suggest possible benefits
in individuals with depressive symptoms (1132) and sug-
gest that long-term psychodynamic psychotherapy mayhave beneficial effects in individuals with depressive and
anxiety symptoms (1130). T o confirm these results and ex-
tend them to individuals diagnosed with major depressive
disorder, further research with more rigorous study de-
signs will be needed.
4. Marital therapy and family therapy
Reviews have concluded that marital therapy is effectivefor treating depressive symptoms and reducing risk for re-
lapse (1134, 1135). In a recent meta-analysis of eight mar-
ital therapy trials, marital therapy had comparable efficacyto individual psychotherapy for the treatment of depres-
sion (1136). A lower dropout rate was found for marital
therapy than for medication therapy, although this resultwas heavily influenced by a single study. Marital therapy
was superior in treating depressive symptoms, compared
with minimal or no treatment. These findings were weak-ened by methodological problems affecting most studies,
such as the small number of cases available for analysis in
almost all comparisons, and the significant heterogeneityamong studies.
Results from individual studies suggest that the efficacy
of marital therapy may depend on whether marital distressis present. In one study, a greater proportion of depressed
subjects with marital distress responded to marital therapy
than to cognitive therapy (88% vs. 71%), but among de-pressed subjects without marital distress, a greater propor-
tion responded to cognitive therapy than to marital therapy
(85% vs. 55%) (1137). In another study of depressed sub-jects with marital discord, marital therapy and CBT were
equally effective and both were more effective than a wait-
ing-list condition (1138). A pilot randomized trial found“conjoint” (marital) IPT for depressed married women
equipotent to individual IPT in alleviating depression and
superior in improving marital satisfaction (1139).
A randomized controlled trial of antidepressant drug
therapy in comparison to couple therapy for depressed out-patients found a lower dropout rate and greater improve-ment in subjective symptoms of depression, at no greater
cost, for the couple therapy group (342). Patients recruitedduring a psychiatric hospitalization for major depressivedisorder were randomly assigned to pharmacotherapy
alone; combined pharmacotherapy and cognitive therapy;combined pharmacotherapy and family therapy; and com-
bined pharmacotherapy, cognitive therapy, and family ther-
apy. Patients who received treatment that included a familytherapy component were more likely to improve and had
significant reductions in interviewer-rated depression and
suicidal ideation, compared with those whose treatment didnot include family therapy (343).
5. Problem-solving therapy
Some studies have reported modest improvement in sub-
jects with mild depressive symptoms treated with prob-
lem-solving therapy. For example, Dowrick et al. (1140)
treated 452 subjects with depressive or adjustment disor-
ders, comparing groups that received eight sessions ofproblem-solving therapy to control groups given six ses-
sions of group preventive education. At 6 months, the au-
thors found a 2.6-point difference on the BDI favoringproblem-solving therapy (NNT=6). T reatment effects at
1 year did not differ. Problem-solving therapy may have
advantages over usual care for home-bound geriatric pa-tients with depressive symptoms (1141). Unfortunately,
usual care often means little care.
Alexopoulos et al. (335) reported that 12 sessions of
problem-solving therapy were superior to supportivepsychotherapy for depressed geriatric patients with major
depressive disorder and executive dysfunction. Anotherstudy showed problem-solving therapy to have greater
benefit than usual care in preventing depression (1142).
6. Group therapy
A mostly European body of research suggests that the in-
dividual psychotherapies validated in treating depressionalso work in group format. Most of these studies have
sought to demonstrate efficacy rather than exploring the
technical aspects of group therapy.
Group cognitive therapy has shown benefits in the acute
treatment of major depressive disorder. For example, Ayenand Hautzinger (347) randomly assigned 51 depressed,menopausal women for 3 months of weekly, 2-hour ses-
sions of cognitive group therapy, of group supportive psy-
chotherapy, or a waiting list. Both active treatments werewell tolerated and relieved depressive and menopausal
symptoms better than the control condition. At 1-year fol-
low-up, group CBT was more beneficial than group sup-portive therapy. In contrast, group CBT was ineffective in
treating dysthymic disorder. Ravindran et al. (293) found
sertraline superior to placebo but 12 weeks of group CBTno better than placebo and ineffective in augmenting ser-
traline in treatment of patients with dysthymia.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
96 APA PRACTICE GUIDELINES
McDermut et al. (1143) conducted a meta-analysis of
48 research reports assessing the efficacy of group therapy
for the treatment of depression in individuals with varioustypes of depressive disorders (depressive spectrum disor-
ders). Analyses suggested that  participants in treatment
showed significant clinical improvement.
Forms of group CBT have also shown promise in low-
ering relapse risk. Bockting et al. (497) reported that for the
41% of 187 patients with remission who had a history of atleast five episodes of recurrent major depressive disorder,
augmenting usual treatment with brief group CBT low-
ered relapse rates from 72% to 46% over a 2-year period.
T easdale et al. (498) found that group mindfulness-
based cognitive therapy as an augmentation strategy wasbeneficial relative to treatment as usual in reducing re-
lapse rates over 60 weeks for 145 patients with recurrent
depression who reported at least three prior major depres-sive episodes.
Interpersonal psychotherapy has also been adapted to a
group format (1144). Although IPT is less well studiedthan CBT, small trials of group IPT suggest its benefits as
both a preventive intervention (350) and a treatment for
postpartum depression (349). A group combining inter-personal and cognitive elements improved outcome rela-
tive to fluoxetine alone among patients with dysthymia
who responded to fluoxetine (1145).
C. PSYCHOTHERAPY COMBINED 
WITH PHARMACOTHERAPY
Although many psychiatrists prefer to use a combination ofpsychotherapy and pharmacotherapy to treat patients withdepression, controlled studies conducted in the 1970s and
1980s did not consistently find  a significant advantage for
routinely combining therapies, compared with one or the
other treatments provided alone (1146). Part of the prob-
lem in establishing the additive value of psychotherapy and
pharmacotherapy in these early studies was methodologi-cal: the specific effects of each modality (i.e., over and above
the so-called nonspecific effects of therapeutic support and
placebo-expectancy factors) are relatively modest, andnone of the early studies of combined therapy had the sta-
tistical power to reliably detect such small effects. Consis-
tent with this appraisal, a meta-analysis of these earlystudies found an average effect size of about 0.3 (1147),
which is both a clinically significant effect and an advantage
that would usually not be found to be statistically signifi-cant in a study of 100 or fewer patients. A meta-analysis of
individual patient data performed by Thase et al. (359),
which compared remission rates of nearly 600 patientstreated in studies of CBT , IPT, and IPT in combinationwith either imipramine or nortriptyline, confirmed a mod-
est overall advantage for combined treatment versus CBT
or IPT alone but found a differential impact linked to se-verity and history of recurrent depressive episodes. Specif-
ically, whereas combined treatment had a small advantage
over psychotherapy alone among patients with less severedepression, there was a fourfold difference in remission
rates among the subset of patients with more severe, recur-
rent depressive episodes.
The advantage of combined treatment over pharmaco-
therapy alone in more severe depression was evident in awell-controlled inpatient study of Schramm et al. (285).Conducted in Germany, this 5-week trial included 124 hos-
pitalized patients with major depressive disorder; results
showed a 70% response rate to IPT plus pharmacotherapy,
compared with a 51% response rate to pharmacotherapy
alone. In a Swiss study in which 74 outpatients were ran-domly assigned to receive 10 weeks of clomipramine plus
psychodynamic therapy or clomipramine alone, the combi-
nation treatment produced greater improvements in globalfunctioning, greater cost savings, lower rates of hospitaliza-
tion, and fewer lost work days (1148).
Keller et al. (362) examined the outcomes of more than
600 patients with chronic depression who were randomlyassigned to treatment with the antidepressant nefazodone
or a form of CBT (cognitive behavioral analysis system ofpsychotherapy [CBASP]) singly or in combination. The
authors found a large additive  advantage for the two treat-
ments in combination. Specifically, response rates for com-
bined treatment were approximately 20% higher at the
end of 12 weeks of treatmen t, compared with the mono-
therapies, which were comparably effective. It is noteworthy
that patients receiving combined treatment experienced theearlier benefit that characterized the pharmacotherapy as
well as the later emerging benefit that characterized thepsychotherapy (362). A post hoc analysis of these results
revealed that the advantage of  the combined approach was
explained by a broader spec trum of efficacy: pharmaco-
therapy alone was significantl y less effective than CBASP
among the subset of patients with a history of childhood
trauma, whereas the opposite trend was evident amongthe patients treated with psychotherapy alone (1149). Pa-
tients with chronic depression were thus more likely to
benefit from combined treatment whether or not they hada history of early adversity.
In the STAR*D study, patients with depression who did
not have remission following an initial 12-week course ofcitalopram therapy were offered the opportunity to add
or change to Beck’s model of cognitive therapy in addition
to the various pharmacotherapy options being studied.Among those who opted to add a therapeutic adjunct to
ongoing citalopram, about one-third consented to be ran-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 97
domly assigned to strata that included both cognitive ther-
apy and medications (buspirone or bupropion). Results at
the end of 12 weeks of therapy indicated that cognitive ther-apy was as effective as medication augmentation, although
patients opting for combined pharmacotherapy responded
faster (369).
One historic limitation of the literature on combined
treatment of depression has been that a vast majority ofstudies have concerned cognitive therapy and IPT, andthere has been a dearth of studies on the more widely prac-
ticed forms of psychodynamic psychotherapy. An informa-
tive series of studies by one group of investigators in theNetherlands has helped to partly address this issue. The
first trial compared outcomes of 167 outpatients with de-
pression across 6 months of treatment with either algo-
rithm-guided antidepressant  pharmacotherapy alone or
pharmacotherapy combined with a manual-based form of
time-limited dynamic psychotherapy (1150). Significant
differences favored combined treatment with respect to
retention in treatment and the likelihood of remission. Asecondary analysis determined that the advantage of com-
bined treatment was largely explained by the large differ-
ence among patients with co-occurring Axis II disorders(1151). In a second study of 191 depressed outpatients,
time-limited dynamic therapy alone was compared against
psychotherapy in combination with algorithm-guidedpharmacotherapy (1152). In this trial, there were signifi-
cant differences favoring combined therapy on patient-
rated outcomes, although the numeric difference betweengroups on remission rates was not statistically significant.
The investigators next conducte d a pooled analysis of the
data from these two trials, also including a third smaller
study that did not include a combined therapy arm (361).
The analysis included data for more than 300 depressed
outpatients and confirmed the advantage of combinedtreatment over the monotherapies across studies on most
outcome variables.
T wo meta-analyses of study results have confirmed the
advantage of combining pharmacotherapy and variousforms of time-limited psychotherapies (360, 1153). The lat-
ter report confirmed that the advantage was larger amongstudies of patients with more severe symptoms and among
those with more chronic depressive disorders (1153).
D. LACK OF RESPONSE TO PHARMACOTHERAPY 
IN THE ACUTE PHASE
1. Maximizing initial treatments
Several studies have shown improved efficacy with higherdoses of medication, supporting the strategy of increasing
the medication dose for patients who do not respond to aninitial trial of a medication. As an example, Bech et al. (1154)
conducted a randomized controlled trial in which patients
meeting the criteria for major depressive disorder wererandomly assigned to receive placebo or citalopram in doses
of 10 mg/day (N=129), 20 mg/day (N=130), 40 mg/day
(N=130), or 60 mg/day (N=129). T reatment continuedfor 6 weeks, and depressive symptoms were measured by
21-item Hamilton Rating Scale for Depression, MADRS,
Clinical Global Impression, and 56-item Symptom Check-list. The percentages of patients lost to follow-up were
9% for placebo, 7% for citalopram at 10 mg/day, 2% for
citalopram at 20 mg/day, 2% for citalopram at 40 mg/day,
and 3% for citalopram at 60 mg/day (nonsignificant p val-
ues). The 10- and 20-mg doses were more efficacious than
placebo, but they were inferior to the 40- and 60-mg doses
(p<0.05). The 20-, 40-, and 60-mg doses had significantly
more side effects than placebo, measured by dropout rates
due to side effects (p <0.05).
2. Changing to other treatments
The recently completed STAR*D trial examined various
strategies for patients with treatment-resistant depression.
STAR*D was a multisite, multistep, prospective random-ized controlled trial comparing treatments and treatment
strategies in outpatients with major depressive disorder
(48). The study provided data on treatment effectiveness,or “real world” outcomes in typical patients, making the
results generalizable to standard practice. The study was
organized into four levels. In level 1, 2,876 outpatientsreceived citalopram for up to 14 weeks. In level 2, nonre-
sponders (N=1,493) were offered three alternatives, which
were selected based on patient choice: change to anothermedication (N=727), augment citalopram with another
medication (N=565), or start psychotherapy (N=147). If
the patient changed to another medication, he or she wasrandomly assigned to receive sertraline, bupropion SR, or
venlafaxine XR. Patients who chose medication augmen-
tation were randomly assigned to augment citalopramwith bupropion SR or buspirone. Patients who agreed to
start psychotherapy were randomly assigned to change to
cognitive therapy (discontinuing citalopram) or to aug-ment with cognitive therapy (continuing citalopram). For
patients who did not respond to level 2, level 3 offered two
alternatives: changing or au gmenting with another medi-
cation. Patients in the change group were randomly as-
signed to receive mirtazapin e (N=114) or nortriptyline
(N=121) for up to 14 weeks. Patients in the augmentation
group were randomly assigned to receive lithium (N=69)
or triiodothyronine (N=73) for up to 14 weeks. Finally,
level 4 randomly assigned nonresponders from level 3to receive tranylcypromine (N=58) or the combination of
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
98 APA PRACTICE GUIDELINES
venlafaxine XR and mirtazapine (N=51). STAR*D therefore
provides data for several randomized controlled trials of
change or augmentation of me dications at various stages.
T wo such studies based on STAR*D data provide evidence
for continued efficacy of medication augmentation (429)
and medication change (471) for treatment-resistant de-
pression. Remission rates were equivalent and approxi-
mately 25% upon changing from citalopram to either an
SSRI or SNRI or bupropion at the second step; there wasno difference in remission between changing to either
mirtazapine or nortriptyline at the third step.
A number of previous studies evaluated changing from
an SSRI to another SSRI, changing from an SSRI to anSNRI, and changing from an SSRI to bupropion or mir-
tazapine. These previous studies were either small in size
or, in the vast majority of instances, were neither random-
ized nor blinded. A few trials have been conducted inwhich patients who did not respond to an initial antide-
pressant medication were changed to a non-MAOI anti-
depressant medication from the same pharmacological class(e.g., from one TCA to another) or to one from a different
pharmacological class (e.g., from a TCA to an SSRI). Al-
though results from these trials have been variable, up to50% of patients have been found to respond (i.e., have symp-
tom improvement of at least 50%) to a second non-MAOI
antidepressant medication trial—even when the second an-tidepressant was from the same class as the first (421). Data
regarding the types of treatment-resistant patients who are
most likely to benefit from particular changes in medica-tion are limited.
3. Augmenting and combining treatments
T raditionally, augmentation agents with the most evi-dence for efficacy have included lithium and thyroid hor-
mone for partial responders to traditional antidepressant
medications (1155). Recent studies have significantly ad-vanced the literature now with the two augmentation ran-
domized controlled trials in STAR*D (429, 446) and the
use of adjunctive aripiprazole (453, 1156). In the mostrecent large-scale trial—a component of the STAR*D
study—lithium augmentation of citalopram was neither
particularly well tolerated nor more effective than thyroidaugmentation (446).
The second-step augmentation trial in the STAR*D
study evaluated the comparative efficacy of add-on sus-tained-release bupropion and add-on buspirone in pa-
tients who had not achieved adequate remission status
following an initial trial with citalopram. Both agents asadjuncts were associated wi th remission rates of around
30% on primary outcome measures. Patients who did nothave remission with up to 12 weeks of citalopram ther-apy were as likely to benefit from adjunctive buspirone(15–60 mg/day) as they were to benefit from adjunctive
bupropion (150–400 mg/day) (429). However, adjunctive
treatment with bupropion SR was superior to adjunctivebuspirone on a number of key secondary measures (224).
The findings of 16 placebo-controlled, randomized
clinical trials of second-gen eration antipsychotic augmen-
tation therapy for patients with major depression disorder
(N=3,480) have recently been evaluated in a meta-analysis
(448). Augmentation with a second-generation antipsy-chotic agent was significantly more effective than placebo
in terms of rates of response and remission. Although arip-
iprazole has received FDA approval as an adjunct to sec-ond-step antidepressant medications for patients who had
not achieved satisfactory response to at least two prior an-
tidepressant medication trials, this meta-analysis showed
no differences in response or remission rates among the in-
dividual medications (448). Discontinuation rates for ad-verse effects were also higher in the active augmentation
groups compared with placebo, suggesting that such effects
need to be taken into consideration when choosing to aug-ment antidepressant response with a second-generation an-
tipsychotic agent. T o date, few data from controlled studies
address the longer term efficacy or side effects of combin-ing antidepressants and antipsychotics.
Combining an SSRI and a TCA induced a rapid anti-
depressant response in one preliminary study (1157). In asecond study, patients taking this combination also had a
greater likelihood of remission, compared with patients
receiving monotherapy with an SSRI or a TCA (1158).The efficacy of combining mi rtazapine and an SSRI was
demonstrated in one placebo-controlled study (432). Mir-tazapine and venlafaxine led to a 13.7% remission rate inpatients who had not responded to three prior medication
trials as part of the STAR*D study (121). Case reports sug-
gest that stimulant medications may be effective adjunctsto antidepressant medication therapy (205), although the re-
sults of larger scale clinical trials have not demonstrated
efficacy (462, 463).
E. CONTINUATION TREATMENT
Although randomized controlled trials of antidepressantmedications in the continuation phase are limited, theavailable data indicate that patients treated for a first epi-
sode of uncomplicated major depressive disorder who
exhibit a satisfactory response to an antidepressant medi-cation should continue to receive a full therapeutic dose of
that agent for at least 16–20 weeks after achieving and main-
taining full remission (105, 225, 495).
T wo clinical trials have examined the effects of contin-
uation treatment following an acute course of ECT . In arandomized double-blind trial that included 84 individu-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 99
als with major depressive disorder whose symptoms had
remitted with ECT , the combination of nortriptyline (tar-
get steady-state level, 75–125 ng/mL) plus lithium (targetsteady-state level, 0.5–0.9 mEq/L) was associated with
lower relapse rates over the 24-week trial (39%) than ei-
ther nortriptyline alone (60%) or placebo (84%) (489). Asubsequent trial found that continuation pharmacother-
apy with lithium plus nortriptyline (N=94) was comparable
in efficacy to continuation ECT (N=89) in maintainingremission (46.3% versus 46.1%) after a successful acute
course of ECT (234). The group receiving medication re-
ported a greater number of treatment-emergent side ef-fects than the ECT group, but there were no differences
in cognitive impairment reported between the treatment
groups.
A few studies have examined treatment with psycho-
therapeutic interventions administered in the continua-tion phase. One study found that among patients who
responded to acute treatment with cognitive therapy, those
who continued this treatment over 2 years had lower re-lapse rates than those who did not have continuation
treatment (493). Results from a series of studies (365, 367,
494) suggest that CBT may be an effective continuationtreatment following antidepressant medication therapy
for preventing relapse (364).
In a randomized controlled trial of cognitive group
therapy as an adjunct to treatment as usual, Bockting et al.(497) studied 187 patients with recurrent major depressive
disorder who were currently in remission. Cognitive grouptherapy was found to be effective in preventing relapse/
recurrence, and this protective effect increased in concert
with the number of previous depressive episodes.
Hollon et al. (68) assessed 104 patients with major de-
pressive disorder who had responded to cognitive therapy,pharmacotherapy, or placebo and had remained improvedduring a 12-month continuation phase. Patients were with-
drawn from treatment and followed for an additional 12
months. Cognitive therapy patients, who were allowed nomore than three booster sessions over that year, had a lower
rate of relapse (31%) than those withdrawn from medica-
tion (76%). They also exhibited no greater likelihood ofdepressive relapse than patients who continued pharma-
cotherapy (47%), suggesting possible lasting benefits of
cognitive therapy.
F. MAINTENANCE TREATMENT
The multicenter Prevention of Recurrent Episodes of
Depression With Venlafaxine for T wo Years (PREVENT)
study was designed to evaluate patients with recurrentunipolar major depressive disorder randomly assigned to
receive venlafaxine XR or fluoxetine. At the end of a 10-week acute phase treatment, response rates were 79% forboth venlafaxine XR and fluox etine, with remission rates
being 49% and 50%, respectively. In the 6-month contin-
uation phase, response rates were 90% (venlafaxine XR)
and 92% (fluoxetine), with rates of sustained remission of
52% and 58%, respectively. The cumulative probability ofrecurrence through the first 12 months of the maintenance
phase treatment was 23.1% for venlafaxine and 42% for
placebo. The cumulative probability of recurrence throughthe second 12 months of maintenance treatment was 8%
in the venlafaxine XR group and 44.8% in the placebo group
(226, 1159).
There have been fewer investigations of the effectiveness
of psychotherapy in the maintenance phase. In one study,maintenance cognitive therapy delivered over 2 years was as
effective as maintenance medication for recurrent major
depressive disorder (514). Other reports indicate that IPTmay effectively lengthen the interepisode interval for
patients with recurrent depression who do not receive
medication (289, 314, 513, 1056). Maintenance CBT asaugmentation to medication prevented relapse relative to
medication plus treatment as usual (368, 497, 1160).
Monthly maintenance psychotherapy with CBASP was
more effective over a 1-year period than an assessment-only control condition for patients with chronic depres-
sion who had responded to acute treatment and remainedimproved in continuation therapy with CBASP (1161). A
6-year follow-up of patients treated with medication and
continuation CBT found weakening but continuing on-going benefits lasting as long as 3.5 years after completing
CBT (1162). Research on cognitive therapy has explored
the concept of an enduring benefit by acquiring persistentskills that reduce the risk of depressive relapse after treat-
ment has ended (68, 1110).
The combined use of psychotherapy, such as CBT,
cognitive therapy, or IPT, and pharmacotherapy in the
maintenance phase has also been considered by investi-
gators. Some results suggest that the combination of an-tidepressant medications plus psychotherapy may be
additionally effective in preventing relapse over treatment
with single modalities (314, 365, 506, 515, 516). However,in individuals older than age 70 years who received main-
tenance treatment with paroxetine and clinical manage-
ment, interpersonal therapy and placebo, paroxetine andinterpersonal therapy, or placebo and clinical manage-
ment, the combination of paroxetine and interpersonal
therapy offered no benefits over paroxetine and clinicalmanagement and each were superior to the other treat-
ment conditions (729).
Electroconvulsive therapy has also been used in the
maintenance phase. Evidence for its benefits comeslargely from case reports and case series (1163–1168), al-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
100 APA PRACTICE GUIDELINES
though a retrospective case-control study (1169) and a
randomized prospective trial in older adults (730) demon-
strated longer times to recurrence with use of maintenanceECT . The optimal frequency, duration, and method ofdiscontinuing maintenance ECT treatment have not been
systematically studied, but typically ECT is tapered grad-
ually with a return to more frequent treatments if depres-sive symptoms emerge (501).
Part C
FUTURE RESEARCH NEEDS
Notable progress has been made in our understanding ofmajor depressive disorder and its treatment. However,there are still many unanswered questions about optimiz-
ing and individualizing treatment. The following areas re-
quire additional study.
T o “personalize” care, and someday even prevent de-
pression, we must understand factors that cause it. In thenearer term, science can focus on predictors of benefit andadverse effects of specific treatments. Potential causes of
depression or moderators of treatment response may be
found through genomics, proteomics, physiological mark-ers, personality traits, personal experiences, co-occurring
conditions, or clusters of specific depressive symptoms.
Culture, race, and ethnicity merit study in shaping treat-ment selection and predicting response and side effects.
Even if science were to offer perfect and personalized
treatments for depression, patients must be able to gainaccess to care and adhere to recommended interventions.
Thus, research must develop better ways to deliver treat-
ment, optimizing effectiveness as well as efficacy. Re-search should also consider the cost-effectiveness of care
and effects of treatment on functioning and quality of life.
As the U.S. population ages and co-occurring illnessesbecome more common, studies are needed on ways to in-
tegrate care for depression with treatment for other psy-
chiatric and medical problems. Most studies of major
depressive disorder have examined the acute phase of treat-ment. More research is required on the continuation and
maintenance phases. Questions abound on the persistenceof biological and psychosoci al treatment effects, when
treatment may safely be discontinued, how recurrent de-pression differs from chronic varieties in the long term, andmore.
The science of psychotherapy research continues to
evolve. We need to understand how specific types of ther-apy compare to one another in  the treatment of major de-
pressive disorder and how to select a treatment for anindividual. Research must di sentangle nonspecific factorsfrom the unique features of a theoretically derived ap-proach. It would be important to determine the compo-nents of specific psychotherapies that are responsible for
efficacy, the patient-specific f actors that moderate the ef-
ficacy of these therapies, th e indications for using a par-
ticular psychotherapy, and the optimal duration andfrequency of psychotherapy for particular patient sub-
groups, types of psychotherapy, or phases of depressiontreatment. Outcome measures of psychotherapy studies
should not only examine acute symptom response but also
whether psychotherapies have enduring, protective ef-fects in averting relapse and re currence of depression after
treatment has ended. A manual-based model of psycho-dynamic therapy for depression (1170) may be helpful inthe development of evidence concerning this approach.
Strategies for sequencing psychotherapy in the overall
treatment of major depressive disorder and for combiningpsychotherapy (either with pharmacotherapy or another
psychotherapy) merit further study.
Much work remains to be done on medication inter-
vention in depression. We should address the comparative
efficacies, relative short- and long-term side effect profiles,
and specific clinical indications of different antidepressantmedications, augmentation strategies (e.g., second-gener-
ation antipsychotic medications, lithium, thyroid hor-
mone) and combination treatment approaches (e.g., SSRIsand other moieties). This would include determining if
particular treatments or combinations of treatments have
differential efficacy in specific subgroups of patients withdepression (e.g., patients with psychotic depression) and,
for medications other than the TCAs, whether relation-
ships exist between medication blood levels and thera-peutic responses or side effects. Initial studies of mono-
therapy with second-generation antipsychotic agents appear
promising, but additional study of the acute and long-termbenefits and side effects is essential. The definition and im-
plications of treatment-resistance for treatment selection
also requires further clarification.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 101
Electroconvulsive therapy remains the treatment of best
established efficacy against which other stimulation treat-
ments (e.g., VNS, deep brain stimulation, TMS, otherelectromagnetic stimulation therapies) should be com-
pared. Approaches to reducing cognitive side effects of
ECT, speeding response to ECT , or determining the indi-cations and best methods for maintenance ECT could im-
prove patient care. More research is also needed on the
optimal approaches (e.g., treatment schedule, stimulationparameters) for delivering newer stimulation therapies. Ad-
ditional research on light therapy would be helpful, includ-
ing determining its effectiveness as adjunctive treatment innonseasonal major depressive disorder or as a primary
treatment for seasonal major depressive disorder in themaintenance phase. Given patients’ frequent use of com-plementary therapies, additional research on these thera-
pies, including acupuncture, is warranted. Further study ofexercise in acute and maintenance treatment of depression
would also be useful, including assessment of the benefits of
exercise in minimizing side effects of the other therapiesand in optimizing health, functioning, and quality of life.
In time, brain imaging, genomics, proteomics, and
other recent advances in neuroscience should help us“carve nature along its joints,” allowing major depressive
disorder to be broken into discrete diseases with defined
and personalized treatments. In  the meantime, clinical in-
vestigation focused on existing and novel treatment strat-
egies remains essential.
Appendix
EDUCATIONAL RESOURCES F OR PATIENTS AND FAMILIES
Academy of Cognitive Therapy
http://www.academyofct.org
California Teratogen Information Service and Clini-
cal Research
T el: 1–800–532–3749 (CA only)T el: (610) 543–2131
http://www.otispregnancy.org
ConsumerLab.com
T ests herbal and vitamin products for purity and posts the
results on the Web
http://www.consumerlab.com
Depression After Delivery, Inc.
91 East Somerset Street
Raritan, NJ 08869T el: (800) 944–4773
http://www.depressionafterdelivery.com
Depression and Bipolar Support Alliance
730 Franklin Street
Suite 501
Chicago, IL 60610–7224T el: (312) 642–0049
T el: (800) 826–3632
http://www.ndmda.orgHealthy Minds, Healthy LivesAmerican Psychiatric Associationhttp://www.healthyminds.org
International Foundation for Research and Educa-
tion on Depression2017-D Renard Court
Annapolis, MD 21401
T el: (410) 268–0044http://www.ifred.org
International Society of Interpersonal Psychotherapy
http://www.interpersonalpsychotherapy.org
KidsHealth.org
http://www.kidshealth.org
Massachusetts General Hospital Women’s Mental
Health Program
http://www.womensmentalhealth.com
Mental Health America
2000 N. Beauregard Street
6th Floor
Alexandria, VA 22311T el: (703) 684–7722
T el: (800) 969–6MHA (6642)
TTY Line: (800) 433–5959http://www.nmha.org
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
102 APA PRACTICE GUIDELINES
MentalHelp.net
http://www.mhnet.org
Motherisk.com
Database maintained by the T oronto Hospital for Sick
Children
http://www.motherisk.com
NARSAD
60 Cutter Mill Road
Suite 404Great Neck, NY 11021
T el: (516) 829–0091
http://www.narsad.org
National Alliance on Mental Illness
Colonial Place Three2107 Wilson Blvd., Suite 300
Arlington, VA 22201
T el: (703) 524–7600Help Line: (800) 950-NAMI [6264]
http://www.nami.org
National Center for Complementary and 
Alternative Medicine
National Institutes of Health
9000 Rockville PikeBethesda, MD 20892
http://nccam.nih.gov/
National Institute of Mental Health
Depression Information Program
6001 Executive BoulevardRoom 8184, MSC 9663Bethesda, MD 20892–9663
T el: (301) 443–4513TTY Line: (301) 443–8431
http://www.nimh.nih.gov/health/topics/depression/
index.shtml
National Institute of Mental Health
Mental Health Topics
http://www.nimh.nih.gov/health/topics/index.shtml
National Institute of Mental Health
Public Information and Communications Branch
6001 Executive Boulevard
Room 8184, MSC 9663
Bethesda, MD 20892T el: (866) 615–6464
http://www.nimh.nih.gov/publicat/index.cfm
National Library of Medicine
U.S. government online repository of articles published
in peer-reviewed medical journals
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
Postpartum Support International
http://postpartum.net
Substance Abuse and Mental Health Services 
Administration’s National Mental Health 
Information Center  
http://mentalhealth.samhsa.gov/
INDIVIDUALS AND ORGANIZATIONS THAT SUBMITTED 
COMMENTS
M.T . Abou-Saleh, M.B.Ch.B., M.Phil., Ph.D.,
F. R. C. Ps y c h.
Jonathan E. Alpert, M.D., Ph.D.
Robert J. Barth, Ph.D.
Carl C. Bell, M.D.Franco Benazzi, M.D., Ph.D.
Joseph Berger, M.D.
Dan G. Blazer, M.D., Ph.D.David W. Brook, M.D.
Joseph R. Calabrese, M.D.
Anita H. Clayton, M.D.C. Edward Coffey, M.D.
Mirean Coleman, M.S.W., L.I.C.S.W., C.T.
C. Deborah Cross, M.D.Mark A. Demitrack, M.D.Wayne H. Denton, M.D., Ph.D.P . Murali Doraiswamy, M.D.
Javier I. Escobar, M.D., M.S.
Giovanni Andrea Fava, M.D.Max Fink, M.D.
To n y  F o w k e ,  A . M .
Andrew J. Francis, M.D., Ph.D.Glen O. Gabbard, M.D.
Gary G. Gintner, Ph.D.
Leslie Hartley Gise, M.D.Michael J. Gitlin, M.D.
Predrag Gligorovic, M.D.
Jack M. Gorman, M.D.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 103
Ellen Grabowitz, M.D.
Michael F . Grunebaum, M.D.
John G. Gunderson, M.D.Ana Maria B. Gutierrez, M.D.
Steven D. Hollon, Ph.D.
Joseph J. Horak, Ph.D.Douglas G. Jacobs, M.D.
Bradley R. Johnson, M.D.
Lewis L. Judd, M.D.Gabor I. Keitner, M.D.
James H. Kocsis, M.D.
Lorrin M. Koran, M.D.Milton Kramer, M.D.
Arthur Lazarus, M.D., M.B.A.
Ellen MacKenzie, M.D.
Lauren Marangell, M.D.
Kathleen Ries Merikangas, Ph.D.Helen Millar, M.D.
Stuart A. Montgomery, M.D.
Anthony T. Ng, M.D.Mary Olinger, M.D.
Maria Oquendo, M.D.
George I. Papkostas, M.D.Jagoda Pasic, M.D., Ph.D.
Michael Posternak, M.D.
Lawrence H. Price, M.D.Mark Hyman Rapaport, M.D.
Steven P . Roose, M.D.
Anthony J. Rothschild, M.D.Peter Roy-Byrne, M.D.
John P .D. Shemo, M.D., D.F.A.P .A.David A. Solomon, M.D.Robert Stern, M.D., Ph.D.
Joel E. Streim, M.D.Shona Sturgeon, M.Soc.Sc.
Richard P . Swinson, M.D., F.R.C.P .C., F.R.C.Psych.
Michael J. T elch, Ph.D.John Chapman Urbaitis, M.D.
Eduard Vieta, M.D., Ph.D.
Karen Dineen Wagner, M.D., Ph.D.Risa B. Weisberg, Ph.D.
Myrna M. Weissman, Ph.D.
Kimberly A. Y onkers, M.D.Mark Zimmerman, M.D.
American Academy of Neurology
American Academy of Psychoanalysis and Dynamic 
Psychiatry
American Association for Marriage and Family TherapyAmerican Association of Emergency Psychiatry
American Geriatrics Society
American Group Psychotherapy AssociationAmerican Mental Health Counselors Association
American Neuropsychiatric AssociationAssociation for Behavior and Cognitive TherapyAssociation of Family Psychiatrists
Canadian Psychiatric Association
Community Mental Health Council, Inc.National Association of Social Workers
Society for Adolescent MedicineWorld Federation for Mental Health
ACKNOWLEDGMENT
Massimiliano Beghi, M.D., assisted with the evidence review for this guideline.
REFERENCES
The following coding system is used to indicate the nature of the supporting evidence in the references:
[A] Randomized double-blind clinical trial.  A study of an intervention in which subjects are prospectively fol-
lowed over time, there are treatment and control groups, subjects are randomly assigned to the twogroups, both the subjects and the investigators are blind to the assignments.
[A−]Randomized clinical trial.  Same as above but not double-blind.
[B] Clinical trial.  A prospective study in which an intervention is made and the results of that intervention are
tracked longitudinally; study does not meet standards for a randomized clinical trial.
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
104 APA PRACTICE GUIDELINES
[C] Cohort or longitudinal study.  A study in which subjects are prospectively followed over time without any spe-
cific intervention.
[D] Case-control study.  A study in which a group of patients and a group of control subjects are identified in the
present and information about them is pursued retrospectively or backward in time.
[E] Review with secondary data analysis.  A structured analytic review of existing data, e.g., a meta-analysis or a
decision analysis.
[F] Review.  A qualitative review and discussion of previously published literature without a quantitative syn-
thesis of the data.
[G] Other. T extbooks, expert opinion, case reports, and other reports not included above.
1. Institute of Medicine: Conflict of Interest in Med-
ical Research, Education, and Practice. Washing-
ton, DC, National Academies Press, 2009 [G]
2. American Psychiatric Association: Practice guide-
line for the treatment of patients with bipolar dis-
order (revision). Am J Psychiatry 2002; 159 (Aprilsuppl):1–50 [G]
3. Birmaher B, Brent D, Bernet W, Bukstein O, Walter
H, Benson RS, Chrisman A, Farchione T , GreenhillL, Hamilton J, Keable H, Kinlan J, Schoettle U, StockS, Ptakowski KK, Medicus J: Practice Parameter forthe Assessment and T reatment of Children and Ado-lescents With Depressive Disorders. J Am Acad ChildAdolesc Psychiatry 2007; 46:1503–1526 [G]
4. Ankarberg P , Falkenstrom F: T reatment of depres-
sion with antidepressants is primarily a psycholog-ical treatment. Psychoth erapy Theory, Research,
Practice, T raining 2008; 45:329–339 [G]
5. Blass DM: A pragmatic approach to teaching psychi-
atry residents the assessment and treatment of reli-gious patients. Acad Psychiatry 2007; 31:25–31 [F]
6. Cooper LA, Gonzales JJ, Gallo JJ, Rost KM,
Meredith LS, Rubenstein LV , Wang NY, Ford DE:The acceptability of treatment for depressionamong African-American, Hi spanic, and white pri-
mary care patients. Med Care 2003; 41:479–489 [G]
7. Givens JL, Katz IR, Bellamy S, Holmes WC: Stig-
ma and the acceptability of depression treatmentsamong African Americans and whites. J Gen InternMed 2007; 22:1292–1297 [G]
8. American Psychiatric Association: Practice Guide-
line for the Psychiatric Evaluation of Adults, Sec-ond Edition. Am J Psychiatry 2006; 163(Junesuppl):3–36 [A −]
9. Keitner GI, Ryan CE, Miller IW, Zlotnick C: Psy-
chosocial factors and the long-term course of majordepression. J Affect Disord 1997; 44:57–67 [G]
10. McDermut W, Miller IW, Solomon D, Ryan CE,
Keitner GI: Family functioning and suicidality indepressed adults. Compr Psychiatry 2001; 42:96–104 [G]
11. Weissman MM, Wickramaratne P , Nomura Y,
Warner V , Verdeli H, Pilowsky DJ, Grillon C,Bruder G: Families at high and low risk for depres-sion: a 3-generation study. Arch Gen Psychiatry2005; 62:29–36 [G]
12. Olino TM, Pettit JW, Klein DN, Allen NB, Seeley
JR, Lewinsohn PM: Influence of parental andgrandparental major depressive disorder on behav-ior problems in early childhood: a three-generationstudy. J Am Acad Child Adolesc Psychiatry 2008;47:53–60 [G]
13. Hoffman RS, Koran LM: Detecting physical illness
in patients with mental disorders. Psychosomatics1984; 25:654–660 [G]
14. Sox HC Jr, Koran LM, Sox CH, Marton KI, Dug-
ger F , Smith T: A medical algorithm for detectingphysical disease in psychiatric patients. Hosp Com-munity Psychiatry 1989; 40:1270–1276 [G]
15. T aylor RL: Psychological Masquerade: Distinguish-
ing Psychological from Organic Disorder, 3rd ed.New York, Springer, 2007 [G]
16. American Psychiatric Association: Diagnostic and
Statistical Manual of Mental Disorders, T ext Revi-sion (DSM-IV-TR), 4th ed. Washington, DC,American Psychiatric Association, 2000 [G]
17. Angst J, Sellaro R: Historical perspectives and nat-
ural history of bipolar disorder. Biol Psychiatry2000; 48:445–457 [G]
18. Hirschfeld RM, Williams JB, Spitzer RL, Calabrese
JR, Flynn L, Keck PE Jr, Lewis L, McElroy SL, PostRM, Rapport DJ, Russell JM, Sachs GS, Zajecka J:Development and validation  of a screening in-
strument for bipolar spectrum disorder: the MoodDisorder Questionnaire. Am J Psychiatry 2000;157:1873–1875 [G]
19. Solomon DA, Leon AC, Maser JD, T ruman CJ,
Coryell W, Endicott J, T eres JJ, Keller MB: Distin-guishing bipolar major depression from unipolarmajor depression with the screening assessment ofdepression-polarity (SAD-P). J Clin Psychiatry2006; 67:434–442 [G]
20. Kocsis J: Chronic depression versus treatment re-
fractory depression: evaluation and treatment, inT reatment Strategies for Refractory Depression.Edited by Roose S, Glassman AH. Washington,DC, American Psychiatric Publishing, 1990, pp195–203 [G]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 105
21. Kocsis JH, Gelenberg AJ, Rothbaum B, Klein DN,
T rivedi MH, Manber R, Keller MB, Howland R,
Thase ME: Chronic forms of major depression arestill undertreated in the 21st century: systematicassessment of 801 patients presenting for treatment.J Affect Disord 2008; 110:55–61 [G]
22. American Psychiatric Association: Practice Guide-
line for the Assessment and T reatment of PatientsWith Suicidal Behaviors. Am J Psychiatry 2003;160(Nov suppl):1–60 [G]
23. Harris EC, Barraclough B: Excess mortality of
mental disorder. Br J Psychiatry 1998; 173:11–53[E]
24. Osby U, Brandt L, Correia N, Ekbom A, Sparen P:
Excess mortality in bipolar and unipolar disorder inSweden. Arch Gen Psychiatry 2001; 58:844–850[C]
25. Bunney WE, Kleinman AM, Bell CC, Brent DA,
Eggert L, Fawcett J, Gibbons RD, Jamison KR,Korbin JE, Mann JJ, May PA, Reynolds CF , T suangMT , Frank RG: Reducing Su icide: A National Im-
perative. Washington, DC, National AcademyPress, 2002 [G]
26. Hammad TA, Laughren T, Racoosin J: Suicidality
in pediatric patients treated with antidepressantdrugs. Arch Gen Psychiatry 2006; 63:332–339 [E]
27. Heru AM, Combrinck-Graham L: The family in
psychiatric emergencies, in Emergency Psychiatry:Principles and Practice. Edited by Glick RL, BerlinJS, Fishkind AB, Zeller SL. Philadelphia, Pa, Lip-pincott Williams & Wilkins, 2008, pp 107–114 [G]
28. Hatters FS, Hrouda DR, Holden CE, Noffsinger
SG, Resnick PJ: Filicide-suicide: common factors inparents who kill their children and themselves. J AmAcad Psychiatry Law 2005; 33:496–504 [D]
29. Logan J, Hill HA, Black ML, Crosby AE, Karch
DL, Barnes JD, Lubell KM: Characteristics of per-petrators in homicide-followed-by-suicide inci-dents: National Violent Death Reporting System—17 US states, 2003–2005. Am J Epidemiol 2008;168:1056– 1064 [G]
30. Schanda H, Knecht G, Schreinzer D, Stompe T,
Ortwein-Swoboda G, Waldhoer T: Homicide andmajor mental disorders: a 25-year study. Acta Psy-chiatr Scand 2004; 110:98–107 [D]
31. Oquendo MA, Galfalvy H, Russo S, Ellis SP ,
Grunebaum MF, Burke A, Mann JJ: Prospectivestudy of clinical predictors  of suicidal acts after a
major depressive episode in patients with majordepressive disorder or bipolar disorder. Am J Psy-chiatry 2004; 161:1433–1441 [C]
32. Oquendo MA, Bongiovi-Garcia ME, Galfalvy H,
Goldberg PH, Grunebaum MF, Burke AK, MannJJ: Sex differences in clinical predictors of suicidalacts after major depression: a prospective study. AmJ Psychiatry 2007; 164:134–141 [C]33. Spinelli MG: Maternal infanticide associated with
mental illness: prevention and the promise of savedlives. Am J Psychiatry 2004; 161:1548–1557 [F]
34. Fang H, Rizzo JA: Do psychiatrists have less access
to medical services for their patients? J Ment HealthPolicy Econ 2007; 10:63–71 [G]
35. Dewan M: Are psychiatrists cost-effective? An anal-
ysis of integrated versus split treatment. Am J Psy-chiatry 1999; 156:324–326 [G]
36. Goldman W, McCulloch J, Cuffel B, Zarin DA,
Suarez A, Burns BJ: Outpatient utilization patternsof integrated and split psychotherapy and pharma-cotherapy for depression. Psychiatr Serv 1998;49:477–482 [G]
37. Mechanic D: Approaches for coordinating primary
and specialty care for persons with mental illness.Gen Hosp Psychiatry 1997; 19:395–402 [G]
38. Ustun TB, Sartorius N (eds): Mental Illness in
General Health Care: An International Study. NewYork, NY, John Wiley and Sons, 1995 [G]
39. Mojtabai R, Olfson M: National patterns in antide-
pressant treatment by psychiatrists and generalmedical providers: results from the National Co-morbidity Survey replication. J Clin Psychiatry2008; 69:1064–1074 [G]
40. T rivedi MH, Rush AJ, Gaynes BN, Stewart JW,
Wisniewski SR, Warden D, Ritz L, Luther JF, Steg-man D, Deveaugh-Geiss J, Howland R: Maximiz-ing the adequacy of medication treatment incontrolled trials and clinical practice: STAR(*)Dmeasurement-based care. Neuropsychopharmacol-ogy 2007; 32:2479–2489 [B]
41. Hamilton M: A rating scale for depression. J Neurol
Neurosurg Psychiatry 1960; 23:56–62 [G]
42. McIntyre RS, Konarski JZ, Mancini DA, Fulton
KA, Parikh SV , Grigoriadis S, Grupp LA, Bakish D,Filteau MJ, Gorman C, Nemeroff CB, KennedySH: Measuring the severity of depression and re-mission in primary care: validation of the HAMD-7 scale. CMAJ 2005; 173:1327–1334 [G]
43. Montgomery SA, Asberg M: A new depression scale
designed to be sensitive to change. Br J Psychiatry1979; 134:382–389 [G]
44. Duffy FF, Chung H, T rivedi M, Rae DS, Regier
DA, Katzelnick DJ: Systematic use of patient-rateddepression severity monitoring: is it helpful andfeasible in clinical psychiatry? Psychiatr Serv 2008;59:1148–1154 [G]
45. Kroenke K, Spitzer RL, Williams JB: The PHQ-9:
validity of a brief depression severity measure. J GenIntern Med 2001; 16:606–613 [G]
46. Beck AT , Steer RA, Brown GK: Manual for the Beck
Depression Inventory-II. San Antonio, T ex, Psy-chological Corporation, 1996 [G]
47. Wisniewski SR, Rush AJ, Balasubramani GK,
T rivedi MH, Nierenberg AA: Self-rated global
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
106 APA PRACTICE GUIDELINES
measure of the frequency, intensity, and burden of
side effects. J Psychiatr Pract 2006; 12:71–79 [G]
48. Rush AJ, Fava M, Wisniewski SR, Lavori PW,
T rivedi MH, Sackeim HA, Thase ME, Nieren-berg AA, Quitkin FM, Kashner TM, Kupfer DJ,Rosenbaum JF , Alpert J, Stewart JW, McGrath PJ,Biggs MM, Shores-Wilson K, Lebowitz BD,Ritz L, Niederehe G: Sequenced treatment alter-natives to relieve depression (STAR*D): rationaleand design. Control Clin T rials 2004; 25:119–142[G]
49. Vanderkooy JD, Kennedy SH, Bagby RM: Antide-
pressant side effects in depression patients treatedin a naturalistic setting: a study of bupropion,
moclobemide, paroxetine, sertraline, and venlafax-
ine. Can J Psychiatry 2002; 47:174–180 [G]
50. Lingjaerde O, Ahlfors UG, Bech P , Dencker SJ,
Elgen K: The UKU side effect rating scale. A newcomprehensive rating scale for psychotropic drugsand a cross-sectional study of side effects in neuro-leptic-treated patients. Acta Psychiatr Scand Suppl1987; 334:1–100 [G]
51. Zimmerman M, McGlinchey JB: Why don’t psy-
chiatrists use scales to measure outcome when treat-ing depressed patients? J Clin Psychiatry 2008;69:1916–1919 [G]
52. T rivedi MH, Kern JK, Grannemann BD, Altshuler
KZ, Sunderajan P: A computerized clinical decisionsupport system as a means of implementing depres-sion guidelines. Psychiatr Serv 2004; 55:879–885[G]
53. Lin EH, Von Korff M, Katon W, Bush T, Simon
GE, Walker E, Robinson P: The role of the primarycare physician in patients’ adherence to antidepres-sant therapy. Med Care 1995; 33:67–74 [B]
54. Mueser KT, Corrigan PW, Hilton DW, T anzman
B, Schaub A, Gingerich S, Essock SM, T arrier N,Morey B, Vogel-Scibilia S, Herz MI: Illness man-agement and recovery: a review of the research.Psychiatr Serv 2002; 53:1272–1284 [F]
55. Dunn AL, T rivedi MH, Kampert JB, Clark CG,
Chambliss HO: The DOSE study: a clinical trial toexamine efficacy and dose response of exercise astreatment for depression. Control Clin T rials 2002;23:584–603 [A]
56. Dunn AL, T rivedi MH, Kampert JB, Clark CG,
Chambliss HO: Exercise treatment for depression:efficacy and dose response. Am J Prev Med 2005;28:1–8 [A]
57. Penninx BW, Rejeski WJ, Pandya J, Miller ME, Di
Bari M, Applegate WB, Pahor M: Exercise anddepressive symptoms: a comparison of aerobic andresistance exercise effects on emotional and physicalfunction in older persons with high and low depres-sive symptomatology. J Gerontol B Psychol Sci SocSci 2002; 57:124–132 [A]58. Mather AS, Rodriguez C, Guthrie MF, McHarg
AM, Reid IC, McMurdo ME: Effects of exercise ondepressive symptoms in older adults with poorlyresponsive depressive disorder: randomised con-trolled trial. Br J Psychiatry 2002; 180:411–415 [A]
59. Blumenthal JA, Babyak MA, Moore KA, Craighead
WE, Herman S, Khatri P , W augh R, NapolitanoMA, Forman LM, Appelbaum M, Doraiswamy PM,Krishnan KR: Effects of exercise training on olderpatients with major depression. Arch Intern Med1999; 159:2349–2356 [A]
60. Herman S, Blumenthal JA, Babyak M, Khatri P ,
Craighead WE, Krishnan KR, Doraiswamy PM:Exercise therapy for depression in middle-aged and
older adults: predictors of early dropout and treat-
ment failure. Health Psychol 2002; 21:553–563 [A]
61. Babyak M, Blumenthal JA, Herman S, Khatri P ,
Doraiswamy M, Moore K, Craighead WE, Bal-dewicz TT , Krishnan KR: Exercise treatment formajor depression: maintenance of therapeutic ben-efit at 10 months. Psychosom Med 2000; 62:633–638 [A]
62. Singh NA, Stavrinos TM, Scarbek Y, Galambos G,
Liber C, Fiatarone Singh MA: A randomized con-trolled trial of high versus low intensity weighttraining versus general practitioner care for clinicaldepression in older adults. J Gerontol A Biol SciMed Sci 2005; 60:768–776 [A]
63. Singh NA, Clements KM, Singh MA: The efficacy
of exercise as a long-term antidepressant in elderly
subjects: a randomized, controlled trial. J GerontolA Biol Sci Med Sci 2001; 56:M497–M504 [A]
64. Brown WJ, Ford JH, Burton NW, Marshall AL,
Dobson AJ: Prospective study of physical activityand depressive symptoms in middle-aged women.Am J Prev Med 2005; 29:265–272 [G]
65. Strawbridge WJ, Deleger S, Roberts RE, Kaplan
GA: Physical activity reduces the risk of subsequentdepression for older adults. Am J Epidemiol 2002;156:328–334 [G]
66. Lai SM, Studenski S, Richards L, Perera S, Reker
D, Rigler S, Duncan PW: Therapeutic exercise anddepressive symptoms after stroke. J Am Geriatr Soc2006; 54:240–247 [A]
67. DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton
RC, Young PR, Salomon RM, O’Reardon JP ,Lovett ML, Gladis MM, Brown LL, Gallop R:Cognitive therapy vs medications in the treatmentof moderate to severe depression. Arch Gen Psychi-atry 2005; 62:409–416 [A −]
68. Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam
JD, Salomon RM, O’Reardon JP , Lovett ML,Young PR, Haman KL, Freeman BB, Gallop R:Prevention of relapse following cognitive therapyvs medications in moderate to severe depression.Arch Gen Psychiatry 2005; 62:417–422 [B]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 107
69. Dunn AL, T rivedi MH, O’Neal HA: Physical activ-
ity dose-response effects on outcomes of depression
and anxiety. Med Sci Sports Exerc 2001; 33:S587–S597 [F]
70. T rivedi MH, Greer TL, Grannemann BD, Church
TS, Galper DI, Sunderajan P , Wisniewski SR,Chambliss HO, Jordan AN, Finley C, Carmody TI:TREAD: TReatment with Exercise Augmentationfor Depression: study rationale and design. ClinT rials 2006; 3:291–305 [G]
71. Khan A, Leventhal RM, Khan SR, Brown WA:
Severity of depression and response to antidepres-sants and placebo: an analysis of the Food and DrugAdministration database. J Clin Psychopharmacol
2002; 22:40–45 [E]
72. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria
A, Moore TJ, Johnson BT: Initial severity and an-
tidepressant benefits: a meta-analysis of data sub-mitted to the Food and Drug Administration. PLoSMed 2008; 5:e45 [E]
73. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian
S, Amsterdam JD, Shelton RC, Fawcett J: Antide-pressant drug effects and depression severity: a pa-tient-level meta-analysis. JAMA 2010; 303:47–53[E]
74. T urner EH, Matthews AM, Linardatos E, T ell RA,
Rosenthal R: Selective publication of antidepres-sant trials and its influence on apparent efficacy. NEngl J Med 2008; 358:252–260 [E]
75. T urner EH, Rosenthal R: Efficacy of antidepres-
sants. BMJ 2008; 336:516–517 [G]
76. Stearns V , Johnson MD, Rae JM, Morocho A,
Novielli A, Bhargava P , Hayes DF, Desta Z, Flock-hart DA: Active tamoxifen metabolite plasma con-centrations after coadministration of tamoxifen andthe selective serotonin reuptake inhibitor paroxe-tine. J Natl Cancer Inst 2003; 95:1758–1764 [G]
77. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH,
Skaar T, Storniolo AM, Li L, Araba A, BlanchardR ,  N g u y e n  A ,  U l l m e r  L ,  H a y d e n  J ,  L e m l e r  S ,Weinshilboum RM, Rae JM, Hayes DF, FlockhartDA: CYP2D6 genotype, antidepressant use, andtamoxifen metabolism during adjuvant breast can-cer treatment. J Natl Cancer Inst 2005; 97:30–39[G]
78. Hoskins JM, Carey LA, McLeod HL: CYP2D6 and
tamoxifen: DNA matters in breast cancer. Nat RevCancer 2009; 9:576–586 [F]
79. Desmarais JE, Looper KJ: Interactions between
tamoxifen and antidepressants via cytochrome P4502D6. J Clin Psychiatry 2009; 70:1688–1697 [F]
80. Goetz MP , Knox SK, Suman VJ, Rae JM, Safgren
SL, Ames MM, Visscher DW, Reynolds C, CouchFJ, Lingle WL, Weinshilboum RM, Fritcher EG,Nibbe AM, Desta Z, Nguyen A, Flockhart DA,Perez EA, Ingle JN: The impact of cytochromeP450 2D6 metabolism in women receiving adjuvanttamoxifen. Breast Cancer Res T reat 2007; 101:113–121 [D]
81. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M,
Pritchard KI, Austin PC, Paszat LF: Selective sero-tonin reuptake inhibitors and breast cancer mortal-ity in women receiving tamoxifen: a populationbased cohort study. BMJ 2010; 340:c693 [C]
82. Lexi-Comp: Lexi-Comp Online [database]. http:/
/www.lexi.com. Accessed Dec 13, 2008. [G]
83. Genelex: GeneMedRx [database]. http://www.
genemedrx.com. Accessed Dec 13, 2008. [G]
84. Cipriani A, Brambilla P , Furukawa T, Geddes J,
Gregis M, Hotopf M, Malvini L, Barbui C: Fluox-
etine versus other types of pharmacotherapy for
depression. Cochrane Database Syst Rev 2005;CD004185 [E]
85. Anderson IM: Selective serotonin reuptake inhibi-
tors versus tricyclic antidepressants: a meta-analysisof efficacy and tolerability. J Affect Disord 2000;58:19–36 [E]
86. Montgomery SA: A meta-analysis of the efficacy
and tolerability of paroxetine versus tricyclic anti-depressants in the treatment of major depression.Int Clin Psychopharmacol 2001; 16:169–178 [E]
87. Macgillivray S, Arroll B, Hatcher S, Ogston S, Reid
I, Sullivan F , Williams B, Crombie I: Efficacy andtolerability of selective serotonin reuptake inhibi-tors compared with tricyclic antidepressants in de-pression treated in primary care: systematic reviewand meta-analysis. BMJ 2003; 326:1014 [E]
88. Arroll B, Elley CR, Fishman T , Goodyear-Smith
FA, Kenealy T, Blashki G, Kerse N, Macgillivray S:Antidepressants versus placebo for depression inprimary care. Cochrane Database Syst Rev 2009;CD007954 [E]
89. Panzer MJ: Are SSRIs really more effective for
anxious depression? Ann Clin Psychiatry 2005;17:23–29 [F]
90. Geddes JR, Freemantle N, Mason J, Eccles MP ,
Boynton J: SSRIs versus other antidepressants fordepressive disorder. Cochrane Database Syst Rev2000; CD001851 [E]
91. Bauer M, Tharmanathan P , Volz HP , Moeller HJ,
Freemantle N: The effect of venlafaxine comparedwith other antidepressants and placebo in the treat-ment of major depression: a meta-analysis. EurArch Psychiatry Clin Neurosci 2009; 259:172–185[E]
92. Barbui C, Hotopf M, Freemantle N, Boynton J,
Churchill R, Eccles MP , Geddes JR, Hardy R,Lewis G, Mason JM: Selective serotonin reuptakeinhibitors versus tricyclic and heterocyclic antide-pressants: comparison of drug adherence. CochraneDatabase Syst Rev 2000; CD002791 [E]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
108 APA PRACTICE GUIDELINES
93. Kennedy SH, Andersen HF , Lam RW: Efficacy of
escitalopram in the treatment of major depressive
disorder compared with conventional selective se-rotonin reuptake inhibitors and venlafaxine XR: ameta-analysis. J Psychiatry Neurosci 2006; 31:122–131 [E]
94. Murdoch D, Keam SJ: Escitalopram: a review of its
use in the management of major depressive disor-der. Drugs 2005; 65:2379–2404 [F]
95. Gartlehner G, Gaynes BN, Hansen RA, Thieda P ,
DeVeaugh-Geiss A, Krebs EE, Moore CG, MorganL, Lohr KN: Comparative benefits and harms ofsecond-generation antidepressants: backgroundpaper for the American College of Physicians. Ann
Intern Med 2008; 149:734–750 [E]
96. Cipriani A, Furukawa TA, Salanti G, Geddes JR,
Higgins JP , Churchill R, Watanabe N, Nakagawa
A, Omori IM, McGuire H, T ansella M, Barbui C:Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatmentsmeta-analysis. Lancet 2009a; 373:746–758 [E]
97. Keller MB: Citalopram therapy for depression: a
review of 10 years of European experience and datafrom US clinical trials. J Clin Psychiatry 2000;61:896–908 [F]
98. Edwards JG, Anderson I: Systematic review and
guide to selection of selective serotonin reuptakeinhibitors. Drugs 1999; 57:507–533 [E]
99. Thase ME, Kornstein SG, Germain JM, Jiang Q,
Guico-Pabia C, Ninan PT: An integrated analysisof the efficacy of desvenlafaxine compared withplacebo in patients with major depressive disorder.CNS Spectr 2009; 14:144–154 [E]
100. Perahia DG, Pritchett YL, Kajdasz DK, Bauer M,
Jain R, Russell JM, Walker DJ, Spencer KA, FroudDM, Raskin J, Thase ME: A randomized, double-blind comparison of duloxetine and venlafaxine inthe treatment of patients with major depressivedisorder. J Psychiatr Res 2008; 42:22–34 [A]
101. Nemeroff CB, Entsuah R, Benattia I, Demitrack M,
Sloan DM, Thase ME: Comprehensive analysis ofremission (COMPARE) with venlafaxine versusSSRIs. Biol Psychiatry 2008; 63:424–434 [E]
102. Thase ME, Pritchett YL, Ossanna MJ, Swindle
RW, Xu J, Detke MJ: Efficacy of duloxetine andselective serotonin reupt ake inhibitors: compari-
sons as assessed by remission rates in patients withmajor depressive disorder. J Clin Psychopharmacol2007; 27:672–676 [E]
103. Papakostas GI, Fava M, Thase ME: T reatment of
SSRI-resistant depression: a meta-analysis compar-ing within- versus across-class switches. Biol Psy-chiatry 2008; 63:699–704 [E]
104. Smith D, Dempster C, Glanville J, Freemantle N,
Anderson I: Efficacy and tolerability of venlafaxinecompared with selective serotonin reuptake inhibi-tors and other antidepressants: a meta-analysis. BrJ Psychiatry 2002; 180:396–404 [E]
105. Agency for Healthcare Policy Research: Evidence
Report on T reatment of Depression—NewerPharmacotherapies. San Antonio Evidence-BasedPractice Center. Washington, DC, AHCPR, Evi-dence-Based Practice Centers, 1999 [F]
106. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM,
Pradko JF , Johnston JA: 15 years of clinical ex-perience with bupropion HCl: from bupropion tobupropion SR to bupropion XL. Prim Care Com-panion. J Clin Psychiatry 2005; 7:106–113 [F]
107. Papakostas GI, Stahl SM, Krishen A, Seifert CA,
T ucker VL, Goodale EP , Fava M: Efficacy of bu-
propion and the selective serotonin reuptake inhib-
itors in the treatment of major depressive disorderwith high levels of anxiety (anxious depression):a pooled analysis of 10 studies. J Clin Psychiatry2008; 69:1287–1292 [E]
108. Papakostas GI, Nutt DJ, Hallett LA, T ucker VL,
Krishen A, Fava M: Resolution of sleepiness andfatigue in major depressive disorder: a comparisonof bupropion and the selective serotonin reuptakeinhibitors. Biol Psychiatry 2006; 60:1350–1355 [E]
109. Hughes JR, Stead LF , Lancaster T: Antidepressants
for smoking cessation. Cochrane Database Syst Rev2007; CD000031 [E]
110. American Psychiatric Association: Practice Guide-
line for the T reatment of Patients With SubstanceUse Disorders, Second Edition. Am J Psychiatry2007; 164(April suppl):5–123 [G]
111. Li Z, Maglione M, T u W, Mojica W, Arterburn D,
Shugarman LR, Hilton L, Suttorp M, Solomon V ,Shekelle PG, Morton SC: Meta-analysis: pharma-cologic treatment of obesity. Ann Intern Med 2005;142:532–546 [E]
112. Artigas F, Nutt DJ, Shelton R: Mechanism of action
of antidepressants. Psychopharmacol Bull 2002;36(suppl 2):123–132 [F]
113. Papakostas GI, Homberger CH, Fava M: A meta-
analysis of clinical trials comparing mirtazapinewith selective serotonin reuptake inhibitors for thetreatment of major depressive disorder. J Psycho-pharmacol 2008; 22:843-848 [E]
114. Schatzberg AF: T razodone: a 5-year review of anti-
depressant efficacy. Psychopathology 1987; 20(sup-pl 1):48–56 [F]
115. Cunningham LA, Borison RL, Carman JS, Choui-
nard G, Crowder JE, Diamond BI, Fischer DE,Hearst E: A comparison of venlafaxine, trazodone,and placebo in major depression. J Clin Psycho-pharmacol 1994; 14:99–106 [A]
116. Papakostas GI, Fava M: A meta-analysis of clinical
trials comparing the serotonin (5HT)-2 receptorantagonists trazodone and nefazodone with selec-tive serotonin reuptake inhibitors for the treatment
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 109
of major depressive disorder. Eur Psychiatry 2007;
22:444–447 [E]
117. Anderson IM: SSRIs versus tricyclic antidepres-
sants in depressed inpatients: a meta-analysis ofefficacy and tolerability. Depress Anxiety 1998;7(suppl 1):11–17 [E]
118. Barbui C, Hotopf M: Amitriptyline v the rest: still
the leading antidepressant after 40 years of ran-domised controlled trials. Br J Psychiatry 2001;178:129–144 [E]
119. Thase ME, T rivedi MH, Rush AJ: MAOIs in the
contemporary treatment of depression. Neuropsy-chopharmacology 1995; 12:185–219 [E]
120. Quitkin F, Rifkin A, Klein DF: Monoamine oxidase
inhibitors: a review of antidepressant effectiveness.Arch Gen Psychiatry 1979; 36:749–760 [A]
121. McGrath PJ, Stewart JW, Fava M, T rivedi MH,
Wisniewski SR, Nierenberg AA, Thase ME, DavisL, Biggs MM, Shores-Wilson K, Luther JF, Nie-derehe G, Warden D, Rush AJ: Tranylcypromineversus venlafaxine plus mirtazapine following threefailed antidepressant medication trials for depres-sion: a STAR*D report. Am J Psychiatry 2006;163:1531–1541 [A]
122. Henkel V , Mergl R, Allgaier AK, Kohnen R, Moller
HJ, Hegerl U: T reatment of depression with atyp-ical features: a meta-analytic approach. PsychiatryRes 2006; 141:89–101 [E]
123. Robinson DS, Gilmor ML, Yang Y, Moonsammy
G, Azzaro AJ, Oren DA, Campbell BJ: T reatmenteffects of selegiline transdermal system on symp-toms of major depressive disorder: a meta-analysisof short-term, placebo-controlled, efficacy trials.Psychopharmacol Bull 2007; 40:15–28 [E]
124. Amsterdam JD: A double-blind, placebo-controlled
trial of the safety and efficacy of selegiline transder-mal system without dietary restrictions in patientswith major depressive disorder. J Clin Psychiatry2003; 64:208–214 [A]
125. Feiger AD, Rickels K, Rynn MA, Zimbroff DL,
Robinson DS: Selegiline transdermal system for thetreatment of major depressive disorder: an 8-week,double-blind, placebo-controlled, flexible-dose ti-tration trial. J Clin Psychiatry 2006; 67:1354–1361[A]
126. Cipriani A, La Ferla T, Furukawa TA, Signoretti A,
Nakagawa A, Churchill R, McGuire H, Barbui C:Sertraline versus other antidepressive agents fordepression. Cochrane Database Syst Rev 2009b;CD006117 [E]
127. Power BM, Hackett LP , Dusci LJ, Ilett KF: Anti-
depressant toxicity and the need for identificationand concentration monitoring in overdose. ClinPharmacokinet 1995; 29:154–171 [F]
128. Zemrak WR, Kenna GA: Association of antipsychot-
ic and antidepressant drugs with Q-T interval pro-longation. Am J Health Syst Pharm 2008; 65:1029–1038 [F]
129. Caley CF: Extrapyramidal reactions and the selec-
tive serotonin-reuptake inhibitors. Ann Pharmaco-ther 1997; 31:1481–1489 [F]
130. Walker PW, Cole JO, Gardner EA, Hughes AR,
Johnston JA, Batey SR, Lineberry CG: Improve-ment in fluoxetine-associated sexual dysfunction inpatients switched to bupropion. J Clin Psychiatry1993; 54:459–465 [B]
131. Landen M, Eriksson E, Agren H, Fahlen T: Effect
of buspirone on sexual dysfunction in depressedpatients treated with selective serotonin reuptakeinhibitors. J Clin Psychopharmacol 1999; 19:268–
271 [A]
132. Clayton AH, Warnock JK, Kornstein SG, Pinker-
ton R, Sheldon-Keller A, McGarvey EL: A placebo-
controlled trial of bupropion SR as an antidote forselective serotonin reuptake inhibitor-induced sex-ual dysfunction. J Clin Psychiatry 2004; 65:62–67[A]
133. Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M,
Lauriello J, Paine S: T reatment of antidepressant-associated sexual dysfunction with sildenafil: a ran-domized controlled trial. JAMA 2003; 289:56–64[A]
134. Segraves RT , Lee J, Stevenson R, Walker DJ, Wang
WC, Dickson RA: T adalafil for treatment of erectiledysfunction in men on antidepressants. J Clin Psy-chopharmacol 2007; 27:62–66 [B]
135. Balon R, Segraves RT: Survey of treatment practic-
es for sexual dysfunction(s) associated with anti-depressants. J Sex Marital Ther 2008; 34:353–365[G]
136. Segraves RT: Sexual dysfunction associated with
antidepressant therapy. Urol Clin North Am 2007;34:575–579, vii [F]
137. Hamilton JA, Halbreich U: Special aspects of neu-
ropsychiatric illness in women: with a focus ondepression. Annu Rev Med 1993; 44:355–364 [F]
138. Doughty MJ, Lyle WM: Medications used to pre-
vent migraine headaches and their potential ocularadverse effects. Optom Vis Sci 1995; 72:879–891 [F]
139. Leo RJ: Movement disorders associated with the
serotonin selective reuptake inhibitors. J Clin Psy-chiatry 1996; 57:449–454 [E]
140. Gerber PE, Lynd LD: Selective serotonin-reuptake
inhibitor-induced movement disorders. Ann Phar-macother 1998; 32:692–698 [E]
141. Thapa PB, Gideon P , Cost TW, Milam AB, Ray
WA: Antidepressants and the risk of falls amongnursing home residents. N Engl J Med 1998;339:875–882 [C]
142. Arfken CL, Wilson JG, Aronson SM: Retrospective
review of selective serotonin reuptake inhibitors
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
110 APA PRACTICE GUIDELINES
and falling in older nursing home residents. Int
Psychogeriatr 2001; 13:85–91 [D]
143. Ensrud KE, Blackwell TL, Mangione CM, Bow-
man PJ, Whooley MA, Bauer DC, Schwartz AV ,Hanlon JT, Nevitt MC: Central nervous system-active medications and risk for falls in older women.
J Am Geriatr Soc 2002; 50:1629–1637 [C]
144. Sterke CS, Verhagen AP , van Beeck EF, van der
Cammen TJ: The influence of drug use on fallincidents among nursing home residents: a system-atic review. Int Psychogeriatr 2008; 20:890–910 [E]
145. Hartikainen S, Lonnroos E, Louhivuori K: Medi-
cation as a risk factor for falls: critical systematicreview. J Gerontol A Biol Sci Med Sci 2007;
62:1172–1181 [E]
146. Mezuk B, Eaton WW, Golden SH: Depression and
osteoporosis: epidemiology and potential mediat-
ing pathways. Osteoporos Int 2008; 19:1–12 [F]
147. Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley
JA, Barrett-Connor E, Orwoll E, Bliziotes MM:Association of low bone mineral density with selec-tive serotonin reuptake inhibitor use by older men.Arch Intern Med 2007; 167:1246–1251 [G]
148. Diem SJ, Blackwell TL, Stone KL, Yaffe K, Haney
EM, Bliziotes MM, Ensrud KE: Use of antidepres-sants and rates of hip bone loss in older women: thestudy of osteoporotic fractures. Arch Intern Med2007; 167:1240–1245 [C]
149. Ensrud KE, Blackwell T, Mangione CM, Bowman
PJ, Bauer DC, Schwartz A, Hanlon JT, Nevitt MC,Whooley MA: Central nervous system active med-ications and risk for fractures in older women. ArchIntern Med 2003; 163:949–957 [C]
150. Isbister GK, Prior FH, Foy A: Citalopram-induced
bradycardia and presyn cope. Ann Pharmacother
2001; 35:1552–1555 [G]
151. Allain H, Bentue-Ferrer D, Polard E, Akwa Y, Patat
A: Postural instability and consequent falls and hipfractures associated with use of hypnotics in theelderly: a comparative review. Drugs Aging 2005;22:749–765 [E]
152. Oliver D, Connelly JB, Victor CR, Shaw FE,
Whitehead A, Genc Y, Vanoli A, Martin FC, Gos-ney MA: Strategies to prevent falls and fractures inhospitals and care homes and effect of cognitiveimpairment: systematic review and meta-analyses.BMJ 2007; 334:82 [E]
153. Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ: Will
my patient fall? JAMA 2007; 297:77–86 [E]
154. Papakostas GI: Limitations of contemporary anti-
depressants: tolerability. J Clin Psychiatry 2007;68(suppl 10):11–17 [G]
155. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC:
Fluoxetine versus sertraline and paroxetine in majordepressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000; 61:863–867[A]
156. Michelson D, Amsterdam JD, Quitkin FM, Reim-
herr FW, Rosenbaum JF, Zajecka J, Sundell KL,Kim Y, Beasley CM Jr: Changes in weight during a1-year trial of fluoxetine. Am J Psychiatry 1999;156:1170–1176 [A]
157. Boyer EW, Shannon M: The serotonin syndrome.
N Engl J Med 2005; 352:1112–1120 [F]
158. Sola CL, Bostwick JM, Hart DA, Lineberry TW:
Anticipating potential linezolid-SSRI interactionsin the general hospital setting: an MAOI in disguise.Mayo Clin Proc 2006; 81:330–334 [G]
159. Huang V , Gortney JS: Risk of serotonin syndrome
with concomitant administration of linezolid andserotonin agonists. Pharmacotherapy 2006; 26:1784–1793 [G]
160. Sandson NB, Armstrong SC, Cozza KL: An over-
view of psychotropic drug-drug interactions. Psy-chosomatics 2005; 46:464–494 [F]
161. Armstrong SC, Cozza KL, Sandson NB: Six pat-
terns of drug-drug interactions. Psychosomatics2003; 44:255–258 [F]
162. Beasley CM Jr, Masica DN, Heiligenstein JH,
Wheadon DE, Zerbe RL: Possible monoamineoxidase inhibitor-serotonin uptake inhibitor in-teraction: fluoxetine clinical data and preclinicalfindings. J Clin Psychopharmacol 1993; 13:312–320 [F]
163. Fava M: Prospective studies of adverse events relat-
ed to antidepressant discontinuation. J Clin Psychi-atry 2006; 67(suppl 4):14–21 [G]
164. T aylor D, Stewart S, Connolly A: Antidepressant
withdrawal symptoms—telephone calls to a nationalmedication helpline. J Affect Disord 2006; 95:129–133 [G]
165. Schatzberg AF, Blier P , Delgado PL, Fava M, Had-
dad PM, Shelton RC: Antidepressant discontinua-tion syndrome: consensus panel recommendationsfor clinical management and additional research.J Clin Psychiatry 2006; 67(suppl 4):27–30 [G]
166. Thase ME: Effects of venlafaxine on blood pres-
sure: a meta-analysis of original data from 3744depressed patients. J Clin Psychiatry 1998; 59:502–508 [E]
167. Thase ME, T ran PV , Wiltse C, Pangallo BA,
Mallinckrodt C, Detke MJ: Cardiovascular profileof duloxetine, a dual reuptake inhibitor of serotoninand norepinephrine. J Clin Psychopharmacol 2005;25:132–140 [E]
168. Clayton AH, Kornstein SG, Rosas G, Guico-Pabia
C, T ourian KA: An integrated analysis of the safetyand tolerability of desvenlafaxine compared withplacebo in the treatment of major depressive disor-der. CNS Spectr 2009; 14:183–195 [E]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 111
169. Thase ME, Haight BR, Richard N, Rockett CB,
Mitton M, Modell JG, VanMeter S, Harriett AE,
Wang Y: Remission rates following antidepressanttherapy with bupropion or selective serotonin re-uptake inhibitors: a meta-analysis of original datafrom 7 randomized controlled trials. J Clin Psychi-atry 2005; 66:974–981 [E]
170. American Psychiatric Association: Practice Guide-
line for the T reatment of Patients With EatingDisorders, Third Edition. Am J Psychiatry 2006;163(July suppl):4–54 [G]
171. Davis R, Wilde MI: Mirtazapine: a review of its
pharmacology and therapeutic potential in themanagement of major depression. CNS Drugs
1996; 5:389–402 [F]
172. Szegedi A, Schwertfeger N: Mirtazapine: a review
of its clinical efficacy and tolerability. Expert Opin
Pharmacother 2005; 6:631–641 [F]
173. Mendelson WB: A review of the evidence for the
efficacy and safety of trazodone in insomnia. J ClinPsychiatry 2005; 66:469–476 [F]
174. Thompson JW Jr, Ware MR, Blashfield RK: Psy-
chotropic medication and priapism: a comprehen-sive review. J Clin Psychiatry 1990; 51:430–433 [F]
175. Jayaram G, Rao P: Safety of trazodone as a sleep
agent for inpatients. Psychosomatics 2005; 46:367–369 [G]
176. Schatzberg AF, Prather MR, Keller MB, Rush AJ,
Laird LK, Wright CW: Clinical use of nefazodonein major depression: a 6-year perspective. J ClinPsychiatry 2002; 63(suppl 1):18–31 [F]
177. Rush AJ, Armitage R, Gillin JC, Yonkers KA, Wi-
nokur A, Moldofsky H, Vogel GW, Kaplita SB,Fleming JB, Montplaisir J, Erman MK, Albala BJ,McQuade RD: Comparative effects of nefazodone
and fluoxetine on sleep in outpatients with majordepressive disorder. Biol Psychiatry 1998; 44:3–14[A]
178. Feiger A, Kiev A, Shrivastava RK, Wisselink PG,
Wilcox CS: Nefazodone versus sertraline in outpa-tients with major depressi on: focus on efficacy, tol-
erability, and effects on  sexual function and
satisfaction. J Clin Psychiatry 1996; 57(suppl 2):53–62 [A]
179. Ferguson JM, Shrivastava RK, Stahl SM, Hartford
JT , Borian F , Ieni J, McQuade RD, Jody D: Reemer-gence of sexual dysfunction in patients with majordepressive disorder: double-blind comparison ofnefazodone and sertraline. J Clin Psychiatry 2001;62:24–29 [A]
180. Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni
S, Atherton J, Mireles R, Feng B, Kubik R, HansonJ, Urda E, Mutlib AE: Inhibition of hepatobiliarytransport as a predictive method for clinical hepa-totoxicity of nefazodone. T oxicol Sci 2006; 90:451–459 [G]181. DeSanty KP , Amabile CM: Antidepressant-induced
liver injury. Ann Pharmacother 2007; 41:1201–1211[F]
182. Miller MD, Curtiss EI, Marino L, Houck PR,
Paradis CF, Mazumdar S, Pollock BG, Foglia J,Reynolds CF III: Long-term ECG changes in de-pressed elderly patients treated with nortriptyline.A double-blind, randomized, placebo-controlledevaluation. Am J Geriatr Psychiatry 1998; 6:59–66[A]
183. Roden DM: Antiarrhythmic drugs, in Goodman
and Gilman’s The Pharmaco logical Basis of Ther-
apeutics. Edited by Brunton LL, Lazo JS, ParkerKL. New York, McGraw-Hill, 2006, pp 899–932
[G]
184. Schwartz PJ, Wolf S: QT interval prolongation as
predictor of sudden death in patients with myocar-
dial infarction. Circulation 1978; 57:1074–1077 [G]
185. Roose SP , Glassman AH, Giardina EG, Walsh BT,
Woodring S, Bigger JT: T ricyclic antidepressants indepressed patients with cardiac conduction disease.Arch Gen Psychiatry 1987; 44:273–275 [A]
186. Roose SP , Miyazaki M: Pharmacologic treatment of
depression in patients with heart disease. Psycho-som Med 2005; 67(suppl 1):S54–S57 [F]
187. Vieweg WV , Wood MA: T ricyclic antidepressants,
QT interval prolongation, and torsade de pointes.Psychosomatics 2004; 45:371–377 [F]
188. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas
SH: QT c-interval abnormalities and psychotropicdrug therapy in psychiatric patients. Lancet 2000;355:1048–1052 [D]
189. Roose SP , Laghrissi-Thode F , Kennedy JS, Nelson
JC, Bigger JT Jr, Pollock BG, Gaffney A, NarayanM, Finkel MS, McCafferty J, Gergel I: Comparisonof paroxetine and nortriptyline in depressed pa-tients with ischemic heart disease. JAMA 1998;279:287–291 [A]
190. Harrigan RA, Brady WJ: ECG abnormalities in
tricyclic antidepressant ingestion. Am J Emerg Med1999; 17:387–393 [F]
191. Thanacoody HK, Thomas SH: T ricyclic antide-
pressant poisoning: cardiovascular toxicity. T oxicolRev 2005; 24:205–214 [F]
192. Joo JH, Lenze EJ, Mulsant BH, Begley AE, Weber
EM, Stack JA, Mazumdar S, Reynolds CF III, Pol-lock BG: Risk factors for falls during treatment oflate-life depression. J Clin Psychiatry 2002; 63:936–941 [C]
193. Baldessarini RJ: Drug therapy of depression and
anxiety disorders, in G oodman and Gilman’s The
Pharmacological Basis of Therapeutics. Editedby Brunton LL, Lazo JS, Parker KL. New York,McGraw-Hill, 2006, pp 429–460 [G]
194. Preskorn SH, Jerkovich GS: Central nervous sys-
tem toxicity of tricyclic antidepressants: phenome-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
112 APA PRACTICE GUIDELINES
nology, course, risk factors,  and role of therapeutic
drug monitoring. J Clin Psychopharmacol 1990;
10:88–95 [E]
195. Deshmukh R, Franco K: Managing weight gain as
a side effect of antidepressant therapy. Cleve Clin JMed 2003; 70:614, 616, 618, passim [G]
196. Garvey MJ, T ollefson GD: Occurrence of myoclo-
nus in patients treated with cyclic antidepressants.Arch Gen Psychiatry 1987; 44:269–272 [E]
197. Ruffmann C, Bogliun G, Beghi E: Epileptogenic
drugs: a systematic review. Expert Rev Neurother2006; 6:575–589 [E]
198. Hayes PE, Kristoff CA: Adverse reactions to five
new antidepressants. Clin Pharm 1986; 5:471–480
[F]
199. Gupta V , Lipsitz LA: Orthostatic hypotension in
the elderly: diagnosis and treatment. Am J Med
2007; 120:841–847 [F]
200. Nelson JC: T ricyclic and tetracyclic drugs, in Essen-
tials of Clinical Psychopharmacology, 2nd ed. Editedby Schatzberg AF, Nemeroff CB. Arlington, VA,American Psychiatric Publishing, 2006, pp 5–29 [G]
201. Perry PJ, Zeilmann C, Arndt S: T ricyclic antidepres-
sant concentrations in plasma: an estimate of theirsensitivity and specificity as a predictor of response.J Clin Psychopharmacol 1994; 14:230–240 [E]
202. Rapaport MH: Dietary restrictions and drug inter-
actions with monoamine oxidase inhibitors: thestate of the art. J Clin Psychiatry 2007; 68(suppl 8):42–46 [G]
203. Gardner DM, Shulman KI, Walker SE, T ailor SA:
The making of a user friendly MAOI diet. J ClinPsychiatry 1996; 57:99–104 [F]
204. Stahl SM, Felker A: Monoamine oxidase inhibitors:
a modern guide to an unrequited class of antidepres-sants. CNS Spectr 2008; 13:855–870 [F]
205. Feighner JP , Herbstein J, Damlouji N: Combined
MAOI, TCA, and direct stimulant therapy of treat-ment-resistant depression. J Clin Psychiatry 1985;46:206–209 [G]
206. Fawcett J, Kravitz HM, Zajecka JM, Schaff MR:
CNS stimulant potentiation of monoamine oxidaseinhibitors in treatment-refractory depression. J ClinPsychopharmacol 1991; 11:127–132 [B]
207. Culpepper L, Kovalick LJ: A review of the literature
on the selegiline transdermal system: an effectiveand well-tolerated monoamine oxidase inhibitor forthe treatment of depression. Prim Care CompanionJ Clin Psychiatry 2008; 10:25–30 [F]
208. Robinson DS, Amsterdam JD: The selegiline trans-
dermal system in major depressive disorder: a sys-tematic review of safety and tolerability. J AffectDisord 2008; 105:15–23 [E]
209. Schenk CH, Remick RA: Sublingual nifedipine in
the treatment of hypertensive crisis associated withmonoamine oxidase inhibitors. Ann Emerg Med1989; 18:114–115 [B]
210. Grossman E, Messerli FH, Grodzicki T , Kowey P:
Should a moratorium be placed on sublingualnifedipine capsules given for hypertensive emer-gencies and pseudoemergencies? JAMA 1996;276:1328–1331 [F]
211. Sternbach H: The serotonin syndrome. Am J Psy-
chiatry 1991; 148:705–713 [F]
212. Amsterdam JD, Bodkin JA: Selegiline transdermal
system in the prevention of relapse of major depres-sive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psy-chopharmacol 2006; 26:579–586 [A]
213. Clayton AH, Campbell BJ, Favit A, Yang Y, Moon-
sammy G, Piontek CM, Amsterdam JD: Symptomsof sexual dysfunction in patients treated for majordepressive disorder: a meta-analysis comparing sel-egiline transdermal system and placebo using a pa-tient-rated scale. J Clin Psychiatry 2007; 68:1860–1866 [E]
214. Katz MM, Koslow SH, Maas JW, Frazer A, Bowden
CL, Casper R, Croughan J, Kocsis J, Redmond EJr: The timing, specificity and clinical prediction oftricyclic drug effects in depression. Psychol Med1987; 17:297–309 [C]
215. T aylor MJ, Freemantle N, Geddes JR, Bhagwagar
Z: Early onset of selective serotonin reuptake inhib-itor antidepressant action: systematic review andmeta-analysis. Arch Gen Psychiatry 2006; 63:1217–1223 [E]
216. Posternak MA, Zimmerman M: Therapeutic effect
of follow-up assessments on antidepressant and pla-cebo response rates in antidepressant efficacy trials:meta-analysis. Br J Psychiatry 2007; 190:287–292[E]
217. Nierenberg AA, McLean NE, Alpert JE, Worthing-
ton JJ, Rosenbaum JF , Fava M: Early nonresponseto fluoxetine as a predictor of poor 8-week outcome.Am J Psychiatry 1995; 152:1500–1503 [B]
218. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon
J, Worthington JJ, Rosenbaum JF , Fava M: Timingof onset of antidepressant response with fluoxetinetreatment. Am J Psychiatry 2000; 157:1423–1428[B]
219. Szegedi A, Muller MJ, Anghelescu I, Klawe C,
Kohnen R, Benkert O: Early improvement undermirtazapine and paroxetine predicts later stable
response and remission with high sensitivity in pa-
tients with major depression. J Clin Psychiatry2003; 64:413–420 [A]
220. Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi
A: Is there a common resilience mechanism under-lying antidepressant drug response? Evidence from2848 patients. J Clin Psychiatry 2007; 68:1195–1205 [G]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 113
221. Quitkin FM, Rabkin JG, Ross D, McGrath PJ:
Duration of antidepressant drug treatment. What
is an adequate trial? Arch Gen Psychiatry 1984;41:238–245 [G]
222. Quitkin FM, Rabkin JD, Markowitz JM, Stewart
JW, McGrath PJ, Harrison W: Use of pattern anal-ysis to identify true drug response: a replication.Arch Gen Psychiatry 1987; 44:259–264 [A]
223. T rivedi MH, Morris DW, Pan JY, Grannemann
BD, Rush AJ: What moderator characteristics areassociated with better prognosis for depression?Neuropsychiatric Disease and T reatment 2005;1:51–57 [G]
224. T rivedi MH, Rush AJ, Wisniewski SR, Nierenberg
AA, Warden D, Ritz L, Norquist G, Howland RH,Lebowitz B, McGrath PJ, Shores-Wilson K, BiggsMM, Balasubramani GK, Fava M: Evaluation ofoutcomes with citalopram for depression usingmeasurement-based care in STAR*D: implicationsfor clinical practice. Am J Psychiatry 2006; 163:28–40 [B]
225. Keller MB, Gelenberg AJ, Hirschfeld RM, Rush AJ,
Thase ME, Kocsis JH, Markowitz JC, Fawcett JA,Koran LM, Klein DN, Russell JM, Kornstein SG,McCullough JP , Davis SM, Harrison WM: Thetreatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipra-mine. J Clin Psychiatry 1998; 59:598–607 [A]
226. Keller MB, T rivedi MH, Thase ME, Shelton RC,
Kornstein SG, Nemeroff CB, Friedman ES, Gelen-berg AJ, Kocsis JH, Dunner DL, Hirschfeld RM,Rothschild AJ, Ferguson JM, Schatzberg AF , Zajec-ka JM, Pedersen RD, Yan B, Ahmed S, MusgnungJ, Ninan PT: The Prevention of Recurrent Episodesof Depression with Venlafaxine for T wo Years(PREVENT) Study: outcomes from the 2-year andcombined maintenance phases. J Clin Psychiatry2007; 68:1246–1256 [A]
227. Rush AJ, T rivedi MH, Wisniewski SR, Nierenberg
AA, Stewart JW, Warden D, Niederehe G, ThaseME, Lavori PW, Lebowitz BD, McGrath PJ,Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J,Fava M: Acute and longer-term outcomes indepressed outpatients requiring one or severaltreatment steps: a STAR*D report. Am J Psychiatry2006; 163:1905–1917 [A–]
228. Eap CB, Jaquenoud SE, Baumann P: Therapeutic
monitoring of antidepressants in the era of pharma-cogenetics studies. Ther Drug Monit 2004; 26:152–155 [F]
229. Malhotra AK, Murphy GM Jr, Kennedy JL: Phar-
macogenetics of psychotropic drug response. Am JPsychiatry 2004; 161:780–796 [F]
230. Lepine JP , Caillard V , Bisserbe JC, T roy S, Hotton
JM, Boyer P: A randomized, placebo-controlledtrial of sertraline for prophylactic treatment ofhighly recurrent major depressive disorder. Am JPsychiatry 2004; 161:836–842 [A]
231. Burke WJ, Gergel I, Bose A: Fixed-dose trial of the
single isomer SSRI escitalopram in depressed out-patients. J Clin Psychiatry 2002; 63:331–336 [A]
232. Preskorn SH, Dorey RC, Jerkovich GS: Therapeu-
tic drug monitoring of tricyclic antidepressants.Clin Chem 1988; 34:822–828 [F]
233. Ulrich S, Lauter J: Comprehensive survey of the
relationship between serum concentration andtherapeutic effect of amitriptyline in depression.Clin Pharmacokinet 2002; 41:853–876 [E]
234. Kellner CH, Knapp RG, Petrides G, Rummans TA,
Husain MM, Rasmussen K,  Mueller M, Bernstein
HJ, O’Connor K, Smith G, Biggs M, Bailine SH,Malur C, Yim E, McClintock S, Sampson S, FinkM: Continuation electroconvulsive therapy vs phar-macotherapy for relapse prevention in major de-pression: a multisite study from the Consortium forResearch in Electroconvulsive Therapy (CORE).Arch Gen Psychiatry 2006; 63:1337–1344 [A −]
235. UK ECT Group: Efficacy and safety of electrocon-
vulsive therapy in depressive disorders: a systematicreview and meta-analysis. Lancet 2003; 361:799–808 [E]
236. Greenhalgh J, Knight C, Hind D, Beverley C,
Walters S: Clinical and cost-effectiveness of elec-troconvulsive therapy for depressive illness, schizo-phrenia, catatonia and mania: systematic reviewsand economic modelling studies. Health T echnolAssess 2005; 9:1-iv [E]
237. Prudic J, Olfson M, Marcus SC, Fuller RB, Sackeim
HA: Effectiveness of electroconvulsive therapy incommunity settings. Biol Psychiatry 2004; 55:301–312 [B]
238. McCall WV , Prudic J, Olfson M, Sackeim H:
Health-related quality of life following ECT in alarge community sample. J Affect Disord 2006;90:269–274 [B]
239. American Psychiatric Association: The Practice of
Electroconvulsive Therapy: Recommendations forT reatment, T raining, and Privileging (A T ask ForceReport of the American Ps ychiatric Association),
Second Edition. Washington, DC, American Psy-chiatric Association, 2001 [B]
240. Husain MM, Rush AJ, Fink M, Knapp R, Petrides
G, Rummans T, Biggs MM, O’Connor K, Rasmus-sen K, Litle M, Zhao W, Bernstein HJ, Smith G,Mueller M, McClintock SM, Bailine SH, KellnerCH: Speed of response and remission in majordepressive disorder with acute electroconvulsivetherapy (ECT): a Consortium for Research in ECT(CORE) report. J Clin Psychiatry 2004; 65:485–491[B]
241. Petrides G, Fink M, Husain MM, Knapp RG, Rush
AJ, Mueller M, Rummans TA, O’Connor KM, Ras-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
114 APA PRACTICE GUIDELINES
mussen KG Jr, Bernstein HJ, Biggs M, Bailine SH,
Kellner CH: ECT remission rates in psychotic ver-sus nonpsychotic depressed patients: a report fromCORE. J ECT 2001; 17:244–253 [B]
242. Bush G, Fink M, Petrides G, Dowling F, Francis A:
Catatonia. II. T reatment with lorazepam and elec-troconvulsive therapy. Acta Psychiatr Scand 1996;93:137–143 [B]
243. Kellner CH, Fink M, Knapp R, Petrides G, Husain
M, Rummans T, Mueller M, Bernstein H, Rasmus-sen K, O’Connor K, Smith G, Rush AJ, Biggs M,McClintock S, Bailine S, Malur C: Relief of ex-pressed suicidal intent by ECT: a consortium forresearch in ECT study. Am J Psychiatry 2005;
162:977–982 [B]
244. Abrams R: The mortality rate with ECT. Convuls
Ther 1997; 13:125–127 [G]
245. Nuttall GA, Bowersox MR, Douglass SB, Mc-
Donald J, Rasmussen LJ, Decker PA, Oliver WC Jr,
Rasmussen KG: Morbidity and mortality in the useof electroconvulsive therapy. J ECT 2004; 20:237–241 [G]
246. Sackeim HA, Portnoy S, Neeley P , Steif BL, Decina
P , Malitz S: Cognitive consequences of low-dosageelectroconvulsive therapy. Ann N Y Acad Sci 1986;462:326–340 [F]
247. Lisanby SH: Electroconvulsive therapy for depres-
sion. N Engl J Med 2007; 357:1939–1945 [F]
248. Lisanby SH, Maddox JH, Prudic J, Devanand DP ,
Sackeim HA: The effects of electroconvulsive ther-apy on memory of autobiographical and publicevents. Arch Gen Psychiatry 2000; 57:581–590 [A]
249. Squire LR, Slater PC, Miller PL: Retrograde am-
nesia and bilateral electroconvulsive therapy. Long-term follow-up. Arch Gen Psychiatry 1981; 38:89–95 [C]
250. Weiner RD, Rogers HJ, Davidson JR, Squire LR:
Effects of stimulus parameters on cognitive sideeffects. Ann N Y Acad Sci 1986; 462:315–325 [B]
251. Sobin C, Sackeim HA, Prudic J, Devanand DP ,
Moody BJ, McElhiney MC: Predictors of retro-grade amnesia following ECT. Am J Psychiatry1995; 152:995–1001 [A]
252. Sackeim HA, Prudic J, Fuller R, Keilp J, Lavori PW,
Olfson M: The cognitive effects of electroconvul-sive therapy in community settings. Neuropsycho-pharmacology 2007; 32:244–254 [B]
253. Sackeim HA, Prudic J, Devanand DP , Kiersky JE,
Fitzsimons L, Moody BJ, McElhiney MC, Cole-man EA, Settembrino JM: Effects of stimulus in-tensity and electrode placement on the efficacy andcognitive effects of electroconvulsive therapy. N EnglJ Med 1993; 328:839–846 [A]
254. Rose D, Fleischmann P , Wykes T, Leese M, Bind-
man J: Patients’ perspectives on electroconvulsivetherapy: systematic review. BMJ 2003; 326:1363 [E]255. Donahue AB: Electroconvulsive therapy and mem-
ory loss: a personal journey. J ECT 2000; 16:133–143 [G]
256. Prudic J, Peyser S, Sackeim HA: Subjective memory
complaints: a review of patient self-assessment ofmemory after electroconvulsive therapy. J ECT2000; 16:121–132 [F]
257. T aylor T avares JV , Clark L, Cannon DM, Erickson
K, Drevets WC, Sahakian BJ: Distinct profiles ofneurocognitive function in unmedicated unipolardepression and bipolar II depression. Biol Psychia-try 2007; 62:917–924 [D]
258. Bearden CE, Glahn DC, Monkul ES, Barrett J, Najt
P , Villarreal V , Soares JC: Patterns of memory im-
pairment in bipolar disorder and unipolar major
depression. Psychiatry Res 2006; 142:139–150 [D]
259. Baghai TC, Marcuse A, Brosch M, Schule C, Eser
D, Nothdurfter C, Steng Y, Noack I, PietschmannK, Moller HJ, Rupprecht R: The influence ofconcomitant antidepressant medication on safety,tolerability and clinical effectiveness of electrocon-vulsive therapy. World J Biol Psychiatry 2006; 7:82–90 [B]
260. Kellner CH, Bourgon LN: Combining ECT and
antidepressants: time to reassess. J ECT 1998; 14:65–67 [G]
261. Naguib M, Koorn R: Interactions between psycho-
tropics, anaesthetics and electroconvulsive therapy:implications for drug choice and patient manage-ment. CNS Drugs 2002; 16:229–247 [F]
262. Dolenc TJ, Rasmussen KG: The safety of electro-
convulsive therapy and lithium in combination: acase series and review of the literature. J ECT 2005;21:165–170 [F]
263. Pettinati HM, Stephens SM, Willis KM, Robin SE:
Evidence for less improvement in depression inpatients taking benzodiazepines during unilateralECT. Am J Psychiatry 1990; 147:1029–1035 [B]
264. Krystal AD, Dean MD, Weiner RD, Tramontozzi
LA III, Connor KM, Lindahl VH, Massie RW:ECT stimulus intensity: are present ECT devicestoo limited? Am J Psychiatry 2000; 157:963–967[G]
265. Lerer B, Shapira B, Calev A, T ubi N, Drexler H,
Kindler S, Lidsky D, Schwartz JE: Antidepressantand cognitive effects of twice- versus three-times-weekly ECT. Am J Psychiatry 1995; 152:564–570[A]
266. Hales RE, Yudofsky SC, Gabbard GO: The Amer-
ican Psychiatric Publishing T extbook of Psychiatry,5th ed. Arlington, VA, American Psychiatric Pub-lishing, 2008 [G]
267. Prudic J: Strategies to minimize cognitive side ef-
fects with ECT: aspects of ECT technique. J ECT
2008; 24:46–51 [F]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 115
268. O’Reardon JP , Solvason HB, Janicak PG, Sampson
S, Isenberg KE, Nahas Z, McDonald WM, Avery
D, Fitzgerald PB, Loo C, Demitrack MA, GeorgeMS, Sackeim HA: Efficacy and safety of transcranialmagnetic stimulation in the acute treatment of ma-jor depression: a multisite randomized controlledtrial. Biol Psychiatry 2007; 62:1208–1216 [A]
269. Herwig U, Fallgatter AJ, Hoppner J, Eschweiler
GW, Kron M, Hajak G, Padberg F , Naderi-HeidenA, Abler B, Eichhammer P , Grossheinrich N, HayB, Kammer T, Langguth B, Laske C, Plewnia C,Richter MM, Schulz M, Unterecker S, Zinke A,Spitzer M, Schonfeldt-Lecuona C: Antidepressanteffects of augmentative transcranial magnetic stim-
ulation: randomised multicentre trial. Br J Psychi-
atry 2007; 191:441–448 [A]
270. Lam RW, Chan P , Wilkins-Ho M, Yatham LN:
Repetitive transcranial magnetic stimulation fortreatment-resistant depression: a systematic reviewand metaanalysis. Can J Psychiatry 2008; 53:621–631 [E]
271. Herrmann LL, Ebmeier KP: Factors modifying the
efficacy of transcranial ma gnetic stimulation in the
treatment of depression: a review. J Clin Psychiatry2006; 67:1870–1876 [E]
272. Schutter DJ: Antidepressant efficacy of high-fre-
quency transcranial magnetic stimulation over theleft dorsolateral prefrontal cortex in double-blindsham-controlled designs: a meta-analysis. PsycholMed 2009; 39:65–75 [E]
273. Couturier JL: Efficacy of rapid-rate repetitive tran-
scranial magnetic stimulation in the treatment ofdepression: a systematic review and meta-analysis.J Psychiatry Neurosci 2005; 30:83–90 [E]
274. Lisanby SH, Husain MM, Rosenquist PB, Maixner
D, Gutierrez R, Krystal A, Gilmer W, MarangellLB, Aaronson S, Daskalakis ZJ, Canterbury R,Richelson E, Sackeim HA, George MS: Daily leftprefrontal repetitive transcranial magnetic stimula-tion in the acute treatment of major depression:clinical predictors of outcome in a multisite, ran-domized controlled clinical trial. Neuropsycho-pharmacology 2009; 34:522–534 [B]
275. Eranti S, Mogg A, Pluck G, Landau S, Purvis R,
Brown RG, Howard R, Knapp M, Philpot M, Rabe-Hesketh S, Romeo R, Rothwell J, Edwards D,McLoughlin DM: A randomized, controlled trialwith 6-month follow-up of repetitive transcranialmagnetic stimulation and electroconvulsive therapyfor severe depression. Am J Psychiatry 2007; 164:73–81 [A–]
276. Rosa MA, Gattaz WF, Pascual-Leone A, Fregni F,
Rosa MO, Rumi DO, Myczkowski M, Silva MF ,Mansur C, Rigonatti SP , Jacobsen TM, MarcolinMA: Comparison of repetitive transcranial mag-netic stimulation and electroconvulsive therapy inunipolar non-psychotic refractory depression: arandomized, single-blind study. Int J Neuropsycho-pharmacol 2006; 9:667–676 [A −]
277. Grunhaus L, Schreiber S, Dolberg OT, Polak D,
Dannon PN: A randomized controlled comparisonof electroconvulsive therapy and repetitive trans-cranial magnetic stimulation in severe and resistantnonpsychotic major depression. Biol Psychiatry 2003;53:324–331 [A–]
278. Janicak PG, Dowd SM, Martis B, Alam D, Beedle
D, Krasuski J, Strong MJ, Sharma R, Rosen C,Viana M: Repetitive transcranial magnetic stimula-tion versus electroconvulsive therapy for major de-pression: preliminary results of a randomized trial.
Biol Psychiatry 2002; 51:659–667 [A −]
279. Schulze-Rauschenbach SC, Harms U, Schlaepfer
TE, Maier W, Falkai P , Wagner M: Distinctive
neurocognitive effects of repetitive transcranialmagnetic stimulation and electroconvulsive therapyin major depression. Br J Psychiatry 2005; 186:410–416 [B]
280. Janicak PG, O’Reardon JP , Sampson SM, Husain
MM, Lisanby SH, Rado JT, Heart KL, DemitrackMA: T ranscranial magnetic stimulation in the treat-ment of major depressive disorder: a comprehensivesummary of safety experience from acute exposure,extended exposure, and during reintroductiontreatment. J Clin Psychiatry 2008; 69:222–232 [G]
281. Sackeim HA, Rush AJ, George MS, Marangell LB,
Husain MM, Nahas Z, Johnson CR, Seidman S,Giller C, Haines S, Simpson RK, Jr., Goodman RR:Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and pre-dictors of outcome. Neuropsychopharmacology2001; 25:713–728 [B]
282. Rush AJ, Marangell LB, Sackeim HA, George MS,
Brannan SK, Davis SM, Howland R, Kling MA,Rittberg BR, Burke WJ, Rapaport MH, Zajecka J,Nierenberg AA, Husain MM, Ginsberg D, CookeRG: Vagus nerve stimulation for treatment-resistantdepression: a randomized, controlled acute phasetrial. Biol Psychiatry 2005; 58:347–354 [A–]
283. Miller IW, Norman WH, Keitner GI, Bishop SB:
Cognitive-behavioral treatment of depressed inpa-tients. Behav Ther 1989; 20:25–47 [B]
284. Stuart S, Wright JH, Thase ME, Beck AT: Cogni-
tive therapy with inpatients. Gen Hosp Psychiatry1997; 19:42–50 [F]
285. Schramm E, van Calker D, Dykierek P , Lieb K,
Kech S, Zobel I, Leonhart R, Berger M: An inten-sive treatment program of interpersonal psychother-apy plus pharmacotherapy for depressed inpatients:acute and long-term results. Am J Psychiatry 2007;164:768–777 [A–]
286. Cuijpers P , van Straten A, Andersson G, van Oppen
P: Psychotherapy for depression in adults: a meta-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
116 APA PRACTICE GUIDELINES
analysis of comparative outcome studies. J Consult
Clin Psychol 2008; 76:909–922 [E]
287. Vittengl JR, Clark LA, Dunn TW, Jarrett RB: Re-
ducing relapse and recurrence in unipolar depres-sion: a comparative meta-analysis of cognitive-behavioral therapy’s effects. J Consult Clin Psychol2007; 75:475–488 [E]
288. Dobson KS, Hollon SD, Dimidjian S, Schmaling
KB, Kohlenberg RJ, Gallop RJ, Rizvi SL, GollanJK, Dunner DL, Jacobson NS: Randomized trial ofbehavioral activation, cognitive therapy, and antide-pressant medication in the prevention of relapse andrecurrence in major depression. J Consult Clin Psy-chol 2008; 76:468–477 [A −]
289. Frank E, Kupfer DJ, Buysse DJ, Swartz HA, Pilkonis
PA, Houck PR, Rucci P , Novick DM, GrochocinskiVJ, Stapf DM: Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapyas maintenance treatment for women with recurrentdepression. Am J Psychiatry 2007; 164:761–767 [A −]
290. Sotsky SM, Glass DR, Shea MT, Pilkonis PA, Col-
lins JF , Elkin I, Watkins JT , Imber SD, Leber WR,Moyer J, Oliveri ME: Patient predictors of responseto psychotherapy and pharmacotherapy: findings inthe NIMH T reatment of Depression CollaborativeResearch Program. Am J Psychiatry 1991; 148:997–1008 [E]
291. Imel ZE, Malterer MB, McKay KM, Wampold BE:
A meta-analysis of psychotherapy and medicationin unipolar depression and dysthymia. J Affect Dis-ord 2008; 110:197–206 [E]
292. Markowitz JC: Psychotherapy of dysthymia. Am J
Psychiatry 1994; 151:1114–1121 [F]
293. Ravindran AV, Anisman H, Merali Z, Charbonneau
Y, T elner J, Bialik RJ, Wiens A, Ellis J, Griffiths J:T reatment of primary dysthymia with group cogni-tive therapy and pharmaco therapy: clinical symp-
toms and functional impairments. Am J Psychiatry1999; 156:1608–1617 [A −]
294. Browne G, Steiner M, Roberts J, Gafni A, Byrne C,
Dunn E, Bell B, Mills M, Chalklin L, Wallik D,Kraemer J: Sertraline and/or interpersonal psycho-therapy for patients with dysthymic disorder inprimary care: 6-month comparison with longitu-
dinal 2-year follow-up of effectiveness and costs.
J Affect Disord 2002; 68:317–330 [A −]
295. Markowitz JC, Kocsis JH, Bleiberg KL, Christos
PJ, Sacks M: A comparativ e trial of psychotherapy
and pharmacotherapy for “pure” dysthymic patients.J Affect Disord 2005; 89:167–175 [A −]
296. Hollon SD, Thase ME, Markowitz JC: T reatment
and prevention of depression. Psychological Sci-ence in the Public Interest 2002; 3:39–77 [F]
297. Markowitz JC: Psychotherapy of the post-dysthymic
patient. J Psychother Pract Res 1993; 2:157–163[G]298. Beck AT, Rush AJ, Shaw BF, Emery G: Cognitive
Therapy of Depression. New York, Guilford, 1979[G]
299. Wampold BE, Minami T, Baskin TW, Callen TS:
A meta-(re)analysis of the effects of cognitive ther-apy versus ‘other therapies’ for depression. J AffectDisord 2002; 68:159–165 [E]
300. Parker G, Roy K, Eyers K: Cognitive behavior
therapy for depression? Choose horses for courses.Am J Psychiatry 2003; 160:825–834 [G]
301. Ferster CB: A functional analysis of depression. Am
Psychol 1973; 28:857–870 [F]
302. Bandura A: Social Learning Theory. Englewood
Cliffs, NJ, Prentice-Hall, 1977 [G]
303. Cuijpers P , van Straten A, Warmerdam L: Behav-
ioral activation treatments of depression: a meta-analysis. Clin Psychol Rev 2007; 27:318–326 [E]
304. Lewinsohn PM, Antonuccio DA, Steinmetz-Breck-
inridge J, T eri L: The Coping With DepressionCourse: A Psychoeducational Intervention for Uni-polar Depression. Eugene, Ore, Castalia Publish-ing, 1984 [G]
305. Lewinsohn PM, Clarke G: Group treatment of
depressed individuals: the Coping With DepressionCourse. Advances in Behavioral Research andTherapy 1984; 6:99–114 [F]
306. Rehm LP: Behavior Therapy for Depression. New
York, Academic Press, 1979 [G]
307. Bellack AS, Hersen M, Himmelhoch JM: A com-
parison of social-skills training, pharmacotherapyand psychotherapy for depression. Behav Res Ther1983; 21:101–107 [A]
308. Nezu AM: Efficacy of a social problem-solving
therapy approach for unipolar depression. J ConsultClin Psychol 1986; 54:196–202 [A]
309. Martell CR, Addis ME, Jacobson NS: Depression
in Context: Strategies for Guided Action. NewYork, W.W. Norton, 2001 [G]
310. Dimidjian S, Hollon SD, Dobson KS, Schmaling
KB, Kohlenberg RJ, Addis ME, Gallop R,McGlinchey JB, Markley DK, Gollan JK, AtkinsDC, Dunner DL, Jacobson NS: Randomized trialof behavioral activation, cognitive therapy, and an-tidepressant medication in the acute treatment ofadults with major depression. J Consult Clin Psy-chol 2006; 74:658–670 [A −]
311. Weissman MM, Markowitz JC, Klerman GL:
Comprehensive Guide to Interpersonal Psycho-therapy. New York, Basic Books, 2000 [G]
312. Weissman MM, Markowitz JC, Klerman GL: Cli-
nician’s Quick Guide to Interpersonal Psychother-apy. New York, Oxford University Press, 2007 [G]
313. Markowitz JC, Weissman MM: Applications of in-
dividual interpersonal psychotherapy to specificdisorders: efficacy and in dications, in T extbook of
Psychotherapeutic T reatments. Edited by Gabbard
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 117
GO. Washington, DC, American Psychiatric Pub-
lishers, 2008, pp 339–364 [G]
314. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett
DB, Mallinger AG, Thase ME, McEachran AB,Grochocinski VJ: Three-year outcomes for main-tenance therapies in recurrent depression. ArchGen Psychiatry 1990; 47:1093–1099 [A −]
315. Reynolds CF III, Frank E, Perel JM, Imber SD,
Cornes C, Miller MD, Mazumdar S, Houck PR,Dew MA, Stack JA, Pollock BG, Kupfer DJ:Nortriptyline and interpersonal psychotherapy asmaintenance therapies for recurrent major depres-sion: a randomized controlled trial in patients olderthan 59 years. JAMA 1999; 281:39–45 [A]
316. Markowitz JC, Kocsis JH, Fishman B, Spielman
LA, Jacobsberg LB, Frances AJ, Klerman GL, PerrySW: T reatment of depressive symptoms in humanimmunodeficiency virus-positive patients. ArchGen Psychiatry 1998; 55:452–457 [A–]
317. Barber JP , Muenz LR: The role of avoidance and
obsessiveness in matching patients to cognitive andinterpersonal psychotherapy: empirical findingsfrom the treatment for depression collaborativeresearch program. J Consult Clin Psychol 1996;64:951–958 [B]
318. Bibring E: Psychoanalysis and the dynamic psycho-
therapies. J Am Psychoanal Assoc 1954; 2:745–770[G]
319. Bash M: Understanding Psychotherapy: The Sci-
ence Behind the Art. New York, Basic Books, 1988[G]
320. Gray SH: Quality assurance and utilization review
of individual medical psychotherapies, in Manual ofQuality Assurance Review. Edited by Mattson MR.Washington, DC, American Psychiatric Press,1992, pp 159–166 [F]
321. Freud S: Mourning and melancholia (1917 [1915]),
in Complete Psychological Works, vol. 14. London,Hogarth Press, 1957, pp 243–258 [G]
322. Zetzel ER: On the incapacity to bear depression
(1965), in The Capacity for Emotional Growth.New York, International Universities Press, 1970,pp 82–224 [G]
323. Kohut H: Thoughts on narcissism and narcissistic
rage. Psychoanal Study Child 1972; 27:360–400 [G]
324. Brenner C: Depression, anxiety and affect theory.
Int J Psychoanal 1974; 55:25–32 [G]
325. Blatt SJ: Contributions of psychoanalysis to the
understanding and treatment of depression. J AmPsychoanal Assoc 1998; 46:722–752 [F]
326. Rado S: The problem of melancholia (1927), in
Psychoanalysis of Behavior: Collected Papers. NewYork, Grune and Stratton, 1956 [G]
327. Brenner C: Psychoanalytic T echnique and Psychic
Conflict. New Y ork, International UniversitiesPress, 1976 [F]328. Loewald HW: Perspectives on memory (1972), in
Papers on Psychoanalysis. New Haven, Conn, YaleUniversity Press, 1980, pp 148–173 [G]
329. Karasu TB: Developmentalist metatheory of de-
pression and psychotherapy. Am J Psychother 1992;46:37–49 [F]
330. T asman A, Kay J, Lieberman JA: Psychiatry. Phila-
delphia, WB Saunders, 1996 [G]
331. Gray SH: Developing practice guidelines for psy-
choanalysis. J Psychother Pract Res 1996; 5:213–227 [F]
332. Arean P , Hegel M, Vannoy S, Fan MY, Unuzter J:
Effectiveness of problem-solving therapy for older,primary care patients with depression: results from
the IMPACT project. Gerontologist 2008; 48:311–
323 [B]
333. Rovner BW, Casten RJ: Preventing late-life depres-
sion in age-related macular degeneration. Am JGeriatr Psychiatry 2008; 16:454–459 [A–]
334. Robinson RG, Jorge RE, Moser DJ, Acion L, So-
lodkin A, Small SL, Fonzetti P , Hegel M, Arndt S:Escitalopram and problem-solving therapy for pre-vention of poststroke depression: a randomizedcontrolled trial. JAMA 2008; 299:2391–2400 [A −]
335. Alexopoulos GS, Raue P , Arean P: Problem-solving
therapy versus supportive therapy in geriatric majordepression with executive dysfunction. Am J Geri-atr Psychiatry 2003; 11:46–52 [A–]
336. Sargeant JK, Bruce ML, Florio LP , Weissman MM:
Factors associated with 1-year outcome of majordepression in the community. Arch Gen Psychiatry1990; 47:519–526 [C]
337. Keitner GI, Miller IW: Family functioning and
major depression: an overview. Am J Psychiatry1990; 147:1128–1137 [G]
338. Beach SRH, Sandeen EE, O’Leary KD: Depression
in Marriage. New York, Guilford, 1990 [G]
339. Yager J: Mood disorders and marital and family
problems, in American Psychiatric Press Review ofPsychiatry, vol. 11. Edited by T asman A, Riba MB.Washington, DC, American Psychiatric Press,1992, pp 477–493 [G]
340. Ryan CE, Epstein BE, Keitner G, Miller IW,
Bishop DS: Evaluating and T reating Families: TheMcMaster Approach. New York, Routledge T aylorFrancis Group, 2005 [G]
341. Coyne JC: Strategic therapy, in Affective Disorders
and the Family: Assessment and T reatment. Editedby Clarkin JF , Haas GL, Glick JD. New York,Guilford, 1988, pp 89–113 [F]
342. Leff J, Vearnals S, Brewin CR, Wolff G, Alexander
B, Asen E, Dayson D, Jones E, Chisholm D, EverittB: The London Depression Intervention T rial.Randomised controlled trial of antidepressants vcouple therapy in the treatment and maintenance ofpeople with depression living with a partner: clinical
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
118 APA PRACTICE GUIDELINES
outcome and costs. Br J Psychiatry 2000; 177:95–
100 [A–]
343. Miller IW, Keitner GI, Ryan CE, Solomon DA,
Cardemil EV , Beevers CG: T reatment matching inthe posthospital care of depressed patients. Am JPsychiatry 2005; 162:2131–2138 [A–]
344. Neimeyer RA, Feixas G: The role of homework and
skill acquisition in the outcome of group cognitivetherapy for depression. Behavior Therapy 1990;21:281–292 [B]
345. Neimeyer RA, Baker KD, Haykal RF, Akiskal HS:
Patterns of symptomatic change in depressed pa-tients in a private inpatient mood disorders pro-gram. Bull Menninger Clin 1995; 59:460–471 [C]
346. Bright JI, Baker KD, Neimeyer RA: Professional
and paraprofessional group treatments for depres-sion: a comparison of cognitive-behavioral and mu-tual support interventions. J Consult Clin Psychol1999; 67:491–501 [A]
347. Ayen I, Hautzinger M: [Cognitive behavior therapy
for depression in menopausal women: a controlled,randomized treatment study]. Zeitschrift fur Klin-ishe Psychologie und Psychotherapie 2004;290–299 [A −]
348. Yalom ID: The Theory and Practice of Group
Psychotherapy, 4th ed. New York, Basic Books,1995 [G]
349. Klier CM, Muzik M, Rosenblum KL, Lenz G:
Interpersonal psychotherapy adapted for the groupsetting in the treatment of postpartum depression.J Psychother Pract Res 2001; 10:124–131 [B]
350. Zlotnick C, Johnson SL, Miller IW, Pearlstein T,
Howard M: Postpartum depression in women re-ceiving public assistance: pilot study of an interper-sonal-therapy-oriented group intervention. Am JPsychiatry 2001; 158:638–640 [A −]
351. Bolton P , Bass J, Neugebauer R, Verdeli H, Clough-
erty KF, Wickramaratne P , Speelman L, NdogoniL, Weissman M: Group interpersonal psychother-apy for depression in rural Uganda: a randomizedcontrolled trial. JAMA 2003; 289:3117–3124 [A −]
352. Smith ML, Glass GV , Miller TI: The Benefits of
Psychotherapy. Baltimore, Md, Johns HopkinsUniversity Press, 1980 [G]
353. T oseland RW, Siporin M: When to recommend
group treatment: a review of the clinical and theresearch literature. Int J Group Psychother 1986;36:171–201 [F]
354. Piper WE, Joyce AS: A consideration of factors
influencing the utilization of time-limited, short-term group therapy. Int J Group Psychother 1996;46:311–328 [F]
355. McRoberts C: Comparative efficacy of individual
and group psychotherapy: a meta-analytic perspec-tive. Group Dynamics: Theory, Research, and Prac-tice 1998; 2:101–117 [E]356. T arg EF , Karasic DH, Diefenbach PN, Anderson
DA, Bystritsky A, Fawzy FI: Structured grouptherapy and fluoxetine to treat depression in HIV-positive persons. Psychosomatics 1994; 35:132–137[B]
357. Lieberman MA, Borman LD: Self-Help Groups for
Coping With Crisis. San Francisco, Calif, Jossey-Bass, 1979 [G]
358. Shapiro DA, Barkham M, Rees A, Hardy GE, Rey-
nolds S, Startup M: Effects of treatment durationand severity of depression on the effectiveness ofcognitive-behavioral and psychodynamic-interper-sonal psychotherapy. J Consult Clin Psychol 1994;62:522–534 [B]
359. Thase ME, Greenhouse JB, Frank E, Reynolds CF
III, Pilkonis PA, Hurley K, Grochocinski V , KupferDJ: T reatment of major depression with psycho-therapy or psychotherapy-pharmacotherapy com-binations. Arch Gen Psychiatry 1997; 54:1009–1015 [E]
360. Pampallona S, Bollini P , Tibaldi G, Kupelnick B,
Munizza C: Combined pharmacotherapy and psy-chological treatment for depression: a systematicreview. Arch Gen Psychiatry 2004; 61:714–719 [E]
361. de Maat S, Dekker J, Schoevers R, van Aalst G,
Gijsbers-van Wilk C, Hendriksen M, Kool S, PeenJ, Van R, de Jonghe F: Short psychodynamic sup-portive psychotherapy, antidepressants, and theircombination in the treatment of major depression:a mega-analysis based on three randomized clinicaltrials. Depress Anxiety 2008; 25:565–574 [E]
362. Keller MB, McCullough JP , Klein DN, Arnow B,
Dunner DL, Gelenberg AJ, Markowitz JC, Nem-eroff CB, Russell JM, Thase ME, T rivedi MH,Zajecka J: A comparison of nefazodone, the cogni-tive behavioral-analysis system of psychotherapy,and their combination for the treatment of chronicdepression. N Engl J Med 2000; 342:1462–1470[A–]
363. Hollon SD, Jarrett RB, Nierenberg AA, Thase ME,
T rivedi M, Rush AJ: Psychotherapy and medicationin the treatment of adult and geriatric depression:which monotherapy or combined treatment? J ClinPsychiatry 2005; 66:455–468 [F]
364. Fava GA, Grandi S, Zielezny M, Canestrari R, Mor-
phy MA: Cognitive behavioral treatment of residualsymptoms in primary major depressive disorder. AmJ Psychiatry 1994; 151:1295–1299 [B]
365. Fava M, Kaji J: Continuation and maintenance
treatments of major depressive disorder. PsychiatrAnnals 1994; 24:281–290 [F]
366. Fava M, Davidson KG: Definition and epidemiol-
ogy of treatment-resistant depression. PsychiatrClin North Am 1996; 19:179–200 [F]
367. Fava GA, Rafanelli C, Grandi S, Conti S, Belluardo
P: Prevention of recurrent depression with cogni-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 119
tive behavioral therapy: preliminary findings. Arch
Gen Psychiatry 1998; 55:816–820 [G]
368. Paykel ES, Scott J, T easdale JD, Johnson AL, Gar-
land A, Moore R, Jenaway A, Cornwall PL, Hay-hurst H, Abbott R, Pope M: Prevention of relapsein residual depression by cognitive therapy: a con-trolled trial. Arch Gen Psychiatry 1999; 56:829–835[A–]
369. Thase ME, Friedman ES, Biggs MM, Wisniewski
SR, T rivedi MH, Luther JF , Fava M, NierenbergAA, McGrath PJ, Warden D, Niederehe G, HollonSD, Rush AJ: Cognitive therapy versus medicationin augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry
2007; 164:739–752 [A–]
370. Davidson JRT, Gadde KM, Fairbank JA, Krishnan
KRR, Califf RM, Binanay C, Parker CB, Pugh N,
Hartwell TD, Vitiello B, Ritz L, Severe J, Cole JO,de Battista C, Doraiswamy PM, Feighner JP , KeckP , Kelsey J, Lin K-M, Londborg PD, NemeroffCB, Schatzberg AF, Sheehan DV , Srivastava RK,T aylor L, T rivedi MH, Weisler RH (HypericumDepression Study Group): Effect of Hypericumperforatum (St John’s wort) in major depressivedisorder: a randomized controlled trial. JAMA2002; 287:1807–1814 [A]
371. Shelton RC, Keller MB, Gelenberg A, Dunner DL,
Hirschfeld R, Thase ME, Russell J, Lydiard RB,Crits-Cristoph P , Gallop R, T odd L, Hellerstein D,Goodnick P , Keitner G, Stahl SM, Halbreich U:Effectiveness of St John’s wort in major depres-sion: a randomized controlled trial. JAMA 2001;285:1978–1986 [A]
372. Mills E, Montori VM, Wu P , Gallicano K, Clarke
M, Guyatt G: Interaction of St John’s wort withconventional drugs: systematic review of clinicaltrials. BMJ 2004; 329:27–30 [E]
373. Mannel M: Drug interactions with St John’s wort:
mechanisms and clinical implications. Drug Saf2004; 27:773–797 [F]
374. Hammerness P , Basch E, Ulbricht C, Barrette EP ,
Foppa I, Basch S, Bent S, Boon H, Ernst E: St John’swort: a systematic review of adverse effects and druginteractions for the consultation psychiatrist. Psy-chosomatics 2003; 44:271–282 [F]
375. Roby CA, Anderson GD, Kantor E, Dryer DA,
B u r s t e i n  A H :  S t  J o h n ’ s  w o r t :  e f f e c t  o n  C Y P 3 A 4activity. Clin Pharmacol Ther 2000; 67:451–457[G]
376. Schwarz UI, Buschel B, Kirch W: Unwanted preg-
nancy on self-medication with St John’s wort de-spite hormonal contraception. Br J Clin Pharmacol2003; 55:112–113 [G]
377. Mischoulon D, Fava M: Role of S-adenosyl-
L-
methionine in the treatment of depression: a reviewof the evidence. Am J Clin Nutr 2002; 76:1158S–1161S [F]
378. Bottiglieri T, Godfrey P , Flynn T, Carney MW,
T oone BK, Reynolds EH: Cerebrospinal fluidS-adenosylmethionine in depression and dementia:
effects of treatment with parenteral and oral S-
adenosylmethionine. J Neurol Neurosurg Psychia-try 1990; 53:1096–1098 [G]
379. Carney MW, Edeh J, Bottiglieri T, Reynolds EM,
T oone BK: Affective illness and S-adenosyl me-
thionine: a preliminary report. Clin Neuropharma-col 1986; 9:379–385 [G]
380. Pies R: Adverse neuropsychiatric reactions to herb-
al and over-the-counter “antidepressants.” J Clin
Psychiatry 2000; 61:815–820 [F]
381. Bressa GM: S-adenosyl-
L-methionine (SAMe) as
antidepressant: meta-analysis of clinical studies.
Acta Neurol Scand Suppl 1994; 154:7–14 [E]
382. Pancheri P , Scapicchio P , Chiaie RD: A double-
blind, randomized parallel-group, efficacy and safe-ty study of intramuscular S -adenosyl-
L-methionine
1,4-butanedisulphonate (SAMe) versus imipraminein patients with major depressive disorder. Int JNeuropsychopharmacol 2002; 5:287–294 [A]
383. Bell KM, Plon L, Bunney WE Jr, Potkin SG: S-
adenosylmethionine treatment of depression: a con-trolled clinical trial. Am J Psychiatry 1988; 145:1110–1114 [B]
384. Parker G, Gibson NA, Brotchie H, Heruc G, Rees
AM, Hadzi-Pavlovic D: Omega-3 fatty acids andmood disorders. Am J Psychiatry 2006; 163:969–978 [F]
385. Freeman MP , Hibbeln JR, Wisner KL, Davis JM,
Mischoulon D, Peet M, Keck PE Jr, Marangell LB,Richardson AJ, Lake J, Stoll AL: Omega-3 fatty acids:evidence basis for treatment and future research inpsychiatry. J Clin Psychiatry 2006; 67:1954–1967 [E]
386. Papakostas GI, Petersen T , Mischoulon D, Ryan JL,
Nierenberg AA, Bottiglieri T, Rosenbaum JF,Alpert JE, Fava M: Serum folate, vitamin B12, andhomocysteine in major depressive disorder, Part 1:predictors of clinical response in fluoxetine-resistantdepression. J Clin Psychiatry 2004; 65:1090–1095 [A]
387. Papakostas GI, Petersen T , Lebowitz BD, Mis-
choulon D, Ryan JL, Nierenberg AA, Bottiglieri T ,Alpert JE, Rosenbaum JF , Fava M: The relationshipbetween serum folate, vitamin B12, and homocys-teine levels in major depressive disorder and thetiming of improvement with fluoxetine. Int J Neu-ropsychopharmacol 2005; 8:523–528 [G]
388. Alpert M, Silva RR, Pouget ER: Prediction of treat-
ment response in geriatric depression from baselinefolate level: interaction with an SSRI or a tricyclicantidepressant. J Clin Psychopharmacol 2003;23:309–313 [G]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
120 APA PRACTICE GUIDELINES
389. Coppen A, Bailey J: Enhancement of the antide-
pressant action of fluoxetine by folic acid: a ran-
domised, placebo controlled trial. J Affect Disord2000; 60:121–130 [A]
390. Eastman CI, Young MA, Fogg LF , Liu L, Meaden
PM: Bright light treatment of winter depression:a placebo-controlled trial. Arch Gen Psychiatry1998; 55:883–889 [B]
391. T erman M, T erman JS, Quitkin FM, McGrath PJ,
Stewart JW, Rafferty B: Light therapy for seasonalaffective disorder. A review of efficacy. Neuropsy-chopharmacology 1989; 2:1–22 [B]
392. Kripke DF, Mullaney DJ, Klauber MR, Risch SC,
Gillin JC: Controlled trial of bright light for non-
seasonal major depressive disorders. Biol Psychiatry
1992; 31:119–134 [A–]
393. Yamada N, Martin-Iverson MT, Daimon K,
T sujimoto T, T akahashi S: Clinical and chronobio-logical effects of light therapy on nonseasonal affec-tive disorders. Biol Psychiatry 1995; 37:866–873 [B]
394. Sumaya IC, Rienzi BM, Deegan JF , Moss DE:
Bright light treatment decreases depression in in-stitutionalized older adults: a placebo-controlledcrossover study. J Gerontol A Biol Sci Med Sci 2001;56:M356–M360 [A–]
395. Golden RN, Gaynes BN, Ekstrom RD, Hamer
RM, Jacobsen FM, Suppes T, Wisner KL, Nemer-off CB: The efficacy of light therapy in the treat-ment of mood disorders: a review and meta-analysisof the evidence. Am J Psychiatry 2005; 162:656–662[E]
396. Avissar S, Schreiber G, Nechamkin Y, Neuhaus I,
Lam GK, Schwartz P, Turner E, Matthews J, NaimS, Rosenthal NE: The effects of seasons and lighttherapy on G protein levels in mononuclear leuko-cytes of patients with seasonal affective disorder.Arch Gen Psychiatry 1999; 56:178–183 [G]
397. Benedetti F, Colombo C, Serretti A, Lorenzi C,
Pontiggia A, Barbini B, Smeraldi E: Antidepressanteffects of light therapy combined with sleep depri-vation are influenced by a functional polymorphismwithin the promoter of the serotonin transportergene. Biol Psychiatry 2003; 54:687–692 [G]
398. Benedetti F, Colombo C, Pontiggia A, Bernasconi
A, Florita M, Smeraldi E: Morning light treatmenthastens the antidepressant effect of citalopram: aplacebo-controlled trial. J Clin Psychiatry 2003;64:648–653 [A–]
399. Levitt AJ, Joffe RT, Kennedy SH: Bright light aug-
mentation in antidepressant nonresponders. J ClinPsychiatry 1991; 52:336–337 [B]
400. Beauchemin KM, Hays P: Phototherapy is a useful
adjunct in the treatment of depressed in-patients.Acta Psychiatr Scand 1997; 95:424–427 [A–]
401. Neumeister A, Goessler R, Lucht M, Kapitany T,
Bamas C, Kasper S: Bright light therapy stabilizesthe antidepressant effect of partial sleep depriva-tion. Biol Psychiatry 1996; 39:16–21 [A–]
402. Colombo C, Lucca A, Benedetti F , Barbini B,
Campori E, Smeraldi E: T otal sleep deprivationcombined with lithium and light therapy in thetreatment of bipolar depression: replication of maineffects and interaction. Psychiatry Res 2000; 95:43–53 [A–]
403. Halbreich U: Systematic reviews of clinical trials of
acupuncture as treatment for depression: how sys-tematic and accurate are they? CNS Spectr 2008;13:293–300 [G]
404. Luo H, Meng F , Jia Y, Zhao X: Clinical research on
the therapeutic effect of the electro-acupuncture
treatment in patients with depression. Psychiatry
Clin Neurosci 1998; 52 Suppl:S338–S340 [A]
405. Allen JJB, Schnyer RN, Hitt SK: The efficacy of
acupuncture in the treatment of major depressivedisorder in women. Psychol Sci 1998; 9:397–401[A–]
406. Allen JJ, Schnyer RN, Chambers AS, Hitt SK,
Moreno FA, Manber R: Acupuncture for depres-sion: a randomized controlled trial. J Clin Psychia-try 2006; 67:1665–1673 [A]
407. Wang H, Qi H, Wang BS, Cui YY, Zhu L, Rong
ZX, Chen HZ: Is acupuncture beneficial in depres-sion: a meta-analysis of 8 randomized controlledtrials? J Affect Disord 2008; 111(2–3):125–134 [E]
408. Rush AJ, Kraemer HC, Sackeim HA, Fava M,
T rivedi MH, Frank E, Ninan PT , Thase ME,Gelenberg AJ, Kupfer DJ, Regier DA, RosenbaumJF, Ray O, Schatzberg AF: Report by the ACNPT ask Force on response and remission in majordepressive disorder. Neuropsychopharmacology2006; 31:1841–1853 [G]
409. Judd LL, Akiskal HS, Zeller PJ, Paulus M, Leon
AC, Maser JD, Endicott J, Coryell W, Kunovac JL,Mueller TI, Rice JP , Keller MB: Psychosocial dis-ability during the long-term course of unipolar ma-jor depressive disorder. Arch Gen Psychiatry 2000;57:375–380 [C]
410. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott
J, Coryell W, Paulus MP , Kunovac JL, Leon AC,Mueller TI, Rice JA, Keller MB: Major depressivedisorder: a prospective study of residual subthresh-old depressive symptoms as predictor of rapid re-lapse. J Affect Disord 1998; 50:97–108 [C]
411. Judd LL, Paulus MJ, Schettler PJ, Akiskal HS,
Endicott J, Leon AC, Maser JD, Mueller T , So-lomon DA, Keller MB: Does incomplete recoveryfrom first lifetime major depressive episode heralda chronic course of illness? Am J Psychiatry 2000;157:1501–1504 [C]
412. Paykel ES: Remission and residual symptomatology
in major depression. Psychopathology 1998; 31:5–14 [C]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 121
413. Guscott R, Grof P: The clinical meaning of re-
fractory depression: a review for the clinician. Am J
Psychiatry 1991; 148:695–704 [G]
414. Sackeim HA, Prudic J, Devanand DP , Decina P ,
Kerr B, Malitz S: The impact of medication resis-tance and continuation pharmacotherapy on relapsefollowing response to electroconvulsive therapy inmajor depression. J Clin Psychopharmacol 1990;10:96–104 [G]
415. Keitner GI, Ryan CE, Solomon DA: Realistic ex-
pectations and a disease management model fordepressed patients with persistent symptoms. J ClinPsychiatry 2006; 67:1412–1421 [E]
416. Badamgarav E, Weingarten SR, Henning JM,
K n i g h t  K ,  H a s s e l b l a d  V ,  G a n o  A  J r ,  O f m a n  J J :Effectiveness of disease management programs indepression: a systematic review. Am J Psychiatry2003; 160:2080–2090 [E]
417. Frank E, Kupfer DJ: Axis II personality disorders
and personality features in treatment-resistant andrefractory depression, in T reatment Strategies forRefractory Depression. Edited by Roose SP , Glass-man AH. Washington, DC, American PsychiatricPress, 1990, pp 207–221 [F]
418. T rivedi MH, Morris DW, Grannemann BD, Maha-
di S: Symptom clusters as predictors of late responseto antidepressant treatment. J Clin Psychiatry 2005;66:1064–1070 [B]
419. Quitkin FM, Petkova E, McGrath PJ, T aylor B,
Beasley C, Stewart J, Amsterdam J, Fava M, Rosen-baum J, Reimherr F , Fawcett J, Chen Y , Klein D:When should a trial of fluoxetine for major depres-sion be declared failed? Am J Psychiatry 2003;160:734–740 [B]
420. Rush AJ, Wisniewski SR, Warden D, Luther JF,
Davis LL, Fava M, Nierenberg AA, T rivedi MH:Selecting among second-step antidepressant medi-cation monotherapies: predic tive value of clinical,
demographic, or first-step treatment features. ArchGen Psychiatry 2008; 65:870–880 [A]
421. Rush AJ, T rivedi MH, Wisniewski SR, Stewart JW,
Nierenberg AA, Thase ME, Ritz L, Biggs MM,Warden D, Luther JF , Shores-Wilson K, NiedereheG, Fava M: Bupropion-SR, sertraline, or venlafax-ine-XR after failure of SSRIs for depression. N EnglJ Med 2006; 354:1231–1242 [A]
422. Wisniewski SR, Fava M, T rivedi MH, Thase ME,
Warden D, Niederehe G, Friedman ES, Biggs MM,Sackeim HA, Shores-Wilson K, McGrath PJ,Lavori PW, Miyahara S, Rush AJ: Acceptability ofsecond-step treatments to depressed outpatients: aSTAR*D report. Am J Psychiatry 2007; 164:753–760 [G]
423. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi
J, Eriksson H: Extended release quetiapine fuma-rate monotherapy for major depressive disorder:results of a double-blind, randomized, placebo con-trolled study. CNS Spectr 2009; 4:299–313 [A]
424. Cutler AJ, Montgomery SA, Feifel D, Lazarus A,
Astrom M, Brecher M: Extended release quetiapinefumarate monotherapy in major depressive dis-order: a placebo- and duloxetine-controlled study.J Clin Psychiatry 2009; 70:526–539 [A]
425. Pagnin D, de Queiroz V , Pini S, Cassano GB: Effi-
cacy of ECT in depression: a meta-analytic review.J ECT 2004; 20:13–20 [E]
426. Rasmussen KG, Mueller M, Knapp RG, Husain
MM, Rummans TA, Sampson SM, O’Connor MK,Petrides G, Fink M, Kellner CH: Antidepressantmedication treatment failure does not predict lower
remission with ECT for major depressive disorder:
a report from the consortium for research inelectroconvulsive therapy. J Clin Psychiatry 2007;68:1701–1706 [B]
427. Prudic J, Sackeim HA, Devanand DP: Medication
resistance and clinical resp onse to electroconvulsive
therapy. Psychiatry Res 1990; 31:287–296 [G]
428. Husain SS, Kevan IM, Linnell R, Scott AI: Electro-
convulsive therapy in depressive illness that has notresponded to drug treatment. J Affect Disord 2004;83:121–126 [B]
429. T rivedi MH, Fava M, Wisniewski SR, Thase ME,
Quitkin F, Warden D, Ritz L, Nierenberg AA,Lebowitz BD, Biggs MM, Luther JF , Shores-Wilson K, Rush AJ: Medication augmentation afterthe failure of SSRIs for depression. N Engl J Med2006; 354:1243–1252 [A]
430. Kennedy SH, McCann SM, Masellis M, McIntyre
RS, Raskin J, McKay G, Baker GB: Combiningbupropion SR with venlafaxine, paroxetine, or flu-oxetine: a preliminary report on pharmacokinetic,therapeutic, and sexual dysfunction effects. J ClinPsychiatry 2002; 63:181–186 [B]
431. Lam RW, Hossie H, Solomons K, Yatham LN:
Citalopram and bupropion-SR: combining versusswitching in patients with treatment-resistant de-pression. J Clin Psychiatry 2004; 65:337–340 [B]
432. Carpenter LL, Yasmin S, Price LH: A double-blind,
placebo-controlled study of antidepressant aug-mentation with mirtazapine.  Biol Psychiatry 2002;
51:183–188 [A]
433. Demyttenaere K, Bonnewyn A, Bruffaerts R, De
GG, Gasquet I, Kovess V , Haro JM, Alonso J:Clinical factors influencing the prescription of an-tidepressants and benzodiazepines: results from theEuropean study of the epidemiology of mental dis-orders (ESEMeD). J Affect Disord 2008; 110:84–93 [G]
434. Valenstein M, T aylor KK, Austin K, Kales HC,
McCarthy JF , Blow FC: Benzodiazepine use amongdepressed patients treated in mental health settings.Am J Psychiatry 2004; 161:654–661 [G]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
122 APA PRACTICE GUIDELINES
435. Smith WT , Londborg PD, Glaudin V , Painter JR:
Short-term augmentation of fluoxetine with clon-
azepam in the treatment of depression: a double-blind study. Am J Psychiatry 1998; 155:1339–1345[A]
436. Asnis GM, Chakraburtty A, DuBoff EA, Krystal A,
Londborg PD, Rosenberg R, Roth-Schechter B,Scharf MB, Walsh JK: Zolpidem for persistent in-somnia in SSRI-treated depressed patients. J ClinPsychiatry 1999; 60:668–676 [A −]
437. Fava M, McCall WV , Krystal A, Wessel T, Rubens
R, Caron J, Amato D, Roth T: Eszopiclone co-administered with fluoxetine in patients with in-somnia coexisting with major depressive disorder.
Biol Psychiatry 2006; 59:1052–1060 [A]
438. Smith WT , Londborg PD, Glaudin V , Painter JR:
Is extended clonazepam cotherapy of fluoxetine
effective for outpatients with major depression?
J Affect Disord 2002; 70:251–259 [A]
439. Krystal A, Fava M, Rubens R, Wessel T, Caron J,
W i l s o n  P ,  R o t h  T ,  M c C a l l  W V :  E v a l u a t i o n  o f
eszopiclone discontinuat ion after cotherapy with
fluoxetine for insomnia with coexisting depression.J Clin Sleep Med 2007; 3:48–55 [A]
440. Crossley NA, Bauer M: Acceleration and augmen-
tation of antidepressants with lithium for depressivedisorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68:935–940[E]
441. Cipriani A, Smith K, Burgess S, Carney S, Goodwin
G, Geddes J: Lithium versus antidepressants in thelong-term treatment of unipolar affective disorder.Cochrane Database Syst Rev 2006; CD003492 [E]
442. Austin MP , Souza FG, Goodwin GM: Lithium
augmentation in antidepressant-resistant patients.A quantitative analysis. Br J Psychiatry 1991;159:510–514 [E]
443. Bauer M, Dopfmer S: Lithium augmentation in
treatment-resistant depression: meta-analysis ofplacebo-controlled studies. J Clin Psychopharma-col 1999; 19:427–434 [E]
444. Cipriani A, Pretty H, Hawton K, Geddes JR: Lith-
ium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: asystematic review of randomized trials. Am J Psy-chiatry 2005; 162:1805–1819 [E]
445. Aronson R, Offman HJ, Joffe RT, Naylor CD:
T riiodothyronine augmentation in the treatment ofrefractory depression. A meta-analysis. Arch GenPsychiatry 1996; 53:842–848 [E]
446. Nierenberg AA, Fava M, T rivedi MH, Wisniewski
SR, Thase ME, McGrath PJ, Alpert JE, Warden D,Luther JF , Niederehe G, Lebowitz B, Shores-Wilson K, Rush AJ: A comparison of lithium andT(3) augmentation following two failed medicationtreatments for depression: a STAR*D report. Am JPsychiatry 2006; 163:1519–1530 [A]
447. Cooper-Kazaz R, Apter JT , Cohen R, Karagichev
L, Muhammed-Moussa S, Grupper D, Drori T ,Newman ME, Sackeim HA, Glaser B, Lerer B:Combined treatment with sertraline and liothyro-nine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry2007; 64:679–688 [A]
448. Nelson JC, Papakostas GI: Atypical antipsychotic
augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.Am J Psychiatry 2009; 166:980–991 [E]
449. Shelton RC, T ollefson GD, T ohen M, Stahl S,
Gannon KS, Jacobs TG, Buras WR, Bymaster FP ,Zhang W, Spencer KA, Feldman PD, Meltzer HY:A novel augmentation strategy for treating resistantmajor depression. Am J Psychiatry 2001; 158:131–134 [A]
450. Shelton RC, Williamson DJ, Corya SA, Sanger
TM, Van Campen LE, Case M, Briggs SD, T ollef-son GD: Olanzapine/fluoxetine combination fortreatment-resistant depression: a controlled studyof SSRI and nortriptyline resistance. J Clin Psychi-atry 2005; 66:1289–1297 [A]
451. Corya SA, Williamson D, Sanger TM, Briggs SD,
Case M, T ollefson G: A randomized, double-blindcomparison of olanzapine/ fluoxetine combination,
olanzapine, fluoxetine, and venlafaxine in treat-ment-resistant depression. Depress Anxiety 2006;23:364–372 [A]
452. Thase ME, Corya SA, Osuntokun O, Case M,
Henley DB, Sanger TM, Watson SB, Dube S: Arandomized, double-blind comparison of olanza-pine/fluoxetine combination, olanzapine, and flu-oxetine in treatment-resistant major depressivedisorder. J Clin Psychiatry 2007; 68:224–236 [A]
453. Berman RM, Marcus RN, Swanink R, McQuade
RD, Carson WH, Corey-Lisle PK, Khan A: Theefficacy and safety of aripiprazole as adjunctive ther-apy in major depressive disorder: a multicenter, ran-domized, double-blind, placebo-controlled study.J Clin Psychiatry 2007; 68:843–853 [A]
454. McIntyre A, Gendron A, McIntyre A: Quetiapine
adjunct to selective serotonin reuptake inhibitors orvenlafaxine in patients with major depression, co-morbid anxiety, and residu al depressive symptoms:
a randomized, placebo-controlled pilot study. De-press Anxiety 2007; 24:487–494 [A]
455. Doree JP , Des Rosiers J, Lew V , Gendron A, Elie R,
Stip E, T ourjman SV: Quetiapine augmentation oftreatment-resistant depre ssion: a comparison with
lithium. Curr Med Res Opin 2007; 23:333–341 [B]
456. Garakani A, Martinez JM, Marcus S, Weaver J,
Rickels K, Fava M, Hirschowitz J: A randomized,double-blind, and placebo-controlled trial of que-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 123
tiapine augmentation of fluoxetine in major depres-
sive disorder. Int Clin Psychopharmacol 2008;23:269–275 [A]
457. Mahmoud RA, Pandina GJ, T urkoz I, Kosik-
Gonzalez C, Canuso CM , Kujawa MJ, Gharabawi-
Garibaldi GM: Risperidone for treatment-refractorymajor depressive disorder: a randomized trial. AnnIntern Med 2007; 147:593–602 [A]
458. Keitner GI, Garlow SJ, Ryan CE, Ninan PT,
Solomon DA, Nemeroff CB, Keller MB: A ran-domized, placebo-controlled trial of risperidoneaugmentation for patients with difficult-to-treatunipolar, non-psychotic major depression. J Psychi-atr Res 2009; 43:205–214 [A]
459. Andersen SW, Clemow DB, Corya SA: Long-term
weight gain in patients treated with open-labelolanzapine in combination with fluoxetine for ma-jor depressive disorder. J Clin Psychiatry 2005;66:1468–1476 [B]
460. Lavretsky H, Park S, Siddarth P , Kumar A, Rey-
nolds CF III: Methylphenidate-enhanced anti-depressant response to citalopram in the elderly:a double-blind, placebo-controlled pilot trial. Am JGeriatr Psychiatry 2006; 14:181–185 [B]
461. Masand PS, Anand VS, T anquary JF: Psychostimu-
lant augmentation of second generation antidepres-sants: a case series. Depress Anxiety 1998; 7:89–91[G]
462. Ravindran AV , Kennedy SH, O’Donovan MC, Fal-
lu A, Camacho F , Binder CE: Osmotic-release oralsystem methylphenidate augmentation of antide-pressant monotherapy in major depressive disorder:results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 2008; 69:87–94[A]
463. Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-
Wood C, Mannelli P , Ciccone P: A randomized,double-blind, placebo-controlled trial of aug-mentation with an extended release formulation ofmethylphenidate in outpa tients with treatment-
resistant depression. J Clin Psychopharmacol 2006;26:653–656 [A]
464. DeBattista C, Doghramji K, Menza MA, Rosenthal
MH, Fieve RR: Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patientswith major depressive disorder: a preliminary dou-ble-blind, placebo-controlled study. J Clin Psychi-atry 2003; 64:1057–1064 [A]
465. Dunlop BW, Crits-Christoph P , Evans DL, Hir-
schowitz J, Solvason HB, Rickels K, Garlow SJ,Gallop RJ, Ninan PT: Coadministration of modafi-nil and a selective serotonin reuptake inhibitor fromthe initiation of treatment of major depressive dis-order with fatigue and sleepiness: a double-blind,placebo-controlled study. J Clin Psychopharmacol2007; 27:614–619 [A]466. Fava M, Thase ME, DeBattista C, Doghramji K,
Arora S, Hughes RJ: Modafinil augmentation ofselective serotonin reuptake inhibitor therapy inMDD partial responders with persistent fatigue andsleepiness. Ann Clin Psychiatry 2007; 19:153–159[A]
467. Ninan PT, Hassman HA, Glass SJ, McManus FC:
Adjunctive modafinil at initiation of treatment witha selective serotonin reuptake inhibitor enhancesthe degree and onset of th erapeutic effects in pa-
tients with major depressive disorder and fatigue.J Clin Psychiatry 2004; 65:414–420 [B]
468. Thase ME, Fava M, DeBattista C, Arora S, Hughes
RJ: Modafinil augmentation of SSRI therapy in
patients with major depressive disorder and exces-
sive sleepiness and fatigue: a 12-week, open-label,extension study. CNS Spectr 2006; 11:93–102 [B]
469. Cephalon: Updated Safety Information: Warn-
ings regarding serious rash, including Stevens-Johnson Syndrome and hypersensitivity reactions,and psychiatric symptoms, Sept 12, 2007. http://www.fda.gov/medwatch/safety/2007/Provigil_dhcpletter091207_final.pdf [G]
470. Cullen M, Mitchell P , Brodaty H, Boyce P , Parker
G, Hickie I, Wilhelm K: Carbamazepine for treat-ment-resistant melancholia. J Clin Psychiatry 1991;52:472–476 [C]
471. Fava M, Rush AJ, Wisniewski SR, Nierenberg AA,
Alpert JE, McGrath PJ, Thase ME, Warden D,Biggs M, Luther JF, Niederehe G, Ritz L, T rivediMH: A comparison of mirtazapine and nortrip-tyline following two consecutive failed medicationtreatments for depressed outpatients: a STAR*Dreport. Am J Psychiatry 2006; 163:1161–1172 [A]
472. Schindler F, Anghelescu IG: Lithium versus lamo-
trigine augmentation in treatment resistant unipo-lar depression: a randomized, open-label study. IntClin Psychopharmacol 2007; 22:179–182 [B]
473. Barbosa L, Berk M, Vorster M: A double-blind,
randomized, placebo-controlled trial of augmenta-tion with lamotrigine or placebo in patients con-comitantly treated with fluoxetine for resistantmajor depressive episodes. J Clin Psychiatry 2003;64:403–407 [A]
474. White K, Simpson G: Combined MAOI-tricyclic
antidepressant treatment: a reevaluation. J ClinPsychopharmacol 1981; 1:264–282 [F]
475. Lader M: Combined use of tricyclic antidepressants
and monoamine oxidase inhibitors. J Clin Psychia-try 1983; 44:20–24 [F]
476. George MS, Rush AJ, Marangell LB, Sackeim HA,
Brannan SK, Davis SM, Howland R, Kling MA,Moreno F, Rittberg B, Dunner D, Schwartz T,Carpenter L, Burke M, Ninan P , Goodnick P: Aone-year comparison of vagus nerve stimulation
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
124 APA PRACTICE GUIDELINES
with treatment as usual for treatment-resistant de-
pression. Biol Psychiatry 2005; 58:364–373 [B]
477. Rush AJ, Sackeim HA, Marangell LB, George MS,
Brannan SK, Davis SM, Lavori P , Howland R,Kling MA, Rittberg B, Carpenter L, Ninan P ,Moreno F, Schwartz T, Conway C, Burke M, BarryJJ: Effects of 12 months of vagus nerve stimulationin treatment-resistant depression: a naturalisticstudy. Biol Psychiatry 2005; 58:355–363 [B]
478. Sackeim HA, Brannan SK, Rush AJ, George MS,
Marangell LB, Allen J: Durability of antidepressantresponse to vagus nerve stimulation (VNS). Int JNeuropsychopharmacol 2007; 10:817–826 [B]
479. Nahas Z, Marangell LB, Husain MM, Rush AJ,
Sackeim HA, Lisanby SH, Martinez JM, GeorgeMS: T wo-year outcome of vagus nerve stimulation(VNS) for treatment of major depressive episodes.J Clin Psychiatry 2005; 66:1097–1104 [B]
480. Daban C, Martinez-Aran A, Cruz N, Vieta E: Safety
and efficacy of vagus nerve stimulation in treatment-resistant depression. A systematic review. J AffectDisord 2008; 110:1–15 [E]
481. Schlaepfer TE, Frick C, Zobel A, Maier W, Heuser
I, Bajbouj M, O’Keane V , Corcoran C, AdolfssonR, T rimble M, Rau H, Hoff HJ, Padberg F, Muller-Siecheneder F, Audenaert K, Van den Abbeele D,Stanga Z, Hasdemir M: Vagus nerve stimulation fordepression: efficacy and safety in a European study.Psychol Med 2008; 38:651–661 [B]
482. Depression Physician’s Manual: VNS Therapy™
Pulse Model 102 Generator and VNS Therapy™Pulse Duo Model 102R Generator (#26-0005-6300/10). Houston, TX, Cyberonics, Inc., July2005. http://www.accessdata.fda.gov/cdrh_docs/pdf/P970003S050c.pdf [G]
483. McGrath PJ, Stewart JW, Petkova E, Quitkin FM,
Amsterdam JD, Fawcett J, Reimherr FW, Rosen-baum JF, Beasley CM Jr: Predictors of relapseduring fluoxetine continuation or maintenancetreatment of major depression. J Clin Psychiatry2000; 61:518–524 [A]
484. Solomon DA, Keller MB, Leon AC, Mueller TI,
Lavori PW, Shea MT , Coryell W, Warshaw M,T urvey C, Maser JD, Endicott J: Multiple recur-rences of major depressive disorder. Am J Psychia-try 2000; 157:229–233 [C]
485. Consensus Development Panel: NIMH/NIH Con-
sensus Development Conference Statement: mooddisorders: pharmacologic prevention of recurrenc-es. Am J Psychiatry 1985; 142:469–476 [F]
486. Maj M, Veltro F, Pirozzi R, Lobrace S, Magliano L:
Pattern of recurrence of illness after recovery froman episode of major depression: a prospective study.Am J Psychiatry 1992; 149:795–800 [B]
487. Depression Guideline Panel: Clinical Practice
Guideline Number 5: Depression in Primary Care,T reatment of Major Depression: HHS Publication93–0551. Rockville, Md, Agency for Health CarePolicy and Research, 1993 [E]
488. T ew JD Jr, Mulsant BH, Haskett RF , Joan P , Begley
AE, Sackeim HA: Relapse during continuationpharmacotherapy after acute response to ECT: acomparison of usual care versus protocolized treat-ment. Ann Clin Psychiatry 2007; 19:1–4 [B]
489. Sackeim HA, Haskett RF, Mulsant BH, Thase ME,
Mann JJ, Pettinati HM, Greenberg RM, CroweRR, Cooper TB, Prudic J: Continuation pharmaco-therapy in the prevention of relapse following elec-troconvulsive therapy: a randomized controlledtrial. JAMA 2001; 285:1299–1307 [A]
490. Papakostas GI, Perlis RH, Seifert C, Fava M: Anti-
depressant dose reduction and the risk of relapse inmajor depressive disorder. Psychother Psychosom2007; 76:266–270 [E]
491. Thase ME, Simons AD, McGeary J, Cahalane JF,
Hughes C, Harden T, Friedman E: Relapse aftercognitive behavior therapy of depression: potentialimplications for longer courses of treatment. Am JPsychiatry 1992; 149:1046–1052 [C]
492. Koran LM, Gelenberg AJ, Kornstein SG, Howland
RH, Friedman RA, DeBattista C, Klein D, KocsisJH, Schatzberg AF , Thase ME, Rush AJ, HirschfeldRM, LaVange LM, Keller MB: Sertraline versusimipramine to prevent relapse in chronic depres-sion. J Affect Disord 2001; 65:27–36 [A]
493. Jarrett RB, Basco MR, Risser R, Ramanan J, Mar-
will M, Kraft D, Rush AJ: Is there a role for con-tinuation phase cognitive therapy for depressedoutpatients? J Consult Clin Psychol 1998; 66:1036–1040 [B]
494. Fava GA, Grandi S, Zielezny M, Rafanelli C,
Canestrari R: Four-year outcome for cognitive be-havioral treatment of residual symptoms in majordepression. Am J Psychiatry 1996; 153:945–947 [B]
495. Prien RF, Kupfer DJ: Continuation drug therapy
for major depressive episodes: how long should itbe maintained? Am J Psychiatry 1986; 143:18–23[B]
496. Bauer M, Dopfmer S: Lithium augmentation in
treatment-resistant depression: meta-analysis ofplacebo-controlled studies. J Clin Psychopharma-col 2000; 20:287 [E]
497. Bockting CL, Schene AH, Spinhoven P , Koeter
MW, Wouters LF , Huyser J, Kamphuis JH: Pre-venting relapse/recurrence in recurrent depressionwith cognitive therapy: a randomized controlledtrial. J Consult Clin Psychol 2005; 73:647–657 [A −]
498. T easdale JD, Segal ZV , Williams JM, Ridgeway VA,
Soulsby JM, Lau MA: Prevention of relapse/recur-rence in major depression by mindfulness-basedcognitive therapy. J Consult Clin Psychol 2000;68:615–623 [A–]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 125
499. Fink M, Rush AJ, Knapp R, Rasmussen K, Mueller
M, Rummans TA, O’Connor K, Husain M, Biggs
M, Bailine S, Kellner CH: DSM melancholic fea-tures are unreliable predictors of ECT response: aCORE publication. J ECT 2007; 23:139–146 [B]
500. Schmidt ME, Fava M, Zhang S, Gonzales J, Raute
NJ, Judge R: T reatment approaches to major de-pressive disorder relapse. Part 1: dose increase. Psy-chother Psychosom 2002; 71:190–194 [A]
501. Lisanby SH, Sampson S, Husain MM, Petrides G,
Knapp RG, McCall V , Young RC, Prudic J, KellnerCH: T oward individualized post-electroconvulsivetherapy care: piloting the Symptom-Titrated, Algo-rithm-Based Longitudinal ECT (STABLE) inter-
vention. J ECT 2008; 24:179–182 [G]
502. Eaton WW, Shao H, Nestadt G, Lee BH, Bienvenu
OJ, Zandi P: Population-based study of first onset
and chronicity in major depressive disorder. ArchGen Psychiatry 2008; 65:513–520 [C]
503. Mueller TI, Leon AC, Keller MB, Solomon DA,
Endicott J, Coryell W, Warshaw M, Maser JD:Recurrence after recovery from major depressivedisorder during 15 years of observational follow-up.Am J Psychiatry 1999; 156:1000–1006 [C]
504. Burcusa SL, Iacono WG: Risk for recurrence in
depression. Clin Psychol Rev 2007; 27:959–985 [F]
505. Solomon DA, Bauer MS: Continuation and main-
tenance pharmacotherapy for unipolar and bipolarmood disorders. Psychiatr Clin North Am 1993;16:515–540 [F]
506. Kupfer DJ, Frank E, Perel JM, Cornes C, Mallinger
AG, Thase ME, McEachran AB, Grochocinski VJ:Five-year outcome for maintenance therapies inrecurrent depression. Arch Gen Psychiatry 1992;49:769–773 [A]
507. Hansen R, Gaynes B, Thieda P , Gartlehner G,
DeVeaugh-Geiss A, Krebs E, Lohr K: Meta-analysisof major depressive disorder relapse and recurrencewith second-generation antidepressants. PsychiatrServ 2008; 59:1121–1130 [E]
508. Frank E, Kupfer DJ, Perel JM, Cornes C, Mallinger
AG, Thase ME, McEachran AB, Grochocinski VJ:Comparison of full-dose versus half-dose pharma-cotherapy in the maintenance treatment of recur-rent depression. J Affect Disord 1993; 27:139–145[A]
509. Solomon DA, Leon AC, Mueller TI, Coryell W,
T eres JJ, Posternak MA, Judd LL, Endicott J, KellerMB: T achyphylaxis in unipolar major depressivedisorder. J Clin Psychiatry 2005; 66:283–290 [C]
510. Posternak MA, Zimmerman M: Dual reuptake
inhibitors incur lower rates of tachyphylaxis thanselective serotonin reuptake inhibitors: a retrospec-tive study. J Clin Psychiatry 2005; 66:705–707 [G]
511. Zimmerman M, Thongy T: How often do SSRIs
and other new-generation antidepressants lose theireffect during continuation treatment? Evidencesuggesting the rate of true tachyphylaxis duringcontinuation treatment is low. J Clin Psychiatry2007; 68:1271–1276 [E]
512. Byrne S, Rothschild AJ: Psychiatrists’ responses to
failure of maintenance therapy with antidepres-sants. Psychiatr Serv 1997; 48:835–837 [G]
513. Frank E, Kupfer DJ, Wagner EF , McEachran AB,
Cornes C: Efficacy of interpersonal psychotherapyas a maintenance treatment of recurrent depression.Contributing factors. Arch Gen Psychiatry 1991;48:1053–1059 [A −]
514. Blackburn IM, Moore RG: Controlled acute and
follow-up trial of cognitive therapy and pharmaco-
therapy in out-patients with recurrent depression.
Br J Psychiatry 1997; 171:328–334 [B]
515. Belsher G, Costello CG: Relapse after recovery
from unipolar depression: a critical review. PsycholBull 1988; 104:84–96 [F]
516. Scott J: Chronic depression: can cognitive therapy
succeed when other treatments fail? BehaviouralPsychotherapy 1992; 20:25–36 [B]
517. Lejoyeux M, Ades J: Antidepressant discontinua-
tion: a review of the literature. J Clin Psychiatry1997; 58(suppl 7):11–15 [F]
518. Coupland NJ, Bell CJ, Potokar JP: Serotonin re-
uptake inhibitor withdrawal. J Clin Psychopharma-col 1996; 16:356–362 [D]
519. Dilsaver SC, Kronfol Z, Sackellares JC, Greden JF:
Antidepressant withdrawal syndromes: evidencesupporting the cholinergic overdrive hypothesis.J Clin Psychopharmacol 1983; 3:157–164 [F]
520. Fava M, Schmidt ME, Zhang S, Gonzales J, Raute
NJ, Judge R: T reatment approaches to major de-pressive disorder relapse. Part 2: reinitiation of anti-depressant treatment. Psychother Psychosom 2002;71:195–199 [A]
521. Prudic J, Sackeim HA: Electroconvulsive therapy
and suicide risk. J Clin Psychiatry 1999; 60(suppl2):104–110 [F]
522. Busch KA, Fawcett J, Jacobs DG: Clinical correlates
of inpatient suicide. J Clin Psychiatry 2003; 64:14–19 [C]
523. Bridge JA, Iyengar S, Salary CB, Barbe RP , Birma-
her B, Pincus HA, Ren L, Brent DA: Clinical re-sponse and risk for reported suicidal ideation andsuicide attempts in pediatric antidepressant treat-ment: a meta-analysis of randomized controlledtrials. JAMA 2007; 297:1683–1696 [E]
524. Dubicka B, Hadley S, Roberts C: Suicidal behaviour
in youths with depression treated with new-genera-tion antidepressants: meta-analysis. Br J Psychiatry2006; 189:393–398 [E]
525. Goodman WK, Murphy TK, Storch EA: Risk of
adverse behavioral effects with pediatric use of an-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
126 APA PRACTICE GUIDELINES
tidepressants. Psychopharmacology (Berl) 2007;
191:87–96 [E]
526. Hall WD, Lucke J: How have the selective seroto-
nin reuptake inhibitor antidepressants affected sui-cide mortality? Aust N Z J Psychiatry 2006; 40:941–950 [F]
527. Hetrick S, Merry S, McKenzie J, Sindahl P , Proctor
M: Selective serotonin reuptake inhibitors (SSRIs)for depressive disorders in children and adolescents.Cochrane Database Syst Rev 2007; CD004851 [E]
528. Kaizar EE, Greenhouse JB, Seltman H, Kelleher K:
Do antidepressants cause suicidality in children? ABayesian meta-analysis. Clin T rials 2006; 3:73–90[E]
529. Mosholder AD, Willy M: Suicidal adverse events in
pediatric randomized, controlled clinical trials ofantidepressant drugs are associated with active drugtreatment: a meta-analysis. J Child Adolesc Psy-chopharmacol 2006; 16:25–32 [E]
530. Wohlfarth TD, van Zwieten BJ, Lekkerkerker FJ,
Gispen-de Wied CC, Ruis JR, Elferink AJ,Storosum JG: Antidepressants use in children andadolescents and the risk of suicide. Eur Neuropsy-chopharmacol 2006; 16:79–83 [E]
531. Hammad TA, Laughren TP , Racoosin JA: Suicide
rates in short-term randomized controlled trials ofnewer antidepressants. J Clin Psychopharmacol2006; 26:203–207 [E]
532. Mann JJ, Emslie G, Baldessarini RJ, Beardslee W,
Fawcett JA, Goodwin FK, Leon AC, Meltzer HY,Ryan ND, Shaffer D, Wagner KD: ACNP T askForce report on SSRIs and suicidal behavior inyouth. Neuropsychopharmacology 2006; 31:473–492 [G]
533. T sapakis EM, Soldani F, T ondo L, Baldessarini RJ:
Efficacy of antidepressant s in juvenile depression:
meta-analysis. Br J Psychiatry 2008; 193:10–17 [E]
534. March JS, Klee BJ, Kremer CM: T reatment benefit
and the risk of suicidality in multicenter, random-ized, controlled trials of sertraline in children andadolescents. J Child Adolesc Psychopharmacol2006; 16:91–102 [E]
535. Simon GE, Savarino J: Suicide attempts among
patients starting depression treatment with medi-cations or psychotherapy. Am J Psychiatry 2007;164:1029–1034 [C]
536. US Food and Drug Administration: FDA Propos-
es New Warnings About Suicidal Thinking, Behav-ior in Young Adults Who T ake AntidepressantMedications, May 2, 2007. http://www.fda.gov/bbs/topics/NEWS/2007/NEW01624.html [G]
537. Stoudemire A, Hill C, Gulley LR, Morris R: Neu-
ropsychological and biomedical assessment of de-pression-dementia syndromes. J NeuropsychiatryClin Neurosci 1989; 1:347–361 [C]538. Caine ED: Pseudodementia. Current concepts
and future directions. Arch Gen Psychiatry 1981;38:1359–1364 [F]
539. American Psychiatric Association: Practice Guide-
line for the T reatment of Patients With Alzheimer’sDisease and Other Dementias, Second Edition. AmJ Psychiatry 2007; 164(Dec suppl):5–56 [A −]
540. Saez-Fonseca JA, Lee L, Walker Z: Long-term
outcome of depressive pseudodementia in the eld-erly. J Affect Disord 2007; 101:123–129 [C]
541. Alexopoulos GS, Meyers BS, Young RC, Mattis S,
Kakuma T: The course of geriatric depression with“reversible dementia”: a controlled study. Am J Psy-chiatry 1993; 150:1693–1699 [C]
542. Alexopoulos GS, Kiosses DN, Heo M, Murphy CF ,
Shanmugham B, Gunning-Dixon F: Executive dys-function and the course of geriatric depression. BiolPsychiatry 2005; 58:204–210 [G]
543. Alexopoulos GS, Kiosses DN, Klimstra S, Kalayam
B, Bruce ML: Clinical presentation of the “depres-sion-executive dysfunction syndrome” of late life.Am J Geriatr Psychiatry 2002; 10:98–106 [G]
544. Andreescu C, Mulsant BH, Peasley-Miklus C,
Rothschild AJ, Flint AJ, Heo M, Caswell M, WhyteEM, Meyers BS: Persisting low use of antipsychoticsin the treatment of major depressive disorder withpsychotic features. J Clin Psychiatry 2007; 68:194–200 [G]
545. Mulsant BH, Haskett RF , Prudic J, Thase ME,
Malone KM, Mann JJ, Pettinati HM, Sackeim HA:Low use of neuroleptic drugs in the treatment ofpsychotic major depression. Am J Psychiatry 1997;154:559–561 [D]
546. Rasmussen KG, Mueller M, Kellner CH, Knapp
RG, Petrides G, Rummans TA, Husain MM,O’Connor MK, Black JL, Sampson S, Fink M:Patterns of psychotropic medication use among pa-tients with severe depres sion referred for elec-
troconvulsive therapy: data from the Consortiumfor Research on Electroconvulsive Therapy. J ECT2006; 22:116–123 [G]
547. Parker G, Roy K, Hadzi-Pavlovic D, Pedic F: Psy-
chotic (delusional) depression: a meta-analysis ofphysical treatments. J Affect Disord 1992; 24:17–24[E]
548. Spiker DG, Weiss JC, Dealy RS, Griffin SJ, Hanin
I, Neil JF , Perel JM, Rossi AJ, Soloff PH: Thepharmacological treatment of delusional depres-sion. Am J Psychiatry 1985; 142:430–436 [A]
549. Rothschild AJ, Williamson DJ, T ohen MF,
Schatzberg A, Andersen SW, Van Campen LE,Sanger TM, T ollefson GD: A double-blind, ran-domized study of olanzapine and olanzapine/fluox-etine combination for major depression withpsychotic features. J Clin Psychopharmacol 2004;24:365–373 [A]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 127
550. Mulsant BH, Sweet RA, Rosen J, Pollock BG,
Zubenko GS, Flynn T, Begley AE, Mazumdar S,
Reynolds CF III: A double-blind randomized com-parison of nortriptyline plus perphenazine versusnortriptyline plus placebo in the treatment of psy-chotic depression in late life. J Clin Psychiatry 2001;62:597–604 [A]
551. Wijkstra J, Lijmer J, Balk FJ, Geddes JR, Nolen
WA: Pharmacological treatment for unipolarpsychotic depression: systematic review and meta-analysis. Br J Psychiatry 2006; 188:410–415 [E]
552. Price LH, Conwell Y, Nelson JC: Lithium augmen-
tation of combined neuroleptic-tricyclic treatmentin delusional depression. Am J Psychiatry 1983;
140:318–322 [E]
553. Rosebush PI, Hildebrand AM, Furlong BG,
Mazurek MF: Catatonic syndrome in a general
psychiatric inpatient population: frequency, clinicalpresentation, and response to lorazepam. J ClinPsychiatry 1990; 51:357–362 [B]
554. Pataki J, Zervas IM, Jandorf L: Catatonia in a uni-
versity inpatient service (1985–1990). ConvulsTher 1992; 8:163–173 [G]
555. Starkstein SE, Petracca G, T eson A, Chemerinski
E, Merello M, Migliorelli R, Leiguarda R: Catato-nia in depression: prevalence, clinical correlates,and validation of a scale. J Neurol Neurosurg Psy-chiatry 1996; 60:326–332 [G]
556. T aylor MA, Fink M: Catatonia in psychiatric clas-
sification: a home of its own. Am J Psychiatry 2003;160:1233–1241 [F]
557. Bush G, Fink M, Petrides G, Dowling F, Francis A:
Catatonia. I. Rating scale and standardized exami-nation. Acta Psychiatr Scand 1996; 93:129–136 [G]
558. Caroff SN, Mann SC, Francis A, Fricchione GL
(eds): Catatonia: From Psychopathology to Neuro-biology. Arlington, VA, American Psychiatric Pub-lishing, 2006 [G]
559. Fink M, T aylor MA: Catatonia: A Clinician’s Guide
to Diagnosis and T reatment Cambridge, UK, Cam-bridge University Press, 2003 [G]
560. White DA, Robins AH: An analysis of 17 catatonic
patients diagnosed with neuroleptic malignant syn-drome. CNS Spectr 2000; 5:58–65 [G]
561. Clerc GE, Ruimy P , Verdeau-Palles J: A double-
blind comparison of venlafaxine and fluoxetine inpatients hospitalized for major depression and mel-ancholia. The Venlafaxine  French Inpatient Study
Group. Int Clin Psychopharmacol 1994; 9:139–143[A]
562. Perry PJ: Pharmacotherapy for major depression
with melancholic features: relative efficacy of tricy-clic versus selective serotonin reuptake inhibitorantidepressants. J Affect Disord 1996; 39:1–6 [F]563. Thase ME, Friedman ES: Is psychotherapy an ef-
fective treatment for melancholia and other severedepressive states? J Affect Disord 1999; 54:1–19 [F]
564. Grunebaum MF , Galfalvy HC, Oquendo MA,
Burke AK, Mann JJ: Melancholia and the probabil-ity and lethality of suicide attempts. Br J Psychiatry2004; 184:534–535 [C]
565. Novick JS, Stewart JW, Wisniewski SR, Cook IA,
Manev R, Nierenberg AA, Rosenbaum JF , Shores-Wilson K, Balasubramani GK, Biggs MM, ZisookS, Rush AJ: Clinical and demographic features ofatypical depression in outpatients with major de-pressive disorder: preliminary findings fromSTAR*D. J Clin Psychiatry 2005; 66:1002–1011 [B]
566. Thase ME: Recognition and diagnosis of atypical
depression. J Clin Psychiatry 2007; 68(suppl 8):11–16 [F]
567. Mitchell PB, Goodwin GM, Johnson GF, Hirsch-
feld RM: Diagnostic guidelines for bipolar depres-sion: a probabilistic approach. Bipolar Disord 2008;10:144–152 [F]
568. Akiskal HS, Benazzi F: At ypical depression: a vari-
ant of bipolar II or a bridge between unipolar andbipolar II? J Affect Disord 2005; 84:209–217 [G]
569. Stewart JW, McGrath PJ, Quitkin FM, Harrison
W, Markowitz J, Wager S, Leibowitz MR: Rele-vance of DMS-III depressive subtype and chronic-ity of antidepressant efficac y in atypical depression.
Differential response to phenelzine, imipramine,and placebo. Arch Gen Psychiatry 1989; 46:1080–1087 [B]
570. Liebowitz MR, Quitkin FM, Stewart JW, McGrath
PJ, Harrison WM, Markowitz JS, Rabkin JG, T ri-camo E, Goetz DM, Klein DF: Antidepressantspecificity in atypical depression. Arch Gen Psychi-atry 1988; 45:129–137 [A −]
571. Quitkin FM, Stewart JW, McGrath PJ, Liebowitz
MR, Harrison WM, T ricamo E, Klein DF , RabkinJG, Markowitz JS, Wager SG: Phenelzine versusimipramine in the treatment of probable atypicaldepression: defining syndrome boundaries of se-lective MAOI responders. Am J Psychiatry 1988;145:306–311 [A]
572. Quitkin FM, Harrison W, Stewart JW, McGrath
PJ, T ricamo E, Ocepek-Welikson K, Rabkin JG,Wager SG, Nunes E, Klein DF: Response tophenelzine and imipramine in placebo nonre-sponders with atypical depression: a new applica-
tion of the crossover de sign. Arch Gen Psychiatry
1991; 48:319–323 [A]
573. Goodnick PJ, Extein I: Bupropion and fluoxetine in
depressive subtypes. Ann Clin Psychiatry 1989; 1:119–122 [C]
574. Goodnick PJ: Acute and long-term bupropion ther-
apy: response and side effects. Ann Clin Psychiatry1991; 3:311–313 [C]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
128 APA PRACTICE GUIDELINES
575. Pande AC, Birkett M, Fechner-Bates S, Haskett RF,
Greden JF: Fluoxetine versus phenelzine in atypical
depression. Biol Psychiatry 1996; 40:1017–1020 [A]
576. Jarrett RB, Schaffer M, McIntire D, Witt-Browder
A, Kraft D, Risser RC: T reatment of atypical depres-sion with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial. Arch Gen Psychiatry1999; 56:431–437 [A −]
577. Shea MT, Elkin I, Sotsky SM: Patient characteris-
tics associated with successful treatment: outcomefindings from the NIMH T reatment of DepressionCollaborative Research Program, in PsychotherapyIndications and Outcomes. Edited by Janowsky DS.Washington, DC, American Psychiatric Publish-
ing, 1999, pp 71–90 [F]
578. Husain MM, McClintock SM, Rush AJ, Knapp RG,
Fink M, Rummans TA, Rasmussen K, Claassen C,
Petrides G, Biggs MM, Mueller M, Sampson S,Bailine SH, Lisanby SH, Kellner CH: The efficacyof acute electroconvulsive therapy in atypical de-pression. J Clin Psychiatry 2008; 69:406–411 [B]
579. Howland RH: Pharmacotherapy of dysthymia: a
review. J Clin Psychopharmacol 1991; 11:83–92 [G]
580. Keller MB, Hanks DL, Klein DN: Summary of the
DSM-IV mood disorders field trial and issue over-view. Psychiatr Clin North Am 1996; 19:1–28 [F]
581. Kocsis JH, Frances AJ, Voss C, Mann JJ, Mason BJ,
Sweeney J: Imipramine treatment for chronic de-pression. Arch Gen Psychiatry 1988; 45:253–257[A]
582. Rush AJ, Thase ME: Psychotherapies for depressive
disorders: a review, in Depressive Disorders. Editedby Maj M, Sartorius N. Chichester, UK, John Wiley& Sons, 2003, pp 161–206 [G]
583. Zimmerman M, Chelminski I, McDermut W: Ma-
jor depressive disorder and Axis I diagnostic comor-bidity. J Clin Psychiatry 2002; 63:187–193 [F]
584. Kessler RC, Chiu WT, Demler O, Merikangas KR,
Walters EE: Prevalence, severity, and comorbidityof 12-month DSM-IV disorders in the NationalComorbidity Survey Replication. Arch Gen Psychi-atry 2005; 62:617–627 [G]
585. Dunner DL: Clinical consequences of under-rec-
ognized bipolar spectrum disorder. Bipolar Disord2003; 5:456–463 [F]
586. Schatzberg AF, Ballenger JC: Decisions for the cli-
nician in the treatment of panic disorder: when totreat, which treatment to use, and how long to treat.J Clin Psychiatry 1991; 52(suppl):26–31 [G]
587. Schneier FR, Blanco C, Campeas R, Lewis-Fernan-
dez R, Lin SH, Marshall R, Schmidt AB, Sanchez-Lacay JA, Simpson HB, Liebowitz MR: Citalopramtreatment of social anxiet y disorder with comorbid
major depression. Depress Anxiety 2003; 17:191–196 [B]588. Brady KT, Clary CM: Affective and anxiety comor-
bidity in post-traumatic stress disorder treatmenttrials of sertraline. Compr Psychiatry 2003; 44:360–369 [A]
589. Simon NM, Emmanuel N, Ballenger J, Worthing-
ton JJ, Kinrys G, Korbly NB, Farach FJ, PollackMH: Bupropion sustained release for panic disor-der. Psychopharmacol Bull 2003; 37:66–72 [B]
590. Sheehan DV , Davidson J, Manschreck T, Van Wyck
FJ: Lack of efficacy of a new antidepressant (bupro-
pion) in the treatment of panic disorder with pho-bias. J Clin Psychopharmacol 1983; 3:28–31 [C]
591. American Psychiatric As sociation: Practice Guide-
lines for the T reatment of Patients With Panic Dis-
order, Second Edition. Am J Psychiatry 2009; 166:(Jan
suppl)1–68 [G]
592. Ninan PT , Rush AJ, Crits-Christoph P , Kornstein
SG, Manber R, Thase ME, Trivedi MH, RothbaumBO, Zajecka J, Borian FE, Keller MB: Symptomaticand syndromal anxiety in chronic forms of major
depression: effect of nefazodone, cognitive behav-ioral analysis system of psychotherapy, and theircombination. J Clin Psychiatry 2002; 63:434–441[A−]
593. Jenike MA, Buttolph L, Baer L, Ricciardi J, Holland
A: Open trial of fluoxetine in obsessive-compulsivedisorder. Am J Psychiatry 1989; 146:909–911 [A]
594. The Clomipramine Collaborative Study Group:
Clomipramine in the treatment of patients withobsessive-compulsive disorder. Arch Gen Psychia-try 1991; 48:730–738 [A]
595. American Psychiatric Association: Practice Guide-
line for the T reatment of Patients With Obsessive-Compulsive Disorder. Am J Psychiatry 2007; 164(Julysuppl):5–53 [G]
596. Alexopoulos GS, Abrams RC, Y oung RC, Shamoian
CA: Cornell Scale for Depression in Dementia. BiolPsychiatry 1988; 23:271–284 [G]
597. Bains J, Birks JS, Dening TR: The efficacy of
antidepressants in the treatment of depression indementia. Cochrane Database Syst Rev 2002;CD003944 [E]
598. Lyketsos CG, DelCampo L, Steinberg M, Miles Q,
Steele CD, Munro C, Baker AS, Sheppard JM,Frangakis C, Brandt J, Rabins PV: T reating depres-sion in Alzheimer diseas e: efficacy and safety of
sertraline therapy, and the benefits of depressionreduction: the DIADS. Arch Gen Psychiatry 2003;60:737–746 [A–]
599. Thompson S, Herrmann N, Rapoport MJ, Lanctot
KL: Efficacy and safety of antidepressants fortreatment of depression in Alzheimer’s disease: ametaanalysis. Can J Psychiatry 2007; 52:248–255[E]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 129
600. Moore AR, O’Keeffe ST: Drug-induced cognitive
impairment in the elderly. Drugs Aging 1999;
15:15–28 [G]
601. Krystal AD, Coffey CE: Neuropsychiatric consid-
erations in the use of electroconvulsive therapy.J Neuropsychiatry Clin Neurosci 1997; 9:283–292[F]
602. Weiner RD, Coffey CE, Krystal AD: Electrocon-
vulsive therapy in the medical and neurologic pa-tient, in Psychiatric Care of the Medical Patient.Edited by Stoudemire A, Fogel B, Greenberg D.New York, Oxford University Press, 2000, pp 419–428 [F]
603. Blair-West GW, Cantor CH, Mellsop GW, Eye-
son-Annan ML: Lifetime suicide risk in major de-pression: sex and age dete rminants. J Affect Disord
1999; 55:171–178 [C]
604. Mann JJ, Waternaux C, Haas GL, Malone KM:
T oward a clinical model of suicidal behavior inpsychiatric patients. Am J Psychiatry 1999; 156:181–189 [C]
605. Dhossche DM, Meloukheia AM, Chakravorty S:
The association of suicid e attempts and comorbid
depression and substance abuse in psychiatric con-sultation patients. Gen Hosp Psychiatry 2000;22:281–288 [C]
606. Arsenault-Lapierre G, Kim C, T urecki G: Psychiat-
ric diagnoses in 3275 suicides: a meta-analysis. BMCPsychiatry 2004; 4:37 [E]
607. Currie SR, Patten SB, Williams JV , Wang J, Beck
CA, El Guebaly N, Maxwell C: Comorbidity ofmajor depression with substance use disorders. CanJ Psychiatry 2005; 50:660–666 [C]
608. Kung HC, Pearson JL, Wei R: Substance use, fire-
arm availability, depressive symptoms, and mentalhealth service utilization among white and AfricanAmerican suicide decedents aged 15 to 64 years.Ann Epidemiol 2005; 15:614–621 [D]
609. Sands BF, Ciraulo DA: Cocaine drug-drug interac-
tions. J Clin Psychopharmacol 1992; 12:49–55 [G]
610. American Psychiatric Association: Practice Guide-
line for the T reatment of Patients With BorderlinePersonality Disorder. Am J Psychiatry 2001;158(Oct suppl):1–52 [G]
611. Linehan MM: Cognitive-Behavioral Therapy for
Borderline Personality Disorder. New York, Guil-ford, 1993 [G]
612. Linehan MM, Armstrong HE, Suarez A, Allmon D,
Heard HL: Cognitive-behavioral treatment ofchronically parasuicidal borderline patients. ArchGen Psychiatry 1991; 48:1060–1064 [A −]
613. Bateman A, Fonagy P: T reatment of borderline
personality disorder with psychoanalytically orient-
ed partial hospitalization: an 18-month follow-up.Am J Psychiatry 2001; 158:36–42 [A −]614. Clarkin JF, Levy KN, Lenzenweger MF, Kernberg
OF: Evaluating three treatments for borderline per-sonality disorder: a multiwave study. Am J Psychia-try 2007; 164:922–928 [A −]
615. Giesen-Bloo J, van Dyck R, Spinhoven P , van Til-
burg W, Dirksen C, van Asselt T, Kremers I, NadortM, Arntz A: Outpatient  psychotherapy for bor-
derline personality disorder: randomized trial ofschema-focused therapy vs transference-focusedpsychotherapy. Arch Gen Psychiatry 2006; 63:649–658 [A −]
616. Newton-Howes G, T yrer P , Johnson T: Personality
disorder and the outcome of depression: meta-analysis of published studies. Br J Psychiatry 2006;
188:13–20 [E]
617. Shea MT, Glass DR, Pilkonis PA, Watkins J, Do-
cherty JP: Frequency and implications of person-
ality disorders in a sample of depressed outpatients.J Personal Disord 1987; 1:27–42 [C]
618. Grilo CM, Sanislow CA, Shea MT, Skodol AE,
Stout RL, Gunderson JG, Yen S, Bender DS, Paga-no ME, Zanarini MC, Morey LC, McGlashan TH:T wo-year prospective naturalistic study of remis-sion from major depressive disorder as a function ofpersonality disorder comorbidity. J Consult ClinPsychol 2005; 73:78–85 [C]
619. Gunderson JG, Stout RL, Sanislow CA, Shea MT ,
McGlashan TH, Zanarini MC, Daversa MT, GriloCM, Yen S, Skodol AE: New episodes and newonsets of major depression in borderline and otherpersonality disorders. J Affect Disord 2008; 111:40–45 [C]
620. Vieta E, Nieto E, Gasto C, Cirera E: Serious suicide
attempts in affective patients. J Affect Disord 1992;24:147–152 [D]
621. Cyranowski JM, Frank E, Winter E, Rucci P , Nov-
ick D, Pilkonis P , Fagiolini A, Swartz HA, Houck P ,Kupfer DJ: Personality pathology and outcome inrecurrently depressed women over 2 years of main-tenance interpersonal psychotherapy. Psychol Med2004; 34:659–669 [E]
622. Grant BF, Chou SP , Goldstein RB, Huang B, Stin-
son FS, Saha TD, Smith SM, Dawson DA, PulayAJ, Pickering RP , Ruan WJ: Prevalence, correlates,disability, and comorbidity of DSM-IV borderlinepersonality disorder: results from the Wave 2 Na-tional Epidemiologic Survey on Alcohol and Relat-ed Conditions. J Clin Psychiatry 2008; 69:533–545[G]
623. Gunderson JG: Borderline Personality Disorder: A
Clinical Guide. Washington, DC, American Psy-chiatric Publishing, 2001 [G]
624. Koenigsberg HW, Anwunah I, New AS, Mitropou-
lou V , Schopick F, Siever LJ: Relationship betweendepression and borderline personality disorder.Depress Anxiety 1999; 10:158–167 [G]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
130 APA PRACTICE GUIDELINES
625. Soloff PH, George A, Nathan RS, Schulz PM, Perel
JM: Paradoxical effects of amitriptyline on border-
line patients. Am J Psychiatry 1986; 143:1603–1605[A]
626. Soloff PH, George A, Nathan RS, Schulz PM,
Ulrich RF , Perel JM: Progress in pharmacotherapyof borderline disorders. A double-blind study ofamitriptyline, haloperidol, and placebo. Arch GenPsychiatry 1986; 43:691–697 [A]
627. Soloff PH: Psychopharmacology of borderline per-
sonality disorder. Psychiatr Clin North Am 2000;23:169–92, ix [G]
628. Soloff PH: Studying the treatment contract in in-
tensive psychotherapy with borderline patients. Inter-
personal and Biological Processes 1993; 56:264–267
[G]
629. Links PS, Steiner M, Boiago I, Irwin D: Lithium
therapy for borderline patients: preliminary find-ings. J Personal Disord 1990; 4:173–181 [G]
630. Gunderson JG, Morey LC, Stout RL, Skodol AE,
Shea MT, McGlashan TH, Zanarini MC, GriloCM, Sanislow CA, Yen S, Daversa MT, Bender DS:Major depressive disorder and borderline person-ality disorder revisited: longitudinal interactions. JClin Psychiatry 2004; 65:1049–1056 [C]
631. Javaras KN, Pope HG, Lalonde JK, Roberts JL,
Nillni YI, Laird NM, Bulik CM, Crow SJ, McElroySL, Walsh BT , T suang MT , Rosenthal NR, HudsonJI: Co-occurrence of binge eating disorder withpsychiatric and medical disorders. J Clin Psychiatry2008; 69:266–273 [G]
632. Stroud CB, Davila J, Moyer A: The relationship
between stress and depression in first onsets versusrecurrences: a meta-analytic review. J Abnorm Psy-chol 2008; 117:206–213 [E]
633. Galea S, Ahern J, Nandi A, T racy M, Beard J,
Vlahov D: Urban neighborhood poverty and theincidence of depression in a population-based co-hort study. Ann Epidemiol 2007; 17:171–179 [E]
634. Huurre T, Eerola M, Rahkonen O, Aro H: Does
social support affect the relationship between socio-economic status and depression? A longitudinalstudy from adolescence to adulthood. J Affect Dis-ord 2007; 100:55–64 [C]
635. Gilman SE, Kawachi I, Fitzmaurice GM, Buka SL:
Socioeconomic status in childhood and the lifetime
risk of major depression. Int J Epidemiol 2002;31:359–367 [C]
636. Breslau N, Davis GC, Peterson EL, Schultz LR: A
second look at comorbidity in victims of trauma: the
posttraumatic stress disorder-major depressionconnection. Biol Psychiatry 2000; 48:902–909 [G]
637. Fazel M, Wheeler J, Danesh J: Prevalence of serious
mental disorder in 7000 refugees resettled in west-ern countries: a systematic review. Lancet 2005;365:1309–1314 [E]638. Gagnon MD, Hersen M, Kabacoff RI, Van Hasselt
VB: Interpersonal and psychological correlates ofmarital dissatisfaction in late life: a review. ClinPsychol Rev 1999; 19:359–378 [G]
639. Whisman MA, Bruce ML: Marital dissatisfaction
and incidence of major depressive episode in a com-munity sample. J Abnorm Psychol 1999; 108:674–678 [C]
640. Shear K, Frank E, Houck PR, Reynolds CF , III:
T reatment of complicated grief: a randomized con-trolled trial. JAMA 2005; 293:2601–2608 [A −]
641. Parkes CM: Bereavement in adult life. BMJ 1998;
316:856–859 [F]
642. Neria Y, Gross R, Litz B, Maguen S, Insel B, Seir-
marco G, Rosenfeld H, Suh EJ, Kishon R, Cook J,Marshall RD: Prevalence and psychological corre-lates of complicated grief among bereaved adults2.5–3.5 years after September 11th attacks. J T rau-ma Stress 2007; 20:251–262 [G]
643. Shear KM, Jackson CT, Essock SM, Donahue SA,
Felton CJ: Screening for complicated grief amongProject Liberty service recipients 18 months afterSeptember 11, 2001. Psychiatr Serv 2006; 57:1291–1297 [G]
644. Zisook S, Shuchter SR: Depression through the
first year after the death of a spouse. Am J Psychiatry1991; 148:1346–1352 [C]
645. Lewis-Fernandez R, Diaz N: The cultural formu-
lation: a method for assessing cultural factors affect-ing the clinical encounter. Psychiatr Q 2002; 73:271–295 [F]
646. Lim RF (ed): Clinical Manual of Cultural Psychia-
try. Arlington, VA, American Psychiatric Publish-ing, 2006 [G]
647. American Psychiatric Association: Appendix I.
Outline for Cultural Formulation and Glossary ofCulture-Bound Syndromes, in Diagnostic and Sta-tistical Manual of Mental  Disorders, T ext Revision
(DSM-IV-TR). Washington, DC, American Psy-chiatric Association, 2000, pp 897–903 [G]
648. Sclar DA, Robison LM, Skaer TL, Galin RS: Eth-
nicity and the prescribing of antidepressant pharma-cotherapy: 1992–1995. Harv Rev Psychiatry 1999;7:29–36 [F]
649. T urner RJ, Lloyd DA: Stress burden and the life-
time incidence of psychiatric disorder in youngadults: racial and ethnic contrasts. Arch Gen Psy-chiatry 2004; 61:481–488 [G]
650. Demyttenaere K, Bruffaerts R, Posada-Villa J,
Gasquet I, Kovess V , Lepine JP , Angermeyer MC,Bernert S, de Girolamo G, Morosini P , Polidori G,Kikkawa T , Kawakami N, Ono Y, T akeshima T, UdaH, Karam EG, Fayyad JA, Karam AN, MneimnehZN, Medina-Mora ME, Borges G, Lara C, de GraafR, Ormel J, Gureje O, Shen Y, Huang Y, Zhang M,Alonso J, Haro JM, Vilagut G, Bromet EJ, Gluzman
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 131
S, Webb C, Kessler RC, Merikangas KR, Anthony
JC, Von Korff MR, Wang PS, Brugha TS, Aguilar-Gaxiola S, Lee S, Heeringa S, Pennell BE,Zaslavsky AM, Ustun TB, Chatterji S: Prevalence,severity, and unmet need for treatment of mentaldisorders in the World Health Organization WorldMental Health Surveys. JAMA 2004; 291:2581–2590 [G]
651. Weissman MM, Bland RC, Canino GJ, Faravelli C,
Greenwald S, Hwu HG, Joyce PR, Karam EG, LeeCK, Lellouch J, Lepine JP , Newman SC, Rubio-Stipec M, Wells JE, Wickramaratne PJ, WittchenH, Yeh EK: Cross-national epidemiology of majordepression and bipolar disorder. JAMA 1996;
276:293–299 [G]
652. Williams DR, Gonzalez HM, Neighbors H, Nesse
R, Abelson JM, Sweetman J, Jackson JS: Prevalence
and distribution of major depressive disorder inAfrican Americans, Caribbean blacks, and non-Hispanic whites: results from the National Surveyof American Life. Arch Gen Psychiatry 2007;64:305–315 [G]
653. Grant BF, Stinson FS, Hasin DS, Dawson DA,
Chou SP , Anderson K: Immigration and lifetimeprevalence of DSM-IV psychiatric disorders amongMexican Americans and non- Hispanic whites in the
United States: results from the National Epidemi-ologic Survey on Alcohol and Related Conditions.Arch Gen Psychiatry 2004; 61:1226–1233 [G]
654. Breslau J, Aguilar-Gaxiola S, Kendler KS, Su M,
Williams D, Kessler RC: Specifying race-ethnicdifferences in risk for psychiatric disorder in a USAnational sample. Psychol Med 2006; 36:57–68 [G]
655. Hasin DS, Goodwin RD, Stinson FS, Grant BF:
Epidemiology of major depressive disorder: resultsfrom the National Epidemiologic Survey on Alco-holism and Related Conditions. Arch Gen Psychi-atry 2005; 62:1097–1106 [G]
656. Parker G, Chan B, Hadzi-Pavlovic D: Lower rates
of depression in wester nised Chinese in the US.
J Affect Disord 2007; 104:175–178 [G]
657. Escobar JI, Gomez J, T uason VB: Depressive phe-
nomenology in North and South American pa-tients. Am J Psychiatry 1983; 140:47–51 [C]
658. Miller G: Mental health in developing countries.
China: healing the metaphorical heart. Science2006; 311:462–463 [G]
659. Marcos LR, Uruyo L, Kesselman M, Alpert M: The
language barrier in evaluating Spanish-Americanpatients. Arch Gen Psychiatry 1973; 29:655–659[C]
660. Rodriguez CI, Cabaniss DL, Arbuckle MR, Oquen-
do MA: The role of culture in psychodynamic psy-chotherapy: parallel process resulting from culturalsimilarities between patient and therapist. Am JPsychiatry 2008; 165:1402–1406 [G]661. Chatters LM, Bullard KM, T aylor RJ, Woodward
AT, Neighbors HW, Jackson JS: Religious partici-pation and DSM-IV disorders among older AfricanAmericans: findings from the National Survey ofAmerican Life. Am J Geriatr Psychiatry 2008;16:957–965 [G]
662. Norton MC, Singh A, Skoog I, Corcoran C,
T schanz JT, Zandi PP , Breitner JC, Welsh-BohmerKA, Steffens DC: Church attendance and new epi-sodes of major depression in a community study ofolder adults: the Cache County Study. J Gerontol BPsychol Sci Soc Sci 2008; 63:129–137 [G]
663. Hatzenbuehler ML, Keyes KM, Narrow WE,
Grant BF , Hasin DS: Racial/ethnic disparities in
service utilization for individuals with co-occurring
mental health and substance use disorders in thegeneral population: results from the national epi-demiologic survey on alcohol and related condi-tions. J Clin Psychiatry 2008; 69:1112–1121 [G]
664. Ojeda VD, McGuire TG: Gender and racial/ethnic
differences in use of outpatient mental health andsubstance use services by depressed adults. Psychi-atr Q 2006; 77:211–222 [G]
665. Mojtabai R, Olfson M: T reatment seeking for de-
pression in Canada and the United States. PsychiatrServ 2006; 57:631–639 [G]
666. Blazer DG, Hybels CF, Simonsick EM, Hanlon JT:
Marked differences in antidepressant use by race inan elderly community sample: 1986–1996. Am JPsychiatry 2000; 157:1089–1094 [C]
667. Melfi CA, Croghan TW, Hanna MP , Robinson RL:
Racial variation in antide pressant treatment in a
Medicaid population. J Clin Psychiatry 2000;61:16–21 [G]
668. Mojtabai R: Increase in antidepressant medication
in the US adult population between 1990 and 2003.Psychother Psychosom 2008; 77:83–92 [G]
669. Sirey JA, Meyers BS, Bruce ML, Alexopoulos GS,
Perlick DA, Raue P: Predictors of antidepressantprescription and early use among depressed outpa-tients. Am J Psychiatry 1999; 156:690–696 [G]
670. Williams MD, Rummans T, Sampson S, Knapp R,
Mueller M, Husain MM, Fink M, Rasmussen K,O’Connor K, Smith G, Petrides G, Kellner CH:Outcome of electroconvulsive therapy by race in theConsortium for Research on ElectroconvulsiveTherapy multisite study. J ECT 2008; 24:117–121[B]
671. Mojtabai R, Olfson M: National trends in psycho-
therapy by office-based psychiatrists. Arch GenPsychiatry 2008; 65:962–970 [G]
672. Richardson J, Anderson T, Flaherty J, Bell C: The
quality of mental health care for African Americans.Cult Med Psychiatry 2003; 27:487–498 [G]
673. Warden D, Rush AJ, Wisniewski SR, Lesser IM,
Kornstein SG, Balasubramani GK, Thase ME,
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
132 APA PRACTICE GUIDELINES
Preskorn SH, Nierenberg AA, Y oung EA, Shores-
Wilson K, T rivedi MH: What predicts attrition insecond step medication treatments for depression?:a STAR*D Report. Int J Neuropsychopharmacol2008;1–15 [B]
674. Gilmer WS, T rivedi MH, Rush AJ, Wisniewski SR,
Luther J, Howland RH, Y ohanna D, Khan A, AlpertJ: Factors associated with chronic depressive epi-sodes: a preliminary report from the STAR-Dproject. Acta Psychiatr Scand 2005; 112:425–433[B]
675. Fogel J, Ford DE: Stigma beliefs of Asian Ameri-
cans with depression in an Internet sample. Can JPsychiatry 2005; 50:470–478 [G]
676. Vega WA, Kolody B, Aguilar-Gaxiola S, Catalano
R: Gaps in service utilization by Mexican Americanswith mental health problems. Am J Psychiatry 1999;156:928–934 [C]
677. Padgett DK, Patrick C, Burns BJ, Schlesinger HJ:
Ethnicity and the use of outpatient mental healthservices in a national insured population. Am JPublic Health 1994; 84:222–226 [E]
678. Greenberg GA, Rosenheck RA: Change in mental
health service delivery among blacks, whites, andHispanics in the Department of Veterans Affairs.Adm Policy Ment Health 2003; 31:31–43 [C]
679. Dwight-Johnson M, Sherbourne CD, Liao D,
Wells KB: T reatment preferences among depressedprimary care patients. J Gen Intern Med 2000;15:527–534 [G]
680. Dunlop DD, Song J, Lyons JS, Manheim LM,
Chang RW: Racial/ethnic differences in rates ofdepression among preretirement adults. Am J Pub-lic Health 2003; 93:1945–1952 [G]
681. Mojtabai R: T rends in contacts with mental health
professionals and cost barri ers to mental health care
among adults with significant psychological distressin the United States: 1997–2002. Am J PublicHealth 2005; 95:2009–2014 [G]
682. Chen ML: Ethnic or racial differences revisited:
impact of dosage regimen and dosage form on phar-macokinetics and pharmacodynamics. Clin Phar-macokinet 2006; 45:957–964 [F]
683. Ozawa S, Soyama A, Saeki M, Fukushima-Uesaka
H ,  I t o d a  M ,  K o y a n o  S ,  S a i  K ,  O h n o  Y ,  S a i t o  Y ,Sawada J: Ethnic differences in genetic poly-morphisms of CYP2D6, CYP2C19, CYP3As andMDR1/ABCB1. Drug Metab Pharmacokinet 2004;19:83–95 [F]
684. Smith MW: Ethnopharmacology, in Clinical Man-
ual of Cultural Psychiatry. Edited by Lim RF . Ar-lington, VA, American Psychiatric Publishing,2006, pp 207–235 [G]
685. Escobar JI, T uason VB: Antidepressant agents—a
cross-cultural study. Psychopharmacol Bull 1980;16:49–52 [C]686. Marcos LR, Cancro R: Pharmacotherapy of His-
panic depressed patients: clinical observations. AmJ Psychother 1982; 36:505–512 [F]
687. Pi EH, Simpson GM: Cross-cultural psychophar-
macology: a current clinical perspective. PsychiatrServ 2005; 56:31–33 [F]
688. Lesser IM, Castro DB, Gaynes BN, Gonzalez J,
Rush AJ, Alpert JE, T rivedi M, Luther JF , Wis-niewski SR: Ethnicity/race and outcome in thetreatment of depression: results from STAR*D.Med Care 2007; 45:1043–1051 [B]
689. Hybels CF, Blazer DG: Epidemiology of late-life
mental disorders. Clin Geriatr Med 2003; 19:663–696 [G]
690. Katz IR, Simpson GM, Curlik SM, Parmelee PA,
Muhly C: Pharmacologic treatment of major de-pression for elderly patients in residential care set-tings. J Clin Psychiatry 1990; 51(suppl):41–47 [A]
691. Conwell Y, Thompson C: Suicidal behavior in el-
ders. Psychiatr Clin North Am 2008; 31:333–356[G]
692. Mutran EJ, Reitzes DC, Mossey J, Fernandez ME:
Social support, depression, and recovery of walkingability following hip fracture surgery. J Gerontol BPsychol Sci Soc Sci 1995; 50:S354–S361 [C]
693. Mossey JM, Knott K, Craik R: The effects of per-
sistent depressive symptoms on hip fracture recov-ery. J Gerontol 1990; 45:M163–M168 [C]
694. Mossey JM, Mutran E, Knott K, Craik R: Determi-
nants of recovery 12 months after hip fracture: theimportance of psychosocial factors. Am J PublicHealth 1989; 79:279–286 [C]
695. Alexopoulos GS: Depression in the elderly. Lancet
2005; 365:1961–1970 [F]
696. Djernes JK: Prevalence and predictors of depres-
sion in populations of elderly: a review. Acta Psychi-atr Scand 2006; 113:372–387 [F]
697. Carney RM, Freedland KE: Depression, mortality,
and medical morbidity in patients with coronary
heart disease. Biol Psychiatry 2003; 54:241–247 [G]
698. Sneed JR, Rindskopf D, Steffens DC, Krishnan KR,
Roose SP: The vascular depression subtype: evi-dence of internal validity. Biol Psychiatry 2008;64:491–497 [G]
699. Krishnan KR, Delong M, Kraemer H, Carney R,
Spiegel D, Gordon C, McDonald W, Dew M, Al-exopoulos G, Buckwalter K, Cohen PD, Evans D,Kaufmann PG, Olin J, Otey E, Wainscott C: Co-morbidity of depression with other medical diseasesin the elderly. Biol Psychiatry 2002; 52:559–588 [G]
700. Ko DT, Hebert PR, Coffey CS, Sedrakyan A, Curtis
JP , Krumholz HM: Beta-blocker therapy and symp-toms of depression, fatigue, and sexual dysfunction.JAMA 2002; 288:351–357 [E]
701. Ried LD, T ueth MJ, T aylor MD, Sauer BC, Lopez
LM, Pepine CJ: Depressive symptoms in coronary
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 133
artery disease patients after hypertension treat-
ment. Ann Pharmacother 2006; 40:597–604 [G]
702. Vaccarino AL, Sills TL, Evans KR, Kalali AH:
Multiple pain complaints in patients with majordepressive disorder. Psychosom Med 2009; 71:159–162 [G]
703. Gerson S, Belin TR, Kaufman A, Mintz J, Jarvik L:
Pharmacological and psychological treatments fordepressed older patients: a meta-analysis and over-view of recent findings. Harv Rev Psychiatry 1999;7:1–28 [E]
704. Mottram P , Wilson K, Strobl J: Antidepressants for
depressed elderly. Cochrane Database Syst Rev2006; CD003491 [E]
705. Sheikh JI, Cassidy EL, Doraiswamy PM, Salomon
RM, Hornig M, Holland PJ, Mandel FS, Clary CM,Burt T: Efficacy, safety, and tolerability of sertralinein patients with late-life depression and comorbidmedical illness. J Am Geriatr Soc 2004; 52:86–92[A]
706. Cuijpers P , van Straten A, Smit F: Psychological
treatment of late-life depression: a meta-analysis ofrandomized controlled trials. Int J Geriatr Psychi-atry 2006; 21:1139–1149 [E]
707. Nelson JC, Delucchi K, Schneider LS: Efficacy of
second generation antidepressants in late-life de-pression: a meta-analysis of the evidence. Am JGeriatr Psychiatry 2008; 16:558–567 [E]
708. Andreescu C, Mulsant BH, Houck PR, Whyte EM,
Mazumdar S, Dombrovski AY, Pollock BG, Rey-nolds CF III: Empirically derived decision trees forthe treatment of late-life depression. Am J Psychi-atry 2008; 165:855–862 [G]
709. Streim JE, Oslin DW, Katz IR, Smith BD, DiFilip-
po S, Cooper TB, T en Have T: Drug treatment ofdepression in frail elderly nursing home residents.Am J Geriatr Psychiatry 2000; 8:150–159 [A]
710. Oslin DW, Streim JE, Katz IR, Smith BD, DiFilip-
po SD, T en Have TR, Cooper T: Heuristic com-parison of sertraline with nortriptyline for thetreatment of depression in frail elderly patients. AmJ Geriatr Psychiatry 2000; 8:141–149 [B]
711. Driscoll HC, Karp JF, Dew MA, Reynolds CF III:
Getting better, getting well: understanding andmanaging partial and non-response to pharmaco-logical treatment of non-psychotic major depres-sion in old age. Drugs Aging 2007; 24:801–814 [F]
712. Dew MA, Whyte EM, Lenze EJ, Houck PR, Mul-
sant BH, Pollock BG, Stack JA, Bensasi S, ReynoldsCF III: Recovery from major depression in olderadults receiving augmentation of antidepressantpharmacotherapy. Am J Psychiatry 2007; 164:892–899 [B]
713. Mandelli L, Serretti A, Zanardi R, Rossini D, De
Ronchi D, T arricone I, Colombo C: Antidepressantresponse in the elderly. Psychiatry Res 2007; 152:37–44 [F]
714. Driscoll HC, Basinski J, Mulsant BH, Butters MA,
Dew MA, Houck PR, Mazumdar S, Miller MD,Pollock BG, Stack JA, Schlernitzauer MA, Rey-nolds CF III: Late-onset major depression: clinicaland treatment-response variability. Int J GeriatrPsychiatry 2005; 20:661–667 [G]
715. O’Connor MK, Knapp R, Husain M, Rummans
TA, Petrides G, Smith G, Mueller M, Snyder K,Bernstein H, Rush AJ, Fink M, Kellner C: Theinfluence of age on the response of major depressionto electroconvulsive therapy: a C.O.R.E. Report.Am J Geriatr Psychiatry 2001; 9:382–390 [B]
716. Gum A, Arean PA: Current status of psychotherapy
for mental disorders in the elderly. Curr PsychiatryRep 2004; 6:32–38 [G]
717. Krishnan KR, Doraiswamy PM, Clary CM: Clini-
cal and treatment response characteristics of late-life depression associated with vascular disease: a
pooled analysis of two multicenter trials with ser-traline. Prog Neuropsychopharmacol Biol Psychi-atry 2001; 25:347–361 [E]
718. Jorge RE, Moser DJ, Acion L, Robinson RG: T reat-
ment of vascular depression using repetitive trans-cranial magnetic stimulation. Arch Gen Psychiatry2008; 65:268–276 [A]
719. Lee MJ, Proctor E, Morrow-Howell N: Depression
outcomes and quality of postdischarge care of eldershospitalized for major depression. Psychiatr Serv2006; 57:1446–1451 [C]
720. Steffens DC, Pieper CF , Bosworth HB, MacFall JR,
Provenzale JM, Payne ME, Carroll BJ, George LK,Krishnan KR: Biological and social predictors oflong-term geriatric depression outcome. Int Psy-chogeriatr 2005; 17:41–56 [C]
721. Nelson JC, Jatlow PI, Mazure C: Rapid desip-
ramine dose adjustment using 24-hour levels. J ClinPsychopharmacol 1987; 7:72–77 [C]
722. Wilson K, Mottram P , Sivanranthan A, Nightin-
gale A: Antidepressant versus placebo for depressedelderly. Cochrane Database Syst Rev 2001;CD000561 [E]
723. Cozza KL, Armstrong SC, Oesterheld JR: Concise
Guide to Drug Interaction Principles for MedicalPractice: Cytochrome P450s, UGT s, P-Glycopro-teins, 2nd ed. Arlington, VA, American PsychiatricPublishing, 2003 [G]
724. Preskorn SH, Shah R, Neff M, Golbeck AL, Choi
J: The potential for clinically significant drug-druginteractions involving the CYP 2D6 system: effectswith fluoxetine and paroxetine versus sertraline. J Psy-chiatr Pract 2007; 13:5–12 [G]
725. Preskorn SH, Greenblatt DJ, Flockhart D, Luo Y,
Perloff ES, Harmatz JS, Baker B, Klick-Davis A,Desta Z, Burt T: Comparison of duloxetine, escitalo-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
134 APA PRACTICE GUIDELINES
pram, and sertraline effects on cytochrome P450
2D6 function in healthy volunteers. J Clin Psycho-
pharmacol 2007; 27:28–34 [B]
726. Wilkinson TJ, Begg EJ, Winter AC, Sainsbury R:
Incidence and risk factors for hyponatraemia fol-lowing treatment with fluoxetine or paroxetine inelderly people. Br J Clin Pharmacol 1999; 47:211–217 [D]
727. Liu BA, Mittmann N, Knowles SR, Shear NH:
Hyponatremia and the syndrome of inappropriatesecretion of antidiuretic  hormone associated with
the use of selective serotonin reuptake inhibitors: areview of spontaneous reports. CMAJ 1996;155:519–527 [G]
728. Movig KL, Leufkens HG, Lenderink AW, van den
Akker V , Hodiamont PP , Goldschmidt HM,Egberts AC: Association between antidepressantdrug use and hyponatraemia: a case-control study.Br J Clin Pharmacol 2002; 53:363–369 [D]
729. Reynolds CF III, Dew MA, Pollock BG, Mulsant
BH, Frank E, Miller MD, Houck PR, Mazumdar S,Butters MA, Stack JA, Schlernitzauer MA, WhyteEM, Gildengers A, Karp J, Lenze E, Szanto K,Bensasi S, Kupfer DJ: Maintenance treatment ofmajor depression in old age. N Engl J Med 2006;354:1130–1138 [A −]
730. Navarro V, Gasto C, T orres X, Masana G, Penades
R, Guarch J, Vazquez M, Serra M, Pujol N, PintorL, Catalan R: Continuation/maintenance treat-ment with nortriptyline versus combined nortrip-tyline and ECT in late-life psychotic depression: atwo-year randomized study. Am J Geriatr Psychia-try 2008; 16:498–505 [A −]
731. Cho HJ, Lavretsky H, Olmstead R, Levin MJ,
Oxman MN, Irwin MR: Sleep disturbance and de-pression recurrence in community-dwelling olderadults: a prospective study. Am J Psychiatry 2008;165:1543–1550 [C]
732. Katon WJ, Schoenbaum M, Fan MY, Callahan CM,
Williams J Jr, Hunkeler E, Harpole L, Zhou XH,Langston C, Unutzer J: Cost-effectiveness of im-proving primary care treatment of late-life depres-sion. Arch Gen Psychiatry 2005; 62:1313–1320 [A −]
733. Ciechanowski P , Wagner E, Schmaling K, Schwartz
S, Williams B, Diehr P , Kulzer J, Gray S, Collier C,LoGerfo J: Community-integrated home-baseddepression treatment in older adults: a randomizedcontrolled trial. JAMA 2004; 291:1569–1577 [A −]
734. Gallo JJ, Bogner HR, Morales KH, Post EP , Lin JY,
Bruce ML: The effect of a primary care practice-based depression intervention on mortality in olderadults: a randomized trial. Ann Intern Med 2007;146:689–698 [A −]
735. Bloch M, Schmidt PJ, Danaceau M, Murphy J,
Nieman L, Rubinow DR: Effects of gonadal ste-roids in women with a history of postpartum de-pression. Am J Psychiatry 2000; 157:924–930 [B]
736. Freeman EW, Sammel MD, Lin H, Nelson DB:
Associations of hormones and menopausal statuswith depressed mood in women with no history ofdepression. Arch Gen Psychiatry 2006; 63:375–382[C]
737. Cohen LS, Soares CN, Vitonis AF, Otto MW, Har-
low BL: Risk for new onset of depression during themenopausal transition: the Harvard study of moodsand cycles. Arch Gen Psychiatry 2006; 63:385–390[C]
738. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A,
Miller J, Nicolaidis C, Walker M, Humphrey L:
Nonhormonal therapies for menopausal hot flash-
es: systematic review and meta-analysis. JAMA2006; 295:2057–2071 [E]
739. Weissman MM, Pilowsky DJ, Wickramaratne PJ,
T alati A, Wisniewski SR, Fava M, Hughes CW,Garber J, Malloy E, King CA, Cerda G, Sood AB,Alpert JE, T rivedi MH, Rush AJ: Remissions inmaternal depression and child psychopathology: aSTAR*D-child report. JAMA 2006; 295:1389–1398[B]
740. Seidman S: Ejaculatory dysfunction and depression:
pharmacological and psycho biological interactions.
Int J Impot Res 2006; 18(suppl 1):S33–S38 [G]
741. Dietz PM, Williams SB, Callaghan WM, Bachman
DJ, Whitlock EP , Hornbrook MC: Clinically iden-tified maternal depression before, during, and afterpregnancies ending in live births. Am J Psychiatry2007; 164:1515–1520 [C]
742. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody
S, Gartlehner G, Swinson T: Perinatal depression:a systematic review of prevalence and incidence.Obstet Gynecol 2005; 106:1071–1083 [E]
743. Spinelli MG, Endicott J: Controlled clinical trial of
interpersonal psychotherapy versus parenting edu-cation program for depressed pregnant women. AmJ Psychiatry 2003; 160:555–562 [A −]
744. Stuart S, O’Hara MW, Gorman LL: The preven-
tion and psychotherapeutic treatment of postpar-tum depression. Arch Womens Ment Health 2003;6(suppl 2):S57–S69 [G]
745. Yonkers KA, Wisner KL, Stewart DE, Oberlander
TF , Dell DL, Stotland N, Ramin S, Caudron L,Lockwood C: The management of depression dur-ing pregnancy: a report from the American Psychi-atric Association and the American College ofObstetricians and Gynecologists. Obstet Gynecol2009; 114:703–713 [G]
746. Dye JL: Fertility of American Women: 2006. US
Census Bureau Current Population Reports, Aug2008. http://www.census.gov/prod/2008pubs/p20–558.pdf [G]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 135
747. Finer LB, Henshaw SK: Disparities in rates of un-
intended pregnancy in the United States, 1994 and
2001. Perspect Sex Reprod Health 2006; 38:90–96[G]
748. Wisner KL, Zarin DA, Holmboe ES, Appelbaum
PS, Gelenberg AJ, Leonard HL, Frank E: Risk-benefit decision making for treatment of depressionduring pregnancy. Am J Psychiatry 2000; 157:1933–1940 [G]
749. Cohen LS, Altshuler LL, Harlow BL, Nonacs R,
Newport DJ, Viguera AC, Suri R, Burt VK, Hen-drick V , Reminick AM, Loughead A, Vitonis AF ,Stowe ZN: Relapse of major depression duringpregnancy in women who maintain or discontinue
antidepressant treatment. JAMA 2006; 295:499–
507 [C]
750. Wisner KL, Gelenberg AJ, Leonard H, Zarin D,
Frank E: Pharmacologic treatment of depressionduring pregnancy. JAMA 1999; 282:1264–1269 [F]
751. Alwan S, Reefhuis J, Rasmussen SA, Olney RS,
Friedman JM: Use of selective serotonin-reuptakeinhibitors in pregnancy and the risk of birth defects.N Engl J Med 2007; 356:2684–2692 [D]
752. Louik C, Lin AE, Werler MM, Hernandez-Diaz S,
Mitchell AA: First-trimester use of selective seroto-nin-reuptake inhibitors and the risk of birth defects.N Engl J Med 2007; 356:2675–2683 [D]
753. GlaxoSmithKline: Change in the Pregnancy sub-
section of the PRECAUTIONS section in the la-bels for PAXIL (paroxetine HCl) and PAXIL CR(paroxetine HCl) Controlled-Release T ablets, Sept2005. http://www.fda.gov/medwatch/safety/2005/Paxil_dearhcp_letter.pdf [G]
754. Cole JA, Ephross SA, Cosmatos IS, Walker AM:
Paroxetine in the first trimester and the prevalenceof congenital malformations. PharmacoepidemiolDrug Saf 2007; 16:1075–1085 [C]
755. Einarson A, Pistelli A, Desantis M, Malm H, Paulus
WD, Panchaud A, Kennedy D, Einarson TR, Koren
G: Evaluation of the risk of congenital cardiovas-cular defects associated with use of paroxetine dur-ing pregnancy. Am J Psychiatry 2008; 165:749–752;errata in Am J Psychiatry 165:777, 1208 [C]
756. Chambers CD, Johnson KA, Dick LM, Felix RJ,
Jones KL: Birth outcomes in pregnant women tak-ing fluoxetine. N Engl J Med 1996; 335:1010–1015[B]
757. Chambers CD, Hernandez-Diaz S, Van Marter LJ,
Werler MM, Louik C, Jones KL, Mitchell AA:Selective serotonin-reuptake inhibitors and risk ofpersistent pulmonary hypertension of the newborn.N Engl J Med 2006; 354:579–587 [D]
758. Andrade SE, McPhillips H, Loren D, Raebel MA,
Lane K, Livingston J, Boudreau DM, Smith DH,Davis RL, Willy ME, Platt R: Antidepressant med-ication use and risk of persistent pulmonary hyper-tension of the newborn. Pharmacoepidemiol DrugSaf 2009; 18:246–252 [D]
759. Wichman CL, Moore KM, Lang TR, St Sauver JL,
Heise RH Jr, Watson WJ: Congenital heart diseaseassociated with selective serotonin reuptake inhibi-tor use during pregnancy. Mayo Clin Proc 2009;84:23–27 [G]
760. Kallen B, Olausson PO: Maternal use of selective
serotonin re-uptake inhibitors and persistent pul-monary hypertension of the newborn. Pharma-coepidemiol Drug Saf 2008; 17:801–806 [G]
761. Suri R, Altshuler L, Hellemann G, Burt VK, Aqui-
no A, Mintz J: Effects of antenatal depression andantidepressant treatment on gestational age at birth
and risk of preterm birth. Am J Psychiatry 2007;
164:1206–1213 [C]
762. Simon GE, Cunningham ML, Davis RL: Outcomes
of prenatal antidepressant exposure. Am J Psychia-try 2002; 159:2055–2061 [D]
763. Wisner KL, Zarin DA, Holmboe ES, Appelbaum
PS, Gelenberg AJ, Leonard HL, Frank E: Risk-benefit decision making for treatment of depressionduring pregnancy. Am J Psychiatry 2000; 157:1933–1940 [G]
764. Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl
K, Levin B, Wisner KL: Neonatal signs after late inutero exposure to serotonin reuptake inhibitors:literature review and implications for clinical appli-cations. JAMA 2005; 293:2372–2383 [G]
765. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A,
Gaylor E, DeBattista A, Hoyme HE: Follow-up ofchildren of depressed mothers exposed or not ex-posed to antidepressant drugs during pregnancy.J Pediatr 2003; 142:402–408 [D]
766. Oberlander TF , Reebye P , Misri S, Papsdorf M,
Kim J, Grunau RE: Externalizing and attentionalbehaviors in children of depressed mothers treatedwith a selective serotonin reuptake inhibitor antide-pressant during pregnancy. Arch Pediatr AdolescMed 2007; 161:22–29 [C]
767. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-
Asciak P , Shuhaiber S, Koren G: Child developmentfollowing exposure to tricyclic antidepressants orfluoxetine throughout fetal life: a prospective, con-trolled study. Am J Psychiatry 2002; 159:1889–1895[D]
768. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner
HA, Theis JG, Kulin N, Koren G: Neurodevelop-ment of children exposed in utero to antidepressantdrugs. N Engl J Med 1997; 336:258–262 [D]
769. Wisner KL, Perel JM, Wheeler SB: Tricyclic dose
requirements across pregnancy. Am J Psychiatry 1993;150:1541–1542 [G]
770. Altshuler LL, Hendrick VC: Pregnancy and psy-
chotropic medication: changes in blood levels. JClin Psychopharmacol 1996; 16:78–80 [G]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
136 APA PRACTICE GUIDELINES
771. Klier CM, Mossaheb N, Saria A, Schloegelhofer M,
Zernig G: Pharmacokinetics and elimination of
quetiapine, venlafaxine, and trazodone during preg-nancy and postpartum. J Clin Psychopharmacol2007; 27:720–722 [G]
772. Hostetter A, Stowe ZN, Strader JR Jr, McLaughlin
E, Llewellyn A: Dose of selective serotonin uptakeinhibitors across pregnancy: clinical implications.Depress Anxiety 2000; 11:51–57 [C]
773. Heikkinen T, Ekblad U, Palo P , Laine K: Pharma-
cokinetics of fluoxetine and norfluoxetine in preg-nancy and lactation. Clin Pharmacol Ther 2003;73:330–337 [G]
774. Sit DK, Perel JM, Helsel JC, Wisner KL: Changes
in antidepressant metabolism and dosing acrosspregnancy and early postpartum. J Clin Psychiatry2008; 69:652–658 [G]
775. Hendrick V , Stowe ZN, Altshuler LL, Hwang S,
Lee E, Haynes D: Placental passage of antidepres-sant medications. Am J Psychiatry 2003; 160:993–996 [G]
776. Stowe ZN, Hostetter AL, Newport DJ: The onset
of postpartum depression: implications for clinicalscreening in obstetrical and primary care. Am J ObstetGynecol 2005; 192:522–526 [G]
777. Bernstein IH, Rush AJ, Yonkers K, Carmody TJ,
Woo A, McConnell K, T rivedi MH: Symptom fea-tures of postpartum depression: are they distinct?Depress Anxiety 2008; 25:20–26 [G]
778. Gitlin MJ, Pasnau RO: Psychiatric syndromes
linked to reproductive function in women: a re-view of current knowledge. Am J Psychiatry 1989;146:1413–1422 [F]
779. Sit D, Rothschild AJ, Wisner KL: A review of
postpartum psychosis. J Womens Health (Larchmt)2006; 15:352–368 [F]
780. McNeil TF: A prospective study of postpartum
psychoses in a high-risk group. 3. Relationship tomental health characteristics during pregnancy.Acta Psychiatr Scand 1988; 77:604–610 [C]
781. Moses-Kolko EL, Roth EK: Antepartum and post-
partum depression: healthy mom, healthy baby. J AmMed Womens Assoc 2004; 59:181–191 [F]
782. Murray L, Fiori-Cowley A, Hooper R, Cooper P:
The impact of postnatal depression and associatedadversity on early mother-infant interactions andlater infant outcome. Child Dev 1996; 67:2512–2526 [C]
783. Appleby L, Warner R, Whitton A, Faragher B:
A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of post-natal depression. BMJ 1997; 314:932–936 [A −]
784. Yonkers KA, Lin H, Howell HB, Heath AC, Cohen
LS: Pharmacologic treatment of postpartum wom-en with new-onset major depressive disorder: a ran-domized controlled trial with paroxetine. J ClinPsychiatry 2008; 69:659–665 [A]
785. Wisner KL, Hanusa BH, Perel JM, Peindl KS,
Piontek CM, Sit DK, Findling RL, Moses-KolkoEL: Postpartum depression: a randomized trial ofsertraline versus nortriptyline. J Clin Psychophar-macol 2006; 26:353–360 [A]
786. Payne JL: Antidepressant use in the postpartum
period: practical considerations. Am J Psychiatry2007; 164:1329–1332 [G]
787. Misri S, Reebye P , Corral M, Milis L: The use of
paroxetine and cognitive-behavioral therapy inpostpartum depression and anxiety: a randomizedcontrolled trial. J Clin Psychiatry 2004; 65:1236–
1241 [A]
788. Weissman AM, Levy BT, Hartz AJ, Bentler S,
Donohue M, Ellingrod VL, Wisner KL: Pooled
analysis of antidepressant levels in lactating moth-ers, breast milk, and nursing infants. Am J Psychia-try 2004; 161:1066–1078 [E]
789. Burt VK, Suri R, Altshuler L, Stowe Z, Hendrick
VC, Muntean E: The use of psychotropic medica-tions during breast-feeding. Am J Psychiatry 2001;158:1001–1009 [F]
790. Nierenberg AA, T rivedi MH, Fava M, Biggs MM,
Shores-Wilson K, Wisniewski SR, BalasubramaniGK, Rush AJ: Family history of mood disorder andcharacteristics of major depressive disorder: aSTAR*D (sequenced treatment alternatives to re-lieve depression) study. J Psychiatr Res 2007;41:214–221 [D]
791. Weissman MM, Wickramaratne P , Nomura Y,
W a r n e r  V ,  P i l o w s k y  D ,  V e r d e l i  H :  O f f s p r i n g  o fdepressed parents: 20 years later. Am J Psychiatry2006; 163:1001–1008 [C]
792. Lieb R, Isensee B, Hofler M, Pfister H, Wittchen
HU: Parental major depression and the risk of de-pression and other mental disorders in offspring: aprospective-longitudinal community study. ArchGen Psychiatry 2002; 59:365–374 [G]
793. Akiskal HS, Walker P , Puzantian VR, King D,
Rosenthal TL, Dranon M: Bipolar outcome in thecourse of depressive illness. Phenomenologic, fa-milial, and pharmacologic predictors. J Affect Dis-ord 1983; 5:115–128 [A]
794. Iosifescu DV , Nierenberg AA, Alpert JE, Smith M,
Bitran S, Dording C, Fava M: The impact of medicalcomorbidity on acute treatment in major depressivedisorder. Am J Psychiatry 2003; 160:2122–2127 [B]
795. Evans DL, Charney DS: Mood disorders and med-
ical illness: a major public health problem. BiolPsychiatry 2003; 54:177–180 [F]
796. Carney RM, Freedland KE, Rich MW, Jaffe AS:
Depression as a risk factor for cardiac events inestablished coronary heart disease: a review of pos-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 137
sible mechanisms. Ann Behav Med 1995; 17:142–
149 [G]
797. Pigott TA, Prakash A, Arnold LM, Aaronson ST,
Mallinckrodt CH, Wohlreich MM: Duloxetineversus escitalopram and placebo: an 8-month, dou-ble-blind trial in patients with major depressivedisorder. Curr Med Res Opin 2007; 23:1303–1318[A]
798. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinck-
rodt C, Demitrack MA: Duloxetine in the treatmentof depression: a double-blind placebo-controlledcomparison with paroxetine. J Clin Psychopharma-col 2004; 24:389–399 [A]
799. Warrington SJ, Padgham C, Lader M: The cardio-
vascular effects of antidepressants. Psychol MedMonogr Suppl 1989; 16:i-40 [G]
800. Van der Kooy K, van Hout H, Marwijk H, Marten
H, Stehouwer C, Beekman A: Depression and therisk for cardiovascular diseases: systematic reviewand meta analysis. Int J Geriatr Psychiatry 2007;22:613–626 [E]
801. Barth J, Schumacher M, Herrmann-Lingen C: De-
pression as a risk factor fo r mortality in patients with
coronary heart disease: a meta-analysis. PsychosomMed 2004; 66:802–813 [E]
802. de Jonge P , Honig A, van Melle JP , Schene AH,
Kuyper AM, T ulner D, Schins A, Ormel J: Non-response to treatment for depression followingmyocardial infarction: association with subsequentcardiac events. Am J Psychiatry 2007; 164:1371–1378 [D]
803. Caney RM, Blumenthal JA, Freedland KE, Young-
blood M, Veith RC, Burg MM, Cornell C, Saab PG,Kaufmann PG, Czajkowski SM, Jaffe AS: Depres-sion and late mortality af ter myocardial infarction
in the Enhancing Recovery in Coronary Heart Dis-ease (ENRICHD) study. Psychosom Med 2004;66:466–474 [A −]
804. Carney RM, Blumenthal JA, Freedland KE, Stein
PK, Howells WB, Berkman LF, Watkins LL,Czajkowski SM, Hayano J, Domitrovich PP , JaffeAS: Low heart rate variability and the effect ofdepression on post-myocardial infarction mortality.Arch Intern Med 2005; 165:1486–1491 [C]
805. Glassman AH, Bigger JT, Gaffney M, Shapiro PA,
Swenson JR: Onset of major depression associatedwith acute coronary syndromes: relationship of on-set, major depressive disorder history, and episodeseverity to sertraline benefit. Arch Gen Psychiatry2006; 63:283–288 [A]
806. Thombs BD, de Jonge P , Coyne JC, Whooley MA,
Frasure-Smith N, Mitchell AJ, Zuidersma M, Eze-Nliam C, Lima BB, Smith CG, Soderlund K,Ziegelstein RC: Depression screening and patientoutcomes in cardiovascular care: a systematic re-view. JAMA 2008; 300:2161–2171 [E]807. Lesperance F, Frasure-Smith N, Koszycki D,
Laliberte MA, van Zyl L T, Baker B, Swenson JR,Ghatavi K, Abramson BL, Dorian P , Guertin MC:Effects of citalopram and interpersonal psychother-apy on depression in patients with coronary arterydisease: the Canadian Cardiac Randomized Evalu-ation of Antidepressant and Psychotherapy Efficacy(CREATE) trial. JAMA 2007; 297:367–379 [A −]
808. Von Ruden AE, Adson DE, Kotlyar M: Effect of
selective serotonin reuptake inhibitors on cardio-vascular morbidity and mortality. J CardiovascPharmacol Ther 2008; 13:32–40 [F]
809. Berkman LF, Blumenthal J, Burg M, Carney RM,
Catellier D, Cowan MJ, Czajkowski SM, DeBusk
R, Hosking J, Jaffe A, Kaufmann PG, Mitchell P ,
Norman J, Powell LH, Raczynski JM, Schneider-man N: Effects of treating depression and low per-ceived social support on clinical events aftermyocardial infarction: the Enhancing Recovery inCoronary Heart Disease Patients (ENRICHD)randomized trial. JAMA 2003; 289:3106–3116 [A −]
810. T aylor CB, Youngblood ME, Catellier D, Veith RC,
Carney RM, Burg MM, Kaufmann PG, Shuster J,Mellman T, Blumenthal JA, Krishnan R, Jaffe AS:Effects of antidepressant medication on morbidityand mortality in depressed patients after myocardialinfarction. Arch Gen Psychiatry 2005; 62:792–798[A]
811. van Melle JP , de Jonge P , Honig A, Schene AH,
Kuyper AM, Crijns HJ, Schins A, T ulner D, van denBerg MP , Ormel J: Effects of antidepressant treat-ment following myocardial infarction. Br J Psychi-atry 2007; 190:460–466 [A −]
812. Nelson JC, Kennedy JS, Pollock BG, Laghrissi-
Thode F , Narayan M, Nobler MS, Robin DW,Gergel I, McCafferty J, Roose S: T reatment ofmajor depression with nortriptyline and paroxetinein patients with ischemic heart disease. Am J Psy-chiatry 1999; 156:1024–1028 [A]
813. Bigger JT, Giardina EG, Perel JM, Kantor SJ,
Glassman AH: Cardiac antiarrhythmic effect of im-ipramine hydrochloride. N Engl J Med 1977;296:206–208 [G]
814. Glassman AH, Johnson LL, Giardina EG, Walsh
BT , Roose SP , Cooper TB, Bigger JT Jr: The useof imipramine in depressed patients with congestiveheart failure. JAMA 1983; 250:1997–2001 [C]
815. Connolly SJ, Mitchell LB, Swerdlow CD, Mason
JW, Winkle RA: Clinical efficacy and electrophysi-ology of imipramine for ventricular tachycardia.Am J Cardiol 1984; 53:516–521 [B]
816. Giardina EG, Barnard T, Johnson L, Saroff AL,
Bigger JT Jr, Louie M: The antiarrhythmic effectof nortriptyline in cardiac patients with ventricularpremature depolarizations. J Am Coll Cardiol 1986;7:1363–1369 [E]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
138 APA PRACTICE GUIDELINES
817. Dalack GW, Roose SP , Glassman AH: T ricyclics
and heart failure (letter). Am J Psychiatry 1991;
148:1601 [E]
818. Yeragani VK, Pesce V , Jayaraman A, Roose S: Major
depression with ischemic heart disease: effects ofparoxetine and nortriptyline on long-term heartrate variability measures. Biol Psychiatry 2002;52:418–429 [B]
819. Glassman AH, O’Connor CM, Califf RM, Swed-
berg K, Schwartz P , Bigger JT Jr, Krishnan KR, vanZyl L T, Swenson JR, Finkel MS, Landau C, ShapiroPA, Pepine CJ, Mardekian J, Harrison WM, BartonD, McIvor M: Sertraline treatment of major depres-sion in patients with acute MI or unstable angina.
JAMA 2002; 288:701–709 [A]
820. Applegate RJ: Diagnosis and management of is-
chemic heart disease in the patient scheduled to
undergo electroconvulsive therapy. Convuls Ther1997; 13:128–144 [F]
821. Dolinski SY, Zvara DA: Anesthetic considerations
of cardiovascular risk during electroconvulsivetherapy. Convuls Ther 1997; 13:157–164 [E]
822. Rayburn BK: Electroconvulsive therapy in patients
with heart failure or valvular heart disease. ConvulsTher 1997; 13:145–156 [F]
823. Paolucci S, Gandolfo C, Provinciali L, T orta R,
T oso V: The Italian multicenter observational studyon post-stroke depression (DESTRO). J Neurol2006; 253:556–562 [C]
824. Hackett ML, Yapa C, Parag V , Anderson CS: Fre-
quency of depression after stroke: a systematic reviewof observational studies. Stroke 2005; 36:1330–1340[E]
825. Hackett ML, Anderson CS, House A, Halteh C:
Interventions for preventing depression after stroke.Cochrane Database Syst Rev 2008; CD003689 [E]
826. Chen Y, Patel NC, Guo JJ, Zhan S: Antidepressant
prophylaxis for poststroke depression: a meta-analysis.Int Clin Psychopharmacol 2007; 22:159–166 [E]
827. Jorge RE, Robinson RG, Arndt S, Starkstein S:
Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry2003; 160:1823–1829 [C]
828. House A, Knapp P , Bamford J, Vail A: Mortality at
12 and 24 months after stroke may be associatedwith depressive symptoms at 1 month. Stroke 2001;32:696–701 [C]
829. Williams LS, Brizendine EJ, Plue L, Bakas T, T u
W, Hendrie H, Kroenke K: Performance of thePHQ-9 as a screening tool for depression afterstroke. Stroke 2005; 36:635–638 [G]
830. Williams LS, Kroenke K, Bakas T, Plue LD, Bri-
zendine E, T u W, Hendrie H: Care management ofpoststroke depression: a randomized, controlled tri-al. Stroke 2007; 38:998–1003 [A −]831. Chen Y, Guo JJ, Zhan S, Patel NC: T reatment
effects of antidepressants in patients with post-stroke depression: a meta-analysis. Ann Pharmaco-ther 2006; 40:2115–2122 [E]
832. Hackett ML, Anderson CS, House AO: Manage-
ment of depression after stroke: a systematic reviewof pharmacological therapies. Stroke 2005; 36:1098–1103 [E]
833. Rasmussen A, Lunde M, Poulsen DL, Sorensen K,
Qvitzau S, Bech P: A double-blind, placebo-controlled study of sertraline in the prevention ofdepression in stroke patients. Psychosomatics 2003;44:216–221 [A]
834. Andersen G, Vestergaard K, Lauritzen L: Effective
treatment of poststroke depression with the selec-tive serotonin reuptake inhibitor citalopram. Stroke1994; 25:1099–1104 [A]
835. Dam M, T onin P , De Boni A, Pizzolato G, Casson
S, Ermani M, Freo U, Piron L, Battistin L: Effectsof fluoxetine and maprotiline on functional recov-ery in poststroke hemiplegic patients undergoingrehabilitation therapy. Stroke 1996; 27:1211–1214[A]
836. Wiart L, Petit H, Joseph PA, Mazaux JM, Barat M:
Fluoxetine in early poststroke depression: a double-blind placebo-controlled study. Stroke 2000;31:1829–1832 [A]
837. Robinson RG, Schultz SK, Castillo C, Kopel T,
Kosier JT, Newman RM, Curdue K, Petracca G,Starkstein SE: Nortriptyline versus fluoxetine in thetreatment of depression and in short-term recoveryafter stroke: a placebo-controlled, double-blindstudy. Am J Psychiatry 2000; 157:351–359 [A]
838. Lipsey JR, Robinson RG, Pearlson GD, Rao K,
Price TR: Nortriptyline treatment of post-strokedepression: a double-blind study. Lancet 1984;1:297–300 [A]
839. Murray V, von Arbin M, Bartfai A, Berggren AL,
Landtblom AM, Lundmark J, Nasman P , Olsson JE,S a m u e l s s o n  M ,  T e r e n t  A ,  V a r e l i u s  R ,  A s b e r g  M ,Martensson B: Double-blind comparison of sertra-line and placebo in stroke patients with minor de-pression and less severe major depression. J ClinPsychiatry 2005; 66:708–716 [A]
840. Fruehwald S, Gatterbauer E, Rehak P , Baumhackl
U: Early fluoxetine treatment of post-stroke de-pression—a three-month double-blind placebo-controlled study with an open-label long-term fol-low up. J Neurol 2003; 250:347–351 [A]
841. Choi-Kwon S, Han SW, Kwon SU, Kang DW,
Choi JM, Kim JS: Fluoxetine treatment in post-stroke depression, emotional incontinence, and an-ger proneness: a double-blind, placebo-controlledstudy. Stroke 2006; 37:156–161 [A]
842. Swenson JR, Doucette S, Fergusson D: Adverse
cardiovascular events in antidepressant trials in-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 139
volving high-risk patients: a systematic review of
randomized trials. Can J Psychiatry 2006; 51:923–929 [E]
843. Cole MG, Elie LM, McCusker J, Bellavance F,
Mansour A: Feasibility and effectiveness of treat-ments for post-stroke depression in elderly in-patients: systematic review. J Geriatr PsychiatryNeurol 2001; 14:37–41 [E]
844. Serebruany VL: Selective serotonin reuptake inhib-
itors and increased bleeding risk: are we missingsomething? Am J Med 2006; 119:113–116 [F]
845. Holbrook AM, Pereira JA, Labiris R, McDonald H,
Douketis JD, Crowther M, Wells PS: Systematicoverview of warfarin and its drug and food interac-
tions. Arch Intern Med 2005; 165:1095–1106 [E]
846. Shabnam GN, Chung TH, Deane KHO, Rickards
H, Clarke CE: Therapies for depression in Parkin-
son’s disease. Cochrane Database Syst Rev 2003;CD003465 [E]
847. Weintraub D, Morales KH, Moberg PJ, Bilker WB,
Balderston C, Duda JE, Katz IR, Stern MB: Anti-depressant studies in Parkinson’s disease: a reviewand meta-analysis. Mov Disord 2005; 20:1161–1169[E]
848. T esei S, Antonini A, Canesi M, Zecchinelli A, Mar-
iani CB, Pezzoli G: T olerability of paroxetine inParkinson’s disease: a prospective study. Mov Dis-ord 2000; 15:986–989 [B]
849. Goetz CG, T anner CM, Klawans HL: Bupropion
in Parkinson’s disease. Neurology 1984; 34:1092–1094 [C]
850. Monoamine oxidase inhibitors for depression. Med
Lett Drugs Ther 1980; 22:58–60 [G]
851. Andersen K, Balldin J, Gottfries CG, Granerus AK,
Modigh K, Svennerholm L, Wallin A: A double-blind evaluation of electroconvulsive therapy inParkinson’s disease with “on-off” phenomena. ActaNeurol Scand 1987; 76:191–199 [A]
852. Rasmussen K, Abrams R: T reatment of Parkinson’s
disease with electroconvulsive therapy. PsychiatrClin North Am 1991; 14:925–933 [F]
853. Moellentine C, Rummans T, Ahlskog JE, Harmsen
WS, Suman VJ, O’Connor MK, Black JL, PileggiT: Effectiveness of ECT in patients with parkin-sonism. J Neuropsychiatry Clin Neurosci 1998;10:187–193 [C]
854. Gaitatzis A, T rimble MR, Sander JW: The psychi-
atric comorbidity of epilepsy. Acta Neurol Scand2004; 110:207–220 [G]
855. Hesdorffer DC, Hauser WA, Annegers JF, Cascino
G: Major depression is a risk factor for seizures inolder adults. Ann Neurol 2000; 47:246–249 [G]
856. Alper K, Schwartz KA, Kolts RL, Khan A: Seizure
incidence in psychopharmaco logical clinical trials:
an analysis of Food and Drug Administration (FDA)summary basis of approval  reports. Biol Psychiatry
2007; 62:345–354 [E]
857. Kanner AM, Kozak AM, Frey M: The use of sertra-
line in patients with epilepsy: is it safe? EpilepsyBehav 2000; 1:100–105 [B]
858. Hovorka J, Herman E, Nemcova I: T reatment of
interictal depression with  citalopram in patients
with epilepsy. Epilepsy Behav 2000; 1:444–447 [B]
859. Schmitz B: Antidepressant drugs: indications and
guidelines for use in epilepsy. Epilepsia 2002; 43(sup-pl 2):14–18 [F]
860. Levinson DF, Devinsky O: Psychiatric adverse
events during vigabatrin therapy. Neurology 1999;53:1503–1511 [E]
861. Kuehn BM: FDA warns of adverse events linked to
smoking cessation drug and antiepileptics. JAMA2008; 299:1121–1122 [G]
862. Ogden CL, Carroll MD, Curtin LR, McDowell
MA, T abak CJ, Flegal KM: Prevalence of over-weight and obesity in the United States, 1999–2004.JAMA 2006; 295:1549–1555 [G]
863. Fabricatore AN, Wadden TA: Obesity. Annu Rev
Clin Psychol 2006; 2:357–377 [F]
864. McElroy SL, Kotwal R, Malhotra S, Nelson EB,
Keck PE, Nemeroff CB: Are mood disorders andobesity related? A review for the mental healthprofessional. J Clin Psychiatry 2004; 65:634–51,quiz [F]
865. Zimmermann U, Kraus T, Himmerich H, Schuld
A, Pollmacher T: Epidemiology, implications andmechanisms underlying drug-induced weight gainin psychiatric patients. J Psychiatr Res 2003; 37:193–220 [F]
866. Malone M, Alger-Mayer SA, Anderson DA: Medi-
cation associated with weight gain may influenceoutcome in a weight management program. AnnPharmacother 2005; 39:1204–1208 [B]
867. Croft H, Houser TL, Jamerson BD, Leadbetter R,
Bolden-Watson C, Donahue R, Metz A: Effect onbody weight of bupropion sustained-release in pa-tients with major depression treated for 52 weeks.Clin Ther 2002; 24:662–672 [A]
868. Jain AK, Kaplan RA, Gadde KM, Wadden TA,
Allison DB, Brewer ER, Leadbetter RA, Richard N,Haight B, Jamerson BD, Buaron KS, Metz A: Bu-propion SR vs placebo for weight loss in obesepatients with depressive symptoms. Obes Res 2002;10:1049–1056 [A]
869. Papakostas GI, Petersen T, Iosifescu DV , Burns AM,
Nierenberg AA, Alpert JE, Rosenbaum JF, Fava M:Obesity among outpatients with major depressivedisorder. Int J Neuropsychopharmacol 2005; 8:59–63 [B]
870. Devlin MJ, Goldfein JA, Petkova E, Liu L, Walsh
BT: Cognitive behavioral th erapy and fluoxetine for
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
140 APA PRACTICE GUIDELINES
binge eating disorder: two-year follow-up. Obesity
(Silver Spring) 2007; 15:1702–1709 [A −]
871. Cooper Z, Fairburn CG, Hawker DM: Cognitive-
Behavioral T reatment of Obesity: A Clinician’sGuide. New York, Guilford, 2003 [G]
872. Khazaal Y, Fresard E, Rabia S, Chatton A, Rothen
S, Pomini V , Grasset F, Borgeat F, Zullino D: Cog-nitive behavioural therapy for weight gain associat-ed with antipsychotic drugs. Schizophr Res 2007;91:169–177 [A −]
873. Rosenberger PH, Henderson KE, Grilo CM: Psy-
chiatric disorder comorbidity and association witheating disorders in bariatric surgery patients: across-sectional study using structured interview-
based diagnosis. J Clin Psychiatry 2006; 67:1080–
1085 [G]
874. Kalarchian MA, Marcus MD, Levine MD,
Courcoulas AP , Pilkonis PA, Ringham RM,Soulakova JN, Weissfeld LA, Rofey DL: Psychiatricdisorders among bariatric surgery candidates: rela-tionship to obesity and functional health status. AmJ Psychiatry 2007; 164:328–334 [G]
875. Collazo-Clavell ML, Clark MM, McAlpine DE,
Jensen MD: Assessment and preparation of patientsfor bariatric surgery. Mayo Clin Proc 2006; 81:S11–S17 [F]
876. Wadden TA, Sarwer DB, Fabricatore AN, Jones L,
Stack R, Williams NS: Psychosocial and behavioralstatus of patients undergoing bariatric surgery: whatto expect before and after surgery. Med Clin NorthAm 2007; 91:451–469 [F]
877. Zimmerman M, Francione-Witt C, Chelminski I,
Young D, Boerescu D, Attiullah N, Pohl D, RoyeGD, Harrington DT: Presurgical psychiatric eval-uations of candidates for bariatric surgery, part 1:reliability and reasons for and frequency of exclu-sion. J Clin Psychiatry 2007; 68:1557–1562 [G]
878. Buchwald H, Avidor Y, Braunwald E, Jensen MD,
Pories W, Fahrbach K, Schoelles K: Bariatric sur-gery: a systematic review and meta-analysis. JAMA2004; 292:1724–1737 [E]
879. Nickel MK, Loew TH, Bachler E: Change in men-
tal symptoms in extreme obesity patients after gas-tric banding, part II: six-year follow up. Int JPsychiatry Med 2007; 37:69–79 [B]
880. Schowalter M, Benecke A, Lager C, Heimbucher J,
Bueter M, Thalheimer A, Fein M, Richard M, Fall-er H: Changes in depression following gastric band-ing: a 5- to 7-year prospective study. Obes Surg2008; 18:314–320 [B]
881. Herpertz S, Kielmann R, Wolf AM, Langkafel M,
Senf W, Hebebrand J: Does obesity surgery im-prove psychosocial functioning? A systematic re-view. Int J Obes Relat Metab Disord 2003; 27:1300–1314 [E]882. Kalarchian MA, Marcus MD, Levine MD, Soulak-
ova JN, Courcoulas AP , Wisinski MS: Relationshipof psychiatric disorders to 6-month outcomes aftergastric bypass. Surg Obes Relat Dis 2008; 4:544–549 [B]
883. Herpertz S, Kielmann R, Wolf AM, Hebebrand J,
Senf W: Do psychosocial variables predict weightloss or mental health after obesity surgery? A sys-tematic review. Obes Res 2004; 12:1554–1569 [E]
884. Seaman JS, Bowers SP , Dixon P , Schindler L: Dis-
solution of common psychiatric medications in aRoux-en-Y gastric bypass model. Psychosomatics2005; 46:250–253 [G]
885. Narayan KM, Boyle JP , Thompson TJ, Gregg EW,
Williamson DF: Effect of BMI on lifetime risk fordiabetes in the US. Diabetes Care 2007; 30:1562–1566 [F]
886. Bateman A, Fonagy P: 8-year follow-up of patients
treated for borderline personality disorder: mental-ization-based treatment versus treatment as usual.Am J Psychiatry 2008; 165:631–638 [A]
887. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K:
The prevalence of co-morbid depression in adultswith type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006; 23:1165–1173 [E]
888. Golden SH, Lazo M, Carnethon M, Bertoni AG,
Schreiner PJ, Roux AV , Lee HB, Lyketsos C: Exam-ining a bidirectional association between depressivesymptoms and diabetes. JAMA 2008; 299:2751–2759 [G]
889. Lustman PJ, Clouse RE: Depression in diabetic
patients: the relationship  between mood and glycemic
control. J Diabetes Complications 2005; 19:113–122 [F]
890. Williams JW Jr, Katon W, Lin EH, Noel PH,
Worchel J, Cornell J, Harpole L, Fultz BA, Hunkel-er E, Mika VS, Unutzer J: The effectiveness ofdepression care management on diabetes-relatedoutcomes in older patients. Ann Intern Med 2004;140:1015–1024 [B]
891. Katon WJ, Von Korff M, Lin EH, Simon G, Lud-
man E, Russo J, Ciechanowski P , W alker E, BushT: The Pathways Study: a randomized trial of col-laborative care in patients with diabetes and depres-sion. Arch Gen Psychiatry 2004; 61:1042–1049 [B]
892. Lustman PJ, Clouse RE, Nix BD, Freedland KE,
Rubin EH, McGill JB, Williams MM, GelenbergAJ, Ciechanowski PS, Hirsch IB: Sertraline forprevention of depression recurrence in diabetesmellitus: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2006; 63:521–529 [A]
893. Weber-Hamann B, Gilles M, Lederbogen F, Heus-
er I, Deuschle M: Improved insulin sensitivity in 80nondiabetic patients with MDD after clinical re-mission in a double-blind, randomized trial of am-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 141
itriptyline and paroxetine. J Clin Psychiatry 2006;
67:1856–1861 [A]
894. Lustman PJ, Freedland KE, Griffith LS, Clouse
RE: Fluoxetine for depression in diabetes: a ran-domized double-blind placebo-controlled trial. Di-abetes Care 2000; 23:618–623 [A]
895. Lustman PJ, Griffith LS, Freedland KE, Kissel SS,
Clouse RE: Cognitive behavior therapy for depres-sion in type 2 diabetes mellitus. A randomized,controlled trial. Ann Intern Med 1998; 129:613–621 [A −]
896. Lustman PJ, Griffith LS, Clouse RE, Freedland
KE, Eisen SA, Rubin EH, Carney RM, McGill JB:Effects of nortriptyline on depression and glycemic
control in diabetes: results of a double-blind, place-
bo-controlled trial. Psychosom Med 1997; 59:241–250 [A]
897. Ghaeli P , Shahsavand E, Mesbahi M, Kamkar MZ,
Sadeghi M, Dashti-Khavidaki S: Comparing theeffects of 8-week treatment with fluoxetine andimipramine on fasting blood glucose of patientswith major depressive disorder. J Clin Psychophar-macol 2004; 24:386–388 [A]
898. Punjabi NM: The epidemiology of adult obstruc-
tive sleep apnea. Proc Am Thorac Soc 2008; 5:136–143 [F]
899. Institute for Clinical Systems Improvement: Diag-
nosis and treatment of obstructive sleep apnea inadults, 6th ed. Bloomington, MN, Institute forClinical Systems Improvement, 2008. http://www.icsi.org/sleep_apnea/sleep_apnea_diagnosis_and_treatment_of_obstructive_.html [G]
900. Bixler EO, Vgontzas AN, Lin HM, Calhoun SL,
Vela-Bueno A, Kales A: Excessive daytime sleepi-ness in a general population sample: the role of sleepapnea, age, obesity, diabetes, and depression. J ClinEndocrinol Metab 2005; 90:4510–4515 [G]
901. Sharafkhaneh A, Giray N, Richardson P , Young T,
Hirshkowitz M: Association of psychiatric disor-ders and sleep apnea in a large cohort. Sleep 2005;28:1405–1411 [G]
902. Ohayon MM: The effects of breathing-related sleep
disorders on mood disturbances in the general pop-ulation. J Clin Psychiatry 2003; 64:1195–1200 [G]
903. Saunamaki T, Jehkonen M: Depression and anxiety
in obstructive sleep apnea syndrome: a review. ActaNeurol Scand 2007; 116:277–288 [F]
904. Peppard PE, Szklo-Coxe M, Hla KM, Young T:
Longitudinal association of sleep-related breathingdisorder and depression. Arch Intern Med 2006;166:1709–1715 [G]
905. Wells RD, Freedland KE, Carney RM, Duntley SP ,
Stepanski EJ: Adherence, reports of benefits, anddepression among patients treated with continuouspositive airway pressure. Psychosom Med 2007;69:449–454 [B]906. Giles TL, Lasserson TJ, Smith BJ, White J, Wright
J, Cates CJ: Continuous positive airways pressurefor obstructive sleep apnea in adults. Cochrane Da-tabase Syst Rev 2006; CD001106 [E]
907. Lu B, Budhiraja R, Parthasarathy S: Sedating med-
ications and undiagnosed obstructive sleep apnea:physician determinants and patient consequences.J Clin Sleep Med 2005; 1:367–371 [G]
908. Glynn M, Rhodes P: Estimated HIV prevalence in
the United States at the end of 2003. Presented atthe 2005 National HIV Prevention Conference,Atlanta, Ga, June 12–15, 2005. http://www.aegis.com/conferences/NHIVPC/2005/T1-B1101.html[G]
909. Angelino AF: Impact of psychiatric disorders on the
HIV epidemic. T op HIV Med 2008; 16:99–103 [F]
910. Janssen RS: Implementing HIV screening. Clin
Infect Dis 2007; 45(suppl 4):S226–S231 [G]
911. Branson BM, Handsfield HH, Lampe MA, Janssen
RS, T aylor AW, Lyss SB, Clark JE: Revised recom-mendations for HIV testing of adults, adolescents,and pregnant women in health-care settings.MMWR Recomm Rep 2006; 55:1–17 [G]
912. Bhaskaran K, Hamouda O, Sannes M, Boufassa F,
Johnson AM, Lambert PC, Porter K: Changes inthe risk of death after HIV seroconversion com-pared with mortality in the general population.JAMA 2008; 300:51–59 [G]
913. Ciesla JA, Roberts JE: Meta-analysis of the relation-
ship between HIV infection and risk for depressivedisorders. Am J Psychiatry 2001; 158:725–730 [E]
914. Repetto MJ, Petitto JM: Psychopharmacology in
HIV-infected patients. Psychosom Med 2008;70:585–592 [F]
915. Himelhoch S, Medoff DR: Efficacy of antidepres-
sant medication among HIV-positive individualswith depression: a systematic review and meta-analysis. AIDS Patient Care STDs 2005; 19:813–822 [E]
916. Rabkin JG, Wagner GJ, McElhiney MC, Rabkin R,
Lin SH: T estosterone versus fluoxetine for depres-sion and fatigue in HIV/AIDS: a placebo-controlledtrial. J Clin Psychopharmacol 2004; 24:379–385 [A]
917. Rabkin JG, Wagner GJ, Rabkin R: Fluoxetine treat-
ment for depression in patients with HIV and AIDS:a randomized, placebo-controlled trial. Am J Psy-chiatry 1999; 156:101–107 [A]
918. Caballero J, Nahata MC: Use of selective seroto-
nin-reuptake inhibitors in the treatment of depres-sion in adults with HIV . Ann Pharmacother 2005;39:141–145 [F]
919. Elliott AJ, Uldall KK, Bergam K, Russo J, Clay-
poole K, Roy-Byrne PP: Randomized, placebo-controlled trial of paroxetine versus imipramine indepressed HIV-positive outpatients. Am J Psychia-try 1998; 155:367–372 [A]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
142 APA PRACTICE GUIDELINES
920. Panel on Antiretroviral Guidelines for Adult and
Adolescents, Department of Health and Human Ser-
vices: Guidelines for the use of antiretroviral agentsin HIV-1-infected adults and adolescents, Nov 3,2008. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf [G]
921. Crepaz N, Passin WF, Herbst JH, Rama SM, Mal-
ow RM, Purcell DW, Wolitski RJ: Meta-analysis ofcognitive-behavioral interventions on HIV-positivepersons’ mental health and immune functioning.Health Psychol 2008; 27:4–14 [E]
922. Himelhoch S, Medoff DR, Oyeniyi G: Efficacy of
group psychotherapy to reduce depressive symp-toms among HIV-infected individuals: a systematic
review and meta-analysis. AIDS Patient Care STDs
2007; 21:732–739 [E]
923. Balfour L, Kowal J, Silverman A, T asca GA, Angel
JB, Macpherson PA, Garber G, Cooper CL, Cam-eron DW: A randomized controlled psycho-educa-tion intervention trial: improving psychologicalreadiness for successful HIV medication adherenceand reducing depression before initiating HAART .AIDS Care 2006; 18:830–838 [A −]
924. Markowitz JC, Klerman GL, Clougherty KF, Spiel-
man LA, Jacobsberg LB, Fishman B, Frances AJ,Kocsis JH, Perry SW III: Individual psychothera-pies for depressed HIV-positive patients. Am J Psy-chiatry 1995; 152:1504–1509 [B]
925. Kelly JA, Murphy DA, Bahr GR, Kalichman SC,
Morgan MG, Stevenson LY, Koob JJ, Brasfield TL,Bernstein BM: Outcome of cognitive-behavioraland support group brief therapies for depressed, HIV-infected persons. Am J Psychiatry 1993; 150:1679–1686 [A −]
926. Carrico AW, Antoni MH, Duran RE, Ironson G,
Penedo F, Fletcher MA, Klimas N, SchneidermanN: Reductions in depressed mood and denial copingduring cognitive behavioral stress management withHIV-positive gay men treated with HAART . AnnBehav Med 2006; 31:155–164 [A− ]
927. Mistler LA, Brunette MF, Marsh BJ, Vidaver RM,
Luckoor R, Rosenberg SD: Hepatitis C treatmentfor people with severe mental illness. Psychosomat-ics 2006; 47:93–107 [F]
928. Thomas DL: The challenge of hepatitis C in the
HIV-infected person. Annu Rev Med 2008; 59:473–485 [F]
929. Dbouk N, Arguedas MR, Sheikh A: Assessment of
the PHQ-9 as a screening tool for depression inpatients with chronic hepatitis C. Dig Dis Sci 2008;53:1100–1106 [G]
930. Schafer A, Wittchen HU, Seufert J, Kraus MR:
Methodological approaches in the assessment ofinterferon-alfa-induced depression in patients withchronic hepatitis C—a critical review. Int J MethodsPsychiatr Res 2007; 16:186–201 [F]931. Asnis GM, De La Garzal R: Interferon-induced de-
pression in chronic hepatitis C: a review of its preva-lence, risk factors, biology, and treatment approaches.J Clin Gastroenterol 2006; 40:322–335 [F]
932. Reichenberg A, Gorman JM, Dieterich DT: Inter-
feron-induced depression and cognitive impairmentin hepatitis C virus patients: a 72 week prospectivestudy. AIDS 2005; 19(suppl 3):S174–S178 [C]
933. Nelligan JA, Loftis JM, Matthews AM, Zucker BL,
Linke AM, Hauser P: Depression comorbidity andantidepressant use in veterans with chronic hepatitisC: results from a retrospective chart review. J ClinPsychiatry 2008; 69:810–816 [G]
934. Morasco BJ, Rifai MA, Loftis JM, Indest DW,
Moles JK, Hauser P: A randomized trial of parox-etine to prevent interferon-alpha-induced depres-sion in patients with hepatitis C. J Affect Disord2007; 103:83–90 [A]
935. Raison CL, Woolwine BJ, Demetrashvili MF,
Borisov AS, Weinreib R, Staab JP , Zajecka JM,Bruno CJ, Henderson MA, Reinus JF , Evans DL,Asnis GM, Miller AH: Paroxetine for prevention ofdepressive symptoms induced by interferon-alphaand ribavirin for hepatitis C. Aliment PharmacolTher 2007; 25:1163–1174 [A]
936. Hauser P , Khosla J, Aurora H, Laurin J, Kling MA,
Hill J, Gulati M, Thornton AJ, Schultz RL, Valen-tine AD, Meyers CA, Howell CD: A prospectivestudy of the incidence and open-label treatment ofinterferon-induced major depressive disorder in pa-tients with hepatitis C. Mol Psychiatry 2002; 7:942–947 [B]
937. Kraus MR, Schafer A, Schottker K, Keicher C,
Weissbrich B, Hofbauer I, Scheurlen M: Therapyof interferon-induced depression in chronic hepa-titis C with citalopram: a randomised, double-blind,placebo-controlled study. Gut 2008; 57:531–536[A]
938. Bialek SR, T errault NA: The changing epidemiol-
ogy and natural history of hepatitis C virus infec-tion. Clin Liver Dis 2006; 10:697–715 [F]
939. Krebs EE, Gaynes BN, Gartlehner G, Hansen RA,
Thieda P , Morgan LC, DeVeaugh-Geiss A, LohrKN: T reating the physical symptoms of depressionwith second-generation antidepressants: a system-atic review and metaanalysis. Psychosomatics 2008;49:191–198 [E]
940. Bair MJ, Robinson RL, Katon W, Kroenke K: De-
pression and pain comorbidity: a literature review.Arch Intern Med 2003; 163:2433–2445 [E]
941. Simon GE, VonKorff M, Piccinelli M, Fullerton C,
Ormel J: An international study of the relationbetween somatic symptoms and depression. N EnglJ Med 1999; 341:1329–1335 [G]
942. Gureje O, Von Korff M, Simon GE, Gater R:
Persistent pain and well-being: a World Health
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 143
Organization study in primary care. JAMA 1998;
280:147–151 [G]
943. Kroenke K, Shen J, Oxman TE, Williams JW Jr,
Dietrich AJ: Impact of pain on the outcomes ofdepression treatment: results from the RESPECTtrial. Pain 2008; 134:209–215 [A −]
944. Thielke SM, Fan MY, Sullivan M, Unutzer J: Pain
limits the effectiveness of collaborative care for de-pression. Am J Geriatr Psychiatry 2007; 15:699–707[A−]
945. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff
RS: Do antidepressants have an analgesic effect inpsychogenic pain and somatoform pain disorder? Ameta-analysis. Psychosom Med 1998; 60:503–509
[E]
946. Spielmans GI: Duloxetine does not relieve painful
physical symptoms in de pression: a meta-analysis.
Psychother Psychosom 2008; 77:12–16 [E]
947. Kroenke K, Messina N III, Benattia I, Graepel J,
Musgnung J: Venlafaxine extended release in the
short-term treatment of depressed and anxious pri-mary care patients with multisomatoform disorder.J Clin Psychiatry 2006; 67:72–80 [A]
948. Dworkin RH, O’Connor AB, Backonja M, Farrar
JT , Finnerup NB, Jensen TS, Kalso EA, Loeser JD,Miaskowski C, Nurmikko TJ, Portenoy RK,Rice AS, Stacey BR, T reede RD, T urk DC, WallaceMS: Pharmacologic management of neuropathicpain: evidence-based recommendations. Pain 2007;132:237–251 [G]
949. Saarto T, Wiffen PJ: Antidepressants for neu-
ropathic pain. Cochrane Database Syst Rev 2007;CD005454 [E]
950. Dubinsky RM, Kabbani H, El Chami Z, Boutwell
C, Ali H: Practice parameter: treatment of posther-petic neuralgia: an evidence-based report of theQuality Standards Subcommittee of the AmericanAcademy of Neurology. Neurology 2004; 63:959–965 [G]
951. Hempenstall K, Nurmikko TJ, Johnson RW,
A ’Hern RP , Rice AS: Ana lgesic therapy in posther-
petic neuralgia: a quantitative systematic review.PLoS Med 2005; 2:e164 [E]
952. Wong MC, Chung JW, Wong TK: Effects of treat-
ments for symptoms of painful diabetic neuropathy:systematic review. BMJ 2007; 335:87 [E]
953. Rasmussen PV , Jensen TS, Sindrup SH, Bach FW:
TDM-based imipramine treatment in neuropathicpain. Ther Drug Monit 2004; 26:352–360 [G]
954. Moja PL, Cusi C, Sterzi RR, Canepari C: Selective
serotonin re-uptake inhibitors (SSRIs) for prevent-ing migraine and tension-type headaches. Coch-rane Database Syst Rev 2005; CD002919 [E]
955. Rampello L, Alvano A, Chiechio S, Malaguarnera
M, Raffaele R, Vecchio I, Nicoletti F: Evaluation ofthe prophylactic efficacy of amitriptyline and citalo-pram, alone or in combin ation, in patients with
comorbidity of depression, migraine, and tension-type headache. Neuropsychobiology 2004; 50:322–328 [A −]
956. Zissis NP , Harmoussi S, Vlaikidis N, Mitsikostas D,
Thomaidis T, Georgiadis G, Karageorgiou K: Arandomized, double-blind, placebo-controlledstudy of venlafaxine XR in out-patients with ten-sion-type headache. Cephalalgia 2007; 27:315–324[A]
957. Ozyalcin SN, T alu GK, Kiziltan E, Yucel B, Ertas
M, Disci R: The efficacy and safety of venlafaxinein the prophylaxis of migraine. Headache 2005;45:144–152 [A]
958. Holroyd KA, O’Donnell FJ, Stensland M, Lipchik
GL, Cordingley GE, Carlson BW: Management ofchronic tension-type headache with tricyclic anti-depressant medication, stress management therapy,and their combination: a randomized controlledtrial. JAMA 2001; 285:2208–2215 [A −]
959. Carville SF, Arendt-Nielsen S, Bliddal H, Blotman
F, Branco JC, Buskila D, Da Silva JA, Danneskiold-Samsoe B, Dincer F, Henriksson C, HenrikssonKG, Kosek E, Longley K, McCarthy GM, PerrotS, Puszczewicz M, Sarzi-Puttini P , Silman A, SpathM, Choy EH: EULAR evidence-based recommen-dations for the management of fibromyalgia syn-drome. Ann Rheum Dis 2008; 67:536–541 [G]
960. Russell IJ, Mease PJ, Smith TR, Kajdasz DK,
Wohlreich MM, Detke MJ, Walker DJ, ChappellAS, Arnold LM: Efficacy and safety of duloxetinefor treatment of fibromyalgia in patients with orwithout major depressive disorder: results from a6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008; 136:432–444 [A]
961. Arnold LM, Rosen A, Pritchett YL, D’Souza DN,
Goldstein DJ, Iyengar S, Wernicke JF: A random-ized, double-blind, placebo-controlled trial ofduloxetine in the treatment of women with fibro-myalgia with or without major depressive disorder.Pain 2005; 119:5–15 [A]
962. Arnold LM, Lu Y, Crofford LJ, Wohlreich M,
Detke MJ, Iyengar S, Goldstein DJ: A double-blind,multicenter trial comparing duloxetine with place-bo in the treatment of fibromyalgia patients with orwithout major depressive disorder. Arthritis Rheum2004; 50:2974–2984 [A]
963. Williams DA, Cary MA, Groner KH, Chaplin W,
Glazer LJ, Rodriguez AM, Clauw DJ: Improvingphysical functional status in patients with fibro-
myalgia: a brief cognitive behavioral intervention.
J Rheumatol 2002; 29:1280–1286 [A −]
964. Goldenberg DL, Burckhardt C, Crofford L: Man-
agement of fibromyalgia syndrome. JAMA 2004;292:2388–2395 [E]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
144 APA PRACTICE GUIDELINES
965. Bird H, Broggini M: Paroxetine versus amitrip-
tyline for treatment of depression associated with
rheumatoid arthritis: a randomized, double blind,parallel group study. J Rheumatol 2000; 27:2791–2797 [A]
966. Parker JC, Smarr KL, Slaughter JR, Johnston SK,
Priesmeyer ML, Hanson KD, Johnson GE, HewettJE, Hewett JE, Irvin WS, Komatireddy GR, WalkerSE: Management of depression in rheumatoid ar-thritis: a combined phar macologic and cognitive-
behavioral approach. Arthritis Rheum 2003; 49:766–777 [A −]
967. Perrot S, Maheu E, Javier RM, Eschalier A, Cou-
taux A, LeBars M, Bertin P , Bannwarth B, T reves R:
Guidelines for the use of antidepressants in painful
rheumatic conditions. Eur J Pain 2006; 10:185–192[G]
968. Zautra AJ, Davis MC, Reich JW, Nicassario P , T en-
nen H, Finan P , Kratz A, Parrish B, Irwin MR:Comparison of cognitive behavioral and mindful-ness meditation interventions on adaptation torheumatoid arthritis for patients with and withouthistory of recurrent depression. J Consult Clin Psy-chol 2008; 76:408–421 [A −]
969. Lin EH, T ang L, Katon W, Hegel MT, Sullivan
MD, Unutzer J: Arthritis pain and disability: re-sponse to collaborative depression care. Gen HospPsychiatry 2006; 28:482–486 [A −]
970. Lin EH, Katon W, Von Korff M, T ang L, Williams
JW, Jr., Kroenke K, Hunkeler E, Harpole L, HegelM, Arean P , Hoffing M, Della PR, Langston C,Unutzer J: Effect of improving depression care onpain and functional outcomes among older adultswith arthritis: a randomized controlled trial. JAMA2003; 290:2428–2429 [A −]
971. Chou R, Huffman LH: Medications for acute and
chronic low back pain: a review of the evidence foran American Pain Society/American College ofPhysicians clinical practice guideline. Ann InternMed 2007; 147:505–514 [E]
972. Urquhart DM, Hoving JL, Assendelft WW, Roland
M, van Tulder MW: Antidepressants for non-specific low back pain. Cochrane Database Syst Rev2008; CD001703 [E]
973. Lieberman E, Stoudemire A: Use of tricyclic anti-
depressants in patients with glaucoma. Assessmentand appropriate precautions. Psychosomatics 1987;28:145–148 [G]
974. Lachkar Y, Bouassida W: Drug-induced acute angle
closure glaucoma. Curr Opin Ophthalmol 2007;18:129–133 [G]
975. Perlis RH, Brown E, Baker RW, Nierenberg AA:
Clinical features of bipolar depression versus majordepressive disorder in large multicenter trials. AmJ Psychiatry 2006; 163:225–231 [G]976. Kessler RC, Berglund P , Demler O, Jin R, Koretz
D, Merikangas KR, Rush AJ, Walters EE, Wang PS:The epidemiology of major depressive disorder:results from the National Comorbidity Survey Rep-lication (NCS-R). JAMA 2003; 289:3095–3105 [G]
977. Merikangas KR, Ames M, Cui L, Stang PE, Ustun
TB, Von Korff M, Kessler RC: The impact ofcomorbidity of mental an d physical conditions on
role disability in the US  adult household popula-
tion. Arch Gen Psychiatry 2007; 64:1180–1188 [G]
978. Pincus HA, Zarin DA, T anielian TL, Johnson JL,
West JC, Pettit AR, Marcus SC, Kessler RC,McIntyre JS: Psychiatric patients and treatments in1997: findings from the American Psychiatric Prac-
tice Research Network. Arch Gen Psychiatry 1999;
56:441–449 [C]
979. Solomon DA, Keller MB, Leon AC, Mueller TI,
Shea MT, Warshaw M, Maser JD, Coryell W, Endi-cott J: Recovery from major depression. A 10-yearprospective follow-up across multiple episodes.Arch Gen Psychiatry 1997; 54:1001–1006 [C]
980. Vieta E, Sanchez-Moreno J, Lahuerta J, Zaragoza
S: Subsyndromal depressive symptoms in patientswith bipolar and unipolar disorder during clinicalremission. J Affect Disord 2008; 107:169–174 [G]
981. Klerman GL, Weissman MM: The course, morbid-
ity, and costs of depression. Arch Gen Psychiatry1992; 49:831–834 [G]
982. Keller MB, Beardslee WR, Dorer DJ, Lavori PW,
Samuelson H, Klerman GR: Impact of severity andchronicity of parental affective illness on adaptivefunctioning and psychopathology in children. ArchGen Psychiatry 1986; 43:930–937 [B]
983. Mintz J, Mintz LI, Arruda MJ, Hwang SS: T reat-
ments of depression and the functional capacity towork. Arch Gen Psychiatry 1992; 49:761–768 [E]
984. Holma KM, Holma IA, Melartin TK, Rytsala HJ,
Isometsa ET: Long-term outcome of major depres-sive disorder in psychiatric patients is variable. JClin Psychiatry 2008; 69:196–205 [C]
985. T rivedi MH, Rush AJ, Crismon ML, Kashner TM,
T oprac MG, Carmody TJ, Key T, Biggs MM,Shores-Wilson K, Witte B, Suppes T, Miller AL,Altshuler KZ, Shon SP: Clinical results for patientswith major depressive disorder in the T exas Medi-cation Algorithm Project. Arch Gen Psychiatry2004; 61:669–680 [B]
986. Rush AJ, T rivedi M, Carmody TJ, Biggs MM,
Shores-Wilson K, Ibrahim H, Crismon ML: One-year clinical outcomes of depressed public sectoroutpatients: a benchmark for subsequent studies.Biol Psychiatry 2004; 56:46–53 [B]
987. Zarin DA, T se T: Medicine. Moving toward trans-
parency of clinical trials. Science 2008; 319:1340–1342 [G]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 145
988. T urner EH: Closing a loophole in the FDA Amend-
ments Act. Science 2008; 322:44–46 [G]
989. Sterne JA, Davey SG: Sifting the evidence-what’s
wrong with significance tests? BMJ 2001; 322:226–
231 [F]
990. Cook RJ, Sackett DL: The number needed to treat:
a clinically useful measure of treatment effect. BMJ1995; 310:452–454 [G]
991. Kraemer HC, Kupfer DJ: Size of treatment effects
and their importance to c linical research and prac-
tice. Biol Psychiatry 2006; 59:990–996 [G]
992. Cipriani A, Santilli C, Furukawa TA, Signoretti A,
Nakagawa A, McGuire H, Churchill R, Barbui C:Escitalopram versus other antidepressive agents for
depression. Cochrane Database Syst Rev 2009;
CD006532 [E]
993. DeMartinis NA, Yeung PP , Entsuah R, Manley AL:
A double-blind, placebo-controlled study of theefficacy and safety of desvenlafaxine succinate in thetreatment of major depressive disorder. J Clin Psy-chiatry 2007; 68:677–688 [A]
994. Septien-Velez L, Pitrosky B, Padmanabhan SK,
Germain JM, T ourian KA: A randomized, double-blind, placebo-controlled trial of desvenlafaxinesuccinate in the treatment of major depressive dis-order. Int Clin Psychopharmacol 2007; 22:338–347[A]
995. Papakostas GI, Thase ME, Fava M, Nelson JC,
Shelton RC: Are antidepressant drugs that combineserotonergic and noradrenergic mechanisms of ac-tion more effective than the selective serotoninreuptake inhibitors in treating major depressive dis-order? A meta-analysis of studies of newer agents.Biol Psychiatry 2007; 62:1217–1227 [E]
996. Thase ME, Entsuah AR, Rudolph RL: Remission
rates during treatment with venlafaxine or selectiveserotonin reuptake inhibitors. Br J Psychiatry 2001;178:234–241 [E]
997. Cipriani A, Barbui C, Brambilla P , Furukawa TA,
Hotopf M, Geddes JR: Are all antidepressants reallythe same? The case of fluoxetine: a systematic re-view. J Clin Psychiatry 2006; 67:850–864 [E]
998. Thase ME, Entsuah R, Cantillon M, Kornstein SG:
Relative antidepressant efficacy of venlafaxine andSSRIs: sex-age interactions. J Womens Health(Larchmt) 2005; 14:609–616 [E]
999. Perahia DG, Wang F , Mallinckrodt CH, Walker DJ,
Detke MJ: Duloxetine in the treatment of majordepressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006; 21:367–378[A]
1000. Perahia DG, Gilaberte I, Wang F, Wiltse CG,
Huckins SA, Clemens JW, Montgomery SA, Mon-tejo AL, Detke MJ: Duloxetine in the prevention ofrelapse of major depressive disorder: double-blindplacebo-controlled study. Br J Psychiatry 2006;188:346–353 [A]
1001. Raskin J, Goldstein DJ, Mallinckrodt CH, Fergu-
son MB: Duloxetine in the long-term treatment ofmajor depressive disorder. J Clin Psychiatry 2003;64:1237–1244 [C]
1002. Rudolph RL, Feiger AD: A double-blind, random-
ized, placebo-controlled trial of once-daily ven-lafaxine extended release (XR) and fluoxetine for the
treatment of depression. J Affect Disord 1999;56:171–181 [A]
1003. Sauer H, Huppertz-Helmhold S, Dierkes W: Effi-
cacy and safety of venlafaxine ER vs amitriptylineER in patients with major depression of moderate
severity. Pharmacopsychiatry 2003; 36:169–175 [A]
1004. Saiz-Ruiz J, Ibanez A, Diaz-Marsa M, Arias F , Padin
J, Martin-Carrasco M, Montes JM, Ferrando L,
Carrasco JL, Martin-Ballesteros E, Jorda L,Chamorro L: Efficacy of venlafaxine in major de-pression resistant to selective serotonin reuptakeinhibitors. Prog Neuropsychopharmacol Biol Psy-chiatry 2002; 26:1129–1134 [C]
1005. Mitchell PB, Schweitzer I, Burrows G, Johnson G,
Polonowita A: Efficacy of venlafaxine and predic-tors of response in a prospective open-label study ofpatients with treatment-resistant major depression.J Clin Psychopharmacol 2000; 20:483–487 [B]
1006. Schweitzer I, Burrows G, T uckwell V , Polonowita
A, Flynn P , George T , Theodoros M, Mitchell P:Sustained response to open-label venlafaxine indrug-resistant major depression. J Clin Psycho-pharmacol 2001; 21:185–189 [B]
1007. Papakostas GI, T rivedi MH, Alpert JE, Seifert CA,
Krishen A, Goodale EP , T ucker VL: Efficacy ofbupropion and the selective serotonin reuptake in-hibitors in the treatment of anxiety symptoms inmajor depressive disorder: a meta-analysis of indi-vidual patient data from 10 double-blind, random-ized clinical trials. J Psychiatr Res 2008; 42:134–140[E]
1008. Chouinard G: Bupropion and amitriptyline in the
treatment of depressed patients. J Clin Psychiatry1983; 44:121–129 [A]
1009. Davidson J, Miller R, Van Wyck FJ, Strickland R,
Manberg P , Allen S, Parrott R: A double-blindcomparison of bupropion and amitriptyline in de-pressed inpatients. J Clin Psychiatry 1983; 44:115–117 [B]
1010. Mendels J, Amin MM, Chouinard G, Cooper AJ,
Miles JE, Remick RA, Saxena B, Secunda SK, SinghAN: A comparative study of bupropion and amitrip-tyline in depressed outpatients. J Clin Psychiatry1983; 44:118–120 [A]
1011. Feighner J, Hendrickson G, Miller L, Stern W:
Double-blind comparison of doxepin versus bupro-
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
146 APA PRACTICE GUIDELINES
pion in outpatients with a major depressive disorder.
J Clin Psychopharmacol 1986; 6:27–32 [A]
1012. Papakostas GI, Montgomery SA, Thase ME, Katz
JR, Krishen A, T ucker VL: Comparing the rapidityof response during treatment of major depressivedisorder with bupropion and the SSRIs: a pooledsurvival analysis of 7 double-blind, randomizedclinical trials. J Clin Psychiatry 2007; 68:1907–1912[E]
1013. Croft H, Settle E Jr, Houser T, Batey SR, Donahue
RM, Ascher JA: A placebo-controlled comparisonof the antidepressant effi cacy and effects on sexual
functioning of sustained-release bupropion and ser-traline. Clin Ther 1999; 21:643–658 [A]
1014. Segraves RT, Kavoussi R, Hughes AR, Batey SR,
Johnston JA, Donahue R, Ascher JA: Evaluationof sexual functioning in depressed outpatients: adouble-blind comparison of sustained-release bu-propion and sertraline treatment. J Clin Psycho-pharmacol 2000; 20:122–128 [A]
1015. Coleman CC, Cunningham LA, Foster VJ, Batey
SR, Donahue RM, Houser TL, Ascher JA: Sexualdysfunction associated wi th the treatment of de-
pression: a placebo-controlled comparison of bu-propion sustained release and sertraline treatment.Ann Clin Psychiatry 1999; 11:205–215 [A]
1016. Kennedy SH, Fulton KA, Bagby RM, Greene AL,
Cohen NL, Rafi-T ari S: Sexual function duringbupropion or paroxetine treatment of major depres-sive disorder. Can J Psychiatry 2006; 51:234–242[A]
1017. Coleman CC, King BR, Bolden-Watson C, Book
MJ, Segraves RT, Richard N, Ascher J, Batey S,Jamerson B, Metz A: A placebo-controlled compar-ison of the effects on sexual functioning of bupro-pion sustained release and fluoxetine. Clin Ther2001; 23:1040–1058 [A]
1018. Clayton AH, Pradko JF, Croft HA, Montano CB,
Leadbetter RA, Bolden-Watson C, Bass KI, Dona-hue RM, Jamerson BD, Metz A: Prevalence ofsexual dysfunction among newer antidepressants.J Clin Psychiatry 2002; 63:357–366 [B]
1019. Clayton AH, McGarvey EL, Abouesh AI, Pinker-
ton RC: Substitution of an SSRI with bupropionsustained release following SSRI-induced sexualdysfunction. J Clin Psychiatry 2001; 62:185–190 [B]
1020. Masand PS, Ashton AK, Gupta S, Frank B: Sus-
tained-release bupropion for selective serotonin re-uptake inhibitor-induced sexual dysfunction: arandomized, double-blind, placebo-controlled, paral-lel-group study. Am J Psychiatry 2001; 158:805–807[A]
1021. T rivedi MH, Rush AJ, Carmody TJ, Donahue RM,
B o l d e n - W a t s o n  C ,  H o u s e r  T L ,  M e t z  A :  D o  b u -propion SR and sertraline differ in their effects onanxiety in depressed patients? J Clin Psychiatry2001; 62:776–781 [E]
1022. Weihs KL, Houser TL, Batey SR, Ascher JA, Bold-
en-Watson C, Donahue RM, Metz A: Continuationphase treatment with bupropion SR effectively de-creases the risk for relapse of depression. Biol Psy-chiatry 2002; 51:753–761 [A]
1023. Claghorn JL, Lesem MD: A double-blind placebo-
controlled study of Org 3770 in depressed outpa-tients. J Affect Disord 1995; 34:165–171 [A]
1024. Holm KJ, Markham A: Mirtazapine: a review of its
use in major depression. Drugs 1999; 57:607–631[F]
1025. Guelfi JD, Ansseau M, Timmerman L, Korsgaard S:
Mirtazapine versus venlafaxine in hospitalized se-verely depressed patients with melancholic features.J Clin Psychopharmacol 2001; 21:425–431 [A]
1026. Benkert O, Szegedi A, Philipp M, Kohnen R, Hei-
nrich C, Heukels A, van der Vegte-Senden M, BakerRA, Simmons JH, Schutte AJ: Mirtazapine orallydisintegrating tablets versus venlafaxine extendedrelease: a double-blind, randomized multicenter tri-al comparing the onset of antidepressant response inpatients with major depressive disorder. J Clin Psy-chopharmacol 2006; 26:75–78 [A]
1027. Bech P: Meta-analysis of placebo-controlled trials
with mirtazapine using the core items of the Hamil-ton depression scale as evidence of a pure antide-pressive effect in the short-term treatment of majordepression. Int J Neuropsychopharmacol 2001;4:337–345 [E]
1028. Kasper S: Clinical efficacy of mirtazapine: a review
of meta-analyses of pooled data. Int Clin Psycho-pharmacol 1995; 10(suppl 4):25–35; correction,1996; 11:153 [F]
1029. Zivkov M, DeJongh G: Org 3770 versus amitrip-
tyline: a 6-week randomized, double-blind multi-centre trial in hospitalized depressed patients. HumPsychopharmacol 1995; 10:173–180 [B]
1030. Quitkin FM, T aylor BP , Kremer C: Does mirtaza-
pine have a more rapid onset than SSRIs? J ClinPsychiatry 2001; 62:358–361 [E]
1031. Watanabe N, Omori IM, Nakagawa A, Cipriani A,
Barbui C, McGuire H, Churchill R, Furukawa TA:Mirtazapine versus other antidepressants in theacute-phase treatment of adults with major depres-sion: systematic review and meta-analysis. J Clin
Psychiatry 2008; 69:1404–1415 [E]
1032. Benkert O, Szegedi A, Kohnen R: Mirtazapine
compared with paroxetine in major depression.J Clin Psychiatry 2000; 61:656–663 [A]
1033. Wade A, Crawford GM, Angus M, Wilson R,
Hamilton L: A randomized, double-blind, 24-weekstudy comparing the efficacy and tolerability ofmirtazapine and paroxetine in depressed patients in
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 147
primary care. Int Clin Psychopharmacol 2003;
18:133–141 [A]
1034. Schatzberg AF, Kremer C, Rodrigues HE, Murphy
GM, Jr.: Double-blind, randomized comparison ofmirtazapine and paroxetine in elderly depressedpatients. Am J Geriatr Psychiatry 2002; 10:541–550[A]
1035. Versiani M, Moreno R, Ramakers-van Moorsel CJ,
Schutte AJ: Comparison of the effects of mirtaza-pine and fluoxetine in severely depressed patients.CNS Drugs 2005; 19:137–146 [A]
1036. Leinonen E, Skarstein J, Behnke K, Agren H, Hels-
dingen JT: Efficacy and tolerability of mirtazapineversus citalopram: a double-blind, randomized
study in patients with major depressive disorder.
Nordic Antidepressant Study Group. Int Clin Psy-chopharmacol 1999; 14:329–337 [A]
1037. Behnke K, Sogaard J, Martin S, Bauml J, Ravindran
AV , Agren H, Vester-Blokland ED: Mirtazapineorally disintegrating tablet versus sertraline: a pro-spective onset of action study. J Clin Psychophar-macol 2003; 23:358–364 [A]
1038. Thase ME, Nierenberg AA, Keller MB, Panagides
J: Efficacy of mirtazapine for prevention of depres-sive relapse: a placebo-controlled double-blind trialof recently remitted high-risk patients. J Clin Psy-chiatry 2001; 62:782–788 [A]
1039. Feighner JP , Pambakian R, Fowler RC, Boyer WF,
D’Amico MF: A comparison of nefazodone, imip-ramine, and placebo in patients with moderate tosevere depression. Psychopharmacol Bull 1989;25:219–221 [A]
1040. Fontaine R, Ontiveros A, Elie R, Kensler TT, Rob-
erts DL, Kaplita S, Ecker JA, Faludi G: A double-blind comparison of nefazodone, imipramine, andplacebo in major depression. J Clin Psychiatry 1994;55:234–241 [A]
1041. Mendels J, Reimherr F, Marcus RN, Roberts DL,
Francis RJ, Anton SF: A double-blind, placebo-controlled trial of two dose ranges of nefazodone inthe treatment of depressed outpatients. J Clin Psy-chiatry 1995; 56(suppl 6):30–36 [A]
1042. Golden RN, Brown TM, Miller H, Evans DL: The
new antidepressants. N C Med J 1988; 49:549–554[F]
1043. Weisler RH, Johnston JA, Lineberry CG, Samara
B, Branconnier RJ, Billow AA: Comparison of bu-propion and trazodone for the treatment of majordepression. J Clin Psychopharmacol 1994; 14:170–179 [A]
1044. Shopsin B, Cassano GB, Conti L: An overview of
new second generation antidepressant compounds:research and treatment implications, in Antidepres-sants: Neurochemical, Behavioral and Clinical Per-spectives. Edited by Enna SJ, Malick J, RichelsonE. New York, Raven, 1981, pp 219–251 [F]1045. Klein HE, Muller N: T razodone in endogenous
depressed patients: a negative report and a criticalevaluation of the pertaining literature. Prog Neu-ropsychopharmacol Biol Psychiatry 1985; 9:173–186 [B]
1046. Kuhn R: The treatment of depressive states with G
22355 (imipramine hydrochloride). Am J Psychia-try 1958; 115:459–464 [B]
1047. Klerman GL, Cole JO: Clinical pharmacology of
imipramine and related antidepressant compounds.Int J Psychiatry 1967; 3:267–304 [F]
1048. Klein DF, Gittelman R, Quitkin FM, Rifkin A:
Diagnosis and Drug T reatment of Psychiatric Dis-orders: Adults and Children, 2nd ed. Baltimore,
Williams and Wilkins, 1980 [G]
1049. Potter WZ, Manji HK, Rudorfer MV: T ricyclics
and tetracyclics, in American Psychiatric Press
T extbook of Psychopharmacology. Edited bySchatzberg AF, Nemeroff CB. Washington, DC,American Psychiatric Press, 1998, pp 199–218 [F]
1050. Barbui C, Guaiana G, Hotopf M: Amitriptyline for
inpatients and SSRIs for outpatients with depres-sion? Systematic review and meta-regression anal-ysis. Pharmacopsychiatry 2004; 37:93–97 [E]
1051. Arroll B, Macgillivray S, Ogston S, Reid I, Sullivan
F , Williams B, Crombie I: Efficacy and tolerabilityof tricyclic antidepressants and SSRIs comparedwith placebo for treatment of depression in primarycare: a meta-analysis. Ann Fam Med 2005; 3:449–456 [E]
1052. Wohlfarth T, Storosum JG, Elferink AJ, van Zwieten
BJ, Fouwels A, van den Brink W: Response totricyclic antidepressants: independent of gender?Am J Psychiatry 2004; 161:370–372 [E]
1053. Reynolds CF III, Miller MD, Pasternak RE, Frank
E, Perel JM, Cornes C, Houck PR, Mazumdar S,Dew MA, Kupfer DJ: T reatment of bereavement-related major depressive episodes in later life: acontrolled study of acute and continuation treat-ment with nortriptyline and interpersonal psycho-therapy. Am J Psychiatry 1999; 156:202–208 [A]
1054. Thompson LW, Coon DW, Gallagher-Thompson
D, Sommer BR, Koin D: Comparison of desip-ramine and cognitive/behavioral therapy in thetreatment of elderly outpatients with mild-to-mod-erate depression. Am J Geriatr Psychiatry 2001;9:225–240 [A]
1055. van den Broek WW, Birkenhager TK, Mulder PG,
Bruijn JA, Moleman P: Imipramine is effective inpreventing relapse in electroconvulsive therapy-responsive depressed inpatients with prior pharma-cotherapy treatment failur e: a randomized, placebo-
controlled trial. J Clin Psychiatry 2006; 67:263–268[A]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
148 APA PRACTICE GUIDELINES
1056. Coryell W, T urner R: Outcome with desipramine
therapy in subtypes of nonpsychotic major depres-
sion. J Affect Disord 1985; 9:149–154 [B]
1057. Fairchild CJ, Rush AJ, Vasavada N, Giles DE,
Khatami M: Which depressions respond to place-bo? Psychiatry Res 1986; 18:217–226 [B]
1058. Brotman AW, Falk WE, Gelenberg AJ: Pharmaco-
logic treatment of acute depressive subtypes, inPsychopharmacology: The Third Generation ofProgress. Edited by Meltzer HY. New York, Raven,1987, pp 1031–1040 [F]
1059. Joyce PR, Paykel ES: Predictors of drug response
in depression. Arch Gen Psychiatry 1989; 46:89–99[F]
1060. Stewart JW, Quitkin FM, Liebowitz MR, McGrath
PJ, Harrison WM, Klein DF: Efficacy of desip-ramine in depressed outpatients: response accord-ing to Research Diagnostic Criteria diagnoses andseverity of illness. Arch Gen Psychiatry 1989;40:220–227 [A]
1061. Paykel ES: Depressive typologies and response to
amitriptyline. Br J Psychiatry 1972; 120:147–156[B]
1062. Raskin A, Crook TH: The endogenous—neurotic
distinction as a predictor of response to antidepres-sant drugs. Psychol Med 1976; 6:59–70 [G]
1063. Danish University Antidepressant Group: Paroxe-
tine: a selective serotonin reuptake inhibitor show-ing better tolerance, but weaker antidepressanteffect than clomipramine in a controlled multi-center study. J Affect Disord 1990; 18:289–299 [A]
1064. White K, Razani J, Cadow B, Gelfand R, Palmer R,
Simpson G, Sloane RB: T ranylcypromine vs nor-triptyline vs placebo in depressed outpatients: acontrolled trial. Psychopharmacology (Berl) 1984;82:258–262 [B]
1065. McGrath PJ, Stewart JW, Harrison W, Wager S,
Quitkin FM: Phenelzine treatment of melancholia.J Clin Psychiatry 1986; 47:420–422 [B]
1066. Davidson J, Raft D, Pelton S: An outpatient evalu-
ation of phenelzine and imipramine. J Clin Psychi-atry 1987; 48:143–146 [B]
1067. Himmelhoch JM, Thase ME, Mallinger AG,
Houck P: T ranylcypromine versus imipramine inanergic bipolar depression. Am J Psychiatry 1991;148:910–916 [A]
1068. Zisook S, Braff DL, Click MA: Monoamine oxidase
inhibitors in the treatment of atypical depression.J Clin Psychopharmacol 1985; 5:131–137 [A]
1069. Quitkin FM, McGrath PJ, Stewart JW, Harrison
W, T ricamo E, Wager SG, Ocepek-Welikson K,Nunes E, Rabkin JG, Klein DF: Atypical depres-sion, panic attacks, and response to imipramine andphenelzine: a replication. Arch Gen Psychiatry1990; 47:935–941 [A]1070. Himmelhoch JM, Fuchs CZ, Symons BJ: A double-
blind study of tranylcypromine treatment of majoranergic depression. J Nerv Ment Dis 1982; 170:628–634 [A]
1071. Thase ME, Mallinger AG, McKnight D, Himmel-
hoch JM: T reatment of imipramine-resistant recur-rent depression, IV: a double-blind crossover studyof tranylcypromine for anergic bipolar depression.Am J Psychiatry 1992; 149:195–198 [A]
1072. Bodkin JA, Amsterdam JD: T ransdermal selegiline in
major depression: a double-blind, placebo-controlled,parallel-group study in outpatients. Am J Psychiatry2002; 159:1869–1875 [A]
1073. Birkenhager TK, van den Broek WW, Mulder PG,
Bruijn JA, Moleman P: Efficacy and tolerability oftranylcypromine versus phenelzine: a double-blindstudy in antidepressant-refractory depressed inpa-tients. J Clin Psychiatry 2004; 65:1505–1510 [A]
1074. Dombrovski AY, Mulsant BH, Haskett RF, Prudic
J, Begley AE, Sackeim HA: Predictors of remissionafter electroconvulsive therapy in unipolar majordepression. J Clin Psychiatry 2005; 66:1043–1049[B]
1075. Prudic J, Haskett RF, Mulsant B, Malone KM,
Pettinati HM, Stephens S, Greenberg R, Rifas SL,Sackeim HA: Resistance to antidepressant medica-tions and short-term clini cal response to ECT. Am
J Psychiatry 1996; 153:985–992 [B]
1076. McCall WV , Dunn A, Rosenquist PB, Hughes D:
Markedly suprathreshold right unilateral ECTversus minimally suprathreshold bilateral ECT:antidepressant and memory effects. J ECT 2002;18:126–129 [A]
1077. McCall WV , Reboussin DM, Weiner RD, Sackeim
HA: Titrated moderately suprathreshold vs fixedhigh-dose right unilateral electroconvulsive thera-py: acute antidepressant and cognitive effects. ArchGen Psychiatry 2000; 57:438–444 [A]
1078. Bailine SH, Rifkin A, Kayne E, Selzer JA, Vital-
Herne J, Blieka M, Pollack S: Comparison of bi-frontal and bitemporal ECT for major depression.Am J Psychiatry 2000; 157:121–123 [A]
1079. Ranjkesh F, Barekatain M, Akuchakian S: Bifrontal
versus right unilateral and bitemporal electrocon-vulsive therapy in major depressive disorder. J ECT2005; 21:207–210 [A]
1080. Eschweiler GW, Vonthein R, Bode R, Huell M,
Conca A, Peters O, Mende-Lechler S, Peters J,Klecha D, Prapotnik M, DiPauli J, Wild B, PlewniaC, Bartels M, Schlotter W: Clinical efficacy andcognitive side effects of bifrontal versus right uni-lateral electroconvulsive therapy (ECT): a short-term randomised controlled trial in pharmaco-resistant major depression. J Affect Disord 2007;101:149–157 [A]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 149
1081. Sackeim HA, Prudic J, Devanand DP , Nobler MS,
Lisanby SH, Peyser S, Fitzsimons L, Moody BJ,
Clark J: A prospective, randomized, double-blindcomparison of bilateral and right unilateral electro-convulsive therapy at different stimulus intensities.Arch Gen Psychiatry 2000; 57:425–434 [A]
1082. Shapira B, T ubi N, Lerer B: Balancing speed of
response to ECT in major depression and adversecognitive effects: role of treatment schedule. J ECT2000; 16:97–109 [A]
1083. Fregni F, Marcolin MA, Myczkowski M, Amiaz R,
Hasey G, Rumi DO, Rosa M, Rigonatti SP , Cam-prodon J, Walpoth M, Heaslip J, Grunhaus L,Hausmann A, Pascual-Leone A: Predictors of anti-
depressant response in clinical trials of transcranial
magnetic stimulation. Int J Neuropsychopharmacol2006; 9:641–654 [E]
1084. McNamara B, Ray JL, Arthurs OJ, Boniface S:
T ranscranial magnetic stimulation for depressionand other psychiatric disorders. Psychol Med 2001;31:1141–1146 [E]
1085. Kozel FA, George MS: Meta-analysis of left pre-
frontal repetitive transcranial magnetic stimulation(rTMS) to treat depression. J Psychiatr Pract 2002;8:270–275 [E]
1086. Martin JL, Barbanoj MJ, Schlaepfer TE, Clos S,
Perez V , Kulisevsky J, Gironell A: T ranscranialmagnetic stimulation for treating depression.Cochrane Database Syst Rev 2002; CD003493 [E]
1087. Burt T, Lisanby SH, Sackeim HA: Neuropsychiat-
ric applications of transcranial magnetic stimula-tion: a meta analysis. Int J Neuropsychopharmacol2002; 5:73–103 [E]
1088. Gross M, Nakamura L, Pascual-Leone A, Fregni F:
Has repetitive transcranial magnetic stimulation(rTMS) treatment for depression improved? A sys-tematic review and meta-analysis comparing therecent vs. the earlier rTMS studies. Acta PsychiatrScand 2007; 116:165–173 [E]
1089. Martin JL, Barbanoj MJ, Schlaepfer TE, Thomp-
son E, Perez V , Kulisevsky J: Repetitive transcranialmagnetic stimulation for the treatment of depres-sion. Systematic review and meta-analysis. Br J Psy-chiatry 2003; 182:480–491 [E]
1090. Avery DH, Isenberg KE, Sampson SM, Janicak PG,
Lisanby SH, Maixner DF, Loo C, Thase ME,Demitrack MA, George MS: T ranscranial magneticstimulation in the acute treatment of major depres-sive disorder: clinical re sponse in an open-label
extension trial. J Clin Psychiatry 2008; 69:441–451[B]
1091. Dannon PN, Dolberg OT, Schreiber S, Grunhaus
L: Three and six-month outcome following coursesof either ECT or rTMS in a population of severelydepressed individuals—preliminary report. BiolPsychiatry 2002; 51:687–690 [A −]1092. Pridmore S: Substitution of rapid transcranial mag-
netic stimulation treatments for electroconvulsivetherapy treatments in a course of electroconvulsivetherapy. Depress Anxiety 2000; 12:118–123 [B]
1093. Linde K, Mulrow CD, Berner M, Egger M: St
John’s wort for depression. Cochrane Database SystRev 2005; CD000448 [E]
1094. Lecrubier Y, Clerc G, Didi R, Kieser M: Efficacy of
St. John’s wort extract WS 5570 in major depres-sion: a double-blind, placebo-controlled trial. Am JPsychiatry 2002; 159:1361–1366 [A]
1095. Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH:
Oral S-adenosylmethionine in depression: a ran-
domized, double-blind, placebo-controlled trial.
Am J Psychiatry 1990; 147:591–595 [A]
1096. Delle CR, Pancheri P , Scapicchio P: Efficacy and
tolerability of oral and intramuscular S-adenosyl-
L-
methionine 1,4-butanedisulfonate (SAMe) in the
treatment of major depression: comparison withimipramine in 2 multicenter studies. Am J ClinNutr 2002; 76:1172S–1176S [A]
1097. Shippy RA, Mendez D, Jones K, Cergnul I, Karpiak
SE: S-adenosylmethionine (SAM-e) for the treatment
of depression in people living with HIV/AIDS.BMC Psychiatry 2004; 4:38 [B]
1098. Salmaggi P , Bressa GM, Nicchia G, Coniglio M, La
Greca P , Le Grazie C: Double-blind, placebo-controlled study of S-adenosyl-
L-methionine in
depressed postmenopausal women. PsychotherPsychosom 1993; 59:34–40 [A]
1099. Marangell LB, Martinez JM, Zboyan HA, Kertz B,
Kim HF, Puryear LJ: A double-blind, placebo-controlled study of the omega-3 fatty acid docosa-hexaenoic acid in the treatment of major depression.Am J Psychiatry 2003; 160:996–998 [A]
1100. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker
RH: Omega-3 treatment of childhood depression:a controlled, double-blind pilot study. Am J Psychi-atry 2006; 163:1098–1100 [A]
1101. Su KP , Huang SY, Chiu TH, Huang KC, Huang
CL, Chang HC, Pariante CM: Omega-3 fatty acidsfor major depressive disorder during pregnancy:results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69:644–651[A]
1102. T erman M, T erman JS: Light therapy for seasonal
and nonseasonal depression: efficacy, protocol,safety, and side effects. CNS Spectr 2005; 10:647–663 [G]
1103. Dobson KS: A meta-analysis of the efficacy of cog-
nitive therapy for depression. J Consult Clin Psy-chol 1989; 57:414–419 [E]
1104. Robinson RG, Starkstein SE: Current research in
affective disorders following stroke. J Neuropsychi-atry Clin Neurosci 1990; 2:1–14 [F]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
150 APA PRACTICE GUIDELINES
1105. Gaffan EA, T saousis I, Kemp-Wheeler SM: Re-
searcher allegiance and meta-analysis: the case of
cognitive therapy for depression. J Consult ClinPsychol 1995; 63:966–980 [E]
1106. Gloaguen V , Cottraux J, Cucherat M, Blackburn
IM: A meta-analysis of the effects of cognitive ther-apy in depressed patients. J Affect Disord 1998;49:59–72 [E]
1107. Jarrett RB, Rush AJ: Short-term psychotherapy of
depressive disorders: current status and future di-rections. Psychiatry 1994; 57:115–132 [F]
1108. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky
SM, Collins JF, Glass DR, Pilkonis PA, Leber WR,Docherty JP: National In stitute of Mental Health
T reatment of Depression Collaborative ResearchProgram. General effectiveness of treatments. ArchGen Psychiatry 1989; 46:971–982 [A]
1109. Hollon SD, DeRubeis RJ, Evans MD, Wiemer MJ,
Garvey MJ, Grove WM, T uason VB: Cognitivetherapy and pharmacother apy for depression. Sin-
gly and in combination. Arch Gen Psychiatry 1992;49:774–781 [A]
1110. Evans MD, Hollon SD, DeRubeis RJ, Piasecki JM,
Grove WM, Garvey MJ, T uason VB: Differentialrelapse following cognitive therapy and pharmaco-therapy for depression. Arch Gen Psychiatry 1992;49:802–808 [B]
1111. Blatt S, Zuroff D, Bondi C, Sanislow C: Short- and
long-term effects of medi cation and psychotherapy
in the brief treatment of depression: further analy-ses of data from the NIMH TDCRP . Psychothera-py Research 2000; 10:215–234 [A]
1112. McLean PD, Hakstian AR: Clinical depression: com-
parative efficacy of outpatient treatments. J ConsultClin Psychol 1979; 47:818–836 [F]
1113. Steuer JL, Mintz J, Hammen CL, Hill MA, Jarvik
LF, McCarley T, Motoike P , Rosen R: Cognitive-behavioral and psychodynamic group psychothera-py in treatment of geriatric depression. J ConsultClin Psychol 1984; 52:180–189 [B]
1114. Beach SR, Jouriles EN, O’Leary KD: Extramarital
sex: impact on depression and commitment in cou-ples seeking marital therapy. J Sex Marital Ther 1985;11:99–108 [D]
1115. Rabin AS, Kaslow NJ, Rehm LP: Factors influenc-
ing continuation in a behavioral therapy. Behav ResTher 1985; 23:695–698 [C]
1116. Thompson JK, Williams DE: An interpersonally
based cognitive-behavioral psychotherapy. ProgBehav Modif 1987; 21:230–258 [G]
1117. Jacobson NS, Dobson K, Fruzzetti AE, Schmaling
KB, Salusky S: Marital therapy as a treatment fordepression. J Consult Clin Psychol 1991; 59:547–557 [G]1118. T aylor S, McLean P: Outcome profiles in the treat-
ment of unipolar depression. Behav Res Ther 1993;31:325–330 [B]
1119. Thase ME, Simons AD, Cahalane J, McGeary J,
Harden T: Severity of depression and response tocognitive behavior therapy. Am J Psychiatry 1991;148:784–789 [B]
1120. McLean P , T aylor S: Severity of unipolar depression
and choice of treatment. Behav Res Ther 1992;30:443–451 [A]
1121. Rohde P , Lewinsohn PM, Seeley JR: Response of
depressed adolescents to cognitive-behavioraltreatment: do differences in initial severity clarifythe comparison of treatments? J Consult Clin Psy-
chol 1994; 62:851–854 [B]
1122. Coffman SJ, Martell CR, Dimidjian S, Gallop R,
Hollon SD: Extreme nonresponse in cognitive
therapy: can behavioral activation succeed wherecognitive therapy fails? J Consult Clin Psychol2007; 75:531–541 [G]
1123. de Mello MF , de Jesus MJ, Bacaltchuk J, Verdeli H,
Neugebauer R: A systematic review of researchfindings on the efficacy of interpersonal therapy fordepressive disorders. Eur Arch Psychiatry ClinNeurosci 2005; 255:75–82 [E]
1124. Weissman MM: Cognitive therapy and interper-
sonal psychotherapy: 30 years later. Am J Psychiatry2007; 164:693–696 [G]
1125. Markowitz JC, Bleiberg KL, Christos P , Levitan E:
Solving interpersonal problems correlates withsymptom improvement in interpersonal psycho-therapy: preliminary findings. J Nerv Ment Dis2006; 194:15–20 [C]
1126. O’Hara MW, Stuart S, Gorman LL, Wenzel A:
Efficacy of interpersonal psychotherapy for post-partum depression. Arch Gen Psychiatry 2000;57:1039–1045 [A −]
1127. Schulberg HC, Block MR, Madonia MJ, Scott CP ,
Rodriguez E, Imber SD, Perel J, Lave J, Houck PR,Coulehan JL: T reating major depression in primarycare practice. Eight-month clinical outcomes. ArchGen Psychiatry 1996; 53:913–919 [A]
1128. Lewis AJ, Dennerstein M, Gibbs PM: Short-term
psychodynamic psychotherapy: review of recentprocess and outcome studies. Aust N Z J Psychiatry2008; 42:445–455 [F]
1129. Gibbons MB, Crits-Christoph P , Hearon B: The
empirical status of psychodynamic therapies. AnnuRev Clin Psychol 2008; 4:93–108 [F]
1130. Leichsenring F, Rabung S: Effectiveness of long-
term psychodynamic psychotherapy: a meta-analysis.JAMA 2008; 300:1551–1565 [E]
1131. Abbass AA, Hancock JT , Henderson J, Kisely S:
Short-term psychodynamic psychotherapies forcommon mental disorders. Cochrane Database SystRev 2006; CD004687 [E]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition 151
1132. Driessen E, Cuijpers P , de Maat SC, Abbass AA, De
Jonghe F , Dekker JJ: The efficacy of short-term
psychodynamic psychotherapy for depression: ameta-analysis. Clin Psychol Rev 2010; 30:25–36 [E]
1133. Cuijpers P , van Straten A, Bohlmeijer E, Hollon
SD, Andersson G: The effects of psychotherapy foradult depression are overestimated: a meta-analysisof study quality and effect size. Psychol Med 2010;40:211–223 [E]
1134. Jacobson NS, Martin B: Behavioral marriage ther-
apy: current status. Psychol Bull 1976; 83:540–556[F]
1135. Hahlweg K, Markman HJ: Effectiveness of behav-
ioral marital therapy: empirical status of behavioral
techniques in preventing and alleviating marital
distress. J Consult Clin Psychol 1988; 56:440–447[F]
1136. Barbato A, D’Avanzo B: Marital therapy for depres-
sion. Cochrane Database Syst Rev 2006; CD004188[E]
1137. Jacobson NS, Addis ME: Research on couples and
couple therapy: what do we know? Where are wegoing? J Consult Clin Psychol 1993; 61:85–93 [F]
1138. O’Leary KD, Beach SR: Marital therapy: a viable
treatment for depression and marital discord. Am JPsychiatry 1990; 147:183–186 [A]
1139. Foley SH, Rounsaville BJ, Weissman MM, Sholom-
skas D, Chevron E: Individual versus conjoint in-terpersonal psychotherapy for depressed patientswith marital disputes. Int J Fam Psychiatry 1989;10:29–42 [A −]
1140. Dowrick C, Dunn G, Ayuso-Mateos JL, Dalgard
OS, Page H, Lehtinen V , Casey P , Wilkinson C,Vazquez-Barquero JL, Wilkinson G: Problem solv-ing treatment and group psychoeducation for de-pression: multicentre randomised controlled trial.Outcomes of Depression International Network(ODIN) Group. BMJ 2000; 321:1450–1454 [A −]
1141. Gellis ZD, McGinty J, Horowitz A, Bruce ML,
Misener E: Problem-solving therapy for late-lifedepression in home care: a randomized field trial.Am J Geriatr Psychiatry 2007; 15:968–978 [A −]
1142. Rovner BW, Casten RJ, Hegel MT, Leiby BE,
T asman WS: Preventing depression in age-relatedmacular degeneration. Arch Gen Psychiatry 2007;64:886–892 [C]
1143. McDermut W, Miller IW, Brown RA: The efficacy
of group psychotherapy for depression: a meta-analysis and review of the empirical research.Clinical Psychology: Science and Practice 2001;8:98–116 [E]
1144. Wilfley DE, MacKenzie KR, Welch RR, Ayres VE,
Weissman MM: Interpersonal Psychotherapy forGroup. New York, Basic Books, 2000 [G]
1145. Hellerstein DJ, Little SA, Samstag LW, Batchelder
S, Muran JC, Fedak M, Kreditor D, Rosenthal RN,Winston A: Adding group psychotherapy tomedication treatment in dysthymia: a randomizedprospective pilot study. J Psychother Pract Res2001; 10:93–103 [A −]
1146. Persons JB, Thase ME, Crits-Christoph P: The
role of psychotherapy in the treatment of depres-sion: review of two practice guidelines. Arch GenPsychiatry 1996; 53:283–290 [G]
1147. Conte HR, Plutchik R, Wild KV , Karasu TB: Com-
bined psychotherapy and pharmacotherapy for de-pression. A systematic analysis of the evidence. ArchGen Psychiatry 1986; 43:471–479 [E]
1148. Burnand Y, Andreoli A, Kolatte E, Venturini A,
Rosset N: Psychodynamic psychotherapy and clo-
mipramine in the treatment of major depression.
Psychiatr Serv 2002; 53:585–590 [A −]
1149. Nemeroff CB, Heim CM, Thase ME, Klein DN,
Rush AJ, Schatzberg AF, Ninan PT, McCullough JPJr, Weiss PM, Dunner DL, Rothbaum BO, Korn-stein S, Keitner G, Keller MB: Differential re-sponses to psychotherapy versus pharmacotherapyin patients with chronic forms of major depressionand childhood trauma. Proc Natl Acad Sci U S A2003; 100:14293–14296 [A −]
1150. De Jonghe F, Kool S, Van Aalst G, Dekker J, Peen
J: Combining psychotherapy and antidepressants inthe treatment of depression. J Affect Disord 2001;64:217–229 [A −]
1151. Kool S, Dekker J, Duijsens IJ, De Jonghe F, Puite
B: Efficacy of combined therapy and pharmacother-apy for depressed patients with or without person-ality disorders. Harv Rev Psychiatry 2003; 11:133–141 [A −]
1152. De Jonghe F, Hendricksen M, Van Aalst G, Kool S,
Peen V , Van R, van den Eijnden E, Dekker J: Psy-chotherapy alone and comb ined with pharmacother-
apy in the treatment of depression. Br J Psychiatry2004; 185:37–45 [A −]
1153. de Maat SM, Dekker J, Schoevers RA, De Jonghe
F: Relative efficacy of psychotherapy and combinedtherapy in the treatment of depression: a meta-analysis. Eur Psychiatry 2007; 22:1–8 [E]
1154. Bech P , T anghoj P , Andersen HF, Overo K: Citalo-
pram dose-response revisited using an alternativepsychometric approach to evaluate clinical effectsof four fixed citalopram doses compared to placeboin patients with major depression. Psychopharma-cology (Berl) 2002; 163:20–25 [A]
1155. Fava M, Rush AJ: Current status of augmentation
and combination treatments for major depressivedisorder: a literature review and a proposal for anovel approach to improve practice. PsychotherPsychosom 2006; 75:139–153 [G]
1156. Marcus RN, McQuade RD, Carson WH, Hennick-
en D, Fava M, Simon JS, T rivedi MH, Thase ME,Berman RM: The efficacy and safety of aripiprazole
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
152 APA PRACTICE GUIDELINES
as adjunctive therapy in major depressive disorder:
a second multicenter, randomized, double-blind,placebo-controlled study. J Clin Psychopharmacol2008; 28:156–165 [A]
1157. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI:
A preliminary, open study of the combination offluoxetine and desipramine for rapid treatmentof major depression. Arch Gen Psychiatry 1991;48:303–307 [C]
1158. Nelson JC, Mazure CM, Jatlow PI, Bowers MB Jr,
Price LH: Combining norepinephrine and sero-tonin reuptake inhibition mechanisms for treat-ment of depression: a double-blind, randomizedstudy. Biol Psychiatry 2004; 55:296–300 [A]
1159. Kocsis JH, Thase ME, T rivedi MH, Shelton RC,
Kornstein SG, Nemeroff CB, Friedman ES, Gelen-berg AJ, Dunner DL, Hirschfeld RM, RothschildAJ, Ferguson JM, Schatzberg AF , Zajecka JM, Ped-ersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT,Keller MB: Prevention of recurrent episodes ofdepression with venlafaxine ER in a 1-year mainte-nance phase from the PREVENT Study. J ClinPsychiatry 2007; 68:1014–1023 [A]
1160. Ma SH, T easdale JD: Mindfulness-based cognitive
therapy for depression: replication and explorationof differential relapse prevention effects. J ConsultClin Psychol 2004; 72:31–40 [A −]
1161. Klein DN, Santiago NJ, Vivian D, Blalock JA, Koc-
sis JH, Markowitz JC, McCullough JP Jr, Rush AJ,T rivedi MH, Arnow BA, Dunner DL, Manber R,Rothbaum B, Thase ME, Keitner GI, Miller IW,Keller MB: Cognitive-behavioral analysis system ofpsychotherapy as a maintenance treatment forchronic depression. J Consult Clin Psychol 2004;72:681–688 [A −]
1162. Paykel ES, Scott J, Cornwall PL, Abbott R, Crane
C, Pope M, Johnson AL: Duration of relapse pre-vention after cognitive therapy in residual depres-sion: follow-up of controlled trial. Psychol Med2005; 35:59–68 [C]
1163. Petrides G, Dhossche D, Fink M, Francis A: Con-
tinuation ECT: relapse prevention in affective dis-orders. Convuls Ther 1994; 10:189–194 [B]
1164. Vanelle JM, Loo H, Galinowski A, de Carvalho W,
Bourdel MC, Brochier P , Bouvet O, Brochier T ,Olie JP: Maintenance ECT in intractable manic-depressive disorders. Convuls Ther 1994; 10:195–205 [C]
1165. Weiner RD: Electroconvulsive therapy, in T reat-
ments of Psychiatric Disorders. Edited by GabbardGO. Washington, DC, American Psychiatric Press,
1995, pp 1237–1262 [G]
1166. Schwarz T, Loewenstein J, Isenberg KE: Mainte-
nance ECT: indications and outcome. Convuls
Ther 1995; 11:14–23 [B]
1167. Gupta S, T obiansky R, Bassett P , Warner J: Efficacy
of maintenance electroconvulsive therapy in recur-rent depression: a naturalistic study. J ECT 2008;24:191–194 [G]
1168. Frederikse M, Petrides G, Kellner C: Continuation
and maintenance electroconvulsive therapy for thetreatment of depressive illness: a response to theNational Institute for Clinical Excellence report.J ECT 2006; 22:13–17 [F]
1169. Gagne GG Jr, Furman MJ, Carpenter LL, Price
LH: Efficacy of continuati on ECT and antidepres-
sant drugs compared to long-term antidepressantsalone in depressed patients. Am J Psychiatry 2000;157:1960–1965 [D]
1170. Busch F , Rudden M, Shapiro T: Psychodynamic
T reatment of Depression. Washington, DC, Amer-ican Psychiatric Publishing, 2004 [G]
Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may  
be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx.
